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Abstract 
Feline infectious peritonitis (FIP) is an almost invariably fatal, feline coronavirus (FCoV)-induced 
disease of both small and large felids with a worldwide distribution. It arises from a combination 
of viral mutations of a ubiquitous enteric virus and an over-exuberant host immune response. The 
initial enteric infection often remains subclinical or causes a mild enteritis and may be associated 
with viraemia. A small minority of infected cats develops FIP, characterised by pyogranulomatous 
vasculitis, fibrino-suppurative serositis, and often protein-rich cavitary effusions. Neither the viral 
nor the host factors leading to this disease are completely understood, and it is almost unique in 
nature for its pathological presentation. Clinical and pathological features all point to excessive 
cytokine release, however the trigger and precise source(s) are unclear. 
This present study focused on the host’s local and systemic immune response to FCoV infection, 
with the mesenteric lymph nodes (MLN) the main organ of interest. The MLN is the likely first site 
of spread beyond the intestine and additionally has a crucial gatekeeper role against entry of 
enteric pathogens. A panel of relevant immune mediators was chosen, including the Toll-like 
receptors (TLRs) and STAT transcription factors; neither group was previously studied in FIP. 
Downstream mediators included type I and II interferons (IFN) and pro-inflammatory cytokines, 
colony stimulating factors and matrix remodelling enzymes. Using post mortem clinical cases, 
comparisons were made between cats with no detectable FCoV in the MLN, cats with FCoV in the 
MLN and no FIP, and infected cats with FIP. The second main focus was on the lesions themselves 
in order to evaluate the direct viral effect on mediator expression. Bone marrow and spleen were 
also studied to gain an appreciation of systemic immune mediator levels across groups.  
The panel was evaluated across groups and organs, identifying TLR 2, 4, and 8 as the main TLRs 
upregulated in FIP (predicted to detect both viral proteins and genome). Correspondingly, the 
inflammatory cytokines IL-1β, IL-6, and TNF-α were also upregulated, as were the anti-viral IFN-α, 
-β, and -γ, the IFN despite the ineffectual defence response by the host.  The greatest response 
was observed in the MLN, whilst cells within the lesions themselves upregulated many 
inflammatory cytokines still further, consistent with a direct viral trigger in addition to amplifying 
cascades. Transcriptional alterations in cases of FCoV infection without disease were rare. To 
examine both these and the effects of FIP itself in greater depth, MLN from the different groups 
were subjected to RNA-Seq by next generation sequencing (NGS). The greatest intergroup 
difference was still found between cats with FIP and controls, in which differentially expressed 
genes were linked to both pro-inflammatory and anti-viral aspects of the immune system, as well 
as cell cycle repression in FIP. However, between the two non FIP groups, cats with FCoV infection 
of the MLN exhibited lower mRNA expression of genes involved in immune responses known to 
be deleterious in FIP such as neutrophil chemotaxis and antibody production. 
This reinforces the host dominance in disease development whilst opening up intriguing 
possibilities regarding host versus virus contribution to disease resistance. 
A parallel aspect of the study assessed the virus, firstly for previously studied ‘FIP specific’ S gene 
mutations, confirming a link to systemic spread but not disease. Secondly the viral transcriptome 
via RNA-Seq. Initial results suggest there may be differential viral gene transcription occurring in 
FIP, affecting the viruses virion forming ability and thus hypothetically its pathogenic potential. 
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Introduction 
 
History of the disease 
Feline infectious peritonitis (FIP) is an almost universally fatal disease of felids with a worldwide 
distribution. It was first reported in 1963 although descriptions of a disease matching FIP can be 
found from Italy dating back earlier than this 1,2. It was a further decade before a viral aetiology 
was shown, demonstrated to be a feline coronavirus (FCoV), which when causing the disease is a 
mutated form of a ubiquitous enteric coronavirus 3–5. Both domestic and wild cats can be affected, 
with the disease being reported in big cats including mountain lions and cheetahs 6–9. Cheetahs 
have been proposed to be particularly at risk because of their severely limited gene pool, meaning 
that ‘susceptible’ genes are likely to be carried by all 7. Within domestic cats, pedigree animals and 
in particular certain pedigrees also show increased susceptibility, demonstrating that both viral 
and host factors contribute to disease 10,11.  
 
Epidemiology 
The epidemiology of the disease has many complexities and there remain many gaps in our 
understanding. Though the causative agent is a coronavirus, it is the cats’ own immune system 
which inflicts the damage, combined with as yet only partially elucidated viral mutations. 
The most common route of natural infection is faeco-oral, though experimentally virus has been 
administered intraperitoneally, intranasally, tracheally or orally with the rate of disease within 
cohorts related to the route of infection. This tends to be highest in peritoneal followed by tracheal 
then oral 12. After experimental oral inoculation of the avirulent, enteric coronavirus (FECV), virus 
was found in the tonsils and small intestine within 24 hours and could be detected in the faeces 
by day two post infection 13. Owing to faecal shedding, cats sharing litter trays or living in close 
proximity are at an increased risk of initial infection. Nevertheless it is only in very rare cases that 
FIP itself appears to be spread horizontally 14,15. Despite this apparently low horizontal 
transmissibility of FIP, many cats with the disease also shed FCoV in their faeces 16. Experimentally, 
some cats in fact stop shedding when they develop disease 17. 
In experimental infection with the virulent form of the virus there are four possible outcomes: the 
cat resists disease, develops effusive disease, develops non-effusive disease, or develops 
enhanced disease 18. The latter is usually seen in cats that were previously challenged e.g. with the 
avirulent form. This discrepancy between individual hosts shows clearly that the virus itself is not 
the deciding factor in terms of disease progression. 
Antibodies against FCoV have been detected in up to 90% of cattery cats compared to 10-50% of 
animals in single cat households. In the former, seropositivity is thought to be maintained by 
reinfection 19–21. Of these infected cats, longitudinal studies have shown that 5-10% in multi-cat 
households develop FIP 21. Seropositivity itself is not an accurate predictor of the likelihood of 
developing FIP; cats may remain seropositive for years before disease develops, or may become 
spontaneously seronegative 20. However, seronegative cats may also develop disease. 
Experimentally, kittens which seroconverted after infection with the virulent form (also referred 
to by some authors as FIP virus or FIPV) all developed disease and died within 6-10 days, whilst 
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half of the seronegative kittens did not develop FIP, and those that did developed the disease 
more slowly 22.  
The role of antibody dependant enhancement (ADE) is controversial and it appears to be more 
common experimentally, where an enhanced form of disease exists in seropositive cats which are 
subsequently virus challenged (as mentioned above) 23,24. This is defined by either a higher 
proportion developing disease, a shorter time course of disease, or an atypical gross picture 25. 
ADE has proven particularly problematic in vaccine trials as prior exposure almost invariably 
worsened rather than prevented disease. No link between rising titre and development of FIP has 
been found 17. On the other hand, maternally derived antibodies appear to be protective against 
FIP; these wane by 4-6 weeks when kittens become more susceptible 26.  
 
Clinical findings 
Coronaviruses in other species are frequently associated with enteric or respiratory disease. In 
farm animals, diarrhoea in neonates is especially common but some coronaviruses are not age 
specific (e.g. transmissible gastroenteritis virus [TGEV] of swine) 27. Infection leads to exfoliation 
of viral infected villus tips leading to severe villus atrophy, blunting and fusion. The result is a 
malabsorptive diarrhoea with a minor secretory component 27. In cats, infection with enteric 
coronavirus (FECV) is often subclinical but may lead to a transient enteritis. In rare cases, a severe 
fatal enteritis can develop 28. In natural infection, therefore, most cases of FIP occur in animals 
with no recorded history of enteric disease.  
FIP can present in many different guises, heavily influencing the ease of diagnosis. Classically FIP 
has been divided into wet and dry forms, with the wet form being that for which the disease was 
named. In reality these are a clinical distinction, representing the two ends of a spectrum of 
disease with the majority of cases being mixed forms. At pathological examination the overlap and 
continuum of lesion development becomes more evident 29. 
Common clinical signs include a biphasic fever, lethargy, anaemia, anorexia, depression, and 
weight loss, though cats may have any combination or none of these. These are accompanied by 
signs relevant to the affected organs/body cavity e.g. abdominal distension in the case of ascites, 
dyspnoea and exercise intolerance in the case of pleural effusions, jaundice with extensive hepatic 
involvement, neurological signs, or renal failure 30. The time scale can range from acute 
presentations to chronically progressing or waxing and waning disease 31,32. Amongst the many 
differential diagnoses are neoplasia, congestive heart failure, toxoplasmosis and lymphocytic 
cholangitis 32. 
Signalment can be helpful but is far from definite. Cats younger than two years and male are 
thought to be predisposed whilst neutered status is not a factor 31. 
It is also not uncommon for animals to present with signs reflecting disease in a single organ 
system. This is especially well documented in the case of neurological FIP in which the brain may 
be the only affected organ and fits to the classic definition of ‘dry FIP’ 33. 
The disease has also been reported presenting as orchitis 34, abdominal masses 35, ocular         
lesions 9,36 or cutaneous lesions 36–38. 
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Pathological findings 
FIP is a disease of contradictions, one of these being that despite the myriad clinical presentations 
and many differentials diagnoses which can make intra-vital diagnosis highly problematic, it is an 
almost unique disease pathologically. To date, the only naturally occurring similar disease known 
is that in ferrets induced by ferret coronavirus 39. Genetic engineering has created a similar disease 
in mice (discussed later).  
In the initial enteric FCoV infection, histologically, the features are as seen with other 
coronaviruses, villus blunting and fusion, with epithelial necrosis, and FCoV antigen expression 
mainly in epithelial cells of the villous tips 13,28. These are unlikely to be observed in natural 
infection as the usually mild disease rarely warrants investigation. 
Early reported cases of FIP, or at least those which were recognised as such, mainly affected the 
peritoneum 1,2,40; extra-serosal lesions were less common and first reported specifically in 1972 41. 
The authors found the kidneys, visceral lymph nodes (LN), lungs, liver, eyes, and leptomeninges to 
be the most commonly affected organs with disseminated granulomas and scant serosal lesions. 
The classical, almost pathognomonic, histological feature is a pyogranulomatous phlebitis, 
targeting particularly venules and small veins 42. This was originally suggested to be immune-
complex, i.e. type III hypersensitivity-mediated as C3, IgG and virus were seen together in vessel 
walls 22. However, the distribution of and cellular composition within the vasculitis varies from 
immune mediated vasculitis of other species 42 and a type IV hypersensitivity reaction has also 
been suggested to cause the granulomas 23,43. It is likely that a combination exists, reflecting the 
balance between humoral and cell-mediated responses in individual animals. FCoV is seemingly 
the only virus to induce immunological granulomas, though in contrast to these entities, 
granulomas in FIP lack multinucleate giant cells and epithelioid macrophages whilst having larger 
numbers of neutrophils. CD8+ cytotoxic T lymphocytes were found at the periphery of FIP 
granulomas and appeared to increase with the age of the lesions, whilst CD4+ helper T 
lymphocytes were more diffusely distributed 43. There is also a progressive influx of B cells and 
plasma cells observed at the periphery of the lesions with time 44. Despite common features, the 
distribution and precise type of lesions can vary between cats, and between organs within an 
individual 45. Additional lesions include diffuse serosal inflammation, and lymphoplasmacytic 
infiltrates in more chronic cases 44. The lymphocytic lesions are dominated by B cells and plasma 
cells and in some cases demarcate areas of inflammation from surrounding tissue 44. Mesenteric 
lymph nodes without lesions have been variably found to show follicular hyperplasia with 
reduction in T cells, or moderate to severe depletion 44,46. This may relate to viral presence 47. An 
increase in the proportion of macrophages seems to be a more consistent feature, being observed 
in the splenic red pulp and lymph node sinuses in FIP cats 48. Bone marrow is usually hyperplastic 
with a left shift and an increased proportion of cells of macrophage lineage in FIP 44,48.  
 
Diagnosis 
Intravital diagnosis is a particular challenge in FIP, especially in the dry form, and many methods 
are available (tending to indicate that no one method is ideal). The gold standard remains 
histological examination of lesions and immunohistology for FCoV antigen which requires an 
invasive procedure on frequently very sick cats.  
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The holy grail of FIP diagnosis is finding a test to reliably identify a pathogenic virus biotype 
alongside identifying host susceptibility. Antibody testing is rarely of benefit as the majority of cats 
have already been exposed. A negative correlation has in fact been found in cats with a higher 
virus load, implying immune exhaustion, and another study found that 10% of cats with FIP were 
antibody negative 49,50. 
As well as developing an antibody response to FCoV, many healthy cats also become viraemic and 
may remain so for years, so that the presence of virus in the blood is not a feature defining the 
pathogenic biotype 51. The same study also showed that remaining viraemic did not increase a 
cat’s chances of developing FIP. As body cavity effusions result from an increased vascular 
permeability, it follows that a viraemic cat with e.g. ascites of cardiac origin may also have 
detectable virus in the fluid, as evidenced by specificities of immunostaining on effusions of 
around 70% 52,53. The degree of viraemia is also not necessarily useful, as healthy FCoV infected 
cats may have high circulating levels 54. Viral load in tissues tends to be higher in cats with FIP but 
this is currently more relevant to research than diagnosis as a precise cut off should first be 
established 55. 
In FIP, as with other veterinary diseases with such a poor prognosis, the specificity of a test is 
arguably of more importance than the sensitivity, as a false positive result may lead to unnecessary 
euthanasia. A number of studies have compared the sensitivity and specificity of various in vivo 
tests for FIP. Quantitative RT-PCR (RT-qPCR) is nowadays one of the most common methods but 
there are still a multiplicity of samples to choose from as well as different laboratories with 
different protocols. Immunofluorescence and immunocytochemistry/ immunohistochemistry are 
the other main diagnostic modalities 32. The Rivalta test is a simple method used to differentiate 
transudates and exudates and hence is a pointer towards the likelihood of FIP but not alone 
diagnostic 56.  
If effusions or detectable masses are present then cytological examination is a non-invasive 
method which, whilst again not 100% diagnostic allows the likelihood of FIP to be determined 57. 
Sensitivity, specificity, and positive and negative predictive value (PPV/NPV) are in all cases of 
course heavily influenced by the nature of the control group, and by the prevalence of FIP within 
the population 58. 
As standard biopsy techniques are invasive, the utility of Trucut biopsies has also been evaluated 
on liver and kidney with the advantage of cost, safety, and surgical requirements but the expected 
disadvantage of a smaller sample requiring a degree of luck to target a diagnostic    area 59. 
Effusions have a higher diagnostic potential than blood, another factor complicating the diagnosis 
of cases without effusion. RT-qPCR on peripheral blood mononuclear cells (PBMCs), serum, and 
effusions found sensitivities of 28.6%, 15.4% and 88.9% respectively 60. A positive immunocytology 
result on effusions was first thought to be 100% specific, a finding which was later questioned by 
the same group following further studies 50,52. The nature of the effusion has a high positive 
predictive value (PPV), being yellow, gelatinous and transparent to cloudy with a high protein 
content and specific gravity 57. The cell count can be variable but the population is composed of 
non-degenerate neutrophils, macrophages, and fewer lymphocytes 57. 
Haematology and biochemistry reveal no pathognomonic changes and rely on increasing the 
suspicion of FIP when multiple suggestive results are obtained (leading to increased specificity but 
lower sensitivity). These include lymphopaenia, neutrophilia, anaemia, hyperproteinaemia, and 
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hypergammaglobulinaemia 61,62. More selective analysis revealed that lymphopaenia tends to only 
affect acute cases and hyperproteinaemia subacute cases 45.  
The hyperproteinaemia is due to an increased globulin fraction leading to an inverted albumin 
globulin ratio in many cases, which can also be used as a guide. The lymphopaenia is particularly 
due to decreased CD4+ T cell numbers (though CD8+, CD5+ and CD21+ cells were also found to be 
reduced); apoptosis was identified as the mechanism of reduction 63–65. Lymphopenia is very non-
specific when comparing cats with FIP to those with other diseases, so this feature is not a useful 
diagnostic tool but can help to rule out FIP as it has a high negative predictive value 65.  
 
Host factors 
In addition to searching for the key viral mutation, many studies have investigated which host 
genetics play a role in disease susceptibility.  
As mentioned previously, breed susceptibilities have been identified, with those purebreds at an 
apparent higher risk of FIP including Abyssinians, Bengals, Holy Birmans, Himalayans, Ragdolls and 
Rexes 10,11.  
The immune profile of Holy Birman cats has been further investigated to try to identify a reason 
for the breed’s apparent predilection for FIP. Findings went against predictions of a skew towards 
humoral immunity (T helper (Th)2) and away from cell mediated immunity (Th1) as these cats 
instead had cytokine profiles favouring cell mediated immunity (CMI) 66. 
Pathogenicity is affected by the viruses’ ability to infect specific cell types but this also has a strong 
host aspect. From the side of the virus, peritoneal macrophages from SPF cats were shown to be 
susceptible to infection by both virulent and avirulent strains of FCoV, but the virulent strains 
infected a higher proportion of cells and were able to sustain replication 67. This was despite 
comparable growth in CrFK cells. This study also observed that prior incubation with anti-FCoV 
antibodies led to enhanced uptake of virulent but not avirulent FCoV 67.   
The host influence is shown in infection kinetic studies on PBMCs from healthy cats. Monocytes 
from just under half of cats are able to sustain viral replication of FIPV and not of FECV, a similar 
proportion can be infected but sustain neither, whilst just over 10% could not be infected at all at 
this time point 68. PBMCs from a particular individual may also vary over time in their ability to 
sustain replication 69.  
Many experimental studies have found that not all cats succumb to disease, as previously 
mentioned. A larger combined study looked into this further, confirming that some cats 
(approximately one third in this case) were resistant to FIPV challenge. However, a second 
challenge resulted in disease in some previously resistant animals. Prior exposure to avirulent 
FCoV did not increase the incidence but was sometimes associated with an earlier disease onset; 
resistance to FIP increased between six months and one year of age 70. Counterintuitively, 
inbreeding of cats resistant to experimental FIP, with the aim of concentrating the gene pool and 
discovering which genes were relevant, produced cats more likely to succumb than the initial 
population 71. 
Purebred cats have been shown to be predisposed. This is apparently a heritable trait, as the 
chances are much higher for a cat to develop FIP if an ancestor had FIP, and this seems to trace 
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back to common predisposed males. Persians and Birmans in particular show a heritability of at 
least 50% 72.  
One study investigating the virus in an epidemic in Persian cats found that, regardless of viral 
factors, most affected kittens had a common sire and that by changing the sire the incidence 
dropped from 75% to 25% 73. 
An analysis of Birman genetic susceptibility identified five possible candidate genes, ELMO1, 
TNFSF10, RRAGA, ERAP1 and ERAP2 74. Following on from this study, the aforementioned loci were 
compared in a genetically diverse population and not found to be significant. Instead, single 
nucleotide polymorphisms (SNPs) in TNF-α and DC-SIGN (CD209) were detected which appeared 
linked to susceptibility 75. 
IFN-g SNPs were separately identified in a targeted comparison of cats with and without FIP, 
suggesting the existence of polymorphisms linked to FIP resistance, as well as to circulating plasma 
levels of the protein 76. 
Human leukocyte antigen (HLA) class II alleles correlate with e.g. viral load of HIV 77. Feline LA class 
II polymorphisms were therefore studied, but no apparent link to susceptibility to FIP was found. 
However, this was a small study with many variables so may warrant further  investigation 78. 
 
Coronavirus biology and immune evasion strategies 
Viral taxonomy  
The causative agent of feline infectious peritonitis, feline coronavirus (FCoV), is a subspecies of 
coronavirus within the order Nidovirales.  
Nidovirales is the order containing the largest known RNA genomes, which can exceed 30,000 
bases 79. All possess a single-stranded positive sense RNA genome which encodes their own 
replication machinery in addition to structural proteins, those involved in immune evasion, and 
proteins of as yet unknown function. Many features are shared by all nidoviruses. The current 
classification places FCoV as a subspecies within the species Alphacoronavirus 1, genus 
Alphacoronavirus, subfamily Coronavirinae and family Coronaviridae (Fig. 2.1) 80. 
 
 
 
Figure 2.1: Viral taxonomy adapted from the latest 2012 classification 80, which replaced the earlier 
classification of Coronavirus as a genus 81. 
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The family Coronaviridae encompasses many viruses of human and veterinary significance. It 
includes the high profile severe acute respiratory distress syndrome (SARS) and Middle East 
respiratory syndrome (MERS) viruses, which led to a surge in interest in coronavirus research. 
MERS has a fatality rate of approximately one third of all diagnosed cases, eclipsing the importance 
of 229E, the common cold virus which is also an alphacoronavirus 82. Alpha and betacoronaviruses 
infect mammals, gammacoronaviruses infect avians, whilst delta coronaviruses may infect         
both 82. 
Unrelated to pathogenicity there are two serotypes of FCoV (I and II). The S proteins of serotype 
II FCoV were found to cluster with canine coronavirus (CCoV) and TGEV, whilst the M and N of 
both FCoVs clustered together away from the canine and porcine viruses 83. Later, further work at 
the viral genome level showed that serotype II FCoV originates from more than one recombination 
event between FCoV serotype I and CCoV 84. In addition to the S protein deriving largely from 
CCoV, 3c also differs between FCoV types, whereas 7b is the same, indicating it was not involved 
in the recombination 84. It is known that CCoV can infect cats; CCoV exposure can cause ADE in 
FIP, and can also cause mild diarrhoea or even FIP itself 85.  
In most parts of the world, FCoV type II is found in only a minority of FIP cases. Many studies have 
evaluated this, ranging from 2.5% in Malaysia to ~20% in Switzerland 86–91. Owing to this relative 
rarity, and evaluation of viral sequences, it has been suggested that the recombination event in 
fact occurs within individuals rather than being a circulating form 92. 
 
Coronavirus replication 
Although this study focusses on the host response, the underlying viral mechanisms are of great 
importance in understanding which factors may affect this host response and which are potential 
targets in inhibiting viral replication or manipulating the immune response.  
The large genome of the Coronavirinae comes with a unique replication strategy 93. In common 
with other nidoviruses, they have a large replicase gene followed by structural and accessory 
genes; the replicase gene arrangement distinguishes the nidoviruses from other orders 79. 
Nidoviruses, meaning ‘nest’ are named for their nested subgenomic mRNAs. Structural and 
accessory genes comprise only approximately one third of the genome, structural including S, E, 
M, and N (spike, envelope, membrane, and nucleocapsid respectively). The Coronavirinae are 
named for their distinctive club shaped spike proteins which project from the surface. The 
spherical virion is ~125 nm in diameter, with a helically symmetrical nucleocapsid (Fig. 2.2). This is 
uncommon amongst positive sense RNA viruses and instead is normally a feature of those which 
are negative stranded 93. 
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Figure 2.2: Schematic image of coronavirus structure.  
 
The S protein is ~150 kDa and forms spikes made up of homotrimers 94,95. M is the most abundant 
protein and may help with maintaining virus shape, whilst E is present at low levels and seems to 
enable assembly and release of the virus. N binds RNA and is heavily phosphorylated; this feature 
appears to lend the N protein a preference for binding viral over host RNA 96.  
The coronavirus must first gain entry into the host cell and many utilise the aminopeptidase N 
protein (APN) of their respective host species as a receptor, including FCoV type II 93,97. FCoV type 
I has been shown not to recognise this receptor but the search for its corresponding receptor is 
still ongoing 98,99. Viruses are not always restricted to their host APN; the human HCoV-229E virus 
can additionally utilise the feline but not porcine APN 100 whilst the feline APN appears in general 
to be a receptor for multiple viruses within the same species as FCoV, with the potential to act as 
a mixing vessel as has occurred to form serotype II 97. Many other receptors have also been 
identified as being used by other coronaviruses 82. Despite the lack of a known primary receptor 
for FCoV type I, it has been shown that both type I and II use DC-SIGN as a co-receptor at least in 
vitro 101,102. 
Apart from entering cells via the receptor, FCoV can enter via Fc receptor binding of the antibody 
against the FCoV S protein 103. Further evidence of the crucial role of the S protein in this process 
is the ADE induced experimentally only by prior exposure to antibodies against the same serotype 
(i.e. the same S protein) 104.  
The S protein is a class I fusion protein which mediates attachment to the host receptor 105. It is 
then cleaved by a host cell furin-like protease to S1 (the receptor binding domain) and S2 (the 
stalk) 106. It also has a transmembrane anchor and a short intracellular tail. The receptor binding 
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domain (RBD) of the S1 protein determines host specificity and tropism. Following binding, 
cleavage occurs at two sites in S2, the first cleavage separates the RBD and fusion domains, the 
second exposes the fusion peptide. The latter fuses the viral and host membranes and releases 
virus into the cell, this usually occurs in acidified endosomes but some may fuse at the plasma 
membrane 93.  
Within coronavirus genera the S1 is very similar but may recognise different receptors. Between 
genera there is significant S1 variation yet it may still recognise the same receptor, a phenomenon 
still to be fully explored 82.  
Having entered the host cell, the virus must now replicate. Replicase expression utilises frame 
shifting to make two alternate polyproteins, 1a and 1ab, although the precise ratio is unknown in 
vivo. These polyproteins then form the non-structural proteins (nsps) 1-16 107. The genome 
structure is portrayed schematically in Fig. 2.3. Coronaviruses encode their own proteases within 
these nsps, which then cleave the remainder. These include papain-like proteases (PLpro) from 
nsp3 and a main protease (Mpro) from nsp5. Many nsps form the replicase-transcriptase complex 
(RTC), responsible for transcription of sub-genomic RNAs. Nsp12 encodes the RNA-dependant 
RNA polymerase (RdRp) domain. The strand shifting ability of this RdRp helps explain the ability of 
the viruses to combine both homologously and non-homologously 93. 
Figure 2.3: Genomic organisation of FCoV. The light grey ORFs are encoded by the replicase gene, 
forming polyprotein 1ab which is cleaved to 16 nsps; structural proteins are coloured as in Fig. 2.2; 
accessory proteins dark grey. 
 
During replication, negative strand intermediates are formed which are ~1% as abundant as 
positive strand templates. Structural proteins S, E, and M are translated after replication and 
subgenomic RNA synthesis has been completed. These proteins insert into the ER, move to the 
ERGIC (endoplasmic reticulum-Golgi intermediate compartment), and viral genomes bud out to 
form mature virions 93. Virus like particles can form with only E and M, but formation is enhanced 
by N 108. S is not required at this stage. In some coronaviruses, S protein that is not packaged goes 
to the cell surface and mediates fusion between cells. This allows syncytia formation and mediates 
viral spread without the virus leaving cells, and hence aids evasion of the host immune         
response 93. This phenomenon has not been observed in FCoV 93.  
Coronaviruses also possess other and varied mechanisms of immune evasion. Host sensing of viral 
RNA relies largely on recognising viral features that are not found in host RNA. These features 
include 5’ uncapped RNA and double stranded (ds)RNA 109. Coronaviruses do however have a 5’ 
cap, with capping enzymes encoded within the RTC 109,110. They also encode an exoribonuclease 
to hydrolyse free RNA structures and remove them as targets for immune surveillance 111. This 
enzyme additionally functions as a proofreading machine, endowing the virus with a very high 
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replication fidelity for an RNA virus 112. A further viral evasion strategy is the apparent shielding of 
dsRNA within double membrane vesicles stolen from the host endoplasmic reticulum 109.  
The above mechanisms are all designed to prevent host detection of viral presence. If these fail 
and receptors are activated, coronaviruses also possess other mechanisms to interfere with host 
signalling. The SARS PLpro enzyme for example inhibits TLR7 and TLR3 signalling via downstream 
pathway cleavage of Lys63-linked ubiquitin chains 113. The same enzyme can also interact with the 
signalling complex formed by STING (stimulator of interferon genes) and others, preventing 
transcription of type I IFNs 114.  
 
Viral factors 
It was first suggested almost half a century ago that the causative agent of FIP, FIPV, is closely 
related to FECV, initially these were thought to be two separate viruses 26. Despite host differences 
in susceptibility, experimental work clearly shows that pathogenic potential varies significantly 
between viruses. It was discovered in the 1980s that the two biotypes have different growth 
requirements in culture, with FECV replicating poorly in macrophages 18,67. Dewerchin also found 
PBMCs were less supportive of FECV infection than of FIPV 68.  
There has been some debate as to whether there are two circulating forms of the virus (the 
circulating virulent/avirulent strain hypothesis), or that mutations develop within individual 
animals, the so-called internal mutation (or in vivo mutation transition) theory 5. The latter is now 
fairly widely accepted though disputed by some 115. One of the main mysteries in the development 
of FIP is which mutations are relevant to viral pathogenicity. Many potential gene candidates have 
been explored, as discussed below, but as yet no single mutation/protein has been linked 
conclusively with disease. Identifying the viral changes of importance is a prerequisite for 
designing a distinguishing diagnostic test (setting host factors aside briefly) and trying to further 
understand the pathogenesis. 
RNA viruses are inherently prone to mutations as they in general lack a proofreading mechanism. 
An average of 0.76 mutations/replication/µg of riboviral genome has been calculated and is fairly 
fixed per cycle, or ≈4 × 10−4 nucleotide substitutions/site/year 116,117. Coronaviruses are an 
exception in possessing their own proofreading mechanisms and as such have lower mutation 
rates than most 112. They nevertheless, like other RNA viruses, exist as quasispecies 112,118. This is 
not due to selection pressure as viruses in cell culture exhibit the same quasispecies 119. FCoV has 
a relatively low rate of mutation in cell culture, indicating relative stability 120.  
Mathematically it can therefore be assumed that anything leading to an increased replication rate 
of the virus increases its chances of acquiring pathogenic mutations. Correspondingly, FCoV-
infected cats with compromised immune systems e.g. those with FIV or FeLV infection have been 
shown to be at increased risk of developing FIP 12,86.    
The increased replication is evidenced by a 10-100 fold higher FCoV titre in the faeces of 
experimentally infected FIV positive cats compared to FIV negative controls. These cats also shed 
for longer, and had lower antibody responses 121. FECV infection led to FIP in 10% of FIV positive 
cats within 10 weeks, compared to none without 86,121. This study also found evidence of 
independent (internal) mutations arising in cats infected with the same FECV to cause FIP.  
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This exemplifies one of the many contradictions of FIP, that despite being caused by an out of 
control immune response, cats with immunosuppression appear predisposed.  
Beginning with the non-structural proteins, ORF1 proteins comprise the replicase machinery and 
have not thus far been implicated. ORF3abc appears to have been involved in a recombination 
with CCoV. Although it does not affect growth in CrFK or Fcwf-4 cells, its presence leads to a 
markedly lower replication in PBMCs 122. FIPV isolated from an infected cat showed a truncated 
ORF3abc, with the theory that this truncation increases viral replication efficiency in and tropism 
for macrophages. This was narrowed down to being a 3c deletion/truncation. Addition of 3c in 
culture seemed to inhibit replication in Fcw-4 cells 123. This theory was supported by in vivo studies, 
in which samples from faeces of healthy cats or organs/effusions of FIP cats showed that most 
healthy cats had an intact 3c whilst most FIP cats had a deletion or nonsense mutation 123,124. It 
was subsequently found that cats with FIP may also have virus with intact 3c, so that this does not 
appear to be a determining factor in virulence 125. Experimental work on this ORF, infecting cats 
either oro-nasally or intraperitoneally with FECVs (all having an intact 3c), or FIPVs (with and 
without intact 3c) found a close link between an intact 3c and the ability to replicate in the 
intestine, as well as showing again that FECVs had a lower ability to replicate systemically 126. 
In vitro deletion of ORF3 or 7, or both, showed that ORF7 was required to maintain replication 
within PBMCs. The lack of only ORF3 still allowed sustained replication but at a much lower level 
compared to wildtype 127. How closely this reflects the in vivo situation is unknown. In vivo, viruses 
with ORF7b deletions were found in both FIP effusions and faeces of healthy cats 128.  
The viral 7a protein was shown in vitro (in Fcwf-4 cells) to help FIPV counteract IFN-a, as measured 
by the ability of the virus to replicate in the presence of the interferon, but that it also required 
ORF3 to achieve this 129. 
The spike protein, with its importance in determining viral cell entry, is of particular interest. Its 
furin cleavage motif is conserved in FECV but was found to often be altered in FIPV 130. This study 
compared cats before and after developing FIP, and cats in the same environment that did not get 
FIP. The same authors found that although all groups had mutations in S1/S2 they were often not 
in a functionally relevant site in cats that did not develop FIP 130. 
Experimental recombinations between the type II cell culture adapted FECV (79-1683) and FIPV 
(79-1146) found that macrophage tropism is linked to the S protein, but that infectivity is not 
linked to receptor usage as both FIPV and FECV can be blocked by antibodies to the fAPN receptor. 
Tropism was found to be in the membrane proximal region of the ectodomain rather than the 
amino-terminal receptor-binding region itself 131. Further S gene analysis compared FCoV 
sequenced from organs of cats with FIP with FCoV sequenced from the faeces of cats without FIP. 
Two mutations were found to identify over 95% of the cats with FIP, namely M1058L (the majority) 
and S1060A (another 4%, the first group still retained S at 1060) 132. These mutations were then 
found in tissue samples of cats without FIP, though at a lower level, and the ‘FIP mutation’ found 
in virus within faeces 91,133. This suggests that the mutations are indeed related to systemic spread 
but neither sufficient alone to cause FIP nor essential. Whether the difference then lies with the 
virus or with the host, and whether cats carrying mutated virus may later go on to develop FIP has 
not been determined. 
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Treatment and prevention 
To date there is no successful treatment, although drug trials are ongoing. In order to succeed, 
any method relies on understanding the peculiarities of the virus. The following list of studies is 
not exhaustive as myriad compounds have been evaluated against FIP, but covers the range of 
tactics that researchers have adopted.  
Vaccination has been attempted in multiple guises but as discussed briefly above with ADE, most 
attempts to immunise cats against subsequent challenge by FIPV have been unsuccessful, if not 
having the opposite effect of enhancing disease. Early efforts involved exposure to low levels of 
virus, to ‘apathogenic’ virus or to antisera from other animals. All led to increased susceptibility or 
to unpredictable responses which could not safely be applied clinically 22,23,134,135. 
More recently, reverse genetics systems have been used to generate vaccines with varying 
success. One group found that viruses with deletions of either ORF3abc, ORF7ab, or both 
replicated well in cell culture (on Fcwf-4 cells), and caused no clinical signs in cats 136. They then 
challenge tested these cats with virulent FCoV and found good protection (9/10 cats survived) 
when using the individual deletion viruses but the classic problem of enhanced disease using the 
double deletion virus 136. A later study did not attempt vaccination but assessed these same 
deletion mutants in feline monocytes, finding impaired growth and/or infectivity in all 127. The 
reasons for these differences must be host cell specific as both studies used the same viruses.   
Another study found that a similar strategy of vaccinating with live ORF3abc attenuated vaccines 
protected SPF but not conventional cats. However as the conventional cats were British Short Hair 
purebreds and the SPF cats were domestic shorthairs, this extra variable of breed complicates 
interpretation of the relative effects of vaccination versus host genetics on outcome 137. 
In the absence of a preventative vaccine, the search for a successful treatment becomes more 
critical and many antiviral therapies have been tried. Interferons, particularly the type Is, are a 
commonly used antiviral therapy in human medicine, later finding their way to veterinary 
medicine 138,139. The first to be licensed for feline use was interferon omega, aimed particularly at 
retroviral infections 140. The use of interferon omega in FIP has been reported as being of partial 
or no benefit 141,142. The discrepancy may be in part due to the varying strictness of the diagnostic 
criteria of FIP used in the two trials. Less specific immune modulators include the 
immunosuppressive glucocorticoids, common in first opinion practice upon making a diagnosis of 
FIP but of no proven benefit 143. Another immunosuppressant, cyclosporine, has had an in vitro 
effect on replication of a range of coronavirus species including FCoV 144,145. 
Small interfering/silencing (si)RNAs can be designed to target specific regions of a viral genome to 
target the RNA for degradation and prevent its replication 146. A side effect of the inherently high 
mutation rate of RNA viruses is the speed at which sequence alterations lead to therapy   
resistance 147. Combination siRNA therapy targeting more than one region of the viral genome 
delayed the onset of viral resistance but has until now only been been tested in vitro 148.   
In view of the fact that TNF-α is produced by virus infected macrophages and seen as a key 
mediator of the pathogenic effects of FIP, anti-TNF-α antibodies were clinically trialled. 1/3 
compared to 3/3 untreated experimentally infected SPF cats developed FIP 149. 
Another predicted inhibitor of inflammatory cytokines, propentofylline was clinically trialled and 
found to have no effect, the prediction having been that it would prevent the development of 
vasculitis and hence avoid the effects of the virus 150. Other drugs trialled with varying success 
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include cholesterol inhibitors, platelet aggregation inhibitors, the antiviral ribavirin and the DNA 
alkylating melphalan 151–154. 
Viral protease inhibitors are currently showing the most promise; different groups have reported 
the ability to reverse the clinical progression of FIP, though with more success in ‘wet’                   
cases 155–157. By targeting this key viral enzyme the drugs interfere with viral replication and protein 
cleavage. 
 
The host immune response 
As described above, the host response is crucial to determining disease outcome. A range of 
immune mediators was chosen for the present study. These reflected those which were known, 
or thought likely, on the basis of previously published functions, to play a role in FIP pathogenesis; 
the aim was to evaluate disease associated quantitative changes. Their main functions, together 
with what is so far known for each as relates to FIP, are presented below. The specific members 
of each group involved in the study are given in brackets for each section. 
 
Toll-like receptors (TLR) [TLR 1-9] 
The immune system of mammals comprises two main branches. Whilst the innate immune 
response is found at a very early stage of evolution and allows for a rapid yet relatively unspecific 
response, the adaptive immune system is only possessed by higher vertebrates and leads to a 
more targeted response. There are various theories as to why the latter has evolved, with reduced 
energy expenditure by the host being one of these 158.  
Four families of pathogen recognition receptors (PRRs) are currently known, TLRs, retinoic acid 
inducible gene I (RIG-I)-like receptors, nucleotide oligomerisation domain-like receptors, and HIN-
200 family members 159,160.  
TLRs are one of the most evolutionarily conserved defence mechanisms of the immune system, 
being found not only in humans and other mammals, but also in sponges, the phylogenetically 
oldest known extant metazoans 161. Even the immune system of plants uses highly similar receptor 
proteins as the first line of defence, sharing leucine rich repeat (LRR) domains with the TLRs 162. 
TLRs were the first PRRs to be discovered and as key components of the innate immune system 
are able to detect a wide range of pathogen associated molecular patterns (PAMPs) present on 
bacteria, viruses, fungi, parasites, and protozoa. PAMPs are those molecular signatures which are 
specific to pathogens and should not be present, or at least not exposed to the immune system, 
in the host. Most microbes are composed of multiple PAMPs, allowing simultaneous activation of 
multiple PRRs, which themselves exhibit receptor redundancy and crosstalk 163.  
Another important function of TLRs is as inducers of dendritic cells which can then activate the 
second branch of the host immune response, adaptive immunity. TLRs are the bridge between 
innate and adaptive immunity which is crucial to co-ordinating an effective immune response and 
immune memory 164. 
To date, 12 functional TLRs have been identified in mice, and ten in humans 163. TLR 1-9 in the 
domestic cat have been sequenced and the lymphatic tissue TLR response to FIV assessed 165. Their 
presence in feline pancreatic islet cells has also been assessed 166. However, investigation into 
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their potential involvement in FIP has thus far only been undertaken for TLR9 and only in vitro 167. 
Subsequently to completion of the experimental work in the current study, TLR4 was found 
incidentally by RNA-seq to be upregulated in peritoneal macrophages of cats with FIP 168. Table 
2.1 shows the reported ligands of TLR 1-9 and references studies of possible relevance to FIP. 
 
Table 2.1: TLR 1-9 and their associated PAMPs, together with literature from other species which may 
be of relevance in FIP. 
TLR Main reported PAMPs169–172 Predicted relevance to FIP 
1 Lipoproteins, LTA, PGN, 
lipoarabinomannan  
- Possible role through TLR2 heterodimer formation 173 
2 Lipoproteins, LTA, PGN, 
lipoarabinomannan 
- Possible S protein recognition 174 
3 dsRNA - dsRNA is replicative intermediate of FCoV 93 
- TLR3 has a protective role in MHV and SARS-CoV 175,176  
4 LPS - Recognition of viral structural protein in other viral species 
169,173 
5 Flagellin - None known 173 
6 Lipoproteins, LTA, PGN, 
lipoarabinomannan 
- Possible role through TLR2 heterodimer formation 173 
7 ssRNA - Predicted FCoV genome recognition  
- Possible inhibition by viral PLpro 113  
8 ssRNA - Predicted FCoV genome recognition  
9 Unmethylated CpG motifs - Possible inhibitory effect on viral replication 167 
 
LPS was the first identified TLR trigger, 20 years ago, with many more discovered since 177. Despite 
crossover with other sensing systems and redundancy between TLRs, loss of one can markedly 
increase susceptibility to specific agents 178. 
TLRs have three domains, an extracellular ligand binding domain specific to each, a 
transmembrane domain, and a cytosolic signalling domain, TIR, standing for Toll-interleukin 1 
receptor homology domain 169. They are grouped by family and by cellular localisation. Though 
mainly active in macrophages, dendritic cells, and B cells they can be expressed by many more cell 
types 178. The TLR1 family includes TLR 1, 2, 6, and 10, and occurred by evolutionary duplication. 
These usually form heterodimers involving TLR2 upon ligand recognition and as such allow a 
greater diversity of detection and response 179. The TLR1 family, plus TLR4 and 5 are found on the 
cell surface and, correspondingly, predominantly recognise membrane components. TLR 3, 7, 8, 
and 9 on the other hand are found within intracellular vesicles and recognise nucleic acid. The 
vesicle shields cellular nucleic acids from the TLRs to prevent auto-immune reactions, whereas 
extracellular free nucleic acids (e.g. following cell damage) are quickly degraded by nucleases. The 
intracellular TLRs require an acidic environment to function; drugs that prevent this from forming 
can also block TLR signalling 178. 
Despite the degree of overlap, there is also huge scope to tailor a specific immune response by 
means of downstream signalling pathways. It remains in many cases to be elucidated exactly how 
a cell is able to correlate different ligands and responses. TLR signalling requires association of 
their TIR-domain with the TIR-domain of an adaptor protein, which occurs following ligand binding 
and induction of conformational changes 178. All TLRs except TLR3 are able to signal through the 
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adaptor protein MyD88, with some being completely dependent on it 178. This pathway usually 
leads to MAP kinase and NF-κB activation with induction of inflammatory cytokines 178. These 
pathways are summarised in Fig. 2.4. 
TLR3 and 4 use the alternative pathway activated by TRIF and culminating in interferon regulatory 
transcription factor (IRF)3 and NF-κB activation which induce type I interferons (IFN) as well as 
inflammatory cytokines 172. 
The response to TLR4 activation is stage dependant, with early and late phase responses. It is able 
to activate two distinct signalling pathways, with an early phase MyD88 dependant pathway and 
a late phase TRIF-dependant 180. Activation of only the TRIF-dependant pathway can induce type I 
IFN, whereas for inflammatory cytokine induction a more robust activation involving both 
pathways is required 180. This implies a level of ‘brake’ on the immune system with a first defensive 
option which is less potentially aggressive to the host itself 180. 
In comparison to bacteria, viruses lack common conserved features, therefore nucleic acid 
recognition is used. This is despite it being a slightly risky strategy on account of potential overlap 
with host nucleic acid 181. Host RNA, if released from damaged cells, is usually broken down rapidly 
by extracellular RNAses 169. In contrast, viral RNA is first contained within viral particles and then, 
upon uptake into phagosomes, released from the particle for detection by PRRs. 
As shown in Table 2.1, many TLRs are known to have a role in viral sensing. TLR3 recognises dsRNA 
(with polyI:C the synthetic analogue) which comprises the nucleic acid of all Baltimore group III 
viruses e.g. the Reoviridae, or can be an intermediate replicative stage of ssRNA viruses, including 
the group IV (+)ssRNA Coronaviridae 93,182; interestingly, negative stranded viruses do not produce 
detectable amounts of dsRNA during replication 182. TLR 7 and 8 recognise ssRNA, whilst TLR9 is a 
DNA sensor but may also detect CpG motifs within RNA sequences 183. Humans but not mice use 
TLR8 as a ssRNA sensor 184, the TLR8 has not been characterised in the cat. The precise motif for 
TLR 7 and 8 is as yet unknown 182.  
In line with their role in viral defence, these intracellular TLRs (3, 7, 8, and 9) strongly upregulate 
type I IFN as well as inflammatory cytokines, the latter being the most common result of 
stimulation of other TLRs. There are two pathways; via signalling adapter TRIF to IRF3 
phosphorylation to type I IFN transcription and translation, or via IRF7 transcription factor. The 
latter is downstream of TLR 7 and 9, primarily expressed in plasmacytoid dendritic cells and 
specialised to produce high levels of type I interferons 169,185. It is thought that this is owing to 
these cells’ high IRF7 levels, but delivery of TLR 7 and 9 to early endosomes in macrophages 
produces the same result 186. Plasmacytoid dendritic cells (pDCs) are the main expressors of TLR 7 
and 9 and are one of the two principal specialised subtypes of dendritic cells. They are 
characterised by distinct cell surface molecule expression in humans and mice, requiring further 
study in cats 185,187,188. pDCs are specialised in sensing nucleic acids and are the primary type I 
interferon secreting cells of the immune system 188,189. 
Viral proteins are also in some cases able to stimulate TLR pathways though this is relatively        
rare 169. Viruses have an inherently high mutation rate, therefore they are often able to evade 
immune detection by alteration of their surface expressed proteins (particularly well-known in the 
case of influenza virus for example) 190,191. As the TLRs are highly conserved, for a protein to be 
recognised it follows that the protein must be stable. This implies either that the conformation is 
required for viral function and hence the virus cannot mutate and remain competent, or that 
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receptor recognition is in fact of benefit to the virus. This has been shown in examples which 
induce a marked inflammatory response detrimental to the host 169. 
In addition to these virus specific TLRs, other TLRs have been implicated in detecting viral proteins. 
TLR 2 and 4 in particular have been shown to have a role. TLR2 can recognise viral proteins 
including the SARS-CoV S protein, with a cell type-specific response 174,192. In response to 
experimental vaccinia virus infection for example, macrophage expressed TLR2 led to downstream 
upregulation of inflammatory cytokines, whilst the same receptor expressed instead on 
monocytes led to type I IFN upregulation 192. This is in contrast to the production of only 
inflammatory cytokines following bacterial ligand recognition 192. As FCoV may infect both 
monocytes and macrophages, the same trigger may hypothetically induce both a pro-
inflammatory cytokine and an interferon response via TLR2 signalling. 
Unmethylated CpG motifs within bacteria were the first TLR9 ligands identified 193. More 
accurately, these motifs were previously known to stimulate a marked, and often fatal, 
inflammatory response via an unidentified signalling pathway 194. Having identified a new receptor 
which they named TLR9, Hemmi et al. tested the response of different knock out (KO) mice to CpG 
DNA challenge. TLR2 or 4-/- mice behaved as wildtypes, whilst TLR9-/- or MyD88-/- mice mounted 
no inflammatory response to challenge 193. This demonstrated both the key role of TLR9 as well as 
the common signalling pathway with TLR2 and 4. In this study the spleen was the main source of 
TLR9 mRNA expression but other haematopoietic organs were not   compared 193. 
Since this discovery, many DNA viruses have also been found to activate TLR9, including herpes-, 
adeno-, and poxviruses 169. RNA viruses are much rarer triggers of TLR9 but examples exist, 
including SARS-CoV and Dengue virus 195,196. Whether this activation is direct or indirect is as yet 
unknown.  
TLR9 is suggested to react to specific CpG motifs; the belief was that mammalian DNA, containing 
four times fewer CpG motifs than bacterial as well as being methylated, did not stimulate this 
receptor. In fact it has been shown that far more important than the sequence is the requirement 
for delivery to the endosomal compartment. This can be induced experimentally by transfection, 
where vertebrate DNA will then stimulate TLR9 197. Although synthetic CpG motifs are used 
experimentally and as adjuvants to stimulate TLR9, it has also been shown that the main role of 
these motifs is in increasing DNA uptake into endosomes and hence exposure to TLR9, rather than 
as a direct trigger 198. 
Serum mitochondrial (mt)DNA, released from cells in trauma patients causes huge TLR9 elevations 
which then upregulate cytokines such as IL-6 triggering an inflammatory state 199. 
Many factors can affect the downstream response to TLR9 binding e.g. early vs late endosomes, 
CpG features, and cell type. Different synthetic CpGs known as oligodeoxynucleotides (ODN) have 
been shown to stimulate different effects. Two classes with different molecular structures are 
defined based on their capacity to stimulate either DCs or B cells 181. These comprise the 
preferentially DC acting type A (CpG-A ODN) and CpG-B ODN, type A remain in the early endosome 
longer, leading to stimulation of type I IFN whereas type B are quickly trafficked to endosomes 
and lysosomes and result in pro-inflammatory cytokine production 178. pDCs are specialised to be 
preferentially driven to type I IFN, regardless of the stimulus 181. 
DCs, regardless of subtype, are specialist antigen-presenting cells whose role it is to alert antigen 
specific cells of the adaptive immune system to the presence of said antigen 200,201. They do this 
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by surface presentation of antigen by the MHCII molecule whilst simultaneously expressing co-
stimulatory molecules such as CD80, CD86, and CD40. These co-stimulatory molecules, and MHCII, 
are upregulated following TLR ligand recognition allowing presentation of antigen to T cells; thus 
linking the adaptive and innate immune responses 164. Furthermore, different DC subsets can react 
to triggering of the same TLR by the same ligand in different ways 164.  
The role of TLRs in disease is complex; they have been variably implicated in both defence and 
induction of disease, and as such targeted therapeutics may aim to either stimulate or antagonise 
them 202.  
 
Figure 2.4: Schematic summary of the main TLR signalling pathways, including receptor location, 
adaptor proteins utilised, and transcription factors induced. Compiled from  172,178,179,203.  
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Cytokines [IL-1β, IL-6, IL-10, IL-15, IL-17, TNF-α, TGF-β] 
Cytokines were first discovered in the 1970s and first named according to their producing cell e.g. 
lymphokine, but this soon proved impossible and the name cytokine took over 204. With the 
exception of erythrocytes, all mammalian cells can produce and respond to cytokines though cells 
of the immune system are of course specialised in this role 204. Evolutionarily they can be traced 
almost as far back as TLRs, with cytokine-like activity observed in Drosophilia 205. Cytokines are 
divided by biological properties and family although huge overlap exists, indeed redundancy and 
pleiotropism are one of the defining features of these molecules. They are non-structural 
signalling proteins, usually signalling as soluble extracellular factors although some remain 
tethered to cell membranes 204. It is difficult to classify cytokines into those with beneficial or 
detrimental effects, as even for a given disease their effects are often influenced by their 
concentration/dose and by the general cytokine milieu. In general they are highly potent, in 
comparison to e.g. hormones 204. 
Cytokines are closely linked to TLRs not only via signalling pathways but also because their 
receptors share a conserved intracellular signalling domain, Toll-IL-1-Receptor (TIR; see above) 206. 
Triggering of TLR pathways can induce a cytokine storm which should spontaneously subside when 
the infection is controlled and cytokine genes are again repressed by histone    acetylation 204.  
Amongst their myriad roles, cytokines are key determinants of lymphocyte differentiation, which 
itself is critical to host immune response and disease outcome 207. 
From naïve precursor cells, T cells have many differentiation options open, determined by 
interactions with antigen-presenting cells, the cytokine milieu and multiple other variables. T 
helper cells are antigen specific effectors, which may be of different subsets depending on the 
direction of differentiation 208. The naïve T helper cell is first activated by interaction of its TCR (T 
cell receptor) with antigen presented by an MHCII molecule. Subsequent division of this T cell 
leads to progeny all recognising the same antigen. All are CD4+ and may be of Th1, Th2 or Th17 
phenotype 208. Th1 cells are thought to be crucial to defence against FCoV as this is the subset 
specialising in defence against intracellular pathogens, and in particular viruses. Induced by IFN-γ 
and IL-12 they secrete mainly IFN-γ 209. Th2 cells upregulate antibody secretion by production of 
cytokines including IL-10 208. The Th17 subset was discovered later, and secretes amongst other 
cytokines IL-6, IL-17 and TNF-α. Th17 cells have an important role in inflammation and neutrophil 
activation. Once T cells are driven in one direction, specific cytokine genes are activated. Genes of 
opposing subtypes are then suppressed, leading to stabilisation and potentiation of the  
phenotype 210. The majority of TLR induced cytokines favour a Th1 phenotype 164. 
Many studies on FIP have examined cytokines in various tissues and at various stages of disease 
in an attempt to establish a cytokine expression profile, yet results are inconsistent. Results of 
these studies are summarised below whilst cytokine effects in FIP which are predicted from the 
results of other studies are described with the individual mediators. Overproduction of pro-
inflammatory cytokines in FIP is thought to be a key feature of disease progression but the precise 
source is unknown. 
The Th1/Th2 balance is of frequent interest, testing the supposition that a Th2 biased antibody 
response is detrimental 22. Following experimental infection of kittens with FIPV, an initial small 
increase in PBMC mRNA levels of IL-6 (a typical Th2 cytokine) and IFN-γ (a typical Th1 cytokine) 
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was observed following infection. As disease developed, IL-6 remained the same and IL-10 and 
IFN-γ became depressed 134, suggesting a lack of cell-mediated immunity. 
Another study evaluated blood samples from immunised and challenge exposed cats, finding 
elevated TNF-α mRNA levels in all cats succumbing to disease together with unchanged or reduced 
IFN-γ. Only one of two surviving cats exhibited a strong IFN-γ elevation but neither upregulated 
TNF-α. IL-6 was unaltered, again suggesting a lack of cell-mediated immunity 24.  
Dean et al. evaluated different lymphoid tissues following experimental infection for both cytokine 
mRNA expression and presence of FCoV as determined by PCR 47. They found a majority of central 
lymphoid tissues (mediastinal and mesenteric lymph nodes, spleen) to be qPCR positive for FCoV, 
but only a minority of peripheral lymphoid tissues, such as popliteal lymph node. The latter were 
more likely to have lymphoid hyperplasia whilst lesions in central lymphoid tissues co-localised 
with virus, showing lymphoid depletion and pyogranulomatous inflammation. Correspondingly, 
leukopaenia was mainly represented by a decrease in lymphocytes. IL-10 was much higher in FCoV 
positive than negative central lymphoid tissue and an increased IL-10:IL-12 ratio suggested a Th2 
bias. A later study on cytokine mRNA levels in haemolymphatic tissues compared bone marrow, 
spleen and mesenteric lymph nodes (MLN) of FCoV infected cats with and without FIP. The bone 
marrow showed no changes whilst IL-1β, IL-10 and TNF-α levels were higher in FCoV infected cats 
without FIP in the spleen. In the MLN, IL-1β and IL-6 were higher in FIP but TNF-α was lower 48.  
Some of these effects are summarised in Fig. 2.5. 
 
Interleukins [IL-1β, IL-6, IL-10, IL-15, IL-17] 
Interleukins, as the name suggests, are a group of cytokines predominantly allowing 
communication between leukocytes including over 40 cytokines 207. 
IL-1 was originally used to define a monocyte product and is now the name of a family, which 
includes IL-1α, IL-1β, and others. The IL-1 family, with currently 11 members, is the family most 
associated with innate immunity but also has a role in acquired immunity 206,211. IL-1β is secreted 
as a precursor protein which must be cleaved by IL-1 converting enzyme (ICE, aka caspase-1), 
present within the inflammasome; an intracellular complex of molecules including NLRP3 
(nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3) 206,212. 
Caspase 1 inhibitors lead to accumulation of precursor protein which is not then cleaved to the 
secreted form. IL-1 may also be cleaved by other mechanisms, e.g. following the death of 
neutrophils in an area of inflammation, the released pro-IL-1 may be cleaved extracellularly by 
common neutrophil proteins such as proteinase-3. The IL-1 family also has inhibitory members 
including IL-1R2 and IL-1Ra. IL-1 signalling activates both MAPKs and NF-κB leading to further pro-
inflammatory cytokine expression. Mice deficient in IL-1 exhibit no spontaneous disease but have 
abnormal reactions to inflammatory stimuli 206. IL-1β is pyrogenic, induced through TLR signalling, 
and able to exert positive feedback on itself and remain high in the absence of microbial  
stimulants 206,213. 
IL-6, now a prototypic member of its own family, was first discovered in 1973 as a soluble factor 
involved in antibody production 214. It has had multiple previous names reflecting the functions 
that were attributed to it, including hepatocyte-stimulating factor and B cell differentiation factor, 
before it was discovered that all were one molecule. It is important in the maturation of B cells to 
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plasma cells, with plasma cells being a feature of chronic FIP lesions 44,215. Antibody production is 
also stimulated; the observed hypergammaglobulinaemia and ADE in FIP 22,61,216 may therefore be 
connected. Chronic stimulation of plasma cells by IL-6 has been shown to lead to the production 
of auto-antibodies 216. Synthesised early in infection, IL-6 induces acute phase protein production 
and reduces the production of albumin in the liver 217; the latter may help contribute to the 
lowered A:G ratio in FIP. Following IL-6 receptor binding, JAK-STAT signalling is activated, leading 
to phosphorylation of STAT3. Soluble decoy receptors exist to counter its effect. In conjunction 
with TGF-β IL-6 pushes Th-17 differentiation in T cells 209. It also helps with the link between innate 
and adaptive immunity and inhibits the TGF-b induced Treg differentiation. An upregulated 
Th17/Treg balance has been shown to contribute to chronic inflammation 216. CD8+ differentiation 
to cytotoxic T cells, VEGF production, and vascular permeability are additionally stimulated 218,219. 
Many cells produce IL-6, including leukocytes, endothelial cells, and mesenchymal cells 220. 
Expression must be tightly regulated as IL-6 production warns the body of an emergency 216. IL-6 
mRNA expression and degradation are regulated both transcriptionally and post-transcriptionally 
so that levels of several proteins and microRNAs determine its fate. One of these methods is by 
microRNA inhibition of STAT3, the main IL-6 activated transcription factor 216. IL-1b, TNF-a and 
TLR signalling can all upregulate IL-6 216. The products of some viruses, including HIV and hepatitis 
B virus, enhance the binding potential of transcription factors upstream of IL-6, including NF-κB 
and NF-IL-6 (nuclear factor IL-6 aka IRF1) 216. Conversely, activation of the glucocorticoid receptor 
can repress transcription of IL-6, this is thought to be one of the anti-inflammatory mechanisms 
of glucocorticoid drugs; they are often used in FIP though with limited success 216,221. IL-6 signals 
via a hexamer consisting of two of each molecule of IL-6, IL-6R and gp130; viral encoded IL-6 in 
KSHV infection can replicate native IL-6 and induce signalling 222. Discovery of the molecular make 
up of IL-6 receptor helped solve the mystery of cytokine redundancy and pleiotropy 223. gp130 is 
the signal transducing domain of the IL-6 receptor and has a broad range of expression 224. The IL-
6R may be membrane bound or soluble and when soluble it can then bind gp130 on any cell, 
known as trans-signalling. However, only select cell types express IL-6R meaning only these cells 
can respond directly 225. Soluble gp130 also exists which can buffer IL-6 until its levels are 
overcome 226. 
Following binding, IL-6 signals mainly via STAT3, but may also, less preferentially, use STAT1 and 
MAPK 216,226. A negative feedback loop suppresses signalling and is designed to prevent an 
excessive inflammatory effect 227.  
In the presence of IL-6, neutrophils are released more rapidly from the bone marrow, and exhibit 
enhanced chemotaxis in response to IL-8, but there is no apparent effect on survival 226. This likely 
explains the early discovery that culture supernatant from cells within FIP ascites is chemotactic 
for neutrophils, as high IL-6 levels have been found in the ascites of cats with FIP, and cells within 
the abdominal exudate were shown capable of its production 228,229. Serum levels of IL-6 in these 
cats did not differ greatly from the control cats, further supporting local production and effect 229.  
IL-10 is also the head of a family of the same name, all typically anti-inflammatory. It was first 
named cytokine synthesis inhibitory factor before being designated a member of the interleukin 
family 230. IL-10 inhibits production of IL-1β, IL-6, TNF-α, G-CSF and GM-CSF at the transcription 
level in stimulated human monocytes 230. It also reduces MHCII expression from monocytes 
following LPS activation and is auto-regulatory 230. IL-10 deficient mice develop spontaneous 
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inflammatory diseases which are often fatal 204. Some viruses (including beta and 
gammaherpesviruses, though not coronaviruses) even encode their own IL-10 to act as an 
immunosuppressant including inhibiting IFN-g 231.  
IL-15 is a T cell regulator and is a part of the four alpha helix bundle cytokine family. It signals 
through a heterodimeric receptor combination 232. Rarely for a cytokine its main method of 
signalling is through cell contact and it is produced by a wider cell range than most cytokines 233. 
One of its main roles is in regulating cytotoxic lymphocyte function, giving it the potential either 
to help remove infected cells or to trigger widespread cell destruction if over or aberrantly 
produced 232. This may be of relevance in the observed lymphocyte apoptosis in FIP 63. 
The IL-17 family includes IL-17A (referred to simply as IL-17), and IL17B-F. Their major source is 
specialised T cells, the Th17 subset, active in innate immunity 234. This subset has its own novel 
differentiation factors, including STAT3, which are distinct from Th1 and Th2 235. IL-17 is 
predominantly pro-inflammatory with downstream induction of other inflammatory cytokines 234. It 
is often implicated in auto-immune disease or chronic inflammation, in particular as a triad with IL-6 
and STAT3, two molecules with a main regulatory role in Th17 function, along with TGF-β 236,237. Th17 
differentiation requires cooperation between two cytokines (IL-6 and TGF-β) of opposing function 209. 
IL-17 also has a defensive role, predominantly against bacteria at mucosal barriers; Th17 cells are able 
to mount a swift first line response to antigens by producing immunoregulatory mediators 234.  
 
Tumour necrosis factor alpha (TNF-α) 
The TNF superfamily consists of type II transmembrane proteins which are primarily produced by 
macrophages. They are secreted as transmembrane precursors of 26kDa which are cleaved to a 
17kDa soluble form by TACE (TNF-a converting enzyme) before trimerising. The soluble form is 
the most potent. However the remaining membrane portion is further cleaved before 
translocating to the nucleus and itself inducing pro-inflammatory signalling 211. TNF-a can signal 
through two receptors, sharing less than a third homology and with distinct biological effects. 
TNFR1 is the more important of the two receptors and has a death domain, allowing it to induce 
inflammation or apoptosis. Receptor binding is first possible at the cell membrane, forming 
complex I which leads to pro-inflammatory gene expression. If this fails, there is the opportunity 
for complex II to form intracellularly which instead has apoptosis as its downstream effect, i.e. 
defence as the first step followed by cell suicide should the defence fail 238. 
TNF-a has myriad roles in inflammation, including triggering lipid mediator expression on vascular 
endothelium which promotes oedema, as well as adhesion molecule expression 211. Adhesion 
molecules have been shown to be upregulated on peripheral leukocytes in FIP, as has CD18 on 
both intravascular monocytes and perivascular macrophages 42,239. 
In vitro, TNF-α production by FIPV infected macrophages upregulates expression of the APN 
receptor, which is used by FCoV serotype II. Alveolar macrophages from cats with FIP have higher 
levels of both APN and TNF-α. Both virus titre and TNF-α are higher in macrophages cultured with 
virus and anti-S protein antibody than controls or those cultured with only one of these, 
demonstrating in vitro ADE. The supernatant of these dual cultured cells also induced higher levels 
of apoptosis in PBMCs 99,240.  
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It has been postulated that in FIP, TNF-α from lymphocytes induces apoptosis 47. Ascitic fluid from 
cats with FIP had previously been shown to induce lymphocyte apoptosis in vitro, as had TNF-α 63. 
 
Chemokines [CCL8 and CXCL10] 
Both CCL8 and CXCL10 have been found to be upregulated in vitro in FIPV infection of CRFK          
cells 241,242. 
The chemokines are divided into two main groups, the CC and CXC classes based on their   
structure 211. Two further but less common subgroups exist, the C and the CXC3 subfamilies. All 
are small 8-12 kDa proteins which induce cell migration from the blood into target tissues 211. They 
and their antagonists are seen as promising therapeutic options 243. Initially, these molecules were 
classified as inflammatory or homeostatic, but several have since been shown to be dual function 
proteins 244.   
Chemokines elicit their effect by binding seven-transmembrane G protein-coupled receptors, with 
uncoupled decoy receptors also existing which act as inhibitors and provide an extra layer of 
modulation potential 244. 
As with the cytokines, there is extensive pleiotropy making extrapolation of individual functions 
difficult 243. CCL8 (monocyte chemotactic protein (MCP)-2) is classified as an inflammatory 
cytokine involved in innate and adaptive immunity, able to bind CCR1, 2, 3, 5, and 11 211,243,244. 
CXCL10 (IFN-γ-inducible protein (IP)-10) on the other hand is a dual function chemokine involved 
in adaptive immunity which attracts CXCR3+ cells. These cells tend to be CD4+ T cells with 
subsequent Th1 differentiation and are a promising target for therapeutic intervention 211,244. In 
addition to attracting CXCR3+ cells, CXCL10 blocks CCR3- cells (preferentially expressed by Th2), 
further contributing to a Th1 polarisation 244. These effects should be beneficial in FIP. 
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Figure 2.5: Hypothesised contribution of inflammatory mediators to the pathogenesis of FIP, following 
on from Fig. 2.4. 
 
Transforming growth factor (TGF)-β 
TGF-b was found in one study to be present at very low levels in the ascites of cats with FIP 63, but 
appears otherwise to not have been of much interest in FIP studies.  
TGF-b is produced as an inactive compound requiring activation; this step is an important layer of 
regulation 245. It classically signals via Smad pathways but may also use MAPK, PI3K and  others 246. 
Simultaneously it stimulates self-regulatory pathways 245. TGF-b plays a crucial role in regulating T 
cell activation; TGF-β-/- mice die early from multi-organ inflammatory disease with widespread T 
cell activation and wasting 247. 
TGF-b has context dependant effects on T cells 245. It promotes apoptosis of CD8+ T cells to limit 
clonal expansion after activation by reducing anti-apoptotic Bcl2 and upregulating pro-apoptotic 
Bim 248,249. However, it may also promote survival by blocking FasL-mediated apoptosis 250. 
Lymphocyte apoptosis, particularly of T cells, is a recognised feature of FIP 44,63,251. Overall TGF-b 
has mainly anti-inflammatory functions, enhancing Treg differentiation together with IL-2, and 
blocking both Th1 and Th2. Together with IL-1β and IL-6 it is able to stimulate Th17, it is rare that 
Th17 cells can develop in the absence of TGF-β 245. The concentration of TGF- β may determine 
whether a T cell becomes an induced Treg or a Th17 cell. Another indirect mechanism of Th1 
inhibition is by inhibition of IFN-g production; interfering with the positive feedback loop between 
IFN-g and Th1 245. Though Th1 responses appear to be the initial targets, Th2 responses can also 
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be potently downregulated by TGF-β 249. Induced overexpression of TGF-β in mice can protect 
them from the effects of allergic airway disease 252. 
 
Type I interferons [IFN-α and IFN-β] 
The type I interferons (IFN) include IFN-α and IFN-β, cytokines specialised in anti-viral              
defence 253,254. These cytokines are intricately linked to the adaptive immune system; phylogenetic 
studies indicate that interferons developed in jawed vertebrates in parallel with it. The adaptive 
immune system, in contrast to the innate, requires B and T cells; no species has been found which 
has these cells without having IFN-a and -b and vice versa 254.  
Two pathways can induce type I IFN; one pathway includes ubiquitous cytosolic receptors for 
PAMPs such as RIG-1 and MDA5, requiring the cell to be infected (cell-intrinsic). The second 
pathway involves the TLRs and can be used by uninfected cells (cell-extrinsic innate immune 
recognition) 170. This is possible as antigen can be presented either at the cell membrane or in 
endosomes following processing. Those TLRs which induce type I IFN tend to be those which 
detect nucleic acids, with the exception being TLR4 which detects LPS but can lead to IFN 
production. TLR 7 and 9 are especially responsible for the high type I IFN levels observed in many 
experimental viral infections, they are (seemingly uniquely amongst the TLRs) expressed by both 
conventional and plasmacytoid dendritic cells rather than just conventional dendritic cells. The 
intracellular TLR 3, 7 and 9 require an acidified endosomal compartment; if TLR9 is relocated to 
the cell membrane it can no longer recognise its ligand 255. 
Almost all cells can produce type I IFNs and one of the main roles of these proteins is to restrict 
viral replication. Downstream effects are focussed on inducing an antiviral state, with the aim 
being to make the cell an inhospitable host for the virus, these effects include induction of 
apoptosis and the shutting down of protein translation. Signalling through STAT1 and STAT2 
represents the canonical pathway of type I IFNs. Type I IFN signalling also leads to differentiation 
and activation of natural killer (NK) cells, which are able to kill virally infected cells using MHC 
downregulation in an attempt to evade the immune system 254. The IFN-stimulated gene factor 3 
(ISGF3) complex is formed by interferon regulatory factor (IRF)9 and phosphorylated STAT1 and 2 
coming together following type I IFN binding of its receptor 256. This complex then binds IFN 
stimulated response elements (ISRE) in gene promoters, leading to hundreds of IFN-stimulated 
genes (ISGs) being transcribed 256. This is summarised in Fig. 2.6. These genes function to control 
viral infection but also infection by other pathogens. To enhance the anti-viral response they 
include the PRRs, STAT1 and 2, and IRFs, providing a positive feedback mechanism 256. Induced 
proteins have a more direct antiviral effect, e.g. viperin, which is upregulated in FCoV infected 
CRFK cells in vitro, and serves to inhibit viral egress 241,256. 
 
Type II interferons [IFN-γ] 
IFN-γ mRNA levels within lesions of FIP have been examined previously by RT-PCR and found to 
be increased 257. This was supported by the finding of higher IFN-γ protein levels in effusions than 
serum of cats with FIP 258. The same study found that serum levels of IFN-γ were higher in healthy 
FIP in-contact cats than either unexposed or FIP cats, suggesting a protective effect. A separate 
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study found that mRNA levels of IL-1β and IFN-γ both peaked in the whole blood of healthy cats 
following exposure to another cat with FIP, with the same implication 259. 
IFN-γ is the only type II IFN. It has no structural homology with type I IFNs but was originally 
classified together with these owing to their ability to ‘interfere’ in viral replication, there is 
significant overlap between the downstream effectors of type I and II IFN 260. IFN-γ is 
predominantly produced by T cells and NK cells 261. Although IFN-γ production is restricted to 
certain cell types, almost all cells express the receptor and are hence able to respond 262. Canonical 
signalling involves IFN-γ dimerisation and subsequent binding to the IFNGR. Receptor chains bind 
JAK 1 and 2 which in turn phosphorylate STAT1, which translocates to the nucleus and binds 
gamma interferon activation site elements (GAS) 263. In the absence of STAT1, STAT3 may be 
activated, along with other non-canonical pathways which involve various responses to IFN-γ 263. 
IFN-γ does not induce the ISGF3 complex as type I IFN do, so it cannot induce genes with only an 
ISRE and not a GAS in their promoters 260. 
Chronic exposure to a low level of IFN-γ can prime cells and lead to overreaction to stimuli, the 
type I and II IFNs become able to utilise each others signalling pathways and hence amplify their 
effects 263.  
Mouse hepatitis virus (MHV) is another CoV existing as two biotypes; enterotropic and      
polytropic 264. IFN-g-/- mice also develop FIP like lesions in response to the enterotropic form which 
exogenous IFN-g can partially dampen 265,266. Interestingly, even in the highly controllable 
environment of experimental mice, with controlled genotype and virus dose, the disease was not 
reliably reproducible 266. IFN-g-/- mice are also able to sustain the replication of MHV, unlike 
wildtype mice 267. 
 
Colony stimulating factors [G-, M-, GM-CSF] 
The colony stimulating factors (CSFs) are members of the cytokine superfamily, first named CSF-
1, -2, -3 for their ability to act as growth factors for haematopoietic cells in vitro. They have since 
been renamed monocyte (M)-CSF, granulocyte monocyte (GM)-CSF and G-CSF respectively. The 
CSFs have overlapping but non-redundant roles. M-CSF is important in homeostasis, being 
detectable in plasma and constitutively expressed by many cell types including macrophages, 
endothelial cells, and fibroblasts 268. GM-CSF is more involved in inflammation and as such is 
mainly produced by activated leukocytes 269. A slightly oversimplified version of their effect on 
mature cells is that they induce an anti- vs pro-inflammatory state (M vs GM-CSF) in macrophages. 
Both M- and GM-CSF, derived from a fibroblast lineage, are commonly used to direct bone marrow 
derived cell differentiation in culture 270,271. 
 
Matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases 
(TIMPs) [MMP-2, -9, -13, TIMP-1, -3] 
MMP9 was found in intravascular monocytes and occasional perivascular infiltrating macrophages 
of FIP lesions and is believed to contribute to basement membrane destruction as a byproduct of 
monocyte emigration 42. 
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MMPs are a family of zinc dependant endoproteinases which function in tissue remodelling as 
well as processes such as cell proliferation and migration, through their ability to degrade 
extracellular matrix components 272. Over 25 MMPs have so far been characterised in     
vertebrates 273. These are grouped and subgrouped. There are four groups, including archetypal 
MMPs and gelatinases. Within the archetypal enzymes are the collagenases, and the stromelysins. 
The former comprise three MMPs including collagenase-3 or MMP-13 which was chosen for the 
present study. In addition to collagen, these enzymes are able to process a number of molecules 
to their active form, including TNF-a 274. The gelatinases are MMP-2 and MMP-9, otherwise known 
as gelatinase-A and -B. They have a broad spectrum of substrates, overlapping with the 
collagenases, which includes components of the basal membrane, collagen IV and laminin 275. 
MMP-2 and -9 can also cleave cytokines including TNF-a, TGF-b and IL-1b, and monocyte 
chemoattractant protein (MCP)-3 to their active forms 274,276. Gene expression is regulated 
primarily, though not exclusively, at the transcriptional level, making RT-PCR a meaningful method 
of measurement 277. Physiological transcription is usually at a low level and there is often co-
expression in response to stimuli as a result of shared promoter elements 278. Some MMP genes 
e.g. MMP-2 have reduced regulatory elements in their proximal promoters and are therefore less 
responsive to stimuli and more important constitutively 279. In inflammation, cytokines such as IL-
1b and TNF-a activate signalling pathways with intermediates including NF-kB, MAPK, and STATs 
which can induce MMP transcription 280. STATs may also inhibit transcription by sequestering 
required proteins (e.g. c-jun) as may occur with MMP-9 and MMP-13. MMP-13 may be induced 
by TGF-b via Smad proteins and MAPK pathways 281,282. In addition to regulation at the 
transcriptional level, and by various post-transcriptional methods, levels are also controlled by 
endogenous inhibitors 273,283. The major inhibitor types are a2-macroglobulin and TIMPs; the 
former are acute phase proteins but do not have a major role in cats 284. Three TIMPs are 
described, of which TIMP-3 appears to be the least redundant in vivo. In addition to targeting 
MMPs, they may also inactivate other enzymes. One of these is thought to be ADAM17 (TACE), as 
TIMP-3-/- mice exhibit inflammatory changes owing to elevated TNF-a levels 283.   
 
Signal transducers and activators of transcription (STATs) 
The JAK-STAT signalling pathways are an essential, extensively studied, and highly conserved, 
aspect of cytokine receptor signalling 285. These have not yet been studied in FIP. JAK-STAT 
pathways are responsible for controlling gene expression downstream of cytokine receptor 
binding, and as in most signalling systems there are elements of both redundancy and       
pleiotropy 286. The JAK family has four, and the STAT family seven members which may combine 
to induce different downstream effects. However, the same combinations can also induce 
different effects. As such, a response may be cell specific or molecule specific. IL-6 for example 
classically signals via STAT3, as does IL-10, though the two induce conflicting downstream 
transcription 287. IL-10 may also use STAT1 288. 
Knock out mice for each STAT have been studied, with some (e.g. Stat3-/-), being embryonically 
lethal 287. The simplified version of the pathway is that the binding of a cytokine to its receptor 
causes association with JAK, phosphorylation of the receptor, and STAT recruitment. The recruited 
STAT is in turn phosphorylated causing it to dimerise and translocate to the nucleus to function as 
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a transcription factor 287. The MAP kinase pathways are the other main pathways involved in 
cytokine signalling.  
The pathogenesis of SARS-CoV has been linked to STAT1, STAT1 being of more importance than 
either type I, II, or III IFNs in determining disease outcome. Experimentally infected STAT1-/- mice 
developed severe disease in contrast to a wild type phenotype exhibited by any of the interferon 
knock out mice 289.  
 
Figure 2.6: IFN signalling through JAK-STAT pathways and its downstream effects. Compiled                 
from 63,129,256,259,260,290. 
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The molecules discussed here comprise only a fraction of those involved in regulating the immune 
response to viral infection, but have been chosen to represent different levels of signalling 
pathways from receptors to responders. The ability to respond to stimuli is not restricted to 
leukocytes but these cells are of course those tasked with the greatest responsibility in regulating 
immunity. As such, haemolymphatic tissues with their role in producing and moulding leukocytes 
are among the first tissues of interest in studying FIP.  
The MLN are at the gateway between the intestine, with its direct exposure to the outside world, 
and the rest of the body. In terms of exposure to orally derived bacteria they act as a firewall and 
are of great importance in inducing immune tolerance 291. The MLN are known as the site of ‘first 
pass’ as antigens or pathogens entering the intestinal lymphatics are first directed here, where 
the MLN ‘decides’ whether to pass on the possible threat to the systemic immune system 292. In 
FCoV infection, induction of tolerance to the virus could be seen as a highly beneficial process. 
Cats may be long term or transient systemic carriers without disease and in these carriers, beyond 
the colon the MLN are one of the most frequently virus positive tissues 293. For this reason, the 
immune status of this organ and its potential positive or negative effects warrants more in depth 
study.  
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Aims and Hypotheses 
 
Aims 
• Design and or optimise a panel of primer and probe sets for assessing inflammatory 
mediator levels in the cat 
• Assess the role of the mesenteric lymph node in the development of FIP  
• Determine which TLR’s are likely to be involved in the pathogenesis of FIP 
• Screen samples for the presence of coronavirus and viral S gene mutations and assess 
relationship between viral load, disease state, S gene mutations and the inflammatory 
response 
• Determine which cell pathways are upregulated in FIP and whether this is more specific 
to the presence of disease or virus 
• Determine cell type expression of significant TLRs and assess co-localisation to FCoV-
infected cells  
 
Hypotheses 
• FCoV infection without disease induces a specific immune mediator expression profile, 
distinct from that in uninfected cats or those with FIP 
• There is a skew towards a pro-inflammatory rather than an interferon dominated 
response in cats with FIP 
• The anti-viral, RNA detecting TLRs 3, 7, 8, and 9 are failing to adequately respond to 
infection whilst the more pro-inflammatory TLR2 and 4 are upregulated in FIP 
• The mediator response is enhanced within the lesions themselves  
• The response to virus is more pronounced locally than systemically 
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Materials and Methods 
 
Case Material 
A number of different approaches were taken to address the aims of the project, as shown in Table 
4.0.1. Cases were prospectively obtained in collaboration with the University of Zurich Small 
Animal Clinic and local veterinary practices. Retrospective cases were available from the University 
of Bristol’s existing biobank of cases which had been seen in the university clinic and surrounding 
practices (Table 4.0.1). All animals were client owned cats euthanased on purely clinical grounds. 
Cats were those with a clinical suspicion of FIP, or with unrelated diseases (used as control 
animals). All cats underwent routine diagnostic necropsies with the owners’ full permission, with 
additional histological and immunohistological examination to confirm FIP or an alternative 
diagnosis. Case numbers with corresponding sample numbers and pathological findings are found 
in each chapter where relevant, the signalment of all cases is provided in Tables 4.0.2-4.0.4.  
 
Sampling 
Necropsies were performed within 1 h of death with routine sampling of a standard organ set 
(brain, heart, lungs, liver, stomach, duodenum, pancreas, jejunum, ileum, caecum, colon, 
mesenteric lymph node, spleen, bone marrow, kidney, bladder, [reproductive organs], thyroid 
gland, adrenal gland, pituitary gland; where permitted by the owner), as well as macroscopical 
lesions, into 10% neutral buffered formalin. Additionally, cubes of tissue up to 5 mm in diameter 
were taken at the time of necropsy into RNAlater (Qiagen, Hombrechtikon, Switzerland) for 
subsequent RNA extraction and downstream analysis. These were from bone marrow (BM), 
spleen, mesenteric lymph nodes (MLN), and additional organs e.g. liver, omentum, and kidney as 
part of the biobank development. In some cases, on owners’ request, only selected organs were 
available to sample. After 24-48 h at 4°C in order to allow permeation of the tissues, samples in 
RNAlater were transferred to -80°C for longer term storage. Bristol samples had had the RNAlater 
removed before storage. Within the Zurich cohort, when classical serosal, or pyogranulomatous 
parenchymatous lesions were grossly visible, these were sampled and cryoblocks prepared (see 
chapter 4).  
After at least 24 h and a maximum of 72 h in formalin tissues were trimmed and routinely paraffin 
wax embedded. Sections (3-5 µm) were prepared and stained with haematoxylin and eosin (HE). 
In addition to the histological examination, lesions from FIP cases underwent immunohistology to 
demonstrate FCoV antigen within infected monocytes and macrophages. This was carried out by 
the Institute of Veterinary Pathology Zurich (IVPZ) histology laboratory as previously described 44, 
using a mouse monoclonal primary antibody (clone FIPV3-70 SC 65653, Santa Cruz, Heidelberg, 
Germany). It is a routine accredited diagnostic method (ISO/IEC 17025), further details are given 
in Chapter 4. 
For the purpose of this study, in addition to a routine diagnostic number for each case, a number 
per sample (i.e. organ or selected region) for RT-qPCR was also allocated. Control cats were 
allocated Group 1, and cats with FIP Group 2. 
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Table 4.0.1: Cases used for each section of the study, with origin, original case number and group. 
 
 
 
 
Methods chapters workflow
B15-0467 1 2 3 1- 54
S15-0966 1 2 6 3 1- 56
S15-1783 1 2 3 1- 59
S15-1871 1 1 2 3 3 1- 63
B16-0919 1 2 3 1- 72
B16-0920 1 2 3 1- 80
S17-0409 1 3 6 3 1- 84
S17-0478 1 3 3 1- 87
S17-0480 1 3 3 1- 89-91
S17-0481 1 3 3 1- 104-105
S17-0568 1 3 6 3 1- 115-116
H15-2389 2 2 5 3 1- 118-119
S15-0134 2 2 4 5 3 1- 123
S15-0259 2 2 4 5 3 1- 126
S15-0983 2 2 4 5 (6) 3 1- 136
S15-1094 2 2 5 3 1- 140-141
S15-1368 2 2 3 5 3 1- 143
S15-1539 2 2 3 4 5 6 3 1- 152
S15-1728 2 2 3 (4) 5 6 6 5 3 1+ 38
S15-1738 2 2 3 (4) 5 5 3 1+ 51
S15-1809 2 2 3 (4) 5 5 3 1+ 69
S15-1842 2 2 3 4 5 5 3 1+ 78
S16-0167 2 2 3 4 5 6 5 3 1+ 102
S16-0454 2 2 3 4 5 6 5 3 1+ 125
S17-0124 2 2 3 (4) 5 6 6 5 3 1+ 132
6 5 3 1+ 135
5 3 1+ 149
5 3 1+ 156
5 3 2 30-32
5 3 2 37
6 5 3 2 42
5 3 2 43
5 3 2 46
5 3 2 50
5 3 2 93
6 5 3 2 94
5 3 2 96
5 3 2 100-101
5 3 2 103
5 3 2 121-122
5 3 2 127
6 5 3 2 128
5 3 2 131
5 3 2 142
5 3 2 146
6. RNA-seq
4. LCM of lesions followed by qRT-PCR
↓
(4). Immunofluorescence of lesions
↓
5. Selected FCoV S gene sequencing 
↓
1. qRT-PCR optimisation 
↓
2. qRT-PCR on BM and spleen
↓
3. qRT-PCR on MLN
↓
Zurich cats Bristol cats
Case no. and 
group Chapters used in
Chapters 
used in 
Group and 
case no.
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Table 4.0.2: Signalment of Zurich cases and sample numbers corresponding to organ and chapter. BM: bone marrow; MLN: mesenteric lymph node; LCM: laser capture 
microdissection; NGS: Next Generation Sequencing (RNA-Seq); DSH: domestic short hair; BSH: British short hair; y: years; m: months; M(N): male (neutered); F(N): female 
neutered; CRD: chronic renal disease; CHF: congestive heart failure; DCM: dilated cardiomyopathy. 
Case no. 
Sample numbers 
Group Breed Age Sex Diagnosis in control cases 
BM
 
sp
le
en
 
M
LN
 
LCM/NGS 
B15-0467 1 2   1 DSH Adult MN Intestinal lymphoma 
S15-0966 3 4   1  Adult MN CRD and hyperthyroidism 
S15-1783 5 6   1 DSH 9 y FN Pulmonary thromboembolism 
S15-1871 7 8 50  1 Ragdoll 4.5 y MN CHF and CRD 
B16-0919 9 10   1 DSH Juvenile  Behavioural 
B16-0920 11 12   1 DSH Juvenile  Behavioural 
S17-0409   51  1 Bengal 11 y MN Colonic adenocarcinoma 
S17-0478   52  1  Adult FN DCM, CRD 
S17-0480   53  1 DSH Adult MN Acute myeloid leukaemia 
S17-0481   54  1 Birma 1 y F Hippocampal necrosis 
S17-0568   55  1 House cat 14 y MN Haemorrhage in brain 
H15-2389  13   2 DSH 9 y M  
S15-0134 37 36  122 2 Birma 4 y FN  
S15-0259 35 34  123-125 2 House cat 4 y F  
S15-0983 33 32  116 2 DSH 1 y FN  
S15-1094 31 30   2 DSH Juvenile ME  
S15-1368  16 17  2 Norwegian Forest 8 m MN  
S15-1539 26 25 24 117 2 Maine Coon 1 y MN  
S15-1728 29 28 27 115, 118, 126 2 DSH 6 m MN  
S15-1738 20 19 18 109-114, 127, 128 2  4 m M  
S15-1809 23 22 21 106-108, 129, 130 2  1.5 y MN  
S15-1842 41 42 43 102-105, 137 2 DSH 4 m F  
S16-0167  14 15 119, 131, 132 2 DSH 10 y FN  
S16-0454 44 45 46 120, 133 2 BSH 6 y MN  
S17-0124 47 48 49 121, 132-136 2 Persian 5 m F  
  37 
 
Table 4.0.3: Signalment and sample numbers of Bristol control cat cases. DSH: domestic short hair; DLH: domestic 
long hair; y: years; m: months; M(N): male (neutered;) F(N): female (neutered); HCM: hypertrophic cardiomyopathy; 
IBD: inflammatory bowel disease; FATE: feline aortic thromboembolism; CRD: chronic renal disease. 
Case 
no. 
Sample 
no. 
Group Breed Age Sex Diagnosis 
54 63 1- DSH 8 y MN Chemodectoma 
56 64 1- Birman 13 y   Pyothorax and  pneumonia 
63 65 1- DSH 6 y MN Astrocytoma 
80 66 1-   10 y MN Diabetes mellitus 
84 67 1- DSH 12 y   Aplastic anaemia 
87 68 1- DSH 6 y   Diarrhoea, suspected torovirus 
89 69 1- DLH 8 y   Gastric lymphoma 
90 70 1- DSH 5 y MN Suppurative meningitis 
91 71 1- DSH 3 y MN Lymphocytic cholangiohepatitis 
115 79 1- DSH 2 y MN Hepatitis and pyelonephritis 
116 80 1- DSH 4 y FN Granulomatous rhinitis & encephalitis 
118 81 1- DSH 8 y FN Chronic enteropathy 
119 82 1- DSH 1 y FN Poxviral pneumonia 
123 85 1- DSH 4 y FN Hepatic encephalopathy 
126 87 1- Ragdoll 3 y MN HCM 
136 93 1- DSH 13 y FN Focal intestinal necrosis 
140 94 1- DSH   F Behavioural 
141 95 1- DSH 3 y FN Invasive meningioma 
143 97 1- Maine Coon 9 y   Meningioencephalitis 
152 100 1- DSH 5 y FN Pulmonary adenocarcinoma 
59 154 1- Devon Rex 8 y   IBD 
72 156 1- DSH 9 y MN Multicentric lymphoma 
104 160 1- DSH 10 m MN HCM and FATE 
105 161 1- Bengal 7 y FN Small intestinal neoplasia 
38 60 1+ Maine Coon 1 y   Connective tissue abnormality  
51 62 1+ DSH 3y MN Lethargy, weight loss, anaemia 
102 77 1+ DSH 10 y MN Diabetes mellitus 
125 86 1+ Ragdoll 4 m M Severe interstitial pneumonia 
132 91 1+ Havana 4 y FN Nasal lymphoma 
135 92 1+ DSH 10 y FN Round cell neoplasia 
149 99 1+ DSH 8 y MN Pleural effusion (PCR neg) 
156 101 1+ DSH 18 y FN CRD 
69 155 1+ DSH 10 y MN Lymphoma 
78 158 1+ DSH   F Anaesthetic death 
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Table 4.0.4: Signalment and sample numbers of Bristol FIP cat cases. DSH: domestic short hair; BSH: 
British short hair; y: years; m: months; M(N): male (neutered); F(N): female (neutered). 
Case 
no. 
Sample 
no. Group Breed Age Sex 
30 56 2   3 y   
31 57 2 Burmese 3 m M 
32 58 2 Abyssinian 4 m F 
37 59 2 DSH     
42 61 2 DSH 5 m   
93 72 2 Siamese 1 y   
94 73 2 BSH 10 m MN 
96 74 2 DSH 2 y MN 
100 75 2 Siamese 3 y MN 
101 76 2 Birman 12 y MN 
103 78 2 BSH 1 y FN 
121 83 2 DSH 2 y MN 
122 84 2 Oriental 3 y M 
127 88 2 Birman 8 m M 
128 89 2 Ragdoll 10 m FN 
131 90 2 BSH 2 y MN 
142 96 2 DSH 6 m F 
146 98 2 DSH 1 y   
43 150 2 DSH 4 m   
46 151 2 DSH  7 m   
50 152 2 DSH   M 
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1. Establishment of quantitative reverse transcriptase polymerase chain reaction (RT-
qPCR) protocols 
The first stage of the study was to design, where required, or optimise, two step RT-qPCR protocols 
to study mRNA expression levels of a panel of immune mediators. This panel (Table 4.1.1) was 
chosen as described in the introduction. 
 
Table 4.1.1. Summary of target molecules investigated by RT-qPCR. 
Target group Targets 
Pathogen recognition receptors TLR1-9 
Cytokines and chemokines IL-1β, -6, -10, -15, -17, TNF-α, TGFβ, CXCL10, CCL8 
Interferons IFN-α, -β, -γ 
Transcription factors STAT1-3 
Matrix remodelling enzymes MMP2, 9, 13, TIMP1, 3 
Colony stimulating factors G-CSF, M-CSF, GM-CSF 
 
RNA extraction and cDNA synthesis 
A test sample (spleen cDNA from cat S15-1871) was used for all trials. The RNeasy Plus Mini Kit 
(Qiagen) was used following the manufacturer’s instructions. The kit includes an on column gDNA 
removal step. Briefly, the sample was removed from -80°C and thawed on ice. Approximately 30 
mg of tissue was placed into RNA extraction buffer with added β-mercaptoethanol (Sigma-Aldrich, 
St Gallen, Switzerland) in a 2 ml round bottomed Eppendorf tube. A 5 mm steel bead (Retsch, 
Haan, Germany) was added to each tube and tissues were disrupted using a tissue homogeniser 
(Mixer-Mill 300, Retsch) set to 30 Hz for 40 s before on-column extraction and elution of RNA. Two 
elutes were performed per sample, giving a final elute volume of 80 µl. Multiple extractions were 
performed from the test spleen to obtain sufficient RNA for all trials.  
The High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific; Waltham, MA, USA) 
was then used according to the manufacturer’s protocol; this results in 20 µl cDNA per 10 µl of 
input RNA. Eight reactions were performed per sample (totalling 160 µl) and the cDNA pooled, to 
which 160 µl RNase free water was added. 
 
Primer Design 
TaqMan qPCR requires specifically designed primer probe combinations; published protocols 
utilising a different method e.g. SYBR Green could therefore not be used. For the planned panel 
of markers, a number of suitable protocols were however already published (Table 4.1.2).  
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Table 4.1.2: Primer and probe sequences used for RT-qPCRs and conventional RT-PCRs. 
Gene Reference/Acc. no. Primer and probe sequences (5'-3') where not previously published 
PCR product 
length (bp) 
GAPDH, IL-10 Leutenegger et al. 1999294    
FCoV (RT-qPCR) Gut et al. 1999295    
FCoV (conventional) Porter et al. 2014133    
TLR1, 2, 4, 5 ,6, 7, 9 Ignacio et al. 2005165    
TLR3, 8, IL-15, IFNα, -β 
Robert-Tissot et al. 
2011296    
IL-1β, IL-6, TNF-α Kipar et al. 2001297    
TGF-β Taglinger et al. 2008298    
G-CSF, M-CSF, GM-CSF Kipar et al. 200648    
IL-17 XM_006931816.1 F-16 ACTTCATCCATGTTCCCATCACT 126 
  R-141 CACATGCTGAGGAAAATTCTTGTC  
  P-83 CATTCCCACAAAATCCAGGATGCCC  
STAT-1 XM_006935443 F-1649 TTGACCTCGAGACGACCTCTCT 135 
  R-1783 GCGGGTTCAGGAAGAAGGA  
  P-1686 CTCCAATGTCAGCCAGCTCCCGAGT  
STAT-2 XM_003988893 F-1182 GCCCAGGTCACGGAGTTG 122 
  R-1303 ACAGTGAACTTGCTCCCTGTCTT  
  P-1212 CTGCACAGAGCCTTTGTGGTAGAAACCC  
STAT-3 XM_006940361.2 F-1626 GCCAGTTGTGGTGATCTCCAA 133 
  R-1758 TTGATCCCAGGTTCCAATCG  
  P-1696 CTGACCAACAACCCCAAGAACGTGAACTTT  
CCL8  XM_003996558 F-95 GGCCACCTTCAGCATCCA 82 
  R-176 CCCTTTGACCACACTGAAGCA  
  P-121 CTCAGCCAGGTTCAGTTTCCATCCCA  
CXCL10 XM_003985274.3 F-386 TGCCATCATTTCCCTACATTCTT 78 
  R-463 CAGTGGTTGGTCACCTTTTAGGA  
  P-411 CAAGCCCTAATTGTCCCTGGATTGCAG  
IFNγ NM_001009873.1 F-214 TGGAAAGAGGAGAGTGATAAAACAA 122 
  R-335 TCCTTGATGGTGTCCATGCT  
  P-284 ACCTGAAAGATGATGACCAGCGCATTCAA  
MMP2 XM_003998042.3  F-1633 CAAGTTCTGGAGGTACAATGAAGTAAAG 102 
  R-1734 ACGGCGTCCAGGTTATCG  
  P-1681 CCCCAAGCTCATCGCGGATGC  
MMP9 XM_003983412.5 F-917 CCCAACCCGAGCTGACTCT 104 
  R-1020 CCCTGGTGCATGTTGAGTACTC  
  P-964 AGCTGTGTGTCTTTCCCTTCATCTTCCTGG  
MMP13 XM_003992308.2 F-297 TGTGGGCGAGTACAACGTTTT 72 
  R-368 TTCACAATCCTGTAGGTTAAGTTCGT  
  P-319 CCCCGAACGCTCAAGTGGTCCA  
TIMP1 XM_011291721.1 F-319 GCTGCTGGCTGCGAAGA 72 
  R-390 GTGAGTGTCATTCTGCAGTTTGC  
  P-337 TGCACCGTATTTTCCTGTTCATCCATCC  
TIMP3 XM_003989216.5 F-41 GATGGTAAGATGTACACAGGACTATGC 127 
  R-167 AGTAGCAGGATTTGATCTTGCAGTT  
  P-89 CAGCTCACCCTCTCCCAGCGCA  
 
Acc. no.: NCBI accession number; F: forward primer and start site; R: reverse primer and start site; P: 
probe and start site; bp: base pairs. All final reactions contained equivalent F and R concentrations of 
900 nM, and P concentration of 250 nM, with the exception of FCoV RT-qPCR: 300 and 250 nM; FCoV 
conventional: 500nM; TGF-β: 200 and 50 nM; STAT3: 600 and 250 nM respectively. 
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Those newly developed were designed using Primer Express software (v3.0.1, Thermo Fisher 
Scientific) to span an exon-exon junction in order to prevent accidental detection of any genomic 
DNA, with the exception of possible pseudogenes. Where possible the junction was covered by a 
probe so that the full gene could not be detected by RT-qPCR (amplification would still be 
possible). Conventional PCR would be capable of amplification and thus detection on a gel (see 
Fig. 4.1.1). Where a suitable primer probe set could not be found meeting these criteria, one of 
the primers was instead placed over the junction. The aim was for these control measures against 
gDNA detection to be rendered superfluous by successful gDNA removal. All primers were checked 
in NCBI BLAST for specificity.  
All primers and probes were manufactured by Microsynth (Balgach, Switzerland). The hydrolysis 
probes were labelled with a 5’ reporter dye FAM (6-carboxyfluorescein), and a 3’ quencher TAMRA 
(6-carboxytetramethylrhodamine). 
Each new primer set was tested for specificity by conventional PCR. Conditions were as for RT-
qPCR below except with omission of the probe. Primer concentrations for this step were 900 nM. 
The PCR product was subjected to gel electrophoresis and the resulting band(s) purified using a 
MinElute Gel Extraction Kit (Qiagen) according to the manufacturer’s instructions. The resulting 
DNA solution was submitted to Microsynth for sequencing following dilution as per Microsynth’s 
submission protocol. NCBI BLAST was used to evaluate the sequence obtained.  
 
 
Figure 4.1.1: Example primer probe design for STAT2. Exon-exon junctions, marked in red, were 
manually inputted into the Primer Express Software using gene annotation data from the NCBI 
database. 
 
Primer probe concentration optimisation 
For all newly designed primer probe sets, varying concentrations were tested to determine the 
optimum (giving the best amplification efficiency). First, a single sample dilution, run in duplicate, 
was used to compare 300 nM, 600 nM, and 900 nM of primer, together with 150 nM vs 250 nM 
probe. Taqman RT-qPCR was performed on an Applied Biosystems 7500 Fast PCR System (Thermo 
Fisher Scientific). The master mix comprised 12.5 µl of Taqman Fast Universal Master Mix (2x) 
(Thermo Fisher Scientific), primer and probes diluted to 10 µl in RNase free water to give the 
desired concentration for a 25 µl final volume, and 2.5 µl sample cDNA. The thermal profile for all 
RT-qPCR was as follows: 50°C for 2 min, 95°C for 10 min, and 45 cycles of 95°C for 10s, and 60°C 
for 1 min. Data collection occurred during the extension phase (60°C).  
The Applied Biosystems 7500 Software v2.0.6 was used to visualise results and calculate a 
threshold cycle (CT) for each sample within the exponential phase of the amplification curve as per 
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the manufacturer’s guidelines. The threshold was equilibrated between runs for each different 
target.  
The primer probe concentration combinations giving the earliest and strongest signal (i.e. highest 
fluorescence) were then evaluated in a sample dilution series for efficiency and replicability. 
Where possible this consisted of seven 1:5 dilutions (i.e ~5 logs); depending on the starting CT the 
dilution curve was adapted accordingly. 
All final protocols (see Table 4.1.2) had an efficiency >95% (see Fig. 4.1.3 for example) and R2 value 
>0.95 (though the majority were >0.99).  
The first primer probe set for IFN-γ did not give reproducible results in a dilution curve (Fig. 4.1.2) 
so a new set was designed and tested as above, yielding appropriate results (Fig. 4.1.3). 
 
 
Figure 4.1.2: Standard curve for dilution series in triplicate for the first IFN-γ primers and probe. 
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Figure 4.1.3: Standard curve for dilution series in triplicate for the second IFN-γ primers and probe. 
 
Testing for gDNA contamination 
The RNA purification protocol is designed to enzymatically remove gDNA, however during 
conventional PCR to test the newly designed STAT2 primers, two bands were obtained. In this case 
the probe spans an exon-exon junction but neither primer does, meaning that by RT-qPCR the 
gene would not be detected as it would not bind the probe, but it could still be amplified and its 
presence interfere with the assay, by competing for primers. Gel electrophoresis revealed a band 
at the predicted PCR product weight of ~120 (122bp) and a heavier band at ~230bp. Sanger 
sequencing revealed the heavy band to derive from the full gene (Fig. 4.1.4) rather than the mRNA 
product. The lighter band was as predicted (Fig. 4.1.5). 
 
 
Figure 4.1.4: Alignment of forward and reverse primer sequencing products of the heavy weight band 
with the STAT2 gene, showing the sequence spans an intron.  
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Figure 4.1.5: Alignment of forward and reverse primer sequencing results from the lighter band shows 
these correspond to the STAT2 mRNA sequence. 
 
To test for gDNA contamination by assessing possible pseudogene presence, all PCR protocols 
were run in parallel on two sets of samples. cDNA was resynthesized in two reactions on a test 
sample, with the reverse transcriptase excluded from one reaction, i.e. the only available DNA will 
be genomic DNA extracted with the RNA (the Qiagen website states that Taq DNA Polymerase 
cannot amplify RNA under PCR reaction conditions;   
https://www.qiagen.com/ch/resources/faq?id=65b9b97f-1961-492f-8510-
2de502a15159&lang=en). 
qPCR reactions were then run in duplicate for each target gene and each reaction condition (i.e. 
four reactions per target). 
Table 4.1.3 shows the cycle difference between runs with and without reverse transcriptase (RT). 
The positive results in the absence of RT enzyme indicate the presence of genomic DNA (in this 
case the contribution is given by the pseudogenes) within the sample despite the supposed gDNA 
removal step. The high variation in results depends on the abundance of pseudogenes present. 
When primers/probe designed over an intron-exon junction still give positive results, this indicates 
the presence of processed pseudogenes. In the absence of pseudogenes, gDNA would not be 
detectable but may still interfere with the efficiency of the PCR reaction 299. 
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Table 4.1.3: Test for gDNA contamination, cDNA synthesis reaction performed with and without the 
inclusion of reverse transcriptase (RT). 
Target +RT -RT CT difference 
GAPDH 19.55 32.00 12.4 
TLR1 24.34 30.50 6.2 
TLR2 24.33 31.02 6.7 
TLR3 25.36 31.32 6.0 
TLR4 22.86 30.80 7.9 
TLR5 27.49 30.00 2.5 
TLR6 27.16 32.75 5.6 
TLR7 26.25 32.24 6.0 
TLR8 23.79 33.40 9.6 
TLR9 27.70 31.21 3.5 
IL-1β 28.37 - - 
IL-6 30.88 - - 
IL-10 27.63 38.12 10.5 
IL-15 30.82 - - 
IL-17 34.01 35.23 1.2 
TNF-α 27.09 - - 
TGF 23.73 - - 
IFN-α 27.68 28.50 0.8 
IFN-β 28.93 30.18 1.3 
STAT1 21.72 34.74 13.0 
STAT2 24.66 32.52 7.9 
STAT3 23.77 - - 
CCL8 30.00 - - 
MMP2 26.25 36.65 10.4 
MMP9 22.66 37.02 14.4 
G-CSF 31.11 - - 
M-CSF 23.87 - - 
 
 
Genomic DNA removal 
As a result of the contamination testing, an extra step was added to further remove gDNA. The 
DNA-freeTM DNA Removal Kit (Thermo Fisher Scientific) was tested following the manufacturer’s 
instructions to determine whether DNA removal had been successful, and whether there was a 
negative impact on RNA levels. The precise level of contaminating gDNA was unknown as samples 
were measured on a Nanodrop (although the 260/280 absorbance ratio will give an indicator of 
RNA purity, the concentration of RNA and DNA are combined as these cannot be distinguished). 
It can, however, be assumed to be heavy; some targets such as the interferons resulted in a CT 
without reverse transcriptase almost equivalent to that with. The DNA removal kit (utilising 
DNase) is limited in the amount it is able to remove to 50 µg DNA/ml RNA, therefore it was 
predicted that the samples would need to be further diluted in order to allow effective enzyme 
activity. A second option was an extension of the clean-up step of the process, these were trialled 
as below.  
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Figure 4.1.6: qPCR amplification plot for GAPDH comparing DNase treatment (Tx) at different dilutions, 
with and without reverse transcriptase (RT). 
 
Table 4.1.4: Tabulated version of Fig. 4.1.7, comparing GAPDH CT levels under different treatment 
conditions. 
Dilution/condition +RT -RT CT difference 
1:10 / untreated 19.73 34.14 14.41 
1:10 / DNase treated 20.07 39.64 19.57 
1:50 / DNase treated 22.59 - >22.41 
 
These results show that at a 1:10 dilution the DNase treatment reduced gDNA contamination by 
5 CTs, or ~32 times (Fig. 4.1.6, Table 4.1.4). It also shows a small but fairly negligible effect on RNA 
levels, which were slightly reduced by the treatment (<0.4 of a cycle). At 1:50 the DNase treatment 
was more effective but with a corresponding reduction in starting level this is risky for low 
expressed genes. A further trial was carried out using IFN-α and an extended treatment step. IFN-
α had originally shown less than a cycle difference between ±RT reactions, however as a low 
expressed gene it was not used for the first trials as the high starting CT level reduces the possible 
comparisons available. At 1:10 and 1:20 dilutions with an extended DNase treatment (as per 
manufacturer’s protocol trouble shooting options) ‘with RT’ CT values of 32.9 and 33.6 respectively 
were detected. ‘Minus RT’ reactions were negative indicating that this protocol achieves an 
improvement exceeding the 5 cycles reduction with the standard protocol.   
RNA extraction and cDNA synthesis were therefore repeated as described above with exclusion of 
on-column DNA removal and addition of an intervening DNase treatment. Concentrations were 
normalised to ~50ng/µl following Nanodrop 2000 (Thermo Fisher Scientific) measurement.  
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Alternative internal reference gene trials 
GAPDH is commonly used and has been published as a reliable reference (housekeeping) gene for 
amplification control in felines 294,298,300,301, however under inflammatory conditions it may 
sometimes be altered 302. RPS7 and GUSB were trialled as alternatives by comparing a subset of 
group 1 and 2 cats. Levels of both reflected GAPDH levels fairly closely so no change to the protocol 
was made 303. 
 
GAPDH duplex trial 
Owing to the number of targets and samples, it would of course not be possible to run all required 
reactions on one plate. Therefore as an extra internal control, and to reduce the total reaction 
number, a duplex GAPDH which could be run with each sample and target was tested. The second 
GAPDH probe was labelled with 5’ VIC and 3’ BHQ (black hole quencher), also supplied by 
Microsynth. The probe concentration was tested at 50, 150 and 250 nM, being optimal at 250 nM 
where CT levels were however still ~1 cycle lower than with the FAM-TAMRA probe. 
The duplex was then trialled on three targets, known to have a range of expression levels, each 
run alone and in combination with GAPDH, shown in Table 4.1.5.  
 
Table 4.1.5: GAPDH duplex trial on selected targets. 
Target CT alone CT with GAPDH CT ‘loss’ 
GAPDH 22.2792 -  
STAT3 24.877449 24.4080505 -0.5 
IL-6 32.0183182 33.8927383 1.9 
TLR1 29.0191936 32.0472107 3.0 
 
These results showed that for highly expressed genes, expressed at a similar level to GAPDH, there 
was no loss of signal. However, those expressed at far lower relative levels were outcompeted and 
detection efficiency was significantly lower. Interestingly, and counter-intuitively, detected levels 
of GAPDH itself were also reduced when combined with lower expressed targets. 
As the results showed that this method could therefore not be applied to all targets without 
extensive individual optimisations it was decided from a cost benefit viewpoint not to pursue this 
further.  
Table 4.1.2 above shows the final primer and probe concentrations used. 
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2. Determination of FCoV and mediator transcription levels in bone marrow and 
spleen using RT-qPCR 
The protocols were first applied to BM and spleen (tissues with a known involvement in FIP 46) 
from the first 20 cats within the Zurich cohort in order to provide early results on the likely 
relevance of the previously untested mediators, particularly the TLRs. 
Group 1 contained six control cats and Group 2 14 cats with FIP. From these cases, all had spleen 
available whilst BM was available from 11 of the 14 G2 cats. Pathological findings are shown in 
Table 4.2.1. 
 
Statistical analysis 
All samples were run in duplicate and any samples with discordant results repeated. After 
confirmation of the automatic threshold for each run, or input of a manual threshold, results were 
exported to Windows Excel. This step ensured that samples from different runs had the same 
threshold for each target. Relative mRNA transcription levels were calculated using the 
comparative CT method 304. The CT of each sample was first normalised to GAPDH as the 
endogenous reference (∆CT) and then, for each target, expressed relative to the G1 ∆CT bone 
marrow mean for that target as the calibrator (2-∆∆CT). The exception was FCoV, for which 2-∆CT was 
used. 
The statistical programme SPSS v.25 (IBM Statistics) was used for all analyses and graphical data 
presentation. Data were first assessed for normality using a Shapiro-Wilk test. As almost all data 
failed the test, non-parametric measures were applied. A two-tailed Mann-Whitney test with a 
significance level of p ≤ 0.05 was used to compare results between groups for each target 
molecule, with the null hypothesis that there is no difference between groups.  
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Table 4.2.1: Histological and immunohistological (IH) findings in association with case numbers used for the BM and spleen studies. NS: not sampled; NAD: no 
abnormality was detected; mɸ: macrophages; MF: multifocal; +ve: positive; -ve: negative. 
 BM spleen 
Case no. Sample no. Histological findings IH 
Sample 
no. Histological findings IH 
H15-2389  NS  13 Multiple small pyogranulomas +ve 
S15-0134 36 NAD -ve 36 Serositis +ve 
S15-0259 35 NS  34 Mild multifocal serositis, neutrophilic splenitis rare +ve 
S15-0983 33 High cellularity -ve 32 Serositis and histiocytosis +ve serosa 
S15-1094 31 NS  30 MF follicular necrosis and granulomas, scant serositis. +ve serosa and follicles 
S15-1368    16 Mild follicular hyperplasia -ve 
S15-1539 26 Moderate cellularity, NAD -ve 25 Serositis and subserosal splenitis, histiocytosis +ve, predominantly serosa 
S15-1728 29 High cellularity -ve 28 Moderate serositis +ve 
S15-1738 20 High cellularity, increased mɸ -ve 19 Cell poor serositis +ve 
S15-1809 23 High cellularity -ve 22 Serositis, follicular hyperplasia +ve, predominantly serosa 
S15-1842 41 High cellularity, increased m0 -ve 42 Mild serositis rare +ve 
S16-0167  NS  14 Serositis and histiocytosis +ve 
S16-0454 44 Moderate cellularity, NAD -ve 45 Very mild serositis rare +ve, mainly in follicles 
S17-0124 47 NS  48 Serositis and subserosal splenitis +ve 
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3. Determination of FCoV and mediator transcription levels in the mesenteric lymph 
nodes (MLN) using RT-qPCR 
Following promising results from BM and spleen, the study was extended to evaluate MLN from a 
greater number of animals. At this stage Bristol biobank cases were used. Macroscopical findings, 
histological, and immunohistological results from the MLN were available from almost all cases, 
giving information such as whether effusions were present and whether or not the MLN itself had 
histologically evident FIP lesions. These details were used to create and compare subgroups.  
From the Bristol database, many tissue samples had already been tested for FCoV and undergone 
pyrosequencing for previous publications 91,133 but the available cDNA stock had been largely 
exhausted necessitating shipping of tissue samples on dry ice to Zurich. A customs delay 
unfortunately resulted in partial thawing of the samples which may have impacted on the RNA 
quality as discussed below. 
Cases used together with histological findings in the MLN are shown in Tables 4.3.2-3. 
 
RNA extraction 
RNA extraction was performed as above on 50 Bristol MLN samples. These were eluted twice into 
a total volume of ~50 µl (accounting for loss to the spin column filter). 
RNA levels were measured using a Nanodrop 2000 (ThermoFisher Scientific) and four samples with 
a concentration of <30 ng/µl were excluded. Those remaining had measured levels ranging from 
34.5 ng/µl to 1994.1 ng/µl; the occasional low levels likely to be related to the thawing in transit. 
Prior to cDNA synthesis, the RNA concentrations were equilibrated to ~400ng/µl with RNase free 
water. Where the starting concentration was lower than this, multiple synthesis reactions were 
carried out and the resulting cDNA pooled with a correspondingly lower volume of water added 
to achieve the same end concentration (e.g. if the starting concentration equilibrated to 200ng/µl 
then two synthesis reactions instead of one contributed to the final cDNA sample). 
 
cDNA synthesis 
As starting material was limited, and following the experience of the previous stage which required 
up to eight cDNA synthesis reactions per sample to provide sufficient starting material, an 
alternative cDNA synthesis protocol was trialled. 
The SuperScript IV VILO kit with ezDNase (Thermo Fisher Scientific) includes a gDNA removal step 
so was tested in comparison to the previous method on a single sample (84) for TLR6.  
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Table 4.3.1: Comparison between the original HC-cDNA synthesis protocol (method 1) and the 
SuperScript IV VILO protocol (method 2), with and without reverse transcriptase (RT). 
Method CT +RT CT -RT 
1 25.09 28.67 
2 22.13 - 
CT difference: 2.96   
 
These results showed that there was an almost three cycle difference (8 x concentration) between 
the methods, therefore only one reaction per sample was carried out. It also shows that the 
ezDNase step was effective at removing contaminating gDNA so this simpler method was used in 
place of the RNA clean up step previously described. 
cDNA synthesis was carried out according to the manufacturer’s protocol, resulting in 20 µl from 
8 µl of starting RNA per sample. All samples were then made up to 250 µl with molecular grade 
water. 
 
RT-qPCR 
This was carried out as described. In total, there were 40 cats in Group 1 (G1), including six cats 
from Zurich, and 30 cats in G2, including 9 cats from Zurich. FCoV results led to subgrouping of G1 
to G1+ and G1-, with 10 and 30 cats positive and negative for FCoV respectively. 
 
Statistical analysis 
Data were processed as in section 2, an exception being that for FCoV RT-qPCR results, the mean 
of G1+ was instead used as the calibrator (to allow for better visualisation graphically). 
In the accepted manuscript, the MLN results were presented as stand-alone results and therefore 
the MLN G1 mean was used. The change to the BM mean does not affect statistical comparisons 
within the MLN group, as the same function was applied to all, but meant that relative values were 
comparable between organs (though not between targets). 
As there were now three groups of cats, first cats with and without FIP (G1 vs G2) were compared. 
This was followed by comparisons between G1- and G1+, and between G1+ and G2. Within G2, 
comparisons were made between cats with and without cavitary effusions and with and without 
histologically observed FIP lesions in the MLN. Correlation between relative FCoV levels and 
inflammatory mediator levels, and also between individual inflammatory mediators, was analysed 
within G2 using a one-tailed Spearman’s rank test. Here a cut off of p ≤ 0.01 was used, with p ≤ 
0.05 indicating weak correlation.  
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Table 4.3.2: Group 1, histological and immunohistological (IH) findings; ND: not done. -ve indicates 
negative immunohistological result. 
Case no. Sample no. Group MLN histology and immunohistology 
S15-1871 50 1- Normal, IH -ve 
S17-0409 51 1- Normal, IH ND 
S17-0478 52 1- Follicular hyalinosis, IH -ve 
S17-0480 53 1- Leukaemia, IH -ve 
S17-0481 54 1- Normal, IH -ve 
S17-0568 55 1- Follicular hyalinosis, IH ND 
54 63 1- Normal, IH -ve 
56 64 1- Pyogranulomatous inflammation, IH -ve 
63 65 1- Normal to reactive, IH -ve 
80 66 1- Reactive hyperplasia & amyloidosis, IH -ve 
84 67 1- Neutrophilic inflammation, IH -ve 
87 68 1- ND 
89 69 1- Normal, IH -ve 
90 70 1- Mild depletion, IH -ve 
91 71 1- Normal to reactive, IH ND 
115 79 1- Reactive hyperplasia & sinus histiocytosis, IH -ve 
116 80 1- ND 
118 81 1- ND 
119 82 1- Multifocal pyogranulomas, IH -ve 
123 85 1- ND 
126 87 1- ND 
136 93 1- Normal, IH ND 
140 94 1- Normal to reactive, IH -ve 
141 95 1- Normal to reactive, IH -ve 
143 97 1- Normal, IH -ve 
152 100 1- Tumour emboli, IH ND 
59 154 1- Normal, IH -ve 
72 156 1- Reactive hyperplasia, IH -ve 
104 160 1- Reactive hyperplasia & sinus histiocytosis, IH -ve 
105 161 1- Follicular depletion, IH -ve  
38 60 1+ ND 
51 62 1+ ND 
102 77 1+ Reactive hyperplasia with collagen scars, IH -ve 
125 86 1+ Normal to hyperplastic, IH -ve 
132 91 1+ ND 
135 92 1+ Sinus histiocytosis, IH -ve 
149 99 1+ Normal, IH -ve 
156 101 1+ Sinus histiocytosis, IH ND 
69 155 1+ Focal cortical inflammation, IH -ve 
78 158 1+ Normal to reactive, IH -ve 
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Table 4.3.3: Group 2, pathological, histological and immunohistological (IH) findings; Y: yes; N: no; A: 
ascites; P: pericardial effusion; T: thoracic effusion; M: multicavitary effusion; ND: not done; LPC: 
lymphoplasmacytic.  
Case no. Sample no. Group 
Effusions 
present? 
LN 
lesions MLN histology and immunohistology 
S16-0167 15 2 Y - A Y Necrotising & pyogranulomatous, IH +ve 
S15-1368 17 2 N Y Necrotising, pyogranulomatous, LPC, IH +ve 
S15-1738 18 2 Y - A Y Granulomatous, IH +ve 
S15-1809 21 2 Y - A Y Pyogranulomatous, IH +ve 
S15-1539 24 2 Y - A Y Pyogranulomatous & LPC, IH +ve 
S15-1728 27 2 Y - A&P Y Granulomatous, IH +ve 
S15-1842 43 2 Y - M Y Granulomatous, IH +ve 
S16-0454 46 2 Y -A Y Pyogranulomatous, IH +ve 
S17-0124 49 2 Y -A Y Pyogranulomatous, IH +ve 
30 56 2 Y -A Y Granulomatous, IH +ve 
31 57 2 Y - T Y Necrotising and granulomatous, IH +ve 
32 58 2 Y - A Y Pyogranulomatous, IH +ve 
37 59 2 Y - T - ND 
42 61 2 Y - A&T Y Necrotising & pyogranulomatous, IH +ve 
93 72 2 Y Y Pyogranulomatous, IH +ve 
94 73 2 Y N Sinus histiocytosis, IH -ve 
96 74 2 Y N Reactive hyperplasia, IH -ve 
100 75 2 Y - A&T N Normal, IH -ve 
101 76 2 Y - M N Reactive hyperplasia, IH +ve 
103 78 2 Y - A&T Y Pyogranulomatous, IH +ve 
121 83 2 N Y Granulomatous, IH +ve 
122 84 2 N Y Granulomatous, IH +ve 
127 88 2 N - ND 
128 89 2 - Y Necrotising & granulomatous, IH +ve 
131 90 2 Y - A Y Necrotising & pyogranulomatous, IH +ve 
142 96 2 N N Normal, IH -ve 
146 98 2 Y - A N Reactive hyperplasia, IH -ve 
43 150 2 - N Reactive hyperplasia, IH -ve 
46 151 2 N Y Pyogranulomatous, IH +ve 
50 152 2 Y - A Y Pyogranulomatous, IH +ve 
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4. Laser Capture Microdissection (LCM) and RT-qPCR 
The Zurich case cryoblocks from organs/tissues with FIP lesions in Group 2 cats were prepared as 
follows: Firstly, an appropriately sized tissue sample (rough dimensions 1 x 1 cm and not exceeding 
5 mm in depth) was removed from the organ using a scalpel. The side of interest was placed face 
down in a mould onto a drop of Cellpath OCT embedding matrix (Thermo Fisher Scientific) before 
placing the block into isopentane cooled by liquid nitrogen. The block was removed from the 
isopentane when a 1 mm bubble of liquid OCT remained centrally at the surface, separated from 
the surrounding mould and placed into a micro-Petridish for storage at -80°C. 
In total, 23 cryoblocks were obtained from 11 cats as in some cases, small lesions were lost 
following block trimming.  
 
Sample optimisation 
To reduce the time pressure on the LCM stage, and to obtain the maximum possible RNA quality, 
an extra step of first placing the tissue sample in RNAlater prior to OCT was tested. As OCT is not 
designed to preserve protein structure, the morphology was unfortunately too compromised so 
this method was not taken further. 
Cryosections of a single sample were tested by scrape test (removal of the whole section from a 
slide using a scalpel) for approximate RNA levels by RNA extraction and RT-qPCR for GAPDH. This 
was for practical reasons in order to optimise the laboratory workflow and determine which steps 
are under time pressure. Six sections were cut as shown in Table 4.4.1. During the LCM procedure 
itself slides are at room temperature and humidity, with the required time span difficult to 
accurately predict in advance. RNA was extracted using a Qiagen RNeasy Microkit according to the 
manufacturer’s protocol. The RT-qPCR reaction was run as a one step reaction with the following 
reagents per sample: 12.5 µl One step RT-qPCR MasterMix (Eurogenteq, Seraing, Belgium); 0.5 µl 
each of 20 µM forward and reverse primer (see chapter 1), 0.75 µl of 10 µM probe, 0.125 µl of 
Moloney Murine leukemia virus reverse transcriptase and RNase Inhibitor (EuroScript RT 0.25 
U/ml and RNase Inhibitor 0.1 U/ml, Eurogentec). The one step method was used to exclude other 
variables e.g. in the cDNA transcription stage and as there was no requirement to store the 
samples for future testing. 
 
Table 4.4.1: Comparison of CT levels obtained from sections under different conditions. 
Condition GAPDH CT 
Direct scrape 26.77 
HE stain then direct scrape 19.91 
1h RT 17.72 
1h on ice 18.06 
2h RT 18.05 
2h on ice 22.67 
Positive control 15.74 
 
This small test only included one sample per condition and as such it would be speculative to draw 
too precise conclusions. The result of the direct scrape is not easily explained as, in the absence of 
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any potentially RNA damaging treatments, this would be expected to give the lowest CT 
(suggesting an error at some stage). However, the results otherwise suggest that working with the 
slides at room temperature for a few hours is unlikely to have any significant detrimental effect. 
The use of RT-qPCR is however much more lenient in terms of sample quality than e.g. next 
generation sequencing. Room temperature actually appeared preferable to ice, though the 
difference was negligible. As dehydration is the most important factor for preventing RNase 
activity, it is possible that the more humid atmosphere under ice conditions played a role. 
Samples were also compared when the work flow was completed the same day as sectioning, or 
sections being left for two days at -20°C (to allow for weekend work on slides prepared during 
normal laboratory working hours). There was again no observable difference. 
 
Cryosectioning 
Sections were cut to 10 µm thickness and mounted onto PEN Membrane Glass slides (Thermo 
Fisher Scientific) using sterile and RNase free technique on a CryoStar NX50 Cryostat (Thermo 
Fisher Scientific) with the temperature set according to the tissue (e.g. mesentery ~-35°C, spleen 
~-10°C). Tests carried out for a parallel project showed that from 20 to 10 µm there was no 
significant loss of yield but there was a significant loss of morphological details from 10 to 20 µm. 
Two consecutive sections of 6 µm were mounted onto positively charged glass slides and routinely 
stained with HE or immunohistologically stained for FCoV antigen (see Chapter 1), to confirm the 
presence of virus within selected lesions. 
 
Staining procedure 
The staining protocol for LCM requires a compromise between the optimal morphology (usually 
provided by HE staining), and the optimal RNA quality (no staining procedure). A number of 
staining procedures were tested for their practicality and effectiveness. These included:  
• with and without acetone fixation 
• with and without a final xylene step 
• basic dehydration with no staining 
• Ambion staining protocol (increased ethanol gradient steps, xylene steps at end 305). 
• haematoxylin staining with ammonium hydroxide as blueing agent (replacing tap water) 
The final staining protocol was based on a previously published protocol as follows 306: 
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Table 4.4.2: Staining protocol for cryosections prior to LCM. 
Solution Incubation time 
95% ethanol 30 s 
75% ethanol 30 s 
1% wt/vol cresyl violet in pH 8.0 75% ethanol 40 s 
75% ethanol 30 s 
95% ethanol 30 s 
100% ethanol 30 s 
100% ethanol 30 s 
100% ethanol 5 min 
 
All reagents were diluted to the required concentration using diethyl pyrocarbonate (DEPC) 
treated-water (to inactivate any RNase contaminants which autoclaving alone may not remove). 
DEPC treated water was prepared using concentrated DEPC (Sigma Aldrich) added to ultrapure 
Milli-Q water (Merck, Lucerne, Switzerland) at a concentration of 0.1%, mixed on a magnetic 
stirrer overnight and autoclaved to inactivate the toxin. Each staining solution was prepared fresh 
each time in a 50 ml Falcon tube filled to 35 ml. Following the last ethanol step, slides were air 
dried on the bench for at least 10 min before proceeding to LCM. 
 
Laser capture microdissection of samples 
An automated Arcturus XT Laser Microdissection Instrument based on a Nikon Eclipse Ti-E 
motorized Microscope was used. The system consists of an inverted microscope equipped with an 
UV-cutting laser and an infrared laser for capturing dissected material. The main aim was to select 
areas highly enriched for FCoV-infected macrophages and to try to compare between serosal 
inflammation and granulomas. Additional samples of interest were taken from some blocks (e.g. 
follicles in the MLN to gain a brief overview of lymphocyte contribution). Consecutive sections of 
the frozen blocks were stained with HE, and by immunohistology for FCoV antigen. This gave 
additional confirmation that the correct regions of interest had been selected. 
 
 
 
 
 
 
 
 
Figure 4.4.1: Intestine (S15-0134) a) Overview; b) close up of selected area showing serositis; c) 
selection of desired area; d) tissue following UV cut and IR capture; e) cap with this region and adjacent 
areas.  
a 
c 
d 
e 
b 
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Figure 4.4.2: Intestine (S15-1842) a) After LCM of Peyers patches (e.g. arrow); b) cap with captured 
tissue 
Table 4.4.3: Cases used for LCM and final sample numbers allocated for RT-qPCR studies. 
Case no. Sample no.  Organ Region sampled by LCM 
S15-1842 102 Small intestine Serosal inflammation 
S15-1842 103 Small intestine Peyer's patches (no lesion) 
S15-1842 105 Liver Serositis 
S15-1809 106 Spleen Serositis  
S15-1809 107 Spleen Follicles (no lesion) 
S15-1738 109 Spleen Follicles (no lesion) 
S15-1738 110 Spleen Serositis 
S15-1738 112 Mesentery Pyogranulomatous vasculitis  
S15-1738 113 MLN Serositis  
S15-1738 114 MLN Follicles (no lesion) 
S15-1728 115 Liver Serositis  
S15-0983 116 MLN Serositis (small granulomas)  
S15-1539 117 MLN Granulomas  
S15-1728 118 MLN Granulomas and vasculitis  
S16-0167 119 MLN Granulomas  
S16-0454 120 MLN Granulomas  
S17-0124 121 MLN Pyogranulomatous inflammation 
S15-0134 122 Large intestine Serositis  
S15-0259 123 MLN Granulomas  
S15-0259 124 Spleen Serositis  
S15-0259 125 Liver Serositis  
S15-1738 128 Liver Macrophages in serositis 
S15-1809 129 Kidney Serositis  
S15-1809 130 Omentum Granulomas  
S16-0167 131 Spleen Serositis  
S16-0167 132 Omentum Granulomatous inflammation 
S16-0454 133 Liver Serositis 
S17-0124 134 Liver Serositis (with small subcapsular granulomas) 
S17-0124 135 Spleen Serositis 
S17-0124 136 Small intestine Pyogranulomatous vasculitis in muscularis 
S15-1842 137 Small intestine Serositis 
a b 
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RNA extraction 
For the final lesion samples, this step was performed using the RNAqueous Micro Total RNA 
Isolation Kit (ThermoFisher Scientific AM1931) kit according to the manufacturer’s protocol 307. 
The change from the previously used Qiagen extraction kit was based on other users’ experience. 
Briefly, the LCM membrane was removed from the cap with a sterile scalpel blade and transferred 
to a 500 µl Eppendorf tube containing 100 µl of Lysis buffer. This was placed in an incubator set to 
42°C for 30 min before progression to on-column RNA elution. At the final elution step, two 
elutions were performed with a volume varying from 10-14 µl per elution depending on the 
amount of starting material. 
 
cDNA synthesis 
The initial optimisation for LCM was carried out in parallel with optimisation of the PCR protocols 
(Chapter 1). As such, the High Capacity cDNA synthesis kit (Thermofisher) was first tested. From a 
10 µl RNA input, 25 µl cDNA are obtained. A test sample of control kidney was first trialled, from 
which microscopic regions were sampled, to mimic small lesional areas. Following RNA extraction 
and cDNA synthesis the samples were subjected to qPCR for GAPDH using undiluted, 1:4, 1:8 and 
1:16 dilutions to evaluate the suitability for large numbers of PCR runs. The undiluted sample had 
a CT of 30.1, increasing to 32.0, 34.0 and 34.5 respectively. This indicated that the protocol was 
not feasible for small samples either in terms of increasing the number of PCR runs possible, or in 
detecting targets with low expression.  
Instead, the SuperScript IV VILO Master Mix with ezDNase (Thermo Fisher Scientific) was used (as 
per Chapter 3).  
A single qPCR for GAPDH was carried out on all samples prior to pre-amplification, using 1 µl of 
undiluted sample, to ensure successful RNA extraction and cDNA synthesis.  
 
Pre-amplification of cDNA  
Owing to earlier tests showing that the cDNA yield would be insufficient for large numbers of PCR 
reactions, the sample first underwent pre-amplification. The TaqMan PreAmp Master Mix Kit 
(Thermo Fisher Scientific) was used according to the manufacturer’s protocol with some 
adaptations. The kit is predominantly designed for use with TaqMan’s own primer and probe sets 
which are supplied as one assay mix at 20x for which the concentrations of individual reagents are 
not provided. A maximum of 100 assays may be pooled. As the precise calculations could therefore 
not be replicated, the concentrations were calculated approximately relative to the most common 
qPCR concentration of 900nM primer (used for reactions without pre-amplification). Allowing for 
a maximum of 50 reactions, 1 µl of each 20 µM primer was added per 100 µl pooled assay mix for 
reactions usually requiring 900nM, adjusted accordingly for those at lower concentrations.  
One trial run was carried out on a single test sample of myocardium from another study (not an 
FIP sample) to ensure that all targets were amplified following the pre-amplification. This was 
successful. Only GAPDH was run on a non pre-amplified sample (1 µl), to ensure there was starting 
material for the pre-amplification. 
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Each pre-amplification reaction consisted of 25 µl of TaqMan PreAmp Master Mix (2x), 12.5 µl of 
pooled assay mix, 7.5 µl of nuclease free water and 5 µl of sample cDNA. All except the cDNA were 
prepared as a single master mix, from which 45 µl per well was pipetted. The reaction thermal 
profile was as shown in Table 4.4.4. 
Table 4.4.4: Reaction conditions for pre-amplification RT-PCR 
Stage Temperature Time 
Hold 95°C 10 min 
Denaturation 95°C 15 s 14 cycles Annealing/extension 60°C 4 min 
Hold 4°C ∞ 
 
The PCR product was then diluted 1:20, giving a total of 1ml per sample. 
 
RT-qPCR 
This was performed as described above (see Chapter 1), though using 5µl of pre-amplified sample 
cDNA per reaction. A CAS-1200 pipetting robot (Corbett Robotics Pty. Ltd., Queensland, Australia) 
was used to pipette the samples into each reaction.  
 
Pre-amplification correction calculations 
Initial comparisons of results showed many targets to be expressed at a lower level than expected, 
including FCoV which should have been higher than in non laser microdissected samples as areas 
high in infected macrophages were specifically chosen. This led to the suspicion that the pre-
amplification step was not amplifying all targets equally.  
There was of course insufficient sample to carry out all PCR reactions on non-pre-amplified cDNA 
therefore it was decided to assess and hopefully correct the error mathematically.  
As all samples already had a GAPDH result, the level of cDNA in each was already known 
approximately (ie. low, medium, high). Groups of samples were then made, each containing 6 
samples over a range of cDNA content. The targets were randomly assigned a group, and the PCR 
repeated with 1 µl of cDNA reactions. For each target, the before and after pre-amplification CT 
values were plotted against each other. When this resulted in a straight-line graph (correlation 
graph), the equation of this line was used to calculate an artificial ‘before pre-amplification’ CT for 
all samples (Fig. 4.4.3 and Table 4.4.5). Targets without a close line of best fit were not used for 
statistical comparisons as it was assumed that the pre-amplification stage was introducing an 
unpredictable rather than a predictable error. This however tended to only apply to targets 
already expressed at low levels such that the direct sample CT was towards the detection limit, 
e.g. Fig 3.2. 
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Figure 4.4.3: Example of method used to predict the pre-amplification CT values of all samples; STAT2 
showing all points are in agreement with the line of best fit. 
 
 
 
Figure 4.4.4: Example of line of best fit deemed insufficiently accurate, target removed from final 
calculations. 
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Table 4.4.5: Equations used to calculate a ‘before pre-amplification’ CT value, derived from graphs 
exemplified above in Fig. 4.4.3. 
Mediator Equation  Mediator Equation 
GAPDH y= 8.8+0.99x  IL-1β y=7.86+1.00x 
FCoV y=5.06+1.09x  IL-6 y=10.4+0.93x 
TLR1 y=7.37+1.05x  IL-10 - 
TLR2 Y=7.12+0.98x  IL-15 - 
TLR3 y=5.98+1.06x  IL-17 - 
TLR4 y=8.75+0.89x  TNF-α y=8.51+1.00x 
TLR5 y=8.47+0.97x  TGFβ y=7.42+1.13x 
TLR6 -  CCL8 y=10.73+0.87x 
TLR7 y=6.67+1.05x  CXCL10 y=5.97+1.10x 
TLR8 y=8.57+0.90x  MMP2 y=4.74+1.04x 
TLR9 y=6.41+1.07x  MMP9 - 
IFN-α y=6.71+0.96x  MMP13 - 
IFN-β y=3.54+1.21x  TIMP1 y=8.67+0.99x 
IFN-γ y=5.17+1.07x  TIMP3 y=7.67+1.05x 
STAT1 y=8.25+0.93x  G-CSF - 
STAT2 y=9.45+0.95x  M-CSF y=12.48+0.79x 
STAT3 y=9.85+0.90x  GM-CSF - 
 
Statistical analysis 
The calculated ‘without pre-amplification’ values were used for all statistical analyses, meaning 
that not all targets could be evaluated. Results were otherwise evaluated as before. Samples from 
lesions were compared as a whole with results from the group 2 MLN, (non-lesional sites were 
excluded from this analysis). Comparisons were then also made between granulomatous and 
serosal lesions. 
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(4). Immunohistology (IH) and Immunofluorescence (IF) 
Following RT-qPCR, the genes of most interest for further investigation were chosen as being TLR 
2, 4, and 8, upregulated in FIP, and STAT2 which showed an intermediate expression in the FCoV 
infected control cats. None of these genes had been previously evaluated in FIP and it was hoped 
to first confirm protein expression by immunohistology and then to correlate this with cell type, 
cellular location, and co-expression of FCoV. Immunohistology allows better visualisation of cell 
morphology, whilst for assessing co-expression, immunofluorescence was planned to allow for 
double labelling. Antibodies directed against FCoV and Iba-1 (a macrophage marker) were already 
in routine and accredited diagnostic use in the Histology Laboratory at the Institute of Veterinary 
Pathology and required optimising only for immunofluorescence.  
Trialled and final protocols for all antibodies are presented in Tables 4.4.6-8.  
  
Antibody trials 
Antibodies were obtained from various sources as shown in Table 4.4.6-8x, based on 
manufacturers’ recommendations regarding their sequence homology and likely cross reactivity. 
To our and the manufacturers’ knowledge, none had been previously tested on feline tissue. An 
archived diagnostic biopsy of a reactive feline lymph node was used as control tissue. As no 
published data on expression in feline haemolymphatic tissues was found, whenever possible ‘The 
Human Protein Atlas’ (https://www.proteinatlas.org/) was used as an approximate predictor of 
the staining pattern to be expected.  
TLR8 
The expectation from function and ‘The Human Protein Atlas’ was of a low level of macrophage 
staining. This antibody showed selective cell staining (see Tables 4.4.6 and 4.4.7 for conditions) 
which could be replicated in IH, IF, and IF double-staining with FCoV.  
TLR8 and the routinely used Iba-1 antibody share a common secondary antibody, so could not be 
used for double labelling. Instead, an alternative Iba-1 was trialled (see Table 4.4.8). This had been 
used successfully in other species but did not appear to cross-react with feline antigen so that this 
particular double staining approach could not be further optimised.  
TLR2, TLR4, STAT2 
‘The Human Protein Atlas’ only had information available for TLR4, for which moderate staining 
of cells in the lymph node with a macrophage morphology was expected (no image annotation is 
provided). None of the trialled reaction conditions (Table 4.4.8) yielded reliable results for any of 
these antibodies with sections either negative or heavily background stained; these antibodies 
were not applied to case material. 
All IH reactions were visualised by 3,3’-Diaminobenzidine (DAB) chromagen (Dako, Waldbronn, 
Germany; 1 drop of DAB+ chromagen in 1ml of DAB+ substrate buffer) for 10 min followed by 2 s 
counterstaining in haematoxylin (Gill no. 1, 20%, Merck).  
All IF sections were counterstained with 0.1µg/ml DAPI (Thermo Fisher Scientific) at room 
temperature for 15 min to visualise nuclei.    
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Table 4.4.6: Final conditions of antibodies used for immunohistology. aa: amino acid; M: mouse; R: rabbit; M: monoclonal; P: polyclonal; NA: not applicable; 
basic/acidic antigen retrieval indicate 20 min incubation in pH 9.0 EDTA buffer/pH 6.0 citrate buffer in a pressure cooker set to 98°. HRP: horseradish peroxidase. 
Primary antibody Secondary antibody/detection 
system and conditions Directed against Immunogen Type 
Homology 
with feline Source 
Antigen 
retrieval 
Dilution and 
incubation 
FCoV clone FIPV3-70 MM NA Santa Cruz (SC 65653) Basic 1:200, RT, 1h 
Mouse EnVision+ System HRP 
labelled polymer (Dako) 
Iba-1 
(anti-human/ 
rat/mouse) 
Synthetic peptide 
corresponding to C 
terminus region 
RP unknown Wako (WDE 1198) Acidic 1:750, RT, 1h 
Rabbit EnVision+ System HRP 
labelled polymer (Dako) 
TLR8 
(anti-human) 
Recombinant fragment 
corresponding to aa 849-
1041 
RP 93% Abcam (ab180610) None 1:50, RT, 2h 
Rabbit EnVision+ System HRP 
labelled polymer (Dako) 
Iba-1 
(anti-human/ 
rat/mouse) 
Synthetic peptide 
corresponding to C 
terminus region 
RP unknown Wako (WDE 1198) Acidic 1:750, RT, 1h 
Rabbit EnVision+ System HRP 
labelled polymer (Dako) 
 
Table 4.4.7: Final conditions of antibodies used for immunofluorescence. aa: amino acid; M: mouse; R: rabbit; M: monoclonal; P: polyclonal; NA: not applicable; 
basic/acidic antigen retrieval indicate 20 min incubation in pH 9.0 EDTA buffer/pH 6.0 citrate buffer in a pressure cooker set to 98°.  
Primary antibody 
Secondary antibody conditions Directed 
against Immunogen Type 
Homology 
with feline Source 
Antigen 
retrieval 
Dilution and 
incubation 
FCoV clone FIPV3-70 MM NA Santa Cruz (SC 65653) Basic 1:50, RT, 1h 
Goat anti-mouse 488 (Invitrogen 
A11001), 1:400, RT, 1h 
TLR8 
(anti-human) 
Recombinant fragment 
corresponding to aa 849-
1041 
RP 93% Abcam (ab180610) None 1:50, RT, 2h 
Goat anti-rabbit 594 (Invitrogen 
A11012), 1:400, RT, 1h 
Iba-1 
(anti-human/ 
rat/mouse) 
Synthetic peptide 
corresponding to C 
terminus region 
RP unknown Wako (WDE 1198) Acidic 1:300, RT, 1h 
Goat anti-rabbit 546 (Invitrogen 
A11010), 1:400, 1h 
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Table 4.4.8: Details and trialled conditions of unsuccessful antibodies. KLH: Keyhole Limpet Haemocyanin; aa: amino acid; M: mouse; R: rabbit; M: monoclonal; 
P: polyclonal; RT: room temperature; prot K: proteinase K (Dako, 25 min RT in a 1x solution). 
Primary antibody Secondary antibody/detection system and 
conditions Antibody Immunogen Type Homology with feline Source 
Antigen 
retrieval 
Dilution and 
incubation 
TLR2 
(anti-
human) 
KLH conjugated 
synthetic peptide 
corresponding to 
aa 711-774 
RP 95% Bioorbyt (orb11487) Basic/acidic 
1:50/100; 
1h/overnight; 
RT/4°C 
Rabbit EnVision+ System HRP labelled polymer 
(Dako) 
TLR2 
(anti-
human) 
Synthetic peptide 
corresponding to 
aa 364-379 
RP 88% Abcam (ab191458) 
Basic/acidic
/prot K 
1:100/300; 
1h/overnight; 
RT/4°C 
Rabbit EnVision+ System HRP labelled polymer 
(Dako) 
TLR4 
(anti-rat) 
KLH-conjugated 
synthetic peptide 
encompassing a 
sequence within 
the C-term region 
RP 
 unknown 
Abbiotec 
(251111) Basic/acidic 
1:50/100; 
1h/overnight; 
RT/4°C  
 
Rabbit EnVision+ System HRP labelled polymer 
(Dako) 
TLR4 
(anti-
human) 
KLH-conjugated 
synthetic peptide 
corresponding to 
aa 100-200 
MM 88% Abcam (ab22048) Basic/acidic 
1:100/300; 
1h/overnight; 
RT/4°C 
Mouse EnVision+ System HRP labelled polymer 
(Dako) 
Iba-1 
(anti-
human) 
Synthetic peptide 
corresponding to 
aa 135-147 
GP 85% Abcam (ab5076) Acidic 
1:100; 
overnight; RT 
Donkey anti-goat (Invitrogen A11055), 1:500, 30 
min 
STAT2 
(anti-
human) 
Recombinant 
fragment (His-T7-
tag) corresponding 
to aa 616-849 
RP 81% Abcam (ab233177) Basic/acidic 
1:100/200/400/
500/1000; 
1h/overnight; 
RT/4°C 
Rabbit EnVision+ System HRP labelled polymer 
(Dako) 
Immunohistology on case material 
All cases had routinely undergone FCoV IH staining (see Chapters 2 and 3) to confirm the absence 
of lesions in group 1 and the presence of lesions in Group 2. A subset of Group 1 and Group 2 cases 
were stained for TLR8 and Iba-1 to attempt localisation of TLR8 staining.  
Immunofluorescence on case material 
Cases and organs selected for IF were those from which cryoblocks and hence LCM sections had 
also been taken. These were double-stained for TLR8 and FCoV. The aims were to correlate protein 
expression levels with the RT-qPCR results and to assess the frequency of double-staining.  
Staining documentation 
All IH and IF slides were first evaluated by AM. Selected cases were scanned to provide appropriate 
files for digital image analysis. This was performed using a NanoZoomer 2.0HT Hamamatsu slide 
scanner.   
A Nikon Eclipse Ni photomicroscope was used for higher quality photodocumentation of specific 
regions. Filters applied to the IF images were DAPI (AHF, Tübingen, Germany; F36-500), TRITC 
(AHF; F36-503), FITC (AHF; F36-501), and TxRed (AHF; F36-504). 
Image analysis 
The image analysis software Visiopharm was used to classify the images and allow digital 
quantification. An application protocol package (APP) was created to evaluate the TLR8-FCoV 
double-IF-stained slides including searching for co-expression. This APP first used thresholding to 
detect intensity in the DAPI, FITC and TRITC channels (set at 50, 50, and 30 respectively) in order 
to classify the staining. The following post-processing corrections were then applied: 
Classifying nuclei:  
- An inversion was applied to the DAPI stain to attempt improved nuclear segregation 
as many nuclei overlapped in tissues such as the mesenteric lymph node. 255 was then 
added to the pixels to return a positive value.  
- Stained areas smaller than 5 µm2 were excluded.  
- ‘Separate by size’ at a 4 µm limit was applied, in conjunction with the blob feature to 
better define nuclei. 
Classifying FCoV antigen- and TLR8-positive cells: 
- Following thresholding for staining, designed to exclude auto-fluorescent staining of 
erythrocytes, ‘change surrounded’ was applied, at a coverage of 0.01.  
Classifying overlapping staining: 
- As FCoV staining was labelled prior to TLR8 staining, and both are cytoplasmic, overlap 
would still be labelled for the first marker. Therefore an intensity correction was used to 
look for staining in the TRITC channel beneath the FITC channel. 
The outputs were defined as: 
- the count of DAPI stained nuclei in the region of interest (ROI), 
- the count of nuclei touching FITC/FCoV staining, 
- the count of nuclei touching TRITC/TLR8 staining, 
- the count of overlapping cells. 
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In total, nine regions of interest were selected from the scanned slides. These corresponded to 
regions taken by LCM from the cryoblocks of the same animal and organ.  
 
5. Selected S gene Sanger sequencing 
All samples that had positive FCoV RT-qPCR results and were not already sequenced (i.e. all Zurich 
samples including LCM samples and a proportion of the Bristol samples) were subjected to 
conventional PCR and subsequent Sanger sequencing using published primer sequences 133. 
Faeces were not subjected to PCR from Zurich cases but Bristol faecal results were evaluated 
where available from previous sequencing. 
The PCR protocol involved 12.5 µl 2x GoTaq master mix, 0.5 µl of 10 µM forward and reverse 
primer (final concentration 0.25 µM), 9.5 µl molecular grade water, and 2 µl of sample cDNA per 
reaction, to a total of 25 µl. Primers used were degenerate and had been designed using multiple 
known FCoV Type I sequences to maximise the binding potential. The primer positions below are 
given relative to the published genome of FCoV strain C1Je, accession number DQ848678. 
Forward: 5’-GCHCARTATTAYAATGGCATAATGG-3’; 23436-23460 
Reverse: 5’-AAGYCTRGCYTGYACTTGCAT-3’; 23588-23568 
Reaction conditions were as follows; 95°C for 2 min, 40 cycles of 95°C for 15 s, 52°C for 20 s and 
72°C for 20 s, before being held at 4°C. 
The resulting product was run on a standard 2 % agarose gel for 40 min at 100 V with 5 µl of 6x 
DNA gel loading dye (Thermo Fisher Scientific) per well, before visualisation using a Benchtop UV 
Transilluminator (Analytik Jena Ag, Jena, Germany). 5 µl GeneRuler (Thermo Fisher Scientific) was 
run to either side of the gel. Visible bands were excised using sterile single use scalpel blades and 
the DNA purified using the MinElute Gel Extraction Kit (Qiagen) according to the manufacturer’s 
instructions. A Nanodrop 2000 (Thermo Fisher Scientific) was then used to determine the correct 
concentration to be submitted to the commercial laboratory Microsynth for sequencing.  
This protocol was tested on a previously sequenced and published sample (no. 58) in addition to 
two untested samples and was at first trial successful. Using samples with higher FCoV RT-qPCR 
CT values however, many PCR products could not be sequenced and a low level of repeatability 
was noted between runs using positive controls, including one run of all negative results. To 
troubleshoot this problem, a test sample was run again with the qRT-qPCR protocol for GAPDH 
and the CT compared, in case of sample degradation. As the RT-qPCR sequences are slightly shorter 
and may thus be detected in more degraded samples than longer sequences (though the 
difference in this case is negligible), RNA was freshly extracted and cDNA newly synthesised. 
Results were still unreliable therefore a new protocol was developed. 
The master mix was changed to Phusion Flash High-Fidelity PCR Master Mix (Thermo Fisher 
Scientific), containing Phusion Flash II DNA Polymerase which is designed to offer a higher degree 
of replication fidelity https://www.thermofisher.com/order/catalog/product/F548S. The 
datasheet states an improvement of 25x in comparison to Taq polymerase, providing a higher 
chance of sequence amenable DNA from low input samples.  
The reaction components (Table 4.5.1) and protocol (Table 4.5.2) were calculated according to the 
manufacturer’s recommendations, though with an increased cycle number based on previous 
experience with these samples. A 3-step protocol rather than a 2-step protocol was used as Tm 
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values were lower than recommended for a 2-step one (at least 69°C for primers >20 nucleotides). 
The manufacturer provides an online calculator (www.thermofisher.com/tmcalculator) as the 
enzyme has different annealing rules than the Taq polymerase. This does not include degenerate 
bases in the calculation. Suggested temperatures were: forward primer 62°C, reverse primer 
57.6°C. A gradient PCR was then run on a known positive sample (no. 14) ranging from 52 – 65°C 
over 12 lanes (Table 4.5.3). 
Table 4.5.1: Components per reaction for S gene conventional PCR. 
Component  20 µl reaction (µl) Final concentration 
2 x Phusion Flash PCR Master Mix 10 1x 
H2O 6  
Forward primer (10µM) 1 0.5 µM 
Reverse primer (10µM) 1 0.5 µM 
Template DNA 2  
 
Table 4.5.2: Reaction conditions for S gene conventional PCR. 
Cycle step 3-step protocol Cycles 
Temp (°C) Time 
Initial denaturation 98 10 s 1 
Denaturation 98 1 s  
40 Annealing See gradient 5 s 
Extension 72 15s/1 kb = 3s 
Final extension 72  1 min 1 
 
Table 4.5.3: Gradient PCR settings and results. 
Lane 1 2 3 4 5 6 7 8 9 10 11 12 
T °C 52    56.2       65 
Result + + + + + + (+) - - - - - 
 
Lanes 1 and 5 were selected as the optimal two lanes, see Fig. 4.5.1 below, producing the brightest 
and most condensed bands respectively.  
 
 
 
 
 
 
Figure 4.5.1: Gradient PCR of sample 14 with positive results in lanes 2-8. 
 
The majority of cases were then sequenced without further problems. Those with a low viral 
genome level required 50 cycles or in some cases PCR of the purified region of an expected band 
1 2 3 4 5 6 7 8 9 10 11 12 13 14  
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(Fig. 4.5.2). First, simple repeat PCR of the product was attempted and compared to PCR of 
purified product; the former was unsuccessful. For all G1+ cases, in which CTs were generally over 
35, cDNA was newly synthesised from previously extracted RNA using the SuperScript IV VILO kit 
(see above, Chapter 3). The product was not diluted as it had previously been for qPCR in order to 
increase the starting copy number. All of these high CT cases required double PCR; positive samples 
were run in alternate lanes to target the regions to be incised.  
 
 
 
 
 
 
 
 
Figure 4.5.2: a) initial PCR run with no or negligible bands visible for many samples, b) results of second 
PCR on purified product of initial run. 
 
6. RNA-Seq by Next Generation Sequencing (NGS) 
Samples were chosen for RNA-Seq on the basis of RT-qPCR results. Mesenteric lymph node 
samples from each of Groups 1-, 1+ and 2 were submitted for initial quality testing. This was 
performed on a Bioanalyzer 2100 (Agilent, Waldbronn, Germany) based in the Functional 
Genomics Centre Zurich (FGCZ) a Core Facility of the University of Zurich, to obtain a RIN (RNA 
integrity number). Among the Bristol samples were occasional samples of very low quality, despite 
performing satisfactorily with RT-qPCR. This may be related to the thawing in transport, meaning 
not all samples were available to select from.  
To utilise a complete run (recommended by the FGCZ for this protocol as 15 samples), three bulk 
MLN samples from each group were selected, in addition to six MLN LCM samples. Three is the 
mathematical minimum number of biological replicates required in order to reliably group results 
and be able to spot outliers (if two samples give different results the difference could be real or 
due to error in one, but which one could not be determined; as for PCR replicates). 
All samples were DNase treated with the Superscript IV VILO ezDNase step as described above 
(Chapter 3). Before application of this method to all samples, sample quality with and without this 
treatment was compared with no deleterious effect on concentration detected.  
Steps subsequent to RNA extraction and cleaning were carried out by the FGCZ.  
The final submitted cases were as in Table 4.6.1 below.  
  
13 16 20 23 26 29 33 34 35 37 41 42 45 47 + - 
+        -  20     23      29     34     35     41      42 
a b 
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Table 4.6.1: Cases used for RNA-Seq NGS. The starred sample failed the pre-sequencing quality checks 
so is not included in the results section. Superscript E indicates effusions, and L lesions. All LCM samples 
were granulomatous. 
   Group and sample number 
NGS sample number Case number G1- (G1) G2 G1+ (G3) LCM 
p2762_4449/1 56 64    
p2762_4449/2 S17-0409 51    
p2762_4449/3 S17-0568 55    
p2762_4449/4 42  61E,L   
p2762_4449/5 128  89L   
p2762_4449/6 94  73E   
p2762_4449/7 38   60  
p2762_4449/8 132   91  
p2762_4449/9 135   92  
p2762_4449/10 S15-0983    116* 
p2762_4449/11 S15-1539    117 
p2762_4449/12 S15-1728    118 
p2762_4449/13 S16-0167    119 
p2762_4449/14 S16-0454    120 
p2762_4449/15 S17-0124    121 
 
Two methods were applied, one to the standard MLN samples, and one to the LCM samples, owing 
to the huge differences in starting concentrations.  
 
Library preparation for samples p2762_4449/1-9 (bulk MLN) 
The quality of the isolated RNA was determined with a Qubit® (1.0) Fluorometer (Life 
Technologies, California, USA) and a Bioanalyzer 2100. Only those samples with a 260 nm/280 nm 
ratio between 1.8–2.1 and a 28S/18S ratio within 1.5–2 were further processed. The TruSeq RNA 
Sample Prep Kit v2 (Illumina, Inc, California, USA) was used, following the manufacturer’s protocol. 
Briefly, total RNA samples (100-1000 ng) were poly A enriched and then reverse-transcribed into 
double-stranded cDNA. The cDNA samples were fragmented, end-repaired and polyadenylated 
before ligation of TruSeq adapters to each end. These contain the index for multiplexing fragments 
and were selectively enriched by PCR. The quality and quantity of the enriched libraries were 
validated using Qubit® (1.0) Fluorometer and the Caliper GX LabChip® GX (Caliper Life Sciences, 
Inc., USA). The product is a smear with an average fragment size of approximately 260 bp. The 
libraries were normalized to 10nM in Tris-Cl 10 mM, pH8.5 with 0.1% Tween 20. 
 
Oligonucleotide adapter sequences for TruSeq™ RNA and DNA Sample Prep Kits were as follows, 
in order from sample 1-9: 
TruSeq Universal Adapter 
5’ AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT  
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TruSeq™ Adapters  
TruSeq Adapter, Index 1 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACATCACGATCTCGTATGCCGTCTTCTGCTTG 
TruSeq Adapter, Index 2 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACCGATGTATCTCGTATGCCGTCTTCTGCTTG 
TruSeq Adapter, Index 3 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACTTAGGCATCTCGTATGCCGTCTTCTGCTTG 
TruSeq Adapter, Index 4 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACTGACCAATCTCGTATGCCGTCTTCTGCTTG 
TruSeq Adapter, Index 5 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACACAGTGATCTCGTATGCCGTCTTCTGCTTG 
TruSeq Adapter, Index 6 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACGCCAATATCTCGTATGCCGTCTTCTGCTTG 
TruSeq Adapter, Index 7 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACCAGATCATCTCGTATGCCGTCTTCTGCTTG 
TruSeq Adapter, Index 8 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACACTTGAATCTCGTATGCCGTCTTCTGCTTG 
TruSeq Adapter, Index 9 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACGATCAGATCTCGTATGCCGTCTTCTGCTTG 
 
Cluster generation and sequencing 
The TruSeq SR Cluster Kit HS4000 (Illumina) was used for cluster generation using 10 pM of pooled 
normalised libraries on the cBOT. Sequencing was performed on the Illumina HiSeq 4000 single 
end 100 bp using the TruSeq SBS Kit HS4000.  
 
Library preparation for samples p2762_4449/10-15 (LCM) 
The quantity and quality of the isolated RNA was determined with a Qubit® (1.0) Fluorometer (Life 
Technologies) and a Tapestation (Agilent). The SMARTer Stranded Total RNA-Seq Kit - Pico Input 
Mammalian (Clontech Laboratories, California, USA) was then used, following the manufacturer’s 
protocol. Briefly, total RNA samples (0.25–10 ng) were reverse-transcribed using random priming 
into double-stranded cDNA in the presence of a template switch oligo (TSO). When the reverse 
transcriptase reaches the 5’ end of the RNA fragment, the enzyme’s terminal transferase activity 
adds non-templated nucleotides to the 3’ end of the cDNA. The TSO pairs with the added non-
templated nucleotide, enabling the reverse transcriptase to continue replicating to the end of the 
oligonucleotide. This results in a cDNA fragment that contains sequences derived from the random 
priming oligo and the TSO. PCR amplification using primers binding to these sequences can now 
be performed. The PCR adds full-length Illumina adapters, including the index for multiplexing. 
Ribosomal cDNA is cleaved by ZapR in the presence of the mammalian-specific R-Probes. The 
remaining fragments are enriched by a second round of PCR amplification using primers designed 
to match Illumina adapters.  
The quality and quantity of the enriched libraries were validated using Qubit® (1.0) Fluorometer 
and the Tapestation (Agilent). The product is a smear with an average fragment size of 
71 
 
approximately 360 bp. The libraries were normalized to 10nM in Tris-Cl 10 mM, pH8.5 with 0.1% 
Tween 20. 
All samples used the i7 Index R3 adapter sequence CGCTCATT, together with i5 index adapter 
sequences as follows:  
sample 10 F1  TATAGCCT   
sample 11 F2  ATAGAGGC  
sample 12 F3  CCTATCCT 
sample 13 F4  GGCTCTGA  
sample 14 F5  AGGCGAAG  
sample 15 F6  TAATCTTA  
Cluster generation and sequencing was performed as for samples 1-9. 
 
Data Analysis 
In the main analysis comparing the G- and LCM groups, reads were quality-checked with FastQC. 
Sequencing adapters were removed with Trimmomatic 308 and reads were hard-trimming by 5 bases 
at the 3’ end. Successively, reads at least 20 bases long, and with an overall average phred quality 
score greater than 10 were aligned to the reference genome and transcriptome of Felis Catus (FASTA 
and GTF files, respectively, downloaded from Ensembl, build 6.2) with STAR v2.5.1 309 with default 
settings for single end reads. In this Ensembl build, genes TLR7 and TLR9 are not annotated, 
therefore the UCSC build felCat5 was used instead to estimate the expression of those two genes. 
Distribution of the reads across genomic isoform expression was quantified using the R package 
GenomicRanges 310 from Bioconductor Version 3.0. Differentially expressed genes (DE) were 
identified using the R package edgeR 311 from Bioconductor Version 3.0.   
A gene is marked as DE if it possesses the following characteristics:  
• at least 10 counts in at least half of the samples in one group;   
• p ≤ 0.01 
• fold change ≥ 2  
The Gene Ontology (GO) gene set analysis was performed via a contingency table-based Fisher’s 
exact test.  
Additionally, a quantification of the viral transcriptome in the different samples was attempted. 
The reference Feline Coronavirus (Accession DQ848678) was obtained from uniprot and RSEM 
v1.2.31 312 was used to directly estimate the expression of the viral segments. 
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Results 
 
1. RT-qPCR on bone marrow and spleen 
The entire panel of immune mediators were expressed constitutively by both organs with only 
rare negative results. The latter were most frequent for IL-17 which was always recorded at a high 
CT, indicating the levels were close to the detection limit and hence not always measurable in this 
system. In the control group, for all targets except MMP9 and MMP13 mRNA levels were higher 
in the spleen than in the bone marrow (BM), frequently without overlap between groups. Results 
are summarised in Figs. 5.1.1-7 and Table 5.1.1. 
FCoV 
Nine of the eleven cats with FIP (G2) for which the BM was available for testing had detectable 
FCoV in the BM. This was despite negative FCoV IH from all cases. The samples for routine 
embedding were of course not the same samples as those used for PCR, but this finding is 
consistent with previous findings in the BM 48. All fourteen cats with FIP had detectable FCoV in 
the spleen and at a higher level than in the BM with no overlap of the interquartile ranges between 
organs. This corresponds to the observed histological lesions present in most, and the FCoV 
positivity observed in all. There was no FCoV detectable in either organ of cats without FIP (G1; 
n=6). See Fig. 5.1.1. 
Toll-like receptors 
TLR9 mRNA levels were significantly higher in G2 for both organs whilst TLR1 and 6 were 
significantly lower in the BM and TLR3 and 6 significantly lower in the spleen. TLR2, 5, and 7 
showed a trend to be increased in the BM with the opposite shown by TLR3. In the spleen, the 
same tendencies were observed, however, here the increase in TLR2 and decrease in TLR3 reached 
significance. See Fig. 5.1.2. 
Cytokines and chemokines 
Of the pyrogenic triad of IL-1β, IL-6 and TNF-a, only IL-1β was significantly increase in G2, and only 
in the BM. However, all three showed a slight trend to increase in the spleen whereas only IL-6 
levels showed no tendency in the BM. IL-15 and IL-17 were both negligibly altered. The 
chemokines CCL8 and CXCL10 were both significantly increased in G2 in the spleen, whilst in the 
BM both were increased but only CXCL10 significantly so. Of the predominantly anti-inflammatory 
cytokines IL-10 and TGF-b, the latter was significantly reduced in G2 for both organs with no 
change in IL-10. See Fig. 5.1.3. 
Interferons 
A significant increase in IFN-b was observed in both organs in G2. For IFN-g a significant increase 
was observed in the spleen only, with little change in the BM, whilst for IFN-a both organs showed 
a non-significant slight increase. See Fig. 5.1.4 
STATs 
Both organs showed significantly increased STAT1 and 2 mRNA levels in G2, with no change in 
STAT3. See Fig. 5.1. 5 
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Matrix remodelling enzymes 
In the BM, MMP2 and MMP9 were significantly lower in G2, whereas in the spleen, MMP2 and 
MMP13 were significantly lower. TIMP1 and 3 were significantly lower in G2 for both organs. See 
Fig. 5.1.6 
Colony stimulating factors 
Within the BM, both G- and M-CSF were significantly lower in G2, and the latter was also 
significantly lower in the spleen. See Fig. 5.1.7. 
 
 
 
 
 
Figures 5.1.1: Boxplots of relative levels of FCoV in each group.  
Groups 1 and 2 refer to the control cases and FIP cases respectively. The amount of target was calculated by          
2-∆∆CT, using fGAPDH as the internal reference gene for normalisation and expressed as an n-fold difference 
relative to the G1 mean of the BM samples as a calibrator. The boxes depict the median and interquartile (IQ) 
range with whiskers extending to the highest and lowest values which are within 1.5 x the IQ range. Outliers 
beyond this are individually marked.  
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Figures 5.1.2: Boxplots of relative mRNA levels of Toll-like receptors in each group.  
Groups 1 and 2 refer to the control cases and FIP cases respectively. The amount of target was calculated by          
2-∆∆CT, using fGAPDH as the internal reference gene for normalisation and expressed as an n-fold difference 
relative to the G1 mean of the BM samples as a calibrator. The boxes depict the median and interquartile (IQ) 
range with whiskers extending to the highest and lowest values which are within 1.5 x the IQ range. Outliers 
beyond this are individually marked. * marks significant differences between groups (p≤0.05).  
 
 
* * * 
* * 
* * 
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Figures 5.1.3: Boxplots of relative mRNA levels of cytokines and chemokines in each group.  
Groups 1 and 2 refer to the control cases and FIP cases respectively. The amount of target was calculated by          
2-∆∆CT, using fGAPDH as the internal reference gene for normalisation and expressed as an n-fold difference 
relative to the G1 mean of the BM samples as a calibrator. The boxes depict the median and interquartile (IQ) 
range with whiskers extending to the highest and lowest values which are within 1.5 x the IQ range. Outliers 
beyond this are individually marked. * marks significant differences between groups (p≤0.05).  
 
 
* 
* 
* * * * 
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Figures 5.1.4: Boxplots of relative mRNA levels of interferons in each group.  
Groups 1 and 2 refer to the control cases and FIP cases respectively. The amount of target was calculated by          
2-∆∆CT, using fGAPDH as the internal reference gene for normalisation and expressed as an n-fold difference 
relative to the G1 mean of the BM samples as a calibrator. The boxes depict the median and interquartile (IQ) 
range with whiskers extending to the highest and lowest values which are within 1.5 x the IQ range. Outliers 
beyond this are individually marked. * marks significant differences between groups (p≤0.05).  
 
 
 
 
 
 
Figures 5.1.5: Boxplots of relative mRNA levels of STATs in each group.  
Groups 1 and 2 refer to the control cases and FIP cases respectively. The amount of target was calculated by          
2-∆∆CT, using fGAPDH as the internal reference gene for normalisation and expressed as an n-fold difference 
relative to the G1 mean of the BM samples as a calibrator. The boxes depict the median and interquartile (IQ) 
range with whiskers extending to the highest and lowest values which are within 1.5 x the IQ range. Outliers 
beyond this are individually marked. * marks significant differences between groups (p≤0.05). 
 
 
* * * * 
* * * 
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Figures 5.1.6: Boxplots of relative mRNA levels of matrix remodelling enzymes in each group.  
Groups 1 and 2 refer to the control cases and FIP cases respectively. The amount of target was calculated by          
2-∆∆CT, using fGAPDH as the internal reference gene for normalisation and expressed as an n-fold difference 
relative to the G1 mean of the BM samples as a calibrator. The boxes depict the median and interquartile (IQ) 
range with whiskers extending to the highest and lowest values which are within 1.5 x the IQ range. Outliers 
beyond this are individually marked. * marks significant differences between groups (p≤0.05). 
Figures 5.1.7: Boxplots of relative mRNA levels of colony stimulating factors in each group.  
Groups 1 and 2 refer to the control cases and FIP cases respectively. The amount of target was calculated by          
2-∆∆CT, using fGAPDH as the internal reference gene for normalisation and expressed as an n-fold difference 
relative to the G1 mean of the BM samples as a calibrator. The boxes depict the median and interquartile (IQ) 
range with whiskers extending to the highest and lowest values which are within 1.5 x the IQ range. Outliers 
beyond this are individually marked. * marks significant differences between groups (p≤0.05). 
* * * * 
* * * * 
* * * 
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Table 5.1.1: Statistical results of Mann-Whitney test, comparing G1 vs G2 for bone marrow and spleen. 
Highlighted results indicate p≤0.05 and arrows indicate whether G2 was higher or lower. 
 BM spleen 
Target G1 vs G2 G1 vs G2 
TLR1 0.001 ↓ 0.274  
TLR2 0.062   0.015 ↑ 
TLR3 0.216   0.033 ↓ 
TLR4 0.404   0.444  
TLR5 0.149   0.130  
TLR6 0.005 ↓ 0.009 ↓ 
TLR7 0.216   0.179  
TLR8 0.350   0.130  
TLR9 0.000 ↑ 0.001 ↑ 
STAT1 0.000 ↑ 0.002 ↑ 
STAT2 0.000 ↑ 0.003 ↑ 
STAT3 0.301   1.000  
IFN-α 0.149  0.239  
IFN-β 0.020 ↑ 0.001 ↑ 
IFN-γ 0.404   0.003 ↑ 
IL-1β 0.048 ↑ 0.153  
IL-6 0.591   0.051  
IL-10 0.149   0.779  
IL-15 0.404   0.397  
IL-17 0.884   0.207  
TNF-α 0.098   0.659  
TGF-β 0.001 ↓ 0.002 ↓ 
CCL8 0.216   0.003 ↑ 
CXCL10 0.007 ↑ 0.000 ↑ 
MMP2 0.003 ↓ 0.000 ↓ 
MMP9 0.000 ↓ 0.494  
MMP13 0.216   0.003 ↓ 
TIMP1 0.001 ↓ 0.041 ↓ 
TIMP3 0.000 ↓ 0.000 ↓ 
G-CSF 0.027 ↓ 0.602  
M-CSF 0.037 ↓ 0.015 ↓ 
GM-CSF 0.216   0.051  
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2. Accepted manuscript 
The following accepted manuscript includes results from the MLN RT-qPCR experiments and part 
of the Sanger sequencing work, such that there is some overlap between chapters. Related and 
further results which were not included in the manuscript are presented subsequently. Alternative 
graphs are also displayed for this chapter, as the manuscript focussed on the MLN only. RT-qPCR 
results were calculated by the DDCT method, relative to levels of the reference gene GAPDH and 
calibrated to the mean of the control group DCT levels for each target.  This calibrator was the 
MLN control group for the publication in order for the results to be stand-alone. However, the BM 
control group was used for these additional graphs, as in the previous chapter, for comparability 
between organs (this affects the y axis of the graphs but has no effect on the statistics as the same 
function is applied to all results for a given target). 
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Summary
Feline infectious peritonitis (FIP) is an almost invariably fatal feline coronavirus (FCoV)-induced disease
thought to arise from a combination of viral mutations and an overexuberant immune response. Natural initial
enteric FCoV infection may remain subclinical, or result in mild enteric signs or the development of FIP; cats
may also carry the virus systemically with no adverse effect. This study screened mesenteric lymph nodes
(MLNs), the presumed first site of FCoV spread from the intestine regardless of viraemia, for changes in the
transcription of a panel of innate immune response mediators in response to systemic FCoV infection and
with FIP, aiming to identify key pathways triggered by FCoV. Cats with and without FIP, the latter with
and without FCoV infection in the MLN, were compared. Higher expression levels in FIP were found for
toll-like receptors (TLRs) 2, 4 and 8. These are part of the first line of defence and suggest a response to
both viral structural proteins and viral nucleic acid. Expression of genes encoding inflammatory cytokines
and chemokines, including interleukin (IL)-1b, IL-6, IL-15, tumour necrosis factor (TNF)-a, CXCL10,
CCL8, interferon (IFN)-a, IFN-b and IFN-g, was higher in cats with FIP, consistent with inflammatory
pathway activation. Expression of genes encoding transcription factors STAT1 and 2, regulating signalling
pathways, particularly of the interferons, was also higher. Among cats without FIP, there were few differences
between virus-positive and virus-negative MLNs; however, TLR9 and STAT2 expression were higher with
infection, suggesting a direct viral effect. The study provides evidence for TLR involvement in the response
to FCoV. This could open up new avenues for therapeutic approaches.
! 2018 Elsevier Ltd. All rights reserved.
Keywords: cytokines; feline coronavirus; mesenteric lymph nodes; toll-like receptors
Introduction
Feline infectious peritonitis (FIP) is a well-known and
widely distributed coronavirus-induced disease of fe-
lids. With as yet no effective vaccine or viable treat-
ment options, FIP is almost invariably fatal, and
understanding the pathogenetic and immunological
mechanisms involved in disease development is
crucial to aiding chances of combating FIP and iden-
tifying novel avenues for possible treatment.
After initial enteric infection, feline coronavirus
(FCoV) may spread beyond the intestine, resulting
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in a monocyte-associated viraemia, with or without
the development of FIP. In cases progressing to
FIP, which may have a time lag of weeks to years,
viral and host factors combine to turn an initial, usu-
ally subclinical, enteritis into an overt immune-
mediated disease (Pedersen et al., 1981; Kipar and
Meli, 2014). Much research has focussed on viral
mutations and has partially elucidated the function
of various viral proteins in the pathogenesis of FIP.
The viral spike (S) protein gene has been of
particular interest, and a switch from methionine
(M) to leucine (L) at amino acid residue 1,058
(M1058L) has been strongly associated with a gain
of virulence (Chang et al., 2012). A second switch
from serine (S) to alanine (A) at amino acid residue
1,060 (S1060A) distinguished tissue-associated
FCoV in a further small subset of FIP cases from
FCoV shed with the faeces by healthy cats (Chang
et al., 2012). These mutations have since been associ-
ated with systemic spread of FCoV, rather than
providing proof of virulence (Porter et al., 2014;
Barker et al., 2017; Felten et al., 2017a), so the two
forms are subsequently referred to here as ‘systemic’
and ‘enteric’ FCoV.
Early experiments demonstrated that not all cats
are susceptible to FCoV infection, even with known
pathogenic strains (Pedersen and Boyle, 1980), indi-
cating the importance of host genetic factors/immune
mechanisms in disease development. More recently it
was shown that cultured monocytes from different
cats vary in their ability to sustain viral replication,
again suggesting that there is a subset of animals
who can resist disease (Dewerchin et al., 2005; Tekes
et al., 2010). Monocytes/macrophages are not the
only cell type beyond enterocytes that may be
infected by FCoV, but they are also key cells in the
innate immune defence system. They are able to
detect pathogen-associated molecular patterns
(PAMPs), triggering a number of intracellular
signalling pathways leading to activation of an
antiviral state in the host (Abbas et al., 2017). Chief
amongst these pathways are those triggered by
engagement of toll-like receptors (TLRs); highly
evolutionarily conserved, membrane-bound path-
ogen recognition receptors (PRRs) (Lester and Li,
2014). Their presence on both the cell surface mem-
brane and internal membrane-bound vesicles allows
detection of external and internal PAMPs; their li-
gands include those associated with viruses, bacteria
and fungi (Arpaia and Barton, 2011). Downstream
mediators include inflammatory cytokines and inter-
ferons that have been assessed in cats with FIP, with
sometimes conflicting results (Dean et al., 2003;
Kipar et al., 2006b). Interferons and the
inflammatory cytokine interleukin (IL)-6 can
activate members of the signal transducer and
regulator of transcription (STAT) family with
downstream effects on replication, differentiation or
inflammatory potential (Aaronson and Horvath,
2002). Cats with a compromised immune system
appear to be more susceptible to FIP, while, paradox-
ically, the lesions are caused by an excessive immune
response (Pedersen, 1987, 2014; Kipar and Meli,
2014). This has been attributed, at least in part, to
increased viral replication in immunosuppressed
animals and, therefore, an increased likelihood
of viral mutations occurring and accumulating
(Poland et al., 1996).
TLRs have been associated with susceptibility to
many diseases, including chronic inflammatory, viral
and more specifically coronaviral diseases (e.g. severe
acute respiratory syndrome, SARS) (Dosch et al.,
2009). Intriguingly though, both TLR stimulation
and antagonism/knock-outs have contributed to
exacerbation of disease in different contexts and there
exists considerable crossover between receptors and
their potential ligands (Arpaia and Barton, 2011).
When FCoV is able to leave the intestine, the
mesenteric lymph nodes (MLNs) are the presumed
first site of viral spread, potentially representing the
interface between local and systemic immune
response; support for this assumption are FIP cases
that present only with MLN lesions (Kipar et al.,
1999). We therefore chose the MLN as our organ of
interest, with the aim of comparing key mediators of
the innate immune system between uninfected cats
and FCoV-infected cats with and without FIP. We
hypothesized that in addition to an excessive pro-
inflammatory cytokine response, there would be a
deficient interferon response, and aimed to gain an
insight into which TLR pathways are involved in
triggering this response. We also wished to further
evaluate the presence and significance of previously
published viral S gene variations and determine
whether a connection with the host immune response
could be detected.
Materials and Methods
Case Selection
The study was undertaken on cats that had all been
seen initially as patients at the university small animal
clinics and local veterinary practices of Bristol, UK,
or Zurich, Switzerland, and humanely destroyed
with or without FIP for clinical reasons unrelated to
this study (Table 1). A post-mortem examination
was performed on each cat with owner consent and
samples ofMLNwere collected intoRNAlater" (Qia-
gen, Hombrechtikon, Switzerland) within 2 h of
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euthanasia and stored at!80"C until use. The Bristol
cases form part of the University of Bristol FIP Bio-
bank built up as a resource for multiple studies;
many of these cases were utilized previously (Porter
et al., 2014; Barker et al., 2017).
Group 1 (G1) comprised of 40 control cats
confirmed to not have FIP and with an alternate
confirmed diagnosis (Tables 1A and 1B), and group
2 (G2) consisted of 30 cats confirmed to have FIP
(Table 1C). A diagnosis of FIP was based on relevant
clinical findings and compatible gross and/or histo-
logical lesions together with immunohistological
demonstration of FCoV antigen-positive macro-
phages within typical lesions (Kipar et al., 1998).
The immunohistochemistry was carried out as previ-
ously described (Kipar et al., 1998), using a mouse
monoclonal primary antibody (clone FIPV3-70 SC
65653, Santa Cruz, Heidelberg, Germany). Based
on the results of the reverse transcriptase quantitative
polymerase chain reaction (RT-qPCR) for FCoV un-
dertaken on the MLNs, group G1 was then subdi-
vided into G1+ (FCoV positive) and G1! (FCoV
negative).
RNA Extraction and cDNA Synthesis
RNA extraction was carried out using the RNeasy
Plus Minikit" (Qiagen) according to the manufac-
turer’s protocol. Briefly, 30 mg of MLN tissue were
disrupted in extraction buffer using a tissue homoge-
nizer (Mixer-Mill 300, Retsch, Haan, Germany) for
40 sec at 30 Hz before on-column extraction and
elution of RNA. As pilot tests revealed that significant
genomic DNA contamination remained, an optional
DNase step was included prior to use of the Super-
script IV VILO" kit (ThermoFisher Scientific, Wal-
tham, Massachusetts, USA) for cDNA synthesis,
following the manufacturer’s instructions, in order
Table 1A
Signalment, histological and immunohistochemical findings and Sanger sequencing results of all cases. Group 1L: cats
without FIP and without evidence of systemic FCoV infection
Breed Age Sex Diagnosis Mesenteric lymph node
Histology IHC (FCoV Ag)
1 Ragdoll 4 y MN Congestive heart failure Normal !
2 Bengal 11 y MN Colonic adenocarcinoma Normal ND
3 DSH Adult FN DCM, chronic kidney disease Follicular hyalinosis !
4 DSH Adult MN Acute myeloid leukaemia Leukaemia !
5 Birma 1 y MN Hippocampal necrosis Normal !
6 House cat 14 y MN Haemorrhage in brain Follicular hyalinosis ND
7 DSH 8 y MN Chemodectoma Normal !
8 Birman 13 y Pyothorax and pneumonia Neutrophilic and histiocytic inflammation !
9 DSH 6 y MN Astrocytoma Normal to reactive hyperplasia !
10 10 y MN Diabetes mellitus Reactive hyperplasia and amyloidosis !
11 DSH 12 y Aplastic anaemia Neutrophilic inflammation !
12 DSH 6 y Diarrhoea, suspected torovirus ND ND
13 DLH 8 y Gastric lymphoma Normal !
14 DSH 5 y MN Suppurative meningitis Mild depletion !
15 DSH 3 y MN Lymphocytic cholangiohepatitis Normal to reactive hyperplasia ND
16 DSH 2 y MN Hepatitis and pyelonephritis Reactive hyperplasia and sinus histiocytosis !
17 DSH 4 y FN Granulomatous rhinitis and encephalitis ND ND
18 DSH 8 y FN Chronic enteropathy ND ND
19 DSH 1 y FN Poxviral pneumonia ND ND
20 DSH 4 y FN Hepatic encephalopathy ND ND
21 Ragdoll 3 y MN Hypertrophic cardiomyopathy ND ND
22 DSH 13 y FN Focal intestinal necrosis Normal ND
23 DSH F Behavioural Normal to reactive hyperplasia !
24 DSH 3 y FN Invasive meningioma Normal to reactive hyperplasia !
25 Maine Coon 9 y Meningoencephalitis Normal !
26 DSH 5 y FN Pulmonary adenocarcinoma Tumour emboli ND
27 Devon Rex 8 y Inflammatory bowel disease Normal !
28 DSH 9 y MN Multicentric lymphoma Reactive hyperplasia !
29 DSH 10 m MN Hypertrophic cardiomyopathy Reactive hyperplasia and sinus histiocytosis !
30 Bengal 7 y FN Jejunal constriction Follicular depletion !
FIP, feline infectious peritonitis; FCoV, feline coronavirus; MLN, mesenteric lymph node; IHC, immunohistochemistry; Ag, antigen; DSH, do-
mestic shorthair; DLH, domestic longhair; blank, data not available; F, female;M,male; FN, female neutered;MN,male neutered; DCM, dilated
cardiomyopathy; ND, not done; !, negative.
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to avoid possible interference with the RT-qPCR re-
sults. Starting RNA levels were equilibrated between
samples to 400 ng/ml, using a NanoDrop 2000"
(ThermoFisher Scientific). Samples were further
diluted 1 in 20 prior to RT-qPCR.
Reverse Transcriptase Quantitative Polymerase Chain
Reaction
TaqMan RT-qPCR was performed on an Applied
Biosystems 7500 Fast PCR System" (ThermoFisher
Scientific) using newly developed, or previously pub-
lished, primer and probe protocols for: FCoV; feline
TLR 1 to 9; STAT 1 to 3; interferon (IFN)-a, -b
and -g; IL-1b, -6, -10, -15, and -17; tumour necrosis
factor (TNF)-a; CXC motif chemokine 10
(CXCL10); CC motif chemokine ligand 8 (CCL8);
transforming growth factor (TGF)-b1; and glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH), as
the reference gene (Table 2) (Leutenegger et al.,
1999). This gene was chosen based on previous expe-
rience in our laboratory and following reference gene
comparisons during optimization. All primers and
probes were manufactured by Microsynth (Balgach,
Switzerland). The hydrolysis probes were labelled
with a 50 reporter dye FAM (6-carboxyfluorescein)
and a 30 quencher TAMRA (6-carboxy-tetramethylr-
hodamine).
Those primers and probes that were newly devel-
oped were designed using Primer Express" software
(v3.0.1, Thermo Fisher Scientific) to span an
exoneexon junction. These were tested for specificity
by conventional PCR of a test sample, gel electropho-
resis, sequencing of the resulting extracted band (Mi-
crosynth) and evaluation using NCBI BLAST.
Conditions were as for RT-qPCR except for omission
of the probe. Primer concentrations for this step were
900 nM. Varying primer/probe concentrations were
then tested to determine the optimal efficiency and
dynamic range as well as replicability using a sample
dilution series. All final protocols (Table 2) had an ef-
ficiency >95%. Those previously published were
tested again in our system, omitting the conventional
RT-PCR step. Each reaction comprised 12.5 ml Taq-
Man Fast Universal Master Mix" (ThermoFisher
Scientific), with 2.5 ml cDNA, primer and probe vol-
umes as per Table 2, made up to 25 ml with RNase-
free water. The thermal profile for all RT-qPCRs
was: 50"C for 2 min, 95"C for 10 min, and 45 cycles
of 95"C for 10 sec and 60"C for 1 min. All samples
were run in duplicate and any samples with discor-
dant results were repeated. Data collection occurred
during the extension phase at 60"C. Appropriate con-
trols were included in each run.
The Applied Biosystems 7500 Software" v2.0.6 was
used to visualize results and allocate a quantification
cycle (Cq) to each sample, and the threshold was
equilibrated between runs for each target.
Viral Sequencing
The particular codons of interest within the FCoV S
gene were 1,058 and 1,060 (Chang et al., 2012).
With reference to the sequence used in the original pa-
per, the mutations in question appear to be at posi-
tions 1,048 and 1,050 rather than 1,058 and 1,060
Table 1B
Group 1+: cats without FIP, but with evidence of systemic FCoV infection
Breed Age Sex Diagnosis Mesenteric lymph node
Histology IHC
(FCoV Ag)
Sequencing
Codon 1,048 Codon 1,050
1 Maine
Coon
1 y Pleural effusion (FCoV
RT-qPCR negative)
ND ND Not possible
2 DSH 3 y MN Lethargy, weight loss, anaemia ND ND TTG Leu ND
3 DSH 10 y MN Diabetes mellitus Reactive hyperplasia with
collagen scars
! CTG Leu ND
4 Ragdoll 4 m M Severe interstitial pneumonia Normal to reactive hyperplasia ! CTG Leu TCC Ser
5 Havana 4 y FN Nasal lymphoma ND ND TTG Leu TCT Ser
6 DSH 10 y FN Round cell neoplasia Sinus histiocytosis ! Not possible
7 DSH 8 y MN Pleural effusion (FCoV
RT-qPCR negative)
Normal ! TTG Leu ND
8 DSH 18 y FN Chronic kidney disease Sinus histiocytosis ND TTG Leu TCT Ser
9 DSH 10 y MN Lymphoma Normal ! CTG Leu ND
10 DSH ! F Anaesthetic death Normal to reactive hyperplasia ! CTG Leu ND
FIP, feline infectious peritonitis; FCoV, feline coronovirus; IHC, immunohistochemistry; Ag, antigen; DSH, domestic shorthair; MN, male neu-
tered; FN female neutered; ND, not done; Leu, leucine; Ser, serine.
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as previously described, and will be referred to subse-
quently by the former numbers.
Following initial FCoV RT-qPCR, all positive
samples not analysed for previous studies by Porter
et al. (2014) or Barker et al. (2017) underwent addi-
tional conventional RT-PCR and Sanger sequencing
targeting the S gene region of interest. PCR was per-
formed using the previously published degenerate
primers (Porter et al., 2014). Each reaction comprised
10 ml Phusion FlashMasterMix" (ThermoFisher Sci-
entific), with 2 ml cDNA, 0.5 mM each of forward and
reverse primers, made up to 20 ml with RNase-free
water. Reactions were run on a T Professional" ther-
mocycler (Biometra GmbH, G€ottingen, Germany)
with the following thermal profile: 98"C for 10 sec,
40 cycles of 98"C for 1 sec, 52"C for 5 sec, 72"C for
3 sec, followed by 72"C for 1 min. Appropriate con-
trols were included in each run.
The reaction product then underwent gel electro-
phoresis. Bands of appropriate size were extracted us-
ing the GeneJETGel ExtractionKit" (ThermoFisher
Scientific) and submitted for Sanger sequencing at a
commercial laboratory (Microsynth). When no
band was visible, the reaction was repeated using 50
cycles and the product was subjected to gel electro-
phoresis. Samples still appearing negative were cut
out in the region of the expected band, purified and
re-subjected to PCR. The bioinformatics software
Geneious 9.1.7", (Biomatters Limited, Silkeborg,
Denmark) was used to map the resulting sequences
to the reference gene FCoV C1Je (Accession number
DQ848678) (Chang et al., 2012).
Table 1C
Group 2: cats with FIP
Breed Age Sex Effusion Mesenteric lymph node
FIP lesions IHC (FCoV Ag) Sequencing
Codon 1,048 Codon 1,050
1 DSH 10 y FN + (A) Necrotizing and pyogranulomatous + TTG Leu TCT Ser
2 Norwegian Forest 8 m MN ! Necrotizing and pyogranulomatous and
lymphoplasmacytic
+ CTG Leu TCT Ser
3 4 m M + (A) Granulomatous + ATG Met GCT Ala
4 1.5 y MN + (A) Pyogranulomatous + TTG Leu TCA Ser
5 Maine Coon 1 y MN + (A) Pyogranulomatous and lymphoplasmacytic + TTG Leu TCC Ser
6 DSH 6 m MN + (A, P) Granulomatous + TTG Leu TCT Ser
7 DSH 4 m F + (M) Granulomatous + TTG Leu TCT Ser
8 BSH 6 y MN + (A) Pyogranulomatous + TTG Leu TCC Ser
9 Persian 5 m F + (A) Pyogranulomatous + TTG Leu TCT Ser
10 3 y + (A) Granulomatous + TTG Leu ND
11 Burmese 3 m M + (T) Necrotizing and granulomatous + TTG Leu ND
12 Abyssinian 4 m F + (A) Pyogranulomatous + TTG Leu ND
13 DSH ! + (T) ND ND TTG Leu ND
14 DSH 5 m + (A, T) Necrotizing and pyogranulomatous + TTG Leu ND
15 Siamese 1 y + Pyogranulomatous + CTG Leu TCC Ser
16 BSH 10 m MN + Sinus histiocytosis ! TTG Leu TCC Ser
17 DSH 2 y MN + Reactive hyperplasia ! TTG Leu TCT Ser
18 Siamese 3 y MN + (A, T) Normal ! c/tTG Leu TCT Ser
19 Birman 12 y MN + (M) Reactive hyperplasia + TTG Leu TCC Ser
20 BSH 1 y FN + (A, T) Pyogranulomatous + ATG Met TCC Ser
21 DSH 2 y MN ! Granulomatous + ATG Met GCC Ala
22 Oriental 3 y M ! Granulomatous + TTG Leu TCC Ser
23 Birman 8 m M ! ND ND TTA Leu TCA Ser
24 Ragdoll 10 m FN Necrotizing and granulomatous + TTG Leu TCC Ser
25 BSH 2 y MN + (A) Necrotizing and pyogranulomatous + TTG Leu TCC Ser
26 DSH 6 m F ! Normal ! CTG Leu TCT Ser
27 DSH 1 y + (A) Reactive hyperplasia ! FCoV Type II
28 DSH 4 m Reactive hyperplasia ! TTG Leu TCC Ser
29 DSH 7 m ! Pyogranulomatous + TTG Leu ND
30 DSH M + (A) Pyogranulomatous + TTG leu ND
FIP, feline infectious peritonitis; FCoV, feline coronavirus; MLN, mesenteric lymph nodes; IHC, immunohistochemistry; Ag, antigen; DSH, do-
mestic shorthair; blank, data not available; BSH, British longhair; F, female; M, male; FN, female neutered; MN, male neutered;+, positive/pre-
sent;!, negative/absent; A, abdominal; P, pericardial; M, multicavitary; T, thoracic; ND, not done; Leu, leucine; Ala, alanine; Met, methionine;
Ser, serine. Nucleotide bases in lower case indicate a mixed infection.
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Statistical Analysis
Relative mRNA transcription levels were calculated
using the comparative Cq method (Pfaffl, 2001).
The Cq of each target was first normalized to GAPDH
as the endogenous reference (DCq) and then ex-
pressed relative to the G1 DCq mean as the calibrator
(2!DDCq). For FCoV RT-qPCR results, the mean of
G1+ was instead used as the calibrator (to allow
for visualization graphically).
The statistical programme SPSS Statistics v.25"
(IBM, Armonk, New York, USA) was used for all an-
alyses and graphical data presentation. Data were
first assessed for normality using a ShapiroeWilk
test. As almost all data failed the test, non-parametric
measures were applied. A two-tailedManneWhitney
test with a significance level of P #0.05 was used to
compare results between groups for each target mole-
cule. Firstly, cats with and without FIP (G1 versus
G2) were compared, followed by comparisons be-
tween each of the three groups (G1!, G1+ and
G2) in turn. Within G2, comparisons were made be-
tween cats with and without cavitary effusions and
with and without histologically observed FIP lesions
in the MLNs. Correlation between relative FCoV
levels and inflammatory mediator gene expression
levels, and also between individual inflammatory
mediator gene expression levels, was analysed within
G2 using a one-tailed Spearman’s rank test. Here a
cut off of P #0.01 was used, with P #0.05 indicating
weak correlation.
Results
Feline Coronavirus Status within the Study Population
Signalments of the cats are shown inTables 1AeC.All
MLN samples from cats with FIP (G2) were positive
for FCoV (n ¼ 30). Of the 40 cats without FIP (G1),
10 (25%) also had a positive FCoV RT-qPCR result;
these were assigned to a new sub-group (G1+). How-
ever, the relative FCoV load was clearly, and signifi-
cantly, lower in G1+ than in G2 (Fig. 1).
None of the G1 cats exhibited histological changes
suggestive of FIP in any tissue examined, including
the MLNs when available for histology (25 of 30
from G1! and seven of 10 from G1+). Inflammation
Table 2
Primer and probe sequences used for RT-qPCR and conventional RT-PCR
Gene Reference or accession number Primer and probe sequences (50-30)
where not previously published
PCR product length
(base pairs)
GAPDH, IL-10 Leutenegger et al. (1999)
FCoV (RT-qPCR) Gut et al. (1999)
FCoV (conventional) Porter et al. (2014)
TLR1, 2, 4, 5, 6, 7, 9 Ignacio et al. (2005)
TLR3, 8, IL-15, IFN-a, -b Robert-Tissot et al., 2011
IL-1b, IL-6, TNF-a Kipar et al. (2001)
TGF-b Taglinger et al. (2008)
IL-17 XM_006931816.1 F-16 ACTTCATCCATGTTCCCATCACT 126
R-141 CACATGCTGAGGAAAATTCTTGTC
P-83 CATTCCCACAAAATCCAGGATGCCC
STAT1 XM_006935443 F-1649 TTGACCTCGAGACGACCTCTCT 135
R-1783 GCGGGTTCAGGAAGAAGGA
P-1686 CTCCAATGTCAGCCAGCTCCCGAGT
STAT2 XM_003988893 F-1182 GCCCAGGTCACGGAGTTG 122
R-1303 ACAGTGAACTTGCTCCCTGTCTT
P-1212 CTGCACAGAGCCTTTGTGGTAGAAACCC
STAT3 XM_006940361.2 F-1626 GCCAGTTGTGGTGATCTCCAA 133
R-1758 TTGATCCCAGGTTCCAATCG
P-1696 CTGACCAACAACCCCAAGAACGTGAACTTT
CCL8 XM_003996558 F-95 GGCCACCTTCAGCATCCA 82
R-176 CCCTTTGACCACACTGAAGCA
P-121 CTCAGCCAGGTTCAGTTTCCATCCCA
CXCL10 XM_003985274.3 F-386 TGCCATCATTTCCCTACATTCTT 78
R-463 CAGTGGTTGGTCACCTTTTAGGA
P-411 CAAGCCCTAATTGTCCCTGGATTGCAG
IFN-g NM_001009873.1 F-214 TGGAAAGAGGAGAGTGATAAAACAA 122
R-335 TCCTTGATGGTGTCCATGCT
P-284 ACCTGAAAGATGATGACCAGCGCATTCAA
Accession number, NCBI accession number; F, forward primer and start site; R, reverse primer and start site; P, probe and start site. All final
reactions contained equivalent F and R concentrations of 900 nM and 250 nM for P, with the exception of FCoV RT-qPCR, 300 and
250 nM; FCoV conventional, 500 nM; TGF-b, 200 and 50 nM; STAT3, 600 and 250 nM, respectively.
74 A.J. Malbon et al.
Fig. 1. Boxplots demonstrating relative levels of FCoV transcription in G1+ and G2. The amount of FCoV was calculated by 2!DDCq,
using fGAPDH as the internal reference gene and expressed as an n fold difference relative to the G1+ mean as a calibrator.
The boxes depict the median and interquartile (IQ) range with whiskers extending to the highest and lowest values, which are
within 1.5$ the IQ range. Outliers beyond this are individually marked. The three columns of individual crosses within G2 depict
the three variations in the viral S protein at codons 1,048 and 1,050, respectively. From left to right: L, leucine at 1,048 (‘systemic’
virus);M&A,methionine and alanine (‘systemic’ virus);M&S,methionine and serine (‘enteric’ virus). 2E+, 2Ee, 2L+and 2Le
represent relative FCoV levels among MLN of cats with and without effusions/lesions.
Fig. 2. Examples ofMLNswith andwithout lesions from cats with FIP. (a, b) Case G2.5. (a) Focal pyogranulomatous inflammation with
central necrosis (*). HE. (b) Viral antigen expression is seen in abundant intact lesional macrophages. IHC. (c, d) Case G2.19. (c)
Reactive hyperplasia with expansion of the marginal sinus by macrophages (*). HE. (d) Some of the latter are FCoV antigen
positive. IHC.
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of other aetiologies was observed in the MLNs of two
of the 30 G1! cats and none of the G1+ animals. All
G1 samples were also negative for FCoV antigen by
immunohistochemistry.
Association between Key Pathological Findings and Relative
Viral Load in Mesenteric Lymph Nodes of Cats with Feline
Infectious Peritonitis
The MLNs were available for histological examina-
tion in 28 of the 30 cats with FIP. In 21 cases
(75%), these exhibited the typical pyogranulomatous
lesions, with or without associated serosal lesions on
the lymph node capsule (e.g. serofibrinous to granulo-
matous serositis). All samples with typical pyogranu-
lomatous lesions also showed FCoV antigen in
lesional macrophages (Figs. 2a, b). Seven MLNs
had no typical lesions; among these was only one
case (G2.19) in which FCoV antigen was detected,
in low numbers of macrophages within the marginal
sinus, suggesting an early lesion (Figs. 2c, d). There
was no significant difference in FCoV load found be-
tweenMLNswith andwithout lesions, although those
with lesions had a tendency to higher FCoV levels
(Fig. 1).
Of the 30 cats with FIP, 22 exhibited effusions
(Table 1C). These were not associated with a higher
relative FCoV load in the MLNs in comparison
with the cats without effusion (n ¼ 6; data not avail-
able for two cats).
Association between Feline Infectious Peritonitis and Feline
Coronavirus Status, Disease Features, Viral Load and Gene
Expression of Immune Mediators
In order to evaluate the effect of FCoV infection and
FIP on target gene transcription, G1 and G2 were
first compared with each other before comparisons
between all three groups (G1+, G1! and G2). The
assessed target genes are described below according
to their positions in immune signalling pathways as
first line receptors, inflammatory mediators or signal
transducers. Detailed results are provided in Table 3.
Toll-like Receptors: Relative TLR2, 4 and 8 gene
transcription levels were significantly higher in G2
than G1. Within G1 there was no difference between
virus-positive and virus-negative MLNs for these
TLRs; however, TLR9 gene expression, although
not elevated in G2, was significantly higher in G1+
than in G1! (Fig. 3).
Table 3
Results of statistical comparisons between groups of cats, using a two-tailed ManneWhitney test
Statistical comparison between FIP group
G1 versus G2 G1! versus G1+ G1+ versus G2 Effusions present versus
absent
MLN lesions present versus
absent
FCoV 0.000a 0.000a 0.000a 0.764 0.071
TLR1 0.610 0.914 0.794 0.643 0.533
TLR2 0.000a 0.724 0.002a 0.259 0.048a
TLR3 0.569 0.724 0.656 0.682 0.189
TLR4 0.019a 0.794 0.022a 1.000 0.208
TLR5 0.053 0.508 0.396 0.806 0.756
TLR6 0.859 0.286 0.469 0.764 0.228
TLR7 0.059 0.770 0.272 0.427 0.568
TLR8 0.012a 0.246 0.015a 0.566 0.435
TLR9 0.991 0.031a 0.140 0.764 0.189
STAT1 0.000a 0.315 0.000a 0.052 0.466
STAT2 0.000a 0.017a 0.000a 0.017a 0.717
STAT3 0.260 0.569 0.414 0.764 1.000
IFN-a 0.041a 1.000 0.077 0.604 0.499
IFN-b 0.004a 0.770 0.036a 0.566 0.604
IFN-g 0.000a 0.131 0.003a 0.806 0.249
IL-1b 0.026a 0.432 0.031a 0.849 0.272
IL-6 0.001a 0.209 0.177 1.000 0.208
IL-10 0.296 0.469 0.939 0.604 0.272
IL-15 0.019a 0.794 0.039a 0.53 0.376
IL-17 0.440 0.528 0.286 0.723 1.000
TGF-b 0.430 0.508 0.396 0.978 0.678
TNF-a 0.004a 0.432 0.346 0.309 0.405
CXCL10 0.000a 0.396 0.000a 0.441 0.263
CCL8 0.000a 0.177 0.000a 0.46 0.071
aIndicates significance level of P# 0.05. In the first three columns, the second group of the comparison is significantly higher in all cases (e.g. for G1
versus G2, G2 levels are higher). In the FIP columns, the value of the ‘present’ group is in both cases higher than in the ‘absent’ group.
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In G2 cats, gene transcription levels were
compared between MLNs with and without FIP le-
sions, and in relation to the presence of effusions. A
significant difference was found only for TLR2
(higher expression in MLNs with lesions) (Fig. 3,
Table 3); in contrast, TLR2 expression appeared
slightly lower in cats with effusions (Fig. 3). A possible
trend not reaching significance was for a slightly
higher TLR4 expression level in MLNs with lesions,
while TLR3 and 9 gene expression levels were slightly
lower (Fig. 3). Investigating this further, we found
that TLR3 gene expression levels in G2 MLNs
without lesions were also slightly higher than levels
in G1 (which were similar to those in G2 MLNs
with lesions), suggesting a potential negative regula-
tion of TLR3 by FCoV (Fig. 3).
Cytokines and Chemokines: Relative IL-1b, IL-6, IL-
15, TNF-a, IFN-a, -b, -g, CCL8 and CXCL10
gene transcription levels were all significantly higher
in G2 compared with G1 (Fig. 4). None of these
showed any significant difference between G1+ and
G1!. For most cytokines, G1+ and G1! clustered
together; however, for IL-6, TNF-a and IFN-g,
G1+ appeared to cluster slightly between the other
two groups (G1! and G2), suggesting a possible in-
termediate stage (Fig. 4). Between groups, the fold
Fig. 3. Boxplots of relative levels of TLRgene expression in each group. The amount of target was calculated by 2!DDCq, using fGAPDHas
the internal reference gene and expressed as an n fold difference relative to theG1mean as a calibrator. The boxes depict themedian
and interquartile (IQ) range with whiskers extending to the highest and lowest values, which are within 1.5 $ the IQ range. Out-
liers beyond this are individuallymarked. *marks significant differences between individual groups (P# 0.05) or,where joinedby a
bar, between G1 as a whole and G2. 2E+, 2Ee, L2+ and L2e represent relative gene expression levels amongMLNs of cats with
and without effusions/lesions.
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Fig. 4. Boxplots of relative levels of cytokine and chemokine gene expression in eachgroup.The amount of targetwas calculatedby 2!DDCq,
using fGAPDHas the internal reference gene and expressed as an n fold difference relative to theG1mean as a calibrator. The boxes
depict themedian and interquartile (IQ) rangewithwhiskers extending to the highest and lowest values, which arewithin 1.5 $ the
IQ range. Outliers beyond this are individually marked. * marks significant differences between individual groups (P# 0.05) or,
where joined by a bar, between G1 as a whole and G2. 2E+, 2Ee, 2L+ and 2Le represent relative gene expression levels among
MLNs of cats with and without effusions/lesions.
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differences in the chemokine gene expression levels
(CXCL10 and CCL8) were mainly in the range of
10e100$ , while those for the pyrogenic cytokines
(IL-1b, IL-6 and TNF-a) rarely exceeded 10$ . IL-
10, IL-17 and TGF-b gene transcription levels
showed no intergroup differences (Fig. 4, Table 3).
For IL-1b, IL-6, IFN-g andCCL8, a possible trend
towards increased transcription (not reaching signifi-
cance) was observed in G2 MLNs with lesions
compared with those without (Fig. 4).
Signal Transducers and Activators of Transcription:
STAT1 and 2 gene expression levels were significantly
higher in G2 than G1. For both transcription factors,
gene expression levels were also higher in G1+ than
in G1!, significantly so for STAT2. STAT3 gene
expression levels were similar across all groups
(Fig. 5).
In G2, STAT2 gene expression levels were signifi-
cantly higher in cats with effusions (Fig. 5, Table 3).
For STAT1, there was an insignificant trend to be
higher with effusions (Fig. 5).
Correlation of Target Immune Mediators and Feline
Coronavirus Load in Cats with Feline Infectious Peritonitis
The majority of gene targets elevated in G2 also
showed significant positive correlation with relative
viral load (Supplementary Table 1). These included
TLR2 and 4, the cytokines IL-1b, IL-6, together
with STAT2, CXCL10, CCL8, IFN-b and IFN-g
(P# 0.01). TLR8 and IFN-a gene expression showed
weaker correlation (P# 0.05), while STAT1, TGF-b,
and TNF-a gene expression showed no correlation,
and TLR9 a weak, although significant, negative cor-
relation (Table 4).
Expression of genes encoding IL-6, IL-17 and
STAT3, a ‘holy trinity’ of autoimmunity
(Camporeale and Poli, 2012), was significantly corre-
lated despite the latter two not showing any correla-
tion with FCoV.
Partial S Gene Sequencing
Of the 40 cats shown by RT-qPCR to carry FCoV in
their MLNs, 38 had analysable S gene sequences
following conventional PCR. From the remaining
two cats (G1+ cats 1 and 6) it was not possible to
obtain samples of sufficient quality even after
repeated attempts (Table 1B).
Of the 30 cats with FIP, one was infected with
FCoV serotype 2 for which the previously described
S gene sequence characterization is not applicable
(Herrewegh et al., 1998; Barker et al., 2017).
Twenty-six MLN samples contained virus that en-
coded leucine (M1048L) (cDNA sequence TTG,
Fig. 5. Boxplots of relative levels of STAT gene expression in each
group. The amount of target was calculated by 2!DDCq, us-
ing fGAPDH as the internal reference gene and expressed
as an n fold difference relative to the G1 mean as a cali-
brator. The boxes depict the median and interquartile
(IQ) range with whiskers extending to the highest and
lowest values, which are within 1.5 $ the IQ range. Out-
liers beyond this are individually marked. * marks signifi-
cant differences between individual groups (P # 0.05) or,
where joined by a bar, between G1 as a whole and G2.
2E+, 2Ee, 2L+ and 2Le represent relative gene expres-
sion levels amongMLNs of cats with and without effusions/
lesions.
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Table 4
Summary of Spearman’s rank one-tailed correlation results within the FIP group, showing immune mediators with significant results
FCoV TLR2 TLR4 TLR8 TLR9 STAT1 STAT2 STAT3 IFN-a IFN-b IFN-g IL-1b IL-6 IL-15 IL-17 TGF-b TNF-a CXCL10 CCL8
FCoV C [[ [[ [ [ [[ [ [[ [[ [[ [[ [ [[ [[
TLR2 [[ C [[ [[ [ [[ [[ [[ [[ [[ [[ [[
TLR4 [[ [[ C [[ [ [[ [[ [ [[ [[ [[ [ [[ [[ [[
TLR8 [ [[ [[ C [[ [[ [[ [ [
TLR9 Y C [[ [ [[ [[ [
STAT1 [ [[ C [[ [[ [ [ [ [ [[ [[ [
STAT2 [[ [ [[ [ [[ C [[ [ [ [[ [[ [[ [ [[ [[ [[
STAT3 [[ [[ [[ [[ [[ [[ C [ [[ [[ [[ [ [[ [[ [[
IFN-a [ [ C [[ [[ [ [ [ [ [
IFN-b [[ [[ [ [ [ [[ C [[ [ [ [[ [ [[
IFN-g [[ [[ [[ [ [ [[ [[ C [[ [[ [ [ [[ [[
IL-1b [[ [[ [[ [[ [ [[ [[ [ [[ C [[ [[ [ [[ [[ [[
IL-6 [[ [[ [[ [[ [ [[ [[ [ [ [[ [[ C [ [[ [[ [[
IL-15 [ [ [ [[ C [[ [
IL-17 [[ [ [ [[ [ [ [ [[ [ C [
TGF-b [[ [ [ C [
TNF-a [ [[ [[ [[ [ [[ [ [[ [[ [[ [ C [ [
CXCL10 [[ [[ [[ [ [[ [[ [[ [ [[ [[ [[ [[ [ C [[
CCL8 [[ [[ [[ [ [ [[ [[ [ [[ [[ [[ [[ [ [ [[ C
[[, positive correlation at a significance level of P # 0.01; [, positive correlation at a significance level P # 0.05; Y, negative correlation at a significance level of P # 0.05.
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CTG or TTA). The remaining three cats encoded
methionine at codon 1,048 (cDNA sequence ATG).
The results are shown in Table 1C. Of the eight se-
quences obtained from the G1+ cats, all encoded
leucine (M1048L). Of the three cases encodingmethi-
onine at codon 1,048, two encoded alanine at codon
1,050 (S1050A), while the third encoded serine
(Table 1B).
The small methionine group size (n ¼ 3), including
only one cat that carried the ‘enteric’ virus (M1048,
S1050), was not considered valid for statistical com-
parison with the leucine group, ‘systemic’ virus.
Instead, individual cases were plotted, revealing the
methionine group to fall within the range of the
leucine group for every target, including FCoV load
(Fig. 1).
Discussion
As predicted from previous studies, the results of the
present investigation confirm the complex effect of
FCoV on the immune system in association with
FIP. The disease is caused by an exaggerated immune
response to FCoV, but it is well known that cats can
also carry FCoV systemically without developing
FIP (Meli et al., 2004). Here we have assessed some
of the key mediators of the innate immune response,
focussing on the MLN, the most likely first site of
infection beyond the intestine and one of the main
sites of viral persistence in experimentally infected
healthy animals (Kipar et al., 2010). By comparing
FCoV-positive, lesion-free MLNs from cats affected
by diseases other than FIP with both FCoV-
negative cats without FIP and cats with FIP, we
aimed to separate the direct viral effects from the
host effects contributing to FIP in a natural setting.
FIP presents as a spectrum of disease with variable
duration rather than as a discrete clinical picture; as
such the pathological features also vary. This was re-
flected by variation in organ involvement and pres-
ence of effusions in our case cohort. We therefore
also wanted to assess whether the inflammatory medi-
ator production in the MLNs showed any correlation
with the form of disease. Although vascular perme-
ability is, to a large extent, cytokine mediated
(Takano et al., 2011), and we found upregulation of
cytokine genes with a role in vascular permeability
in the FIP cases, the inflammatory mediator gene
expression profile of the MLNs differed only mini-
mally between cats with and without effusions. This
suggests that the MLN is unlikely to make a large sys-
temic contribution to vascular permeability. Simi-
larly, Safi et al. (2017) evaluated inflammatory
mediators within peripheral blood mononuclear cells
of FIP cats with and without effusions and found little
consistent pattern to distinguish those with effusions
from those without. Both studies therefore provide
further, although indirect, support that vascular
endothelial growth factor, which was previously
shown to correlate with the degree of effusion in
FIP, is key to this phenomenon (Takano et al.,
2011). Interestingly, the presence or absence of histo-
logical FIP lesions was not correlated with many sig-
nificant differences between mediator gene
expression. Alongside this, and surprisingly, although
FCoV levels appeared higher in association with le-
sions, they were not significantly so. This may partly
explain the lack of significant differences in mediator
gene expression. Additionally, it cannot be entirely
excluded that the area of the MLN sampled for
RNA extraction was not within an FIP lesion and
vice versa. An alternative explanation for the lack of
significant differences between gene expression for
most mediators in MLNs, while many exhibit higher
overall levels in FIP, would be that systemic stimula-
tion to upregulate inflammatory mediators is more
relevant than local or lesion-specific stimulation.
Finally, as trends were occasionally observed when
cases with and without effusions and MLN lesions
were compared, the lack of significance may also be
due to the small group sizes once subgroups were
created, which was a limitation of this study.
The MLNs of cats without FIP had significantly
lower viral loads than their counterparts from cats
with FIP. This confirms previous findings in natural
infection, where cats with FIP were reported to carry
higher viral loads in haemopoietic and lymphoid tis-
sues, including MLNs, than asymptomatic FCoV-
infected cats (Kipar et al., 2006a). Without the dis-
ease, however, the presence or absence of FCoV in
the MLN seems not to influence the transcription
level of most of our target immune mediators. This
would indicate that, in the main, the host response
has a greater influence than any direct viral effect.
Still, there were exceptions. Even among those medi-
ators not attaining significance, IFN-g, IL-6 and
TNF-a showed a trend towards higher gene expres-
sion levels in FCoV-positive MLNs. This suggests at
least a modest direct viral effect; it may have been
masked by low group numbers, requiring a larger
sample size to confirm or refute. Another study limita-
tion was the composition of the groups. As all were
field cases it was not possible to control for confound-
ing factors (e.g. ensuring control cases were free of any
inflammatory processes, that FIP cases were at similar
disease stages, and that cats were initially subject to
the same FCoV infection pressures).
Inflammatory cytokines have been previously stud-
ied in FIP, with conflicting results, possibly depen-
dent on variations in disease form between animals
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included in the different studies and/or the type of
sample/organ evaluated. TNF-a gene transcription,
for example, was found to be decreased in the
MLNs of cats with FIP compared with FCoV-free
specific pathogen-free cats, while IL-1b gene expres-
sion was elevated (Kipar et al., 2006b). In the present
study, gene expression for all three pyrogenic cyto-
kines (IL-1b, IL-6 and TNF-a) was upregulated in
the MLNs in FIP, as well as that for IL-15 (a stimu-
lator of lymphocyte proliferation). We also found
significantly higher transcription levels for the
monocyte-recruiting chemokines CXCL10 and
CCL8, which have both been found to be upregulated
in CrandelleRees feline kidney cells after in vitro
FCoV infection (Harun et al., 2013), indicating a
mechanism of monocyte recruitment as a direct viral
effect. Our results confirm their relevance in vivo, with
recruitment of monocytes as the infected cell type be-
ing a potential amplifying step that is worthy of
further investigation. The increase in inflammatory
cytokine gene transcription supports the observation
that an overexuberant inflammatory response is a
key factor in the development and progression of
FIP. Expression of the gene encoding the anti-
inflammatory cytokine IL-10 was, in contrast, not up-
regulated in FIP, implying there was no local brake
on the inflammatory process. This is in line with pre-
vious findings, where IL-10 expression was higher in
the spleen of healthy FCoV-infected cats, but not in
the MLN (Kipar et al., 2006b). Gene expression for
the interferons was also higher in FIP, IFN-g being
one of the cytokines to show an intermediate level in
infected asymptomatic cats in our study. These type
I and II interferons have major antiviral roles in the
innate immune system. IFN-g in particular has
been of interest in FIP, as levels of this potentially pro-
tective cytokine tend to be low in the peripheral blood
of diseased animals and host gene polymorphisms
have been identified that may contribute to resistance
against the disease (Gelain et al., 2006; Hsieh and
Chueh, 2014). Similarly to the apparent lack of
impact of mediator levels on the presence of lesions
or effusions in FIP, this suggests that MLN IFN
production has a more local effect.
TLRs have been used for targeted therapy against a
number of diseases in human medicine, both with ad-
juvants and inhibitors; however, veterinary medicine
lags behind in this respect (Hennessy et al., 2010;
Klingemann, 2018). Here we identified increased
gene expression levels of TLRs 2, 4, 8 and 9 with
FIP and FCoV infection, respectively, indicating a
possible role for these molecules in FIP and hence
identifying them as potential targets for FIP control.
Assessment at the protein level would be a useful
avenue for further investigations; however, this is
particularly challenging in feline studies owing to
the lack of availability of appropriate antibodies. In
most mammals, TLRs 2 and 4 are located on the
cell membranes, while TLRs 8 and 9 are found
in intracytoplasmic vesicles, most commonly in
professional antigen presenting cells (Lester and Li,
2014). TLR2, together with TLRs 1, 6 and 10,
comprise the TLR1 family (Roach et al., 2005). These
latter three receptors arose through evolutionary
gene duplication (Hughes and Piontkivska, 2008;
Hennessy et al., 2010). TLR2 is able to signal as a
heterodimer with any of its co-family members in or-
der to allow a wider range of antigen recognition. It is
typically responsible for detecting bacterial and
fungal components (Beutler, 2009). TLR2 has been
linked to detection of the SARS-CoV S protein
in vitro (Dosch et al., 2009); its upregulation in FIP
could indicate that the FCoV S protein is also able
to act as a ligand.
TLR4 classically detects lipopolysaccharide; how-
ever, one study linked it to protection against murine
coronavirus, as TLR4-deficient mice were found to
exhibit greater susceptibility to murine hepatitis virus
infection. The precise mechanism was not established
in that case, but it involved inflammatory cell influx
in the TLR4-deficient mice (Khanolkar et al., 2009).
No such protective effect was observed in our study,
despite upregulation of TLR4 gene expression in the
MLNs in association with FIP, although its individ-
ual effect in this case cannot be separated from the
mediator milieu.
TLR9 gene expression was not elevated in the
MLNs of cats with FIP, but was instead increased
in the FCoV-positive MLNs of cats without FIP.
Considering that a previous in vitro study found
reduced viral replication when TLR9 was stimulated
with a synthetic CpG ligand prior to FCoV infection
(Robert-Tissot et al., 2012), the increased gene expres-
sion in FCoV-infected cats without FIP could indi-
cate that TLR9 has a protective effect, which may
even have helped prevent the development of disease.
Stimulation by co-infectious agents could therefore
also be hypothesized to be protective against FIP.
Along these lines, co-infection must also be considered
a possible alternative explanation for the raised TLR2
and 4 gene expression levels, as these TLRs are more
typically associated with bacterial infections. Enteric
coronavirus infection or the generalized inflamma-
tory state induced by FIP may have increased the
permeability of the intestinal barrier to microorgan-
isms. The resulting TLR stimulation would therefore
not be virus induced. A third alternative is the upre-
gulation of TLR2 and 4 by endogenous ligand
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stimulation, reported as a response to alarmin release
from damaged cells (van Beijnum et al., 2008). This
alternative also fits with upregulation of TLR2 gene
expression in lesional MLNs compared with non-
lesional MLNs in FIP.
From their known ligands, TLRs 3, 7 and 8 would
be predicted to be triggered in infection by FCoV as it
is a ssRNA virus (triggering TLRs 7 and 8), possessing
a double-stranded RNA intermediate replicating
phase (triggering TLR3) (Arpaia and Barton,
2011). That no upregulation occurs for TLR3 and
TLR7 with FIP suggests either the lack of an appro-
priate trigger (TLR7 and 8 are known to show
differing, if overlapping, specificity, and dsRNA in-
termediate replicates are a minority of the viral
RNA present; Jensen and Thomsen, 2012), or that
the virus is able to inhibit TLR transcription.
SARS-CoV is known to inhibit both TLR3 and 7 sig-
nalling via papain-like protease activity (PLpro) (Li
et al., 2016). This mechanism may also contribute in
FCoV infection, but would be expected to affect the
signalling pathways rather than the TLR mRNA
levels directly. In cats with FIP, we observed slightly
lower TLR3 gene transcription in MLNs with typical
FIP lesions, as compared with MLNs without lesions,
down to the levels seen in MLNs from cats without
FIP. This could indicate a general systemic stimulus
to upregulate TLR3 in FIP, which is counteracted
locally by viral inhibition of TLR3. Prior stimulation
of TLR3 has also been shown in vitro to contribute to
defence against murine coronavirus via type I inter-
feron induction (Mazaleuskaya et al., 2012), so is
another potential avenue for future FIP research. A
larger sample population, in particular with larger
numbers of systemically infected cats without FIP,
might have revealed significant intergroup differences
for TLR3.
The STAT transcription factors are a key part of
the antiviral pathways, mediating many downstream
IFN effects (Aaronson and Horvath, 2002). They
have also been linked to other coronavirus infections
(e.g. STAT1 knock-out mice show a markedly
increased susceptibility to SARS-CoV, while avian
infectious bronchitis coronavirus uses STAT1 inhibi-
tion of IFN responses) (Frieman et al., 2010; Kint
et al., 2015). STAT1 and 2 gene transcription
levels correlated with type II and I interferon
transcription levels, respectively, in our study, while
in virus-positive MLNs of cats without FIP, STAT1
and 2 levels (the latter significantly so), as well as
IFN-g levels, lay between the other two groups.
This shows that the levels of IFNs and their down-
stream transcription factors are closely linked. Inter-
estingly, STAT2 gene expression levels were
significantly higher in the MLNs of cats with FIP
and with effusions, a finding that cannot be readily
explained. STAT2 has been linked to IL-6 upregula-
tion, which itself has been linked to increased vascular
permeability (Maruo et al., 1992; Nan et al., 2018);
however, the IL-6 gene was not upregulated in our
cohort, suggesting that responsibility lies with another
pathway.
The results of our S gene codon mutation analysis
add weight to recent findings that the M1058L muta-
tion (referred to asM1048L in the present study due to
re-evaluation of the reference sequence) is likely to
contribute to systemic spread, but does not itself confer
pathogenicity (Chang et al., 2012; Porter et al., 2014).
This indicates that further host and/or viral factors are
required for the development of FIP or, more
precisely, the activation of virus-infected monocytes
as a prerequisite to set off FIP vasculitis (Kipar and
Meli, 2014). Most likely owing to the low viral RNA
levels within theMLNs of cats without FIP, obtaining
an adequate sequence from this group proved prob-
lematic. Other researchers experienced similar prob-
lems, often finding that FCoV RT-PCR-positive
samples from cats without FIP were not amenable to
sequencing (Felten et al., 2017b). The lack of FCoV
antigen expression in these cats was not unexpected
and reflects the rarity of infected cells and/or the low
virus load in infected cells; this is in line with the results
of a previous study that found only rare positive mac-
rophages in the MLNs of experimentally persistently-
infected cats (Kipar et al., 2010).
It was not possible to compare statistically the
induced immune response of viruses showing S pro-
tein amino acid variations (codons 1,048 and 1,050)
as only one cat had the ‘enteric’ form.
The future outcome of our FCoV infected cats
without FIP, had they not succumbed to other dis-
eases, is unknown, as is the contribution of yet to be
defined viral factors. These cats may have remained
carriers or have been demonstrating a transitional
phase to later development of disease. However,
based on our observations, activation of genes encod-
ing TLRs 2, 4 and 8 in MLNs is associated with a
negative outcome (i.e. FIP), while carrier animals up-
regulated the gene encoding TLR9. IFN-g, and
particularly STAT2 with its myriad opportunities to
direct cell fate, displayed intermediate levels of upre-
gulation in the MLNs of the carrier/transitional
group, not associated with a widespread increase in
mediators of inflammation.
This study is only the start of determining the
extent of involvement of PRRs in FIP; the down-
stream effects of these transcriptional alterations
must be further investigated. However, our results
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reinforce the need for a balanced immune response
against the virus, with the hypothesis that the moder-
ate response in cats without FIP is part of the key to
controlling the virus; when this balance is lost the an-
imal may be at risk of succumbing to disease.
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Association between FIP and FCoV infection status, disease features, viral load, and mRNA 
levels of immune mediators  
In order to keep the focus on the TLR responses and allow more space for discussion of these, the 
publication did not include all the mediators involved in the thesis. The matrix metalloproteinases 
(MMP2, 9, 13, TIMP1, 3) and colony stimulating factors (G-CSF, M-CSF, GM-CSF) were left out as 
it was felt that these results did not directly enhance the TLR results and that these were groups 
in themselves for separate discussion.  
The following graphs and table are extensions of those in the preceding manuscript so only 
additional information will be described. This includes additional targets that were not included 
in the publication. All graphs are based on the same raw data as is presented in the manuscript 
(see page 1 of this chapter) but presented calibrated to the bone marrow mean. 
Those results portrayed in the manuscript are shown with the new calibrator in Fig. 5.2.1-5.2.5. 
 
Matrix remodelling enzymes 
The direction of trends varied between enzymes. MMP2 mRNA levels were significantly higher in 
Group 2 cats than Group 1, and MMP13 significantly lower. MMP9 levels were not significantly 
altered. For the TIMPs, TIMP1 mRNA levels were significantly higher in Group 2, with no alteration 
between groups for TIMP3. 
 
Colony stimulating factors 
Only G-CSF showed significantly altered expression levels between groups, being higher in Group 
2 than Group 1 cats. M- and GM-CSF showed no variation. 
 
 
 
 
Figures 5.2.1: Boxplots of relative mRNA levels of FCoV in each group. The amount of target was 
calculated by 2-∆∆CT, using fGAPDH as the internal reference gene for normalisation and expressed as 
an n-fold difference relative to the G1 mean of the BM samples as a calibrator. The boxes depict the 
median and interquartile (IQ) range with whiskers extending to the highest and lowest values which 
are within 1.5 x the IQ range. Outliers beyond this are individually marked. * marks significant 
differences between groups (p≤0.05). 
* 
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Figures 5.2.3: Boxplots of relative mRNA levels of cytokines and chemokines in each group. The amount 
of target was calculated by 2-∆∆CT, using fGAPDH as the internal reference gene for normalisation and 
expressed as an n-fold difference relative to the G1 mean of the BM samples as a calibrator. The boxes 
depict the median and interquartile (IQ) range with whiskers extending to the highest and lowest values 
which are within 1.5 x the IQ range. Outliers beyond this are individually marked. * marks significant 
differences between groups (p≤0.05). Where the bar begins between G1+ and G1-, this indicates a 
significant difference to G1 as a whole. 
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Figures 5.2.4: Boxplots of relative mRNA levels of interferons in each group. The amount of target was 
calculated by 2-∆∆CT, using fGAPDH as the internal reference gene for normalisation and expressed as 
an n-fold difference relative to the G1 mean of the BM samples as a calibrator. The boxes depict the 
median and interquartile (IQ) range with whiskers extending to the highest and lowest values which 
are within 1.5 x the IQ range. Outliers beyond this are individually marked. * marks significant 
differences between groups (p≤0.05). Where the bar begins between G1+ and G1-, this indicates a 
significant difference to G1 as a whole. 
 
 
 
 
Figures 5.2.5: Boxplots of relative mRNA levels of STATs in each group. The amount of target was 
calculated by 2-∆∆CT, using fGAPDH as the internal reference gene for normalisation and expressed as 
an n-fold difference relative to the G1 mean of the BM samples as a calibrator. The boxes depict the 
median and interquartile (IQ) range with whiskers extending to the highest and lowest values which 
are within 1.5 x the IQ range. Outliers beyond this are individually marked. * marks significant 
differences between groups (p≤0.05). Where the bar begins between G1+ and G1-, this indicates a 
significant difference to G1 as a whole. 
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Figures 5.2.6: Boxplots of relative mRNA levels of matrix remodelling enzymes in each group. The 
amount of target was calculated by 2-∆∆CT, using fGAPDH as the internal reference gene for 
normalisation and expressed as an n-fold difference relative to the G1 mean of the BM samples as a 
calibrator. The boxes depict the median and interquartile (IQ) range with whiskers extending to the 
highest and lowest values which are within 1.5 x the IQ range. Outliers beyond this are individually 
marked. * marks significant differences between groups (p≤0.05). Where the bar begins between G1+ 
and G1-, this indicates a significant difference to G1 as a whole. 
 
 
Figures 5.2.7: Boxplots of relative mRNA levels of CSFs in each group. The amount of target was 
calculated by 2-∆∆CT, using fGAPDH as the internal reference gene for normalisation and expressed as 
an n-fold difference relative to the G1 mean of the BM samples as a calibrator. The boxes depict the 
median and interquartile (IQ) range with whiskers extending to the highest and lowest values which 
are within 1.5 x the IQ range. Outliers beyond this are individually marked. * marks significant 
differences between groups (p≤0.05). Where the bar begins between G1+ and G1-, this indicates a 
significant difference to G1 as a whole. 
* 
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Table 5.2.1: Statistical results of intergroup comparisons, with significant results (p≤0.05) highlighted 
in blue. The arrow indicates the direction of change of the second versus the first group of the 
comparison; *absent versus present. 
Target G1 vs G2 G1- vs G1+ G1+ vs G2 lesions* effusions* 
FCoV 0.000 ↑ NA   0.000 ↑ 0.071   0.764   
TLR1 0.610   0.914   0.794   0.533   0.643   
TLR2 0.000 ↑ 0.724   0.002 ↑ 0.048 ↑ 0.259   
TLR3 0.569   0.724   0.656   0.189   0.682   
TLR4 0.019 ↑ 0.794   0.022 ↑ 0.208   1.000   
TLR5 0.053   0.508   0.396   0.756   0.806   
TLR6 0.859   0.286   0.469   0.228   0.764   
TLR7 0.059   0.770   0.272   0.568   0.427   
TLR8 0.013 ↑ 0.246   0.015 ↑ 0.435   0.566   
TLR9 0.991   0.031 ↑ 0.140   0.189   0.764   
STAT1 0.000 ↑ 0.315   0.000 ↑ 0.466   0.052   
STAT2 0.000 ↑ 0.017 ↑ 0.000 ↑ 0.717   0.017 ↑ 
STAT3 0.260   0.569   0.414   1.000   0.764   
IFN-α 0.041 ↑ 0.988   0.077   0.499   0.604   
IFN-β 0.004 ↑ 0.770   0.036 ↑ 0.604   0.566   
IFN-γ 0.000 ↑ 0.131   0.006 ↑ 0.272   0.764   
IL-1β 0.026 ↑ 0.432   0.031 ↑ 0.272   0.849   
IL-6 0.001 ↑ 0.209   0.158   0.172   0.935   
IL-10 0.296   0.469   0.914   0.376   0.427   
IL-15 0.019 ↑ 0.794   0.039 ↑ 0.376   0.530   
IL-17 0.440   0.569   0.818   0.189   1.000   
TNF-α 0.004 ↑ 0.432   0.346   0.405   0.309   
TGFβ 0.430   0.508   0.396   0.678   0.978   
CCL8 0.000 ↑ 0.177   0.000 ↑ 0.071   0.460   
CXCL10 0.000 ↑ 0.396   0.000 ↑ 0.376   0.566   
MMP2 0.035 ↑ 0.167   0.548   0.296   0.530   
MMP9 0.204   0.866   0.432   0.435   0.194   
MMP13 0.011 ↓ 0.432   0.187   0.376   0.365   
TIMP1 0.000 ↑ 0.866   0.012 ↑ 0.055   0.309   
TIMP3 0.117   0.569   0.095   0.090   0.336   
G-CSF 0.000 ↑ 0.590   0.002 ↑ 0.080   0.395   
M-CSF 0.476   0.747   1.000   0.756   0.460   
GM-CSF 0.921   0.125   0.363   0.717   0.604   
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Correlation between relative viral load and immune mediator mRNA levels in the MLN of 
cats with FIP 
Correlation was investigated within the FIP group in order to determine whether the mere 
presence of the virus in a diseased animal set off an inflammatory chain, or whether this response 
appeared to be directly linked to the local level of virus in the tissue. A table of correlation was 
presented and briefly discussed in the manuscript. This did not include either the additional 
mediators or the graphs  
For each mediator, the result for each Group 2 cat was plotted against that cat’s viral load. 
From the graphs it could be seen whether a positive or negative correlation, or no trend was 
visible. The Spearman’s rank correlation applied was therefore one-tailed. The statistical results 
are summarised in Table 5.2.2. 
 
TLRs 
Within the TLRs, there was positive correlation at the 0.01 level for TLR 2, 4, and 5. TLR 2 and 4 
had been significantly elevated in FIP. TLR8, the third to have been significantly elevated was 
significant only at the p<0.05 level (subsequently referred to in this section as a weak correlation). 
TLR9 mRNA levels showed a weak negative correlation with viral load. Fig. 5.2.8. 
 
 
 
** 
** ** 
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Figure 5.2.8: Correlation between relative mRNA levels of TLRs and FCoV viral loads. Significance levels 
are marked by ** = p£0.01; * = p£0.05.   
 
Inflammatory cytokines and chemokines 
The inflammatory cytokines IL-1b and IL-6, but not TNF-a, showed a positive correlation with viral 
load. All three had been significantly elevated in FIP. IL-15 was also positively correlated as were 
the chemokines CCL8 (which showed the strongest correlation) and CXCL10 (all at p≤0.01); 
Fig.5.2.9.  
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Figure 5.2.9: Correlation between relative mRNA levels of cytokines and chemokines, and FCoV viral 
loads. Significance levels are marked by ** = p£0.01; * = p£0.05.   
 
Interferons 
All three interferons showed positive correlation, this was only weak in the case of IFN-a. Fig. 
5.2.10. 
 
 
Figure 5.2.10: Correlation between relative mRNA levels of interferons and FCoV viral loads. 
Significance levels are marked by ** = p£0.01; * = p£0.05.   
 
STATs 
STAT2 was the only STAT to show significant correlation with viral load. Fig. 5.2.11. 
 
 
Figure 5.2.11: Correlation between relative mRNA levels of STATs and FCoV viral loads. Significance 
levels are marked by ** = p£0.01; * = p£0.05.   
** 
** ** * 
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Matrix remodelling enzymes 
These were one of the two groups of newly included mediators; MMP2 and TIMP1 were the only 
matrix remodelling enzymes to show correlation (with both being positive); both had been 
elevated in FIP. Fig. 5.2.12. 
 
 
 
Figure 5.2.12: Correlation between relative levels of matrix remodelling enzymes and FCoV viral loads. 
Significance levels are marked by ** = p£0.01; * = p£0.05.   
 
Colony stimulating factors 
GM-CSF was the only CSF to show correlation with viral load, in a positive direction. 
 
 
 
 
Figure 5.2.13: Correlation between relative levels of colony stimulating factors and FCoV viral loads. 
Significance levels are marked by ** = p£0.01; * = p£0.05.   
** 
** 
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Table 5.2.2: Summarised results of a one-tailed Spearman’s rank test correalting results between FCoV viral loads and each mediator. The direction of the arrows indicates a 
positive or negative correlation and the number of arrows indicates the degree of significance (p<0.01 or p<0.05 respectively).  
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FCoV ● ↑↑ ↑↑ ↑↑ ↑ ↓ ↑↑ ↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑
TLR1 ● ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑ ↑↑ ↑ ↑ ↑↑ ↑ ↑↑ ↑↑ ↑↑ ↑ ↑↑ ↑ ↑
TLR2 ↑↑ ● ↑↑ ↑↑ ↑↑ ↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑ ↑↑
TLR3 ↑↑ ● ↑↑ ↑↑ ↑↑ ↑↑ ↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑ ↑ ↑↑ ↑↑ ↑ ↑ ↑↑ ↑↑ ↑↑ ↑
TLR4 ↑↑ ↑↑ ↑↑ ↑↑ ● ↑↑ ↑↑ ↑↑ ↑↑ ↑ ↑↑ ↑↑ ↑ ↑↑ ↑↑ ↑↑ ↑ ↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑ ↑↑
TLR5 ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ● ↑↑ ↑ ↑↑ ↑ ↑↑ ↑↑ ↑↑ ↑ ↑ ↑↑ ↑ ↑↑ ↑ ↑↑ ↑ ↑ ↑ ↑ ↑↑ ↑ ↑
TLR6 ↑↑ ↑↑ ↑↑ ↑↑ ● ↑↑ ↑ ↑↑ ↑↑ ↑ ↑↑ ↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑
TLR7 ↑↑ ↑↑ ↑↑ ↑ ↑↑ ● ↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑ ↑ ↑ ↑↑ ↑↑ ↑↑ ↑
TLR8 ↑ ↑↑ ↑↑ ↑ ↑↑ ↑↑ ↑ ↑ ● ↑↑ ↑↑ ↑↑ ↑↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑↑
TLR9 ↓ ↑↑ ↑↑ ↑↑ ↑↑ ● ↑↑ ↑ ↑↑ ↑ ↑ ↑↑ ↑ ↑↑ ↑↑ ↑
STAT1 ↑↑ ↑↑ ↑ ↑↑ ↑↑ ↑↑ ● ↑↑ ↑↑ ↑ ↑ ↑ ↑ ↑↑ ↑↑ ↑ ↑↑ ↑ ↑↑
STAT2 ↑↑ ↑ ↑ ↑↑ ↑↑ ↑ ↑ ↑↑ ↑ ↑↑ ● ↑↑ ↑ ↑↑ ↑↑ ↑ ↑↑ ↑ ↑↑ ↑↑ ↑↑ ↑ ↑↑
STAT3 ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ● ↑ ↑ ↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑ ↑ ↑↑ ↑↑ ↑ ↑↑ ↑↑ ↑↑ ↑↑
IFN-α ↑ ↑ ↑ ↑↑ ↑ ● ↑↑ ↑↑ ↑ ↑ ↑ ↑ ↑↑ ↑
IFN-β ↑↑ ↑ ↑↑ ↑ ↑ ↑↑ ↑ ↑ ↑ ↑↑ ● ↑↑ ↑↑ ↑ ↑↑ ↑ ↑↑ ↑↑ ↑
IFN-γ ↑↑ ↑↑ ↑↑ ↑ ↑ ↑↑ ↑↑ ● ↑↑ ↑↑ ↑ ↑ ↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑ ↑↑
IL-1β ↑↑ ↑↑ ↑↑ ↑ ↑↑ ↑ ↑↑ ↑↑ ↑ ↑↑ ● ↑↑ ↑ ↑↑ ↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑
IL-6 ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑ ↑↑ ↑↑ ↑ ↑↑ ↑↑ ↑↑ ● ↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑ ↑↑
IL-10 ↑↑ ↑↑ ↑ ↑ ↑↑ ↑ ● ↑ ↓ ↑ ↓↓
IL-15 ↑ ↑ ↑ ↑↑ ↑ ↑↑ ↑ ● ↑ ↑↑ ↑
IL-17 ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑ ↑ ↑ ↑ ↑↑ ↑ ↑ ↑ ↑ ↑ ↑ ● ↑↑ ↑ ↑ ↑ ↑↑ ↑ ↑↑
TNF-α ↑ ↑ ↑ ↑↑ ↑↑ ↑↑ ↑ ↑↑ ↑ ↑↑ ↑↑ ↑↑ ● ↑ ↑ ↑ ↑ ↑↑ ↑↑ ↑↑
TGFβ ↑ ↑↑ ↑ ↑ ↓ ↑ ● ↑↑ ↑↑ ↑↑
MMP2 ↑↑ ↑↑ ↑↑ ↑ ↑↑ ↑↑ ↑↑ ↑ ↑ ↑ ↑ ● ↑ ↑↑ ↑↑ ↑ ↑ ↑
MMP9 ↑ ↑ ●
MMP13 ↑↑ ↑↑ ↑ ↑↑ ↑ ↑↑ ↑ ↑↑ ↑ ↑ ↑↑ ● ↑
CXCL10 ↑↑ ↑ ↑↑ ↑↑ ↑ ↑↑ ↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑ ↑ ↑ ● ↑↑ ↑↑ ↑↑ ↑
CCL8 ↑↑ ↑↑ ↑↑ ↑ ↑ ↑ ↑↑ ↑↑ ↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑ ↑ ↑↑ ↑↑ ● ↑↑ ↑↑ ↑ ↑↑
TIMP1 ↑↑ ↑↑ ↑↑ ↑ ↑ ↑ ↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ● ↑ ↑ ↑↑
TIMP3 ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑ ↑↑ ↑↑ ↑↑ ↑ ↑↑ ↑ ↑ ● ↑
G-CSF ↑↑ ↑ ↑ ↑↑ ↑↑ ↑↑ ↑↑ ↓↓ ↑↑ ↑↑ ↑↑ ↑ ● ↑↑
M-CSF ↑ ↑ ↑↑ ↑ ↑ ↑↑ ↑↑ ↑ ↑↑ ↑↑ ↑↑ ↑ ↑↑ ↑ ↑ ↑↑ ↑↑ ↑ ↑↑ ↑ ↑ ↑ ↑↑ ● ↑↑
GM-CSF ↑ ↑ ↑↑ ↑ ↑↑ ↑ ↑ ↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑ ↑ ↑↑ ↑↑ ↑↑ ●
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Relationship between the presence of specific amino acid sequences and mediator levels 
Following selected S gene sequencing, comparisons between animals carrying virus with M or L at 
codon 1048 were described in the manuscript. With only one cat infected by a ‘non-mutated 
enteric virus’, no statistical comparisons were possible. Instead the sequencing results for the MLN 
from Group 2 cats were compared visually by plotting results for individual cats in columns relating 
to sequence within the overall group results. Only the FCoV result was portrayed graphically in the 
publication, therefore the remainder are displayed in full here, along with the additional mediator 
groups. FCoV is shown again for direct comparison with the mediators. 
These results show that the ‘non-pathogenic’ virus levels, with M and S at the described codons, 
are at the upper limit of the whiskers (Fig. 5.2.14), indicating a spread of 1.5 times the interquartile 
range (IQR). For brevity, this cat will be referred to in this section as ‘E’ for enteric virus. 
Results for the single E cat were near the top of the interquartile range for the significantly 
elevated TLRs 2, 4, and 8 (Fig. 5.2.15). It is known that these correlate with FCoV so this is 
compatible with the viral load. 
All cytokine and chemokine levels in cat E except IL-1b and TGFb (i.e. IL-6, IL-10, IL-15, IL-17, TNF-
a, CCL8, CXCL10) are above the group interquartile range. All these targets were generally 
elevated in FIP except IL-10, IL-17 and TGFb. See Fig. 5.2.16 
IFNs were all expressed in the upper half (IFN-a), to upper limit (IFN-b and -g) of the IQR by cat E 
(Fig. 5.2.17). 
STAT expression was in the upper half (STAT1 and 3) or above the IQR (STAT2). See Fig. 5.2.17. 
Cat E expressed MMPs 2 and 9, and TIMPs 1 and 3 within the IQR. MMP13 was below it. See Fig. 
5.2.18. 
Of the CSFs, only G-CSF was elevated in Group 2, cat E had the median G-CSF result, within range 
M-CSF and above range GM-CSF. See Fig. 5.2.18. 
These results show that cat E had a tendency towards the extremes of the ranges, usually in the 
same direction as the significance of that target (i.e. the top end in targets elevated in FIP). 
However, reliable conclusions cannot be drawn from these results; the tendency was not always 
consistent, is only the result of one cat, and may relate to the high FCoV load relative to the group. 
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Figure 5.2.14: Results for relative viral mRNA loads in the MLN of cats within Group 2. Columns of 
crosses represent from left to right: M1048L (27 cats); 1048M-S1050A (2 cats); 1048M-1050S (1 cat).  
 
 
Figure 5.2.15: Results for relative TLR mRNA levels in the MLN of cats within Group 2. Columns of 
crosses represent from left to right: M1048L (27 cats); 1048M-S1050A (2 cats); 1048M-1050S (1 cat).  
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Figure 5.2.16: Results for relative cytokine and chemokine mRNA  levels in the MLN of cats within group 
2. Columns of crosses represent from left to right: M1048L (27 cats); 1048M-S1050A (2 cats); 1048M-
1050S (1 cat). 
 
 
Figure 5.2.17: Results for relative interferon (left) and STAT (right) mRNA levels in the MLN of cats 
within group 2. Columns of crosses represent from left to right: M1048L (27 cats); 1048M-S1050A (2 
cats); 1048M-1050S (1 cat). 
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Figure 5.2.18: Results for relative matrix remodelling enzyme (left) and colony stimulating factor (right) 
mRNA levels within Group 2. Columns of crosses represent from left to right: M1048L (27 cats); 1048M-
S1050A (2 cats); 1048M-1050S (1 cat). 
 
3. Results of RT-qPCR for immune mediators on laser capture microdissection (LCM) 
samples 
Cryoblocks made from FIP lesions of the cats sampled in Zurich were used for LCM. LCM samples 
were taken from the typical, macrophage-dominated FIP lesions both on the serosa (e.g. Fig. 5.3.1) 
and within tissues (parenchymal lesions e.g. 5.3.2). All lesion samples were assembled into a new 
group (Group 2+) and compared with the entire Group 2 MLN results (as presented in the previous 
chapter) (shown in Fig. 5.3.3-Fig. 5.3.9 and Table 5.3.1). None of the LCM samples taken included 
recognisable pre-existing parenchyma (e.g. a sample from hepatic serositis contained only cells 
from a focal inflammatory infiltrate and no hepatocytes), therefore samples were not further 
segregated by organ. Instead, they were subsequently further divided into those dominated by a 
fibrinous exudate (serositis; though the macrophage dominated regions were still targeted) and 
granulomatous lesions, and these two subgroups compared (Fig. 5.3.3.5.3.9 and Table 5.3.1). 
Examples of the cryoblock sections are shown in Fig. 5.3.1 and 5.3.2. As a smaller investigation, 
and in order to exclude as far as possible the macrophage contribution within the red pulp, LCM 
samples of lymphoid follicles were also taken from four cats (see below for more details and Fig. 
5.3.10-5.3.14).  
When the term ‘bulk’ tissue is used, it refers to the organ samples taken into RNAlater in which there 
was no selection for region.  
It was not possible to reliably compare TLR6, IL-10, IL-15, IL-17, MMP9, MMP13, IFN-b, G-CSF or GM-
CSF mRNA levels owing to uneven pre-amplification (see methods section 4); these results were not 
included in the evaluation. 
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Figure 5.3.1: Splenic serositis from case S16-0167, example of cryoblock quality stained by HE (a) and 
IH for FCoV (b) versus FFPE section stained by HE (c). 
 
Figure 5.3.2: Small intestine from case S17-0124; a) example HE stained cryoblock of a sampled 
granulomatous lesion (arrow) beneath serositis; b) FCoV IH of a consecutive section confirming 
concentration of FCoV infected cells in the lesions (there are also positively stained epithelial cells); c) 
cresyl violet stained membrane slide during LCM, the cap is overlying the slide and arrows mark the 
selected and laser captured areas, corresponding to lesions shown in a) and b).  
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FCoV 
Viral RNA levels were significantly higher in the LCM lesion samples in comparison to the bulk MLN 
results from Group 2 cats (Fig. 5.3.3), reinforcing that regions dominated by infected macrophages 
had been successfully sampled. The levels in granulomatous lesions were significantly higher than 
in serositis lesions, likely due to the overall higher number of macrophages, though the groups 
overlapped. 
 
 
Figure 5.3.3: Boxplots of (left) relative mRNA levels of FCoV in the FIP (Group 2) MLN samples (n=30) 
versus the LCM lesion samples (n=27); boxplots of (right) relative mRNA levels of FCoV between serosal 
lesions (n=17) and granulomatous parenchymal lesions (n=10) within the LCM lesion group. The 
amount of target was calculated by 2-∆∆CT, using fGAPDH as the internal reference gene for 
normalisation and expressed as an n-fold difference relative to the G1 mean of the BM samples as a 
calibrator. The boxes depict the median and interquartile (IQ) range with whiskers extending to the 
highest and lowest values which are within 1.5 x the IQ range. Outliers beyond this are individually 
marked. * marks significant differences between individual groups (p≤0.05). 
 
Toll-like receptors 
TLR2, 4, and 8 mRNA levels were significantly higher in LCM lesion samples in comparison to the 
bulk MLN levels from Group 2 cats, whilst TLR1, 7, and 9 were significantly lower in lesions. TLR3 
had a very mild tendency (not significant) to be lower in lesions. None of the TLRs showed any 
significant differences, or noticeable tendencies, between the lesion subtypes. Fig. 5.3.4. 
 
* 
* * 
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Figure 5.3.4: Red and turquoise: Boxplots of relative TLR mRNA levels in the FIP MLN samples ((Group 
2; n=30) versus the LCM lesion samples (Group 2+; n=27). Blue and green: Boxplots of relative TLR 
mRNA levels between serosal lesions (n=17) and granulomatous parenchymal lesions (n=10) within the 
LCM lesion group. The amount of target was calculated by 2-∆∆CT, using fGAPDH as the internal 
reference gene for normalisation and expressed as an n-fold difference relative to the G1 mean of the 
BM samples as a calibrator. The boxes depict the median and interquartile (IQ) range with whiskers 
extending to the highest and lowest values which are within 1.5 x the IQ range. Outliers beyond this 
are individually marked. * marks significant differences between individual groups (p≤0.05). 
 
Cytokines and chemokines 
Of the interleukins, only IL-1b and IL-6 could be evaluated, with only IL-1b significantly higher in 
LCM lesions in comparison to the bulk MLN levels from Group 2 cats. IL-6 exhibited no difference 
at all between LCM samples and bulk MLN but was higher in granulomatous parenchymal lesions 
than in serosal lesions. TGF-b levels were significantly lower in LCM samples than in the bulk MLN 
and yet significantly higher in granulomatous lesions than in serosal lesions. CCL8 but not CXCL10 
levels were significantly higher in LCM lesions than in the bulk MLN, neither differed between 
subgroups. Fig. 5.3.5 
* 
* 
* * 
* 
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Figure 5.3.5: Red and turquoise: Boxplots of relative cytokine and chemokine mRNA levels in the FIP 
MLN samples (Group 2; n=30) versus the LCM lesion samples (Group 2+; n=27). Blue and green: 
Boxplots of relative cytokine and chemokine mRNA levels between serosal lesions (n=17) and 
granulomatous parenchymal lesions (n=10) within the LCM lesion group. The amount of target was 
calculated by 2-∆∆CT, using fGAPDH as the internal reference gene and expressed as an n fold 
difference relative to the G1 mean of the BM samples as a calibrator. The boxes depict the median and 
interquartile (IQ) range with whiskers extending to the highest and lowest values which are within 1.5 
x the IQ range. Outliers beyond this are individually marked. * marks significant differences between 
individual groups (p≤0.05). 
 
Interferons 
IFN-a and -g were evaluated, with only the former significantly higher in LCM lesions in 
comparison to bulk MLN. Neither IFN showed a significant difference between granulomatous and 
serosal lesions. Fig. 5.3.6. 
 
* * 
* 
* * 
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Figure 5.3.6: Red and turquoise: Boxplots of relative interferon mRNA levels in the FIP MLN samples 
(Group 2; n=30) versus the LCM lesion samples (Group 2+; n=27). Blue and green: Boxplots of relative 
interferon mRNA levels between serosal lesions (n=17) and granulomatous parenchymal lesions (n=10) 
within the LCM lesion group. The amount of target was calculated by 2-∆∆CT, using fGAPDH as the 
internal reference gene for normalisation and expressed as an n-fold difference relative to the G1 mean 
of the BM samples as a calibrator. The boxes depict the median and interquartile (IQ) range with 
whiskers extending to the highest and lowest values which are within 1.5 x the IQ range. Outliers 
beyond this are individually marked. * marks significant differences between individual groups 
(p≤0.05). 
 
STATs 
All three STATs were significantly lower in LCM lesions than in bulk MLN. Interestingly, none of the 
comparisons in previous chapters (between the control group and the FIP group for the BM, 
spleen, and MLN) had shown a significant difference for STAT3. STAT1 and 3 mRNA levels were 
significantly higher in granulomatous than serosal lesions, with STAT2 levels just failing to reach 
significance in the same direction. Fig. 5.3.7. 
 
 
 
Figure 5.3.7: Red and turquoise: Boxplots of relative STAT mRNA levels in the FIP MLN samples (Group 
2; n=30) versus the LCM lesion samples (Group 2+; n=27). Blue and green: Boxplots of relative STAT 
* 
* * 
* * 
* 
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mRNA levels between serosal lesions (n=17) and granulomatous parenchymal lesions (n=10) within the 
LCM lesion group. The amount of target was calculated by 2-∆∆CT, using fGAPDH as the internal 
reference gene for normalisation and expressed as an n-fold difference relative to the G1 mean of the 
BM samples as a calibrator. The boxes depict the median and interquartile (IQ) range with whiskers 
extending to the highest and lowest values which are within 1.5 x the IQ range. Outliers beyond this 
are individually marked. * marks significant differences between individual groups (p≤0.05). 
 
Matrix remodelling enzymes 
Only MMP2 and the TIMPs could be evaluated, with significantly lower MMP2 and TIMP3 mRNA 
levels in lesions and significantly higher TIMP1 levels than in bulk MLN. Granulomatous lesions 
had significantly higher levels than serosal lesions for all three enzymes. Fig. 5.3.8. 
  
  
Figure 5.3.8: Red and turquoise: Boxplots of relative matrix remodelling enzyme mRNA levels in the FIP 
MLN samples ((Group 2; n=30) versus the LCM lesion samples (Group 2+; n=27). Blue and green: 
Boxplots of relative matrix remodelling enzyme mRNA levels between serosal lesions (n=17) and 
granulomatous parenchymal lesions (n=10) within the LCM lesion group. The amount of target was 
calculated by 2-∆∆CT, using fGAPDH as the internal reference gene for normalisation and expressed as 
an n-fold difference relative to the G1 mean of the BM samples as a calibrator. The boxes depict the 
median and interquartile (IQ) range with whiskers extending to the highest and lowest values which 
are within 1.5 x the IQ range. Outliers beyond this are individually marked. * marks significant 
differences between individual groups (p≤0.05). 
 
 
 
 
 
* * * 
* * 
* 
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Colony stimulating factors 
Only M-CSF could be evaluated, this was significantly lower in LCM lesions than in bulk MLN, and 
significantly higher in granulomatous than in serosal lesions. Fig. 5.3.9. 
 
Figure 5.3.9: Red and turquoise: Boxplots of relative M-CSF mRNA levels in the FIP MLN samples (Group 
2; n=30) versus the LCM lesion samples (Group 2+; n=27). Blue and green: Boxplots of relative M-CSF 
mRNA levels between serosal lesions (n=17) and granulomatous parenchymal lesions (n=10) within the 
LCM lesion group. The amount of target was calculated by 2-∆∆CT, using fGAPDH as the internal 
reference gene for normalisation and expressed as an n-fold difference relative to the G1 mean of the 
BM samples as a calibrator. The boxes depict the median and interquartile (IQ) range with whiskers 
extending to the highest and lowest values which are within 1.5 x the IQ range. Outliers beyond this 
are individually marked. * marks significant differences between individual groups (p≤0.05). 
* * 
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Table 5.3.1: Statistical results of a Mann-Whitney comparison between MLN G2 samples and LCM 
lesion samples, and between serosal (S) and granulomatous (G) lesions. Significant results (p£0.05) 
are highlighted in blue. ↑: increased in G2+/G. Targets written in grey could not be compared for 
LCM samples. The G1 vs G2 result from Chapter 2 is included for reference. 
Target G1 vs G2  G2 vs G2+  G2+: S vs G  
FCoV 0.000 ↑ 0.009 ↑ 0.223   
TLR1 0.610   0.000 ↓ 0.473   
TLR2 0.000 ↑ 0.000 ↑ 0.286   
TLR3 0.569   0.144   0.505   
TLR4 0.019 ↑ 0.000 ↑ 0.604   
TLR5 0.053   0.350   0.414   
TLR6 0.859          
TLR7 0.059   0.000 ↓ 0.639   
TLR8 0.013 ↑ 0.000 ↑ 0.749   
TLR9 0.991   0.000 ↓ 0.141   
STAT1 0.000 ↑ 0.000 ↓ 0.003 ↑ 
STAT2 0.000 ↑ 0.000 ↓ 0.052   
STAT3 0.260   0.000 ↓ 0.003 ↑ 
IFN-α 0.041 ↑ 0.002 ↑ 0.414   
IFN-β 0.004 ↑        
IFN-γ 0.000 ↑ 0.225   0.537   
IL-1β 0.026 ↑ 0.002 ↑ 0.473   
IL-6 0.001 ↑ 0.988   0.040 ↑ 
IL-10 0.296          
IL-15 0.019 ↑        
IL-17 0.440          
TNF-α 0.004 ↑ 0.586   0.083   
TGFβ 0.430   0.000 ↓ 0.040 ↑ 
CCL8 0.000 ↑ 0.003 ↑ 0.443   
CXCL10 0.000 ↑ 0.384   0.204   
MMP2 0.035 ↑ 0.000 ↓ 0.000 ↑ 
MMP9 0.204          
MMP13 0.011 ↓        
TIMP1 0.000 ↑ 0.046 ↑ 0.023 ↑ 
TIMP3 0.117   0.001 ↓ 0.004 ↑ 
G-CSF 0.000 ↑        
M-CSF 0.476   0.000 ↓ 0.001 ↑ 
GM-CSF 0.921           
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Comparisons of selected mediator levels between organs and lesions  
From all mediators examined, a selection were chosen which were of most interest based on the 
results of the current and previous chapters. These comprised: the TLRs upregulated in the MLN 
in FIP (TLR 2, 4, and 8); the TLRs with a possible viral-mediated downregulation in the MLN in FIP 
(TLR 3 and 7); TLR9 which was upregulated in the MLN of FCoV-infected control cats in comparison 
to cats without FCoV positive MLN; IFNs, the main cytokines downstream of anti-viral TLRs; the 
main cytokines downstream of pro-inflammatory TLR signalling (IL-1b, IL-6, TNF-a,); the 
chemokines with a potential role in cell recruitment to lesions (CCL8 and CXCL10); the 
transcription factors mediating IFN signalling (STATs). 
For each of these mediators, the relative mRNA levels detected in different tissues were 
compared. The bone marrow, a primary haemolymphatic organ, was used as a basal level (n=10). 
This organ showed no lesions or immunohistologically detectable virus in any animal yet was, in 
all except one of the animals in this cohort, PCR positive for FCoV; suggesting this is mainly a result 
of virus within monocytes and indicating that animals with FIP are generally viraemic at the final 
stage of disease. As far as possible, splenic samples were taken from lesion free areas so that levels 
here mainly reflect the systemic response of this lymphatic organ (n=11). The MLN, as previously 
described, were of specific interest as the first site of viral spread beyond the intestine (n=8). 
Lymphoid follicles, free of lesions and morphologically detectable coronavirus infection, were 
taken by LCM from four cases, from spleen, MLN, and Peyer’s patches, with the aim of largely 
excluding the macrophage contribution to mediator production (n=4). It was also of interest to 
see how similarly these various lymphoid follicles behaved in terms of mediator transcription, i.e. 
the importance of cell type versus anatomic location. Finally, the lesions themselves were 
evaluated to gain an approximation of the contribution of the infected cells themselves. These 
were pooled without reference to the affected organ as all excluded adjacent parenchyma (n=27). 
All cases from which lesion samples had been taken were included, with the number of samples 
available for each tissue varying (see materials and methods).  
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FCoV 
Relative viral load was as expected, being lowest in the BM and lymphoid follicles and progressing 
from spleen through MLN to lesions where the highest mRNA levels were found. Fig. 5.3.10. 
 
 
 
 
 
 
Figure 5.3.10: Boxplots of relative FCoV mRNA levels in different tissues of cats with FIP, taken from 
within the LCM lesion group. The amount of target was calculated by 2-∆∆CT, using fGAPDH as the 
internal reference gene for normalisation and expressed as an n-fold difference relative to the G1 mean 
of the BM samples as a calibrator (depicted on the y axis). The boxes depict the median and 
interquartile (IQ) range with whiskers extending to the highest and lowest values which are within 1.5 
x the IQ range. Outliers beyond this are individually marked. 
 
Toll-like receptors 
The BM transcribed the lowest levels of all TLRs except TLR9. For all those elevated in FIP (TLR 2, 
4, and 8), levels were highest in the lesions but there was no dominant trend between the spleen, 
MLN, and lymphoid follicles. TLR3 mRNA levels showed little variation between organs whilst TLR 
7 and 9 levels were lowest in the lesions and highest in follicles. Fig. 5.3.11. 
 
 
 
n=10       n=11       n=8        n=4       n=27 
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Figure 5.3.11: Boxplots of relative TLR mRNA levels in different tissues of cats with FIP, taken from 
within the LCM lesion group. The amount of target was calculated by 2-∆∆CT, using fGAPDH as the 
internal reference gene for normalisation and expressed as an n-fold difference relative to the G1 mean 
of the BM samples as a calibrator (depicted on the y axis). The boxes depict the median and 
interquartile (IQ) range with whiskers extending to the highest and lowest values which are within 1.5 
x the IQ range. Outliers beyond this are individually marked.  
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Inflammatory cytokines and chemokines 
IL-1b and IL-6 displayed very similar expression profiles but with higher basal expression of IL-1b 
in the BM. For both, levels decreased from spleen to MLN to lymphoid follicles, with levels in 
lesions similar to those in the spleen. TNF-a mRNA levels were lowest in the BM but otherwise 
showed little variation across tissues and lesions. The chemokines CCL8 and CXCL10 also had the 
lowest expression in the BM and the highest in the lesions, but whereas for CCL8 the levels within 
lymphoid follicles were lower than in the spleen and MLN (and similar to the BM), for CXCL10 
these three tissues were all on a par, above the BM levels. Fig. 5.3.12. 
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Figure 5.3.12: Boxplots of relative inflammatory cytokine and chemokine mRNA levels in different 
tissues of cats with FIP, taken from within the LCM lesion group. The amount of target was calculated 
by 2-∆∆CT, using fGAPDH as the internal reference gene for normalisation and expressed as an n-fold 
difference relative to the G1 mean of the BM samples as a calibrator (depicted on the y axis). The boxes 
depict the median and interquartile (IQ) range with whiskers extending to the highest and lowest values 
which are within 1.5 x the IQ range. Outliers beyond this are individually marked.  
 
 
Interferons 
IFN-a relative mRNA levels increased steadily from BM to spleen, MLN, lymphoid follicles and 
finally lesions. IFN-g showed a similar progression with the exception of levels in lymphoid follicles 
which were very slightly below the levels of the spleen and MLN. Fig. 5.3.13. 
  
Figure 5.3.13: Boxplots of relative interferon mRNA levels in different tissues of cats with FIP, taken 
from within the LCM lesion group. The amount of target was calculated by 2-∆∆CT, using fGAPDH as the 
internal reference gene for normalisation and expressed as an n-fold difference relative to the G1 mean 
of the BM samples as a calibrator (depicted on the y axis). The boxes depict the median and 
interquartile (IQ) range with whiskers extending to the highest and lowest values which are within 1.5 
x the IQ range. Outliers beyond this are individually marked.  
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STATs 
For STAT1, the lowest levels were in the BM, followed by the lesions, though with overlap between 
lesions, spleen, MLN and lymphoid follicles. The latter three were the most similar. STAT2 mRNA 
levels were similar in the BM, lymphoid follicles and lesions, being higher in the spleen and MLN. 
Fig 5.3.14. 
 
  
Figure 5.3.14: Boxplots of relative STAT mRNA levels in different tissues of cats with FIP, taken from 
within the LCM lesion group. The amount of target was calculated by 2-∆∆CT, using fGAPDH as the 
internal reference gene for normalisation and expressed as an n-fold difference relative to the G1 mean 
of the BM samples as a calibrator (depicted on the y axis). The boxes depict the median and 
interquartile (IQ) range with whiskers extending to the highest and lowest values which are within 1.5 
x the IQ range. Outliers beyond this are individually marked.  
 
    n=10      n=11       n=8      n=4       n=27     n=10       n=11       n=8      n=4       n=27 
127 
 
(3). Immunohistological examination 
Immunohistology (IH) was undertaken using cross-reacting antibodies against TLR8 and Iba-1 on 
control cat MLN to approximately characterise which cells express this receptor before 
progression to IF and correlation with FCoV staining.  
TLR8 staining showed rare scattered cells exhibiting a strong cytoplasmic reaction. These cells had 
a moderate to abundant amount of cytoplasm (resembling macrophages/DC) and were most 
frequently found in the sinuses and medullary cords (Fig. 5.3.15). The number of TLR8 positive 
cells was far outweighed by the number of cells staining positively for Iba-1 (i.e. macrophages). 
Only very rarely were TLR8 positive cells observed within the follicles. 
 
 
Figure 5.3.15: a) and b) Overview of MLN stained for Iba-1 and TLR8 respectively; c) and d) close up 
view of medulla stained for Iba-1 and TLR8 respectively, TLR8 positive cells appear to correlate with 
Iba-1 positive cells as indicated by upwards and left facing arrow pair examples .  
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Immunofluorescence 
Sections were all double stained for TLR8 and FCoV antigen, with an Iba-1 FCoV double stain used. 
All regions were evaluated, with the regions of interest (ROI) used for digital image analysis those 
corresponding to lesions sampled by LCM for RT-qPCR. These lesions were from various organ as 
shown in Table 5.3.2 below. As the virus-infected cells were clearly visible and restricted to certain 
areas, each of these areas was carefully evaluated for the presence of TLR8 staining. Only very 
rare examples of cells double-stained for FCoV and TLR8 could be found, exemplified in Fig. 5.3.16, 
within a lymph node paracortex. 
 
Figure 5.3.16: S15-1842 MLN, x40: Lymph node (paracortex) showing cells double-stained (arrows) for 
FCoV (green) and TLR8 (red). 
 
Figure 5.3.17: S15-1539 MLN; provided as orientation for Fig. 5.3.18 below; a) and b) overview of 
cortical lesions with HE and IH for FCoV antigen respectively, 4x; c) and d) close up of cortical lesion 
with HE and FCoV IH respectively, showing central necrosis surrounded by numerous infected 
macrophages, x20.  
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Figure 5.3.18: S15-1539 MLN a) Iba1 (red) and FCoV (green) staining showing the frequency of 
macrophages within the lymph node, the scale of which is often underappreciated by HE staining; 
shown as a prelude to TLR8 staining 10x; b) cortical granulomatous infiltrates are prominently outlined 
by FCoV staining (green and arrowhead example) 5x; c) close up view of a lesion. Centrally there are 
very rare TLR8 positive cells (arrowheads) with increasing numbers in the surrounding tissue (arrows, 
staining is of lower intensity than FCoV). 
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Digital Image Analysis 
Following traditional evaluation of the slides it appeared clear that a high level of correlation 
between FCoV staining and TLR8 staining would not be observed. Slides were nevertheless 
processed in case digital analysis was able to offer a greater sensitivity.  
 
Figure 5.3.19: Overview of small intestine (cross section) from case S17-0124, fluorescently stained for 
FCoV antigen (green) and TLR8 (red). Green dashed lines mark the regions of interest (ROI) selected for 
image analysis, the white box marks the location shown in Fig. 5.3.20 below. 
 
 
Figure 5.3.20: Close up view of an ROI from case S17-0124 following image analysis. Red label: TLR8 
staining; white: nucleus of cell expressing TLR8; green: FCoV antigen staining; turquoise: nucleus of cell 
infected with FCoV; blue: nucleus of cell associated with neither stain.   
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The APP had also been programmed to label double stained cells yellow, however these were not 
detected. 
The output was as follows: 
Table 5.3.2: Visiopharm output of image classification combined with calculated ratios. 
  Nucleus label % of total PCR result 
Organ Sample no. None FCoV TLR8 FCoV TLR8 FCoV TLR8 
Spleen - serosa 106 2244 387 36 14.51069 1.349831 278161.6 3.604915 
Spleen - follicles 107 14978 0 48 0 0.319446 3.066604 3.034988 
Spleen - serosa 110 2306 14 97 0.57923 4.01324 52507.86 2.97885 
Spleen - follicles 111 16798 0 1093 0 6.109217 27.9118 0.928768 
MLN - serosa 113 13599 11 365 0.078712 2.611807 83747.15 4.69659 
MLN - follicles 114 18394 9 180 0.048431 0.968627 0.422382 0.493353 
Liver - serosa 115 7214 1364 218 15.50705 2.478399 134383 5.484345 
Liver - serosa 134 1451 1164 680 35.32625 20.63733 4548819 2.520724 
SI - granulomatous 136 2752 1318 730 27.45833 15.20833 8645755 4.183775 
 
These results were plotted but showed no real correlation and multiple discrepancies between 
the IH and protein levels in the sections. With only nine results, a few discrepancies are able to 
distort the dataset.  
This has a number of possible explanations. Firstly, owing to the lack of homogeneity of the 
lesions, there are often marked differences between sections even from the same block 
subsequent to multiple sectioning. As a consequence, the proportions of cells taken for PCR will 
differ from those stained by IH. This is thought to have made the greatest contribution to the 
occasional discrepancies. Taking the known entity of FCoV, the majority of lesions correlated 
approximately (e.g. no cells seen by IH in follicles, negligible qPCR levels) whereas others (e.g. case 
113), appeared mismatched. The expected level of correlation for TLR8 was unknown, additionally 
the small range of results by RT-qPCR further complicated interpretation of discrepancies 
observed.  
Secondly, despite multiple optimisation steps, the classification system struggles when applied to 
densely cellular areas (common in the lesions). As a positive staining cytoplasm is in contact with 
multiple nuclei, even accurate nuclear segregation cannot lead to completely accurate nuclear 
allocation.  
Image analysis was therefore not further investigated at this stage. 
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4. Selected FCoV S gene Sanger sequencing  
The particular S gene region of interest was sequenced based on a previous study purporting to 
be able to distinguish FIPV from FECV in the majority of cases 132. The mutations in question were 
reported at codons 1058 and 1060 on the reference gene, however re-evaluation shows these to 
be at 1048 and 1050, and they will therefore be referred to subsequently as such.  The previous 
study found that, at codon 1048, a transition from methionine to leucine (M1048L) was present 
in the majority of tissue samples from cats with FIP in comparison to faecal samples of healthy 
cats. A smaller group of cats with FIP retained this M1048 but instead had a second mutation at 
codon 1050, serine to alanine (S1050A). 
More recent studies found the mutations to be an indicator of the virus’ capacity to spread 
systemically instead of remaining solely enteric rather than its direct pathogenicity so these 
former terms will be used here to describe the mutations 91,133. 
In total, there were 101 tissue samples from cats with FIP, from which 96 had had a positive RT-
qPCR FCoV result. Following a second conventional PCR directed against a section of the S gene 
(see methods and below), adequate sequencing results were obtained from 86 of the 96. These 
are shown below grouped by organ, disease status and by individual cat. 
From many of the Bristol cases, faecal samples had also been analysed and results were available 
for interpretation. This procedure was not performed on Zurich cases, as this was not the area of 
interest of the study. 
 
FCoV S gene sequencing results from the bone marrow of cats with FIP 
All 11 BM samples from FIP cats were from Zurich cases; of these, nine were FCoV RT-qPCR 
positive, and the samples were amenable to sequencing. One of these cats carried virus encoding 
methionine (M) at codon 1048 and serine (S) at codon 1050, corresponding to ‘enteric’ virus. The 
remaining eight encoded leucine (L) at 1048, displaying the ‘systemic’ M1048L mutation, as well 
as S1050. Table 5.4.1. No Group 1 cats were found to carry FCoV in the BM, so samples were not 
subjected to conventional PCR. 
Table 5.4.1: Viral sequencing results from the bone marrow of cats with FIP, with the only example of 
‘enteric’ virus highlighted. 
 
Case no. Sample no. FCoV CT
S15-1738 20 38.8 CTG Leu TCT Ser
S15-1809 23 31.1 TTG Leu TCA Ser
S15-1539 26 30.5 TTG Leu TCC Ser
S15-1728 29 39.2 TTG Leu TCT Ser
S15-1094 31 -
S15-0983 33 32.4 ATG Met TCC Ser
S15-0259 35 38.5 TTG Leu TCT Ser
S15-0134 37 30.9 TTG Leu TCT Ser
S15-1842 41 34.2 TTG Leu TCT Ser
S16-0454 44 -
S17-0124 47 31.9 TTG Leu TCT Ser
Codon 1048 Codon 1050
no sequence
no sequence
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FCoV S gene sequencing results from the spleen of cats with FIP 
All 14 Group 2 splenic samples (again, all from Zurich cases), were FCoV positive by RT-qPCR and 
were amenable to sequencing. There was again only one cat carrying ‘enteric’ virus (S15-1094) 
but this was not the same cat as the one found to carry ‘enteric’ virus in the BM (S15-0983). Cat 
S15-0983 had virus with M1048 in both organs however, in the spleen, the second (and less 
common) systemic associated mutation, from S to alanine (A) at 1050 was also present. A third 
cat (S15-1738) carried this second S1050A mutation; this cat carried virus with L and S respectively 
in the BM. Table 5.4.2. 
 
Table 5.4.2: Summary of viral sequencing results from the spleen of cats with FIP, with the only 
example of ‘enteric’ virus highlighted. 
Case no. Sample no. FCoV CT Codon 1048 Codon 1050 
H15-2389 13 33.29 TTG Leu TCT Ser 
S16-0167 14 20.76 TTG Leu TCT Ser 
S15-1368 16 29.47 CTG Leu TCT Ser 
S15-1738 19 29.9 ATG Me GCT Ala 
S15-1809 22 21.26 TTG Leu TCA Ser 
S15-1539 25 22.72 TTG Leu TCC Ser 
S15-1728 28 20.07 TTG Leu TCT Ser 
S15-1094 30 22.52 ATG Met TCC Ser 
S15-0983 32 23.32 ATG Met GCC Ala 
S15-0259 34 33.67 CTG Leu TCT Ser 
S15-0134 36 26.39 TTG Leu TCC Ser 
S15-1842 42 32.41 TTG Leu TCT Ser 
S16-0454 45 31.72 TTG Leu TCC Ser 
S17-0124 48 27.24 TTG Leu TCT Ser 
 
FCoV S gene sequencing results from MLN and faeces of cats with FIP 
This group includes both cats from Zurich (indicated by an Sxx-xxxx case number) and Bristol. 
Of the 30 cats with FIP, one was infected with FCoV serotype 2 for which the previously described 
S gene sequence characterisation is not applicable 91,313. Twenty-six MLN samples contained virus 
that encoded leucine (M1048L) (cDNA sequence TTG, CTG, or TTA). The remaining three cats 
encoded methionine at codon 1048 (cDNA sequence ATG). Of these three cases, two carried 
S1050A, whilst the third encoded S1050.The results are shown in Table 5.4.3.  
Within the faeces, a 50:50 split between ‘enteric’ and ‘systemic’ virus was observed; all the former 
being found in cats with M1058L in the MLN. The cat with systemic ‘enteric’ virus had no 
detectable faecal FCoV with which to compare.  
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Table 5.4.3: Summary of viral sequencing results from the MLN of cats with FIP, and from faecal 
samples of the same cats, with ‘enteric’ virus highlighted. Bases in lower case indicate a mixed 
sequencing result (sample 75); neg: negative; ND: not done. 
 
FCoV S gene sequencing results from MLN and faeces of cats without FIP 
From the 10 cats in Group 1+, it was possible to obtain a usable sequence from eight of the MLN 
samples. All of these eight encoded leucine (M1048L). The quality of the remaining two was not 
high enough to reliably interpret in the region of interest even after repeated attempts. These 
cases are shown in Table 5.4.4 together with those G1- cases from which faecal virus was 
sequenced (20 cases). The Zurich cases and four untested Bristol cases have not been included. 
These results show that, where measurable, all of the non FIP cats with detectable virus in the 
MLN were carrying the ‘systemic’ form. Codon 1050 could not always be sequenced, where 
analysable it was a serine amino acid, consistent with the original publication findings that this 
remains unchanged in virus expressing leucine 132.  
S16-0167 15 TTG Leu TCT Ser
S15-1368 17 CTG Leu TCT Ser
S15-1738 18 ATG Met GCT Ala
S15-1809 21 TTG Leu TCA Ser
S15-1539 24 TTG Leu TCC Ser
S15-1728 27 TTG Leu TCT Ser
S15-1842 43 TTG Leu TCT Ser
S16-0454 46 TTG Leu TCC Ser
S17-0124 49 TTG Leu TCT Ser
30 56 TTG Leu ND -
31 57 TTG Leu ND - ATG Met TCC Ser
32 58 TTG Leu ND - ATG Met TCC Ser
37 59 TTG Leu ND - ATG Met TCC Ser
42 61 TTG Leu ND - ATG Met TCC Ser
93 72 CTG Leu TCC Ser CTT Leu TCC Ser
94 73 TTG Leu TCC Ser TTG Leu TCC Ser
96 74 TTG Leu TCT Ser
100 75 c/tTG Leu TCT Ser
101 76 TTG Leu TCC Ser TCT Leu TCC Ser
103 78 ATG Met TCC Ser
121 83 ATG Met GCC Ala
122 84 TTG Leu TCC Ser
127 88 TTA Leu TCA Ser
128 89 TTG Leu TCC Ser ATG Met TCC Ser
131 90 TTG Leu TCC Ser TTG Leu TCC Ser
142 96 CTG Leu TCT Ser
146 98
43 150 TTG Leu TCC Ser
46 151 TTG Leu ND - TTG Leu ND - 
50 152 TTG Leu ND -
neg
neg
neg
ND
ND
neg
neg
FCoV Type II neg
ND
ND
ND
ND
neg
neg
Case no. Sample no.
ND
MLN Faeces
codon 1048 codon 1050 codon 1048 codon 1050
ND
ND
ND
ND
ND
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Table 5.4.4: Summary of viral sequencing results from the MLN, and from faecal samples of the same 
cats, with ‘enteric’ virus highlighted in blue. Neg: negative; ND: not done. 
Case no. Sample no. FCoV CT Group 
MLN Faeces 
codon   1048 codon 1050 codon    1048 codon 1050 
54 63 - 1-         neg 
56 64 - 1-       neg 
63 65 - 1-       neg 
80 66 - 1-       ATG Met TCC Ser 
84 67 - 1-       neg 
87 68 - 1-       neg 
89 69 - 1-       neg 
91 71 - 1-       neg 
115 79 - 1-       not possible to sequence 
116 80 - 1-       neg 
118 81 - 1-       neg 
119 82 - 1-       neg 
126 87 - 1-       ATG Met TCC Ser 
136 93 - 1-       neg 
141 95 - 1-       neg 
143 97 - 1-       neg 
59 154 - 1-       ATG Met TCC Ser 
72 156 - 1-       neg 
104 160 - 1-       neg 
105 161 - 1-         neg 
38 60 39.8 1+ not possible to sequence ATG Met TCC Ser 
51 62 37.81 1+ TTG Leu ND - neg 
102 77 39.30 1+ CTG Leu ND - neg 
125 86 29.21 1+ CTG Leu TCC Ser neg 
132 91 37.60 1+ TTG Leu TCT Ser neg 
135 92 36.38 1+ not possible to sequence ND 
149 99 37.00 1+ TTG Leu ND - neg 
156 101 34.88 1+ TTG Leu TCT Ser ND 
69 155 38.50 1+ CTG Leu ND - ATG Met TCC Ser 
78 158 39.84 1+ CTG Leu ND - ATG Met TCC Ser 
 
FCoV S gene sequencing results from LCM samples of cats with FIP 
Finally, the viral RNA obtained from the LCM samples was also subjected to Sanger sequencing. 
These should therefore contain virus capable of inducing lesions and not just of becoming 
systemic. The success rate was lower owing to the exponentially reduced sample size, however 26 
of 32 RT-qPCR positive samples were possible to sequence. All comprised ‘systemic’ virus with 
three (from two cats) exhibiting the S1050A rather than M1048L. 
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Table 5.5.5: Summary of viral sequencing results from LCM samples. The generally lower CT values 
than in the tables above are following pre-amplification of samples. SI, small intestine; S, serositis; PP, 
Peyer’s patches; A arteries; F, follicles; G, granulomatous lesions; LI, large intestine; M, sinus 
macrophages; LPC, subcapsular lymphoplasmacytic inflammation.   
Case no. Sample no. Organ FCoV CT codon 1048 codon 1050 
S15-1842 102 SI (S) 11.87 TTG Leu TCT Ser 
S15-1842 103 SI (PP) 30.90 TTG Leu TCA Ser 
S15-1842 104 SI (A) - sequencing not attempted 
S15-1842 105 liver (S) 14.21 TTG Leu TCT Ser 
S15-1809 106 spleen (S) 16.35 TTG Leu TCA Ser 
S15-1809 107 spleen (F) 31.81 TTG Leu TCA Ser 
S15-1809 108 spleen (A) 26.06 TTG Leu TCA Ser 
S15-1738 109 spleen (F) 31.42 not possible to sequence 
S15-1738 110 spleen (S) 14.93 ATG Met GCT Ala 
S15-1738 111 spleen (A) 34.40 TTG Leu TCT Ser 
S15-1738 112 MLN (G) 31.43 TTG Leu TCT Ser 
S15-1738 113 MLN (S) 15.02 ATG Met GCT Ala 
S15-1738 114 MLN (F) 32.06 TTG Leu TCT Ser 
S15-1728 115 liver (S) 18.31 TTG Leu TCT Ser 
S15-0983 116 MLN (S) 23.35 ATG Met GCC Ala 
S15-1539 117 MLN (G) 15.94 TTG Leu TCC Ser 
S15-1728 118 MLN (G) 19.17 TTG Leu TCT Ser 
S16-0167 119 MLN (G) 12.26 TTG Leu TCT Ser 
S16-0454 120 MLN (G) 20.83 TTG Leu TCC Ser 
S17-0124 121 MLN (G) 15.41 TTG Leu TCT Ser 
S15-0134 122 LI (S) 15.49 TTG Leu TCC Ser 
S15-0259 123 MLN (G) 20.46 TTG Leu TCT Ser 
S15-0259 124 spleen (S) - sequencing not attempted 
S15-0259 125 liver (S) 21.01 not possible to sequence 
S15-1728 126 MLN (M) 27.94 TTG Leu TCT Ser 
S15-1738 127 liver (LPC) - sequencing not attempted 
S15-1738 128 liver (S) 31.96 not possible to sequence 
S15-1809 129 kidney (S) 23.49 not possible to sequence 
S15-1809 130 omentum (G) 14.27 TTG Leu TCA Ser 
S16-0167 131 spleen (S) 17.55 TTG Leu TCT Ser 
S16-0167 132 omentum (G) 17.00 not possible to sequence 
S16-0454 133 liver (S) 28.36 not possible to sequence 
S17-0124 134 liver (S) 13.67 TTG Leu TCT Ser 
S17-0124 135 spleen (S) 28.68 not possible to sequence 
S17-0124 136 SI (G) 13.80 TTG Leu TCT Ser 
S15-1842 137 SI (S) 16.78 TTG Leu TCT Ser 
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Comparison of the S gene sequence within different organs of individual cats 
In order to evaluate the level of viral variation within individual cats, sequences derived from 
different samples from each cat were compared. The amplified sequence is a 153 bp stretch of 
the S gene (reference sequence FCoV C1Je), with the codons of interest 1048 and 1050 at bp 94-
96 and 100-103, as labelled in the images. Images are centred on these codons, highlighted in red 
and salmon pink respectively. The sequences have been quality trimmed so do not all cover the 
entire amplified region. A dot indicates a base match with the reference sequence.  
 
Figure 5.4.6: S15-0134. The spleen and small intestinal lesion samples are identical, differing from the 
virus within the BM sample which is closer to the reference gene.  
 
Figure 5.4.7: S15-0259. The sequence derived from the spleen differs from that from the MLN and bone 
marrow at six visible sites. There are no amino acid variations.  
 
Figure 5.4.8: S15-0983. Spleen and MLN are identical in this region whilst the BM sequence differs only 
slightly, this cat carried virus encoding methionine at codon 1048 in all evaluated organs, in the bone 
marrow only was there an S1050, encoding ‘enteric’ virus. 
 
Figure 5.4.9: S15-1368. Virus from both organs, i.e. spleen and MLN, was identical in this region, and 
identical in amino acid sequence to the reference. 
 
Figure 5.4.10: S15-1539. In all samples from this cat, the virus was identical in the sequenced region, 
differing from the reference sequence at 14 bases (almost 10%) yet having no alterations in the amino 
acid sequence.  
 
Figure 5.4.11: S15-1728. Numerous base mutations are shared by virus in all organs, there are no 
amino acid changes. 
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Figure 5.4.12: S15-1738. The bone marrow sample exhibits 10 SNPs from all other samples, whilst the 
remaining seven samples split into two groups. These two groups differ at only two bases but these are 
within codons 1048 and 1050, causing a leucine/methionine switch at the former and a serine/alanine 
at the latter. All remain consistent with ‘systemic’ virus.  
 
Figure 5.4.13: S15-1809. There were no variations between organs and only one amino acid difference, 
I1051F, from the reference. 
 
Figure 5.4.14: S15-1842. Only the virus extracted from the small intestinal Peyer’s patches (PP) differed 
from the others, leading to an amino acid alteration I1051F as for Fig. 4.8. 
 
Figure 5.4.15: S16-0167. There are no viral variations and no amino acid variations. 
 
Figure 5.4.16: S17-0124. There are no viral variations and no amino acid variations.  
These results show that despite frequent variation from the reference sequence, virus within an 
individual shows very little variation in this genomic region. 
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5. Results of RNA-Seq by NGS 
The overall output from the sequencing run is first displayed, followed by the results of pairwise 
comparisons between groups, comparisons with the RT-qPCR results from earlier chapters, and 
then comparisons with other published datasets. For simplicity, groups were inputted as 1-3, 
therefore G1 indicates G1- (control cats with FCoV RT-qPCR negative MLN), whilst G3 is equivalent 
to G1+ (control cats with FCoV positive MLN). G2 remains cats with FIP. 
Figures 5.5.1 – 5.5.5 show the overall quality and clustering of all samples. 
 
Count Statistics 
 
 
Figure 5.5.1: LCM samples take up a greater proportion of reads than the bulk MLN samples (top) but 
reads above threshold are at a consistent proportion (bottom). NB: LCM1 failed the pre-sequencing 
quality control and was not included in the sequencing run.  
 
Quality Control 
  
Figure 5.5.2: Representative LCM (left) and bulk MLN (right) quality score across all bases showing 
almost all reads remaining within the high quality >28 score zone. 
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Sample Clustering 
 
 
 
Figure 5.5.3: Sample clustering using all genes (left) or the top 100 differentially expressed genes 
(right). In both cases, LCM samples (dark green) and G2 samples (pale blue) cluster in their groups, and 
closest to each other. All nine bulk MLN samples (G1-G3) cluster but G1 (brown) and G3 (yellow) are 
intermingled. 
 
 
 
 
 
 
 
 
Figure 5.5.4: 3D (left) and 2D (right) clustering of the top genes again shows grouping of the FIP 
samples away from the non FIP groups. The non FIP groups do not segregate. 
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Figure 5.5.5: Group average pairs, showing high similarity within groups (top left to bottom right 
diagonal row), and the smallest variability between groups G1 and G3 (i.e. G1-, G1+). 
 
 
Pairwise comparisons  
Cats without FIP or detectable FCoV in the MLN versus cats with FIP (G1(-) over G2) 
 
Figure 5.5.6: Overview of results ordered by significance and fold change. FDR = false discovery rate 
(0.1 means 10% could be expected to not be truly differentially expressed), fc = fold change. Out of 
19493 possible features, 12533 were above the threshold. 
 
To evaluate the level of variation within each group, each sample was compared to its group mean 
(example in Fig. 5.5.7). Those marked as significant (red) apply to the group comparisons above, 
therefore when the red genes are close to the central line it means they are very similarly 
expressed by all samples in the group. Within each pair, individual samples were compared to the 
mean of the opposite group (example in Fig. 5.5.8), in these graphs, a clearing of the red genes 
along the central line shows that group differences are notable.  
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Figure 5.5.7: Intragroup comparisons using G1 as an example. Individual G1 samples vs G1 mean. 
 
 
Figure 5.5.8: Intergroup comparisons using individual G1 vs the G2 mean as an example. 
 
 
Figure 5.5.9: Comparison between average group expressions (left), with significant values indicated 
together with their fold change log ratio (right). A negative log ratio indicates a higher expression in 
G2. 
All differentially expressed genes are displayed graphically in Fig. 5.5.9. Of the top 20 differentially 
expressed individual genes by fold change, all except one were higher in FIP. Tables 5.5.1 and 5.5.2 
below show the top 20 up and down regulated genes. The term ‘upregulated’ in the software 
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generated charts relates to the group name as they were compared (with all comparisons being 
in numerical order i.e. 1 vs 2, 1 vs 3), rather than to a direction of a biological process.  
The mapping software was unable to name five of the top 20 upregulated genes. Comparison of 
individual identifiers with the UniProt website http://UniProt.org was able to name two further 
genes, with the remainder being predicted (remaining unnamed but having a predicted protein 
function). This programme was also used to summarise the main functions of these genes 314. 
The second gene on the list had a fold change of greater than 100 but was unnamed. The identifier 
was therefore put into the STRING consortium website https://string-db.org to search for 
predicted networks involving the gene and hence predict its function from the surrounding genes.  
Fig. 5.5.10 shows the resulting network. In this case, the most informative functional enrichments 
in this network were shown as KEGG pathways https://www.genome.jp/kegg/pathway.html. 
These are presented in Table 5.5.3. 
 
 
Figure 5.5.10: Predicted gene associations of ENSFCAG00000001764, the second most upregulated 
gene detected in G2 compared with G1. 
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Table 5.5.1: The top 20 upregulated genes in G2 compared to G1(-) by fold change.  
Identifier Gene Protein p log2 Ratio fc Function 
^010436 ACOD1 aconitate decarboxylase 1 4E-06 -6.9 117.87 defence response 
^001764 
  
1E-05 -6.7 102.25 U.P.; predicted apoptosis regulation 
^013594 CCL8 C-C motif chemokine ligand 8 1E-06 -6.6 96.94 cell signalling 
^018779 IFIT3 interferon induced protein with tetratricopeptide repeats 3 1E-05 -6.5 87.67 response to IFN-α 
^025965 SAA2* Serum amyloid A protein 0.0002 -6.2 71.56 acute phase response, chemotaxis 
^025002 SAA1 Serum amyloid A protein 0.0002 -5.9 59.92 acute phase response, chemotaxis 
^000708 RSAD2 radical S-adenosyl methionine domain-containing protein 2  4E-06 -5.9 58.44 predicted ↑regulation of TLR7 and 9 signalling 
^029623 
  
0.0038 -5.6 49.32 U.P.; predicted involvement in Ag and Ig R binding 
^030236 SFRP2 secreted frizzled related protein 2  2E-05 -5.4 43.68 apoptosis regulation (both ↑ and ↓ cited) 
^031821 IRF7 interferon regulatory factor 7  5E-06 -5.3 40.64 regulates IFN transcription 
^005933 IFIT1* interferon induced protein with tetratricopeptide repeats 1 6E-07 -5.3 39.18 predicted response to IFN-α 
^011708 IFIT2 interferon induced protein with tetratricopeptide repeats 2 9E-07 -5.3 38.32 response to IFN-α 
^003362 ISG15 interferon stimulated gene 15 4E-06 -5.2 38.03 response to Type I, reg of Type II, viral defence 
^000645 C5 complement C5 6E-07 -5.2 37.98 ↑ chemokine secretion, ↓ macrophage chemotaxis 
^008365 CXCL9 C-X-C motif chemokine ligand 9 0.0002 -5.1 34.80 cell signalling 
^025088 
  
0.0061 -5.1 33.54 U.P.; predicted involvement in immune response 
and Ig production 
^029292 IGKV4-1* Immunoglobulin kappa variable 4-1 0.0061 -5.0 32.31 antibody response 
^009503 CXCL10 C-X-C motif chemokine ligand 10 0.0002 -5.0 31.89 cell signalling 
^007076 CLEC4D C-type lectin domain family 4 member D 4E-05 -4.9 29.04 Ig receptor binding 
^027331 
  
7E-06 -4.8 28.82 U.P.; predicted role in phagocytosis 
 
Key: The colour of the fold change (fc) indicates the cluster to which the gene belongs (see below); ^  indicates the prefix ENSFCAG00000; *: name derived from UniProt 
search; a negative log ratio indicates upregulation in G2; U.P.: unclassified protein; Ag: antigen; R: receptor; Ig: immunoglobulin 
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Table 5.5.2: The top 20 downregulated genes in G2 compared to G1(-) by fold change. 
Identifier Gene Protein p 
log2 
Ratio 
fc Function 
^006464 CIDEA cell death-inducing DFFA-like effector A 0.006317 6.3 77.39 apoptosis 
^022678 LIPE lipase E, hormone sensitive type 0.00909 4.6 24.32 metabolism and catabolism 
^001359 CLEC10A C-type lectin domain containing 10A 2.46E-06 4.6 23.70 not described 
^026891 S100A1 S100 calcium binding protein A1 0.005927 4.5 22.98 angiogenesis and NOS activity 
^021944 APCDD1 APC down-regulated 1 0.008284 4.3 19.40 ↓Wnt signalling 
^002851 SLC22A1 solute carrier family 22 member 1 0.006278 3.9 14.85 U.P.: neurotransmitter transport 
^030063 FADS6 fatty acid desaturase 6 0.0007 3.7 13.20 lipid metabolism 
^007290 STAB2 stabilin 2 0.00535 3.7 13.06 cell adhesion 
^001421 SORBS1 sorbin and SH3 domain containing 1 0.009127 3.7 12.82 actin filament organisation 
^006864 GPC3 glypican 3 3.64E-05 3.7 12.64 signal transduction regulation 
^014026 MARCO macrophage receptor with collagenous structure 0.00016 3.7 12.62 apoptotic cell clearance 
^019173 SCART1 scavenger receptor family member expressed on T-cells 1 0.006174 3.7 12.61 scavenger receptor activity 
^008518 LPIN1 lipin 1 0.005304 3.6 12.49 metabolism, catabolism, and transcription 
^006231 PPARG peroxisome proliferator activated receptor gamma 0.009438 3.6 12.19 myriad, most cell proliferation 
^028966 TIMP4 TIMP metallopeptidase inhibitor 4 0.000499 3.5 11.54 MMP inhibition 
^030062 RBP7 retinol binding protein 7 0.000183 3.5 11.50 retinoid binding 
^023768 IGHE immunoglobulin heavy constant epsilon 0.001687 3.5 11.38 Ag and Ig binding 
^001602 CLEC4G C-type lectin domain family 4 member G 0.000998 3.4 10.59 negative T cell regulation 
^024268 CD36 CD36 molecule 0.005317 3.4 10.51 lipoprotein binding 
^010296 GYG2 glycogenin 2 0.005071 3.4 10.43 transferase activity 
 
Key: The colour of the fold change (fc) indicates the cluster to which the gene belongs (see below, black: no cluster); ^ indicates the prefix ENSFCAG00000; U.P.: 
unclassified protein; Ag: antigen; Ig: immunoglobulin
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Table 5.5.3: KEGG pathways predicted to be enriched in the STRING predicted network associated with 
the unnamed gene ENSFCAG00000001764. The gene count is out of the 11 in the network. 
ID Pathway description Gene count fdr 
4210 Apoptosis 6 1.70E-10 
4064 NF-kappa B signalling pathway 5 4.48E-08 
4621 NOD-like receptor signalling pathway 3 0.000104 
4612 Antigen processing and presentation 3 0.000109 
4510 Focal adhesion 4 0.000114 
4120 Ubiquitin mediated proteolysis 3 0.00139 
4151 PI3K-Akt signalling pathway 3 0.0145 
4668 TNF signalling pathway 2 0.0262 
 
A ‘colorectal cancer’ pathway as well as ‘tuberculosis’ were also mildly enriched and are not shown 
here. These names relate to manually drawn pathway maps allocated by the software, 
representing current knowledge of molecular interactions, reactions, and relationships in 
different functions and conditions.  Of the genes in this network, none showed significant 
differential expression at the 0.01 level, and only BCL2-like protein 1 showed significant 
differential expression at the 0.05 level, being upregulated in FIP. Except for CSTA and BIRC5, there 
was insignificant upregulation found. This network was therefore not further analysed. The 
apoptosis regulator BCL2 could not be identified within the database. 
 
The data was then analysed by cluster analysis. An automated function generates the six most 
distinct clusters by expression values. The clusters are defined based on the two groups in the 
comparison, with the scheme displayed as applying to all. This shows that in this analysis, G3 
clusters with G1 and LCM with G2. 
All clusters (shown on the y axis as different coloured bands) appear differentially expressed 
between G1 and G2. However, at this stage the cluster generation process is only associated with 
the expression values. The next stage of GO (gene ontology) analysis evaluates the genes in each 
cluster which may or may not result in significantly enriched categories.  
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Figure 5.5.11: Cluster plot comparing G1(-) and G2; colours on the y axis represent GO (gene ontology) 
category feature clusters, with each individual sample marked on the x axis. The chart colour intensity 
indicates comparative up or down regulation (blue -; red +).  
 
Ontology is split into three classes; BP (biological process), MF (molecular function), and CC 
(cellular component). Here the focus was on the former two. Each cluster containing significantly 
enriched categories is listed below (Tables 5.5.4 – 5.5.7). The yellow and green clusters were lower 
in G2 than G1- but the green cluster produced no significant categories and the yellow only three, 
which are instead listed subsequently. These two categories were also those containing the top 
downregulated genes in FIP.  
The individual genes contributing to these cluster results are far greater in number than the GO 
categories they can be associated with. They were filtered from the overall results chart using a 
p£0.01 cut off. There were found to be 249 differentially expressed red cluster genes, 228 orange, 
162 blue and 38 cyan cluster genes. All except two blue genes were upregulated in G2 compared 
to G1-.  
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Table 5.5.4: Red feature cluster of GO categories in G1- vs G2, ranked by probability (p), where N shows 
the number of significant genes (p<0.01) within the total number of genes in the category. 
Class Rank Term ID p N 
BP 1 collagen fibril organization GO:0030199 1.95e-8 8/24 
BP 2 collagen biosynthetic process GO:0032964 0.0000369 3/4 
 
 
Table 5.5.5: Orange feature cluster of GO categories in G1- vs G2, ranked by probability (p), where N 
shows the number of significant genes (p<0.01) within the total number of genes in the category. 
Class Rank Term ID p N 
BP 1 interferon-gamma-mediated signalling pathway GO:0060333 0.0000291 3/4 
BP 2 negative regulation of viral release from host cell GO:1902187 0.0000422 4/11 
BP 3 positive regulation of calcium ion transport into cytosol GO:0010524 0.0000718 3/5 
CC 1 death-inducing signalling complex GO:0031264 0.0000234 3/4 
 
 
Table 5.5.6: cyan feature cluster of GO categories in G1- vs G2, ranked by probability (p), where N 
shows the number of significant genes (p<0.01) within the total number of genes in the category. ‘.’ 
represents a ‘child’ term of the term above it.  
Class Rank Term ID p N 
BP 1 immunoglobulin production GO:0002377 5.01e-17 10/45 
BP 2 phagocytosis, recognition GO:0006910 1.61e-11 7/38 
BP 3 positive regulation of B cell activation GO:0050871 1.96e-11 7/39 
BP 4 phagocytosis, engulfment GO:0006911 3.42e-11 7/42 
BP 5 immune response GO:0006955 3.03e-10 10/203 
BP 6 .innate immune response GO:0045087 2.04e-7 7/142 
BP 7 defense response to bacterium GO:0042742 1.43e-9 7/70 
MF 1 immunoglobulin receptor binding GO:0034987 1.29e-12 7/37 
MF 2 antigen binding GO:0003823 3.35e-12 7/42 
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Table 5.5.7: Blue feature cluster of GO categories in G1- vs G2, ranked by probability (p), where N 
shows the number of significant genes (p<0.01) within the total number of genes in the category. ’./..’ 
represent ‘child’ terms of the term above.  
Class Rank Term ID p N 
BP 1 immune response GO:0006955 2.11e-14 22/203 
BP 2 .innate immune response GO:0045087 5.4e-9 14/142 
BP 3 chemotaxis GO:0006935 7.17e-13 13/60 
BP 4 response to virus GO:0009615 2.55e-12 12/52 
BP 5 .defense response to virus GO:0051607 2.89e-18 17/63 
BP 6 chemokine-mediated signalling pathway GO:0070098 8.35e-12 11/44 
BP 7 G-protein coupled receptor signalling pathway GO:0007186 2.78e-9 17/212 
BP 8 response to lipopolysaccharide GO:0032496 1.21e-7 10/82 
BP 9 .cellular response to lipopolysaccharide GO:0071222 4.29e-11 12/65 
BP 10 . .lipopolysaccharide-mediated signalling pathway GO:0031663 0.00000119 6/27 
BP 11 positive regulation of cAMP-mediated signalling GO:0043950 1.5e-7 4/5 
BP 12 positive regulation of chemokine production GO:0032722 1.71e-7 5/11 
BP 13 negative regulation of viral genome replication GO:0045071 3.17e-7 6/22 
BP 14 positive regulation of interleukin-8 production GO:0032757 0.00000153 5/16 
BP 15 positive regulation of cAMP metabolic process GO:0030816 0.00000233 3/3 
BP 16 defense response GO:0006952 0.00000519 5/20 
BP 17 .inflammatory response GO:0006954 6.67e-21 25/150 
BP 18 .innate immune response GO:0045087 5.4e-9 14/142 
BP 19 cellular response to interleukin-1 GO:0071347 0.00000984 6/38 
BP 20 positive regulation of gene expression GO:0010628 0.0000141 12/200 
BP 21 positive regulation of interferon-alpha production GO:0032727 0.0000452 3/6 
BP 22 interleukin-1 beta secretion GO:0050702 0.0000452 3/6 
BP 23 .positive regulation of interleukin-1 beta secretion GO:0050718 0.00000932 4/11 
BP 24 cellular response to lipoteichoic acid GO:0071223 0.0000452 3/6 
BP 25 positive regulation of ERK1 and ERK2 cascade GO:0070374 0.0000505 8/99 
BP 26 positive regulation of interleukin-6 production GO:0032755 0.0000506 5/31 
BP 27 regulation of cytokine secretion GO:0050707 0.0000783 3/7 
BP 28 .positive regulation of cytokine secretion GO:0050715 0.0000804 4/18 
BP 29 positive regulation of nitric oxide biosynthetic process GO:0045429 0.0000804 4/18 
MF 1 cytokine activity GO:0005125 5.34e-16 16/67 
MF 2 .chemokine activity GO:0008009 5.64e-13 10/25 
MF 3 CCR chemokine receptor binding GO:0048020 3.04e-8 6/15 
MF 4 double-stranded RNA binding GO:0003725 0.00000191 7/43 
MF 5 CXCR3 chemokine receptor binding GO:0048248 0.00000269 3/3 
MF 6 carbohydrate binding GO:0030246 0.00000274 8/64 
MF 7 lipopolysaccharide binding GO:0001530 0.000033 4/14 
MF 8 interleukin-1 receptor binding GO:0005149 0.0000521 3/6 
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Within the individually upregulated genes in G2, the blue cluster is highly overrepresented and is 
the also the largest cluster to be generated. Blue, cyan and orange clusters all centre on the 
immune response and particularly the anti-viral response, with involvement of both innate and 
adaptive factors. The red cluster is far smaller and involves matrix synthesis.  
The downregulated genes fall within green or yellow; of these the only BP GO term produced was 
peptidyl-tyrosine autophosphorylation in the yellow cluster (not shown in tabular from).   
The biological process (BP) class contained the highest number of GO categories of interest; an 
enrichment diagram was created (Fig. 5.5.12) showing which categories were of most significance 
and how heavily they were represented amongst differentially expressed genes. 
 
 
Figure 5.5.12: Enriched biological process categories which are upregulated in G2 vs G1. 
 
In total, 1775 GO categories were identified from which at least one significantly upregulated gene 
in G2 was present. 125 of these had a p value £0.01 and the list can be further narrowed by FDR 
to a top 30 with an FDR <0.01. Those shown below are those significant when also selected by 
clustered genes (Table 5.5.8).  
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Table 5.5.8: significant BP categories in G1- versus G2 which are also enriched by cluster 
Rank Term ID p N 
1 inflammatory response GO:0006954 8.44e-17 39/150 
2 immune response GO:0006955 3.64e-13 42/203 
3 .innate immune response GO:0045087 7.68e-12 34/142 
4 . .response to interferon-gamma GO:0034341 0.00000363 6/9 
5 response to virus GO:0009615 1.44e-8 17/52 
6 .defence response to virus GO:0051607 1.44e-17 28/63 
7 . . . .positive regulation of defence response to virus by host GO:0002230 0.0000622 6/13 
8 negative regulation of viral genome replication GO:0045071 4.02e-7 10/22 
9 collagen fibril organization GO:0030199 7.22e-7 10/24 
10 chemokine-mediated signalling pathway GO:0070098 9.72e-7 12/44 
11 response to lipopolysaccharide GO:0032496 0.00000104 18/82 
12 .cellular response to lipopolysaccharide GO:0071222 0.00000643 15/65 
13 . .lipopolysaccharide-mediated signalling pathway GO:0031663 0.00000279 10/27 
14 positive regulation of interleukin-8 production GO:0032757 0.00000138 8/16 
15 defence response to bacterium GO:0042742 0.00000157 17/70 
16 chemotaxis GO:0006935 0.00000184 14/60 
17 positive regulation of interleukin-6 production GO:0032755 0.00000353 10/31 
18 phagocytosis, recognition GO:0006910 0.00000652 12/38 
19 positive regulation of NF-kappaB transcription factor activity GO:0051092 0.0000068 16/77 
20 positive regulation of chemokine production GO:0032722 0.0000083 6/11 
21 positive regulation of interleukin-1 beta secretion GO:0050718 0.0000108 6/11 
22 G-protein coupled receptor signalling pathway GO:0007186 0.0000132 26/212 
23 immunoglobulin production GO:0002377 0.0000403 12/45 
24 positive regulation of cAMP-mediated signalling GO:0043950 0.0000504 4/5 
25 negative regulation of endopeptidase activity GO:0010951 0.0000588 12/53 
26 positive regulation of type I interferon production GO:0032481 0.0000687 6/12 
27 positive regulation of interleukin-5 production GO:0032754 0.0000703 4/6 
28 endoplasmic reticulum unfolded protein response GO:0030968 0.0000989 10/39 
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Cats without FIP but with detectable FCoV in the MLN versus cats with FIP [G2 vs G3 (G2 vs G1+)] 
 
Figure 5.5.13: Results summary ordered by significance and fold change, where FDR = false discovery 
rate and fc = fold change. 12472/19493 features had counts above the threshold. 
 
Genes designated ‘upregulated’ by the software in this comparison are higher in G2 than G3 (G1+). 
 
 
 
Figure 5.5.14: Comparison between average group expressions (left), with significant values indicated 
together with their fold change log ratio (right). A negative log ratio indicates a higher expression in 
G2. 
 
The 20 top up and down regulated genes are shown in Table 5.5.9 and 5.5.10, together with 
significant clusters and the most significantly upregulated GO categories from all clusters. 
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Table 5.5.9: The top 20 genes by fold change which were higher in G2 than G3 (G1+). 
Identifier Gene Protein p log2 Ratio fc Function 
^029292 IGKV4-1 Immunoglobulin kappa variable 4-1 0.00016 7.7 208.51 Ig R binding 
^024010   0.00014 5.9 58.81 U.P.: Ag and Ig R binding 
^025088   0.002266 5.7 52.06 U.P.: Ig production 
^029623   0.001997 5.6 47.34 U.P.: Ag and Ig R binding 
^026111   0.004063 5.2 36.28 U.P.: Ig production 
^001764   4.68E-05 6.3 77.98 unknown 
^025965 SAA2 serum amyloid A protein 0.00028 6.2 72.91 acute phase response 
^013594 CCL8 C-C motif chemokine ligand 8 7.44E-08 6.1 67.56 cell signalling and chemotaxis 
^025002 SAA1 Serum amyloid A protein Amyloid protein A 0.00039 6.0 66.21 acute phase response 
^010436 ACOD1 aconitate decarboxylase 1 0.000171 5.9 59.06 defence response 
^014062 S100A12 S100 calcium binding protein A12 2.39E-06 5.3 40.25 innate immune response, many 
^003199 S100A9 S100 calcium binding protein A9 2.33E-05 5.2 36.81 innate immune response, many 
^001290 S100A8 S100 calcium binding protein A8 2.68E-05 5.0 32.67 innate immune response, many 
^018779 IFIT3 interferon induced protein with tetratricopeptide repeats 3 6.36E-05 5.0 30.95 response to IFN-α 
^009575 IL1RN interleukin 1 receptor antagonist 8.07E-05 4.9 30.59 negative regulation of IL-1 
^031821 IRF7 interferon regulatory factor 7 1.06E-05 4.9 30.53 regulates IFN transcription 
^007076 CLEC4D C-type lectin domain family 4 member D 7.63E-06 4.9 30.32 Ig R binding 
^028244 AQP9 aquaporin 9 8.68E-05 4.9 30.09 response to cAMP 
^000708 RSAD2 radical S-adenosyl methionine domain containing 2 2.64E-07 4.9 29.61 predicted ↑regulation of TLR7 and 9 signalling 
^024242   3.90E-07 4.9 29.04 U.P.: response to biotic stimuli 
 
Key: The colour of the fold change (fc) indicates the cluster to which the gene belongs (see below; yellow, cyan, orange); ^  indicates the prefix ENSFCAG00000; function 
derived from UniProt search; U.P.: unclassified protein; Ag: antigen; R: receptor; Ig: immunoglobulin 
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Table 5.5.10: The top 20 genes by fold change which were lower in G2 than G3 (G1+). 
Identifier Gene Protein p 
log2 
Ratio 
fc Function 
^023768 IGHE immunoglobulin heavy constant epsilon 0.004754 -6.7 104.33 Ig binding 
^028847 HBA1 Globin C1 0.001727 -5.0 32.85 haemoglobin subunit 
^030143   0.004289 -4.5 23.12 U.P. haem binding 
^006464 CIDEA cell death-inducing DFFA-like effector A 7.95E-06 -4.5 22.50 apoptosis 
^011920 FRMPD1 FERM and PDZ domain containing 1 0.000775 -3.7 12.95 G protein couple R signalling 
^013351 PLIN1 perilipin 1 0.000986 -3.7 12.91 lipid metabolism* 
^004411 CELA1 chymotrypsin like elastase family member 1 0.004254 -3.4 10.31 protease 
^013832 FCAMR Fc fragment of IgA and IgM receptor 0.003971 -3.4 10.26 Ig binding 
^012336 MYCBPAP MYCBP associated protein 0.001349 -3.4 10.22 spermatogenesis 
^004058 VPREB3 V-set pre-B cell surrogate light chain 3 0.001538 -3.3 10.18 Ig production and response 
^006286 PLIN4 perilipin 4 0.002712 -3.3 9.78 lipid transport and metabolism 
^005424 LYZ lysozyme 0.001605 -3.1 8.75 defence against bacteria 
^000419 PCK1 phosphoenolpyruvate carboxykinase 1 0.003607 -3.1 8.68 cellular metabolism 
^014052 GZMK granzyme K 5.04E-05 -3.1 8.64 cell defence 
^004909 PLA2G2D phospholipase A2 group IID 0.000556 -3.1 8.59 cellular metabolism 
^019173 SCART1 
scavenger receptor family member expressed on T-cells 
1 0.001236 -3.1 8.48 scavenger receptor activity 
^004635 DGAT2 diacylglycerol O-acyltransferase 2 0.000121 -3.1 8.46 lipid metabolism 
^001089 CPNE5 copine 5 0.000561 -3.1 8.44 dendrite extension 
^006864 GPC3 glypican 3 9.63E-07 -3.1 8.39 signal transduction regulation 
^027632   3.30E-05 -3.1 8.30 unknown 
 
Key: The colour of the fold change indicates the cluster to which the gene belongs (see below); ^ indicates the prefix ENSFCAG00000; function derived from UniProt; 
a negative log ratio indicates upregulation in G2; U.P.: unclassified protein; R: receptor; Ig: immunoglobulin 
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Seven of the top 20 genes higher in G2 than in G1 were also amongst the top 20 higher in G2 than 
G3. Three of the top 20 genes which are lower in G1 or G3 than G2 also overlapped.  
Cluster analysis results for G2 versus G3 are shown below. With reference to individual genes, 
there are 58 in the red cluster, all lower in FIP; 201 in yellow, all upregulated; 321 in orange all 
upregulated; 625 in green, all downregulated; 370 in blue, all upregulated; 191 in cyan with all 
except one upregulated in FIP.  
In keeping with these findings, the top 20 upregulated individual genes come from clusters yellow, 
orange and cyan and the bottom regulated from red and green. By far the largest cluster was the 
cyan cluster, this is also where over half of the individual upregulated genes came from.  
Those lower in FIP largely involve cellular metabolism, and those upregulated the immune system 
with an emphasis on viral defence and cytokine signalling.  
 
Table 5.5.11: Red feature cluster of GO categories, ranked by probability (p), where N shows the 
number of significant genes within the total number of genes in the category.  
Class Rank Term ID p N 
BP 1 lipid storage GO:0019915 2.36e-8 5/19 
BP 2 low-density lipoprotein particle clearance GO:0034383 6E-06 3/8 
BP 3 negative regulation of lipid catabolic process GO:0050995 9E-06 3/9 
BP 4 triglyceride biosynthetic process GO:0019432 1E-05 3/10 
MF 1 lipid binding GO:0008289 5E-06 5/50 
 
 
Table 5.5.12: Yellow feature cluster of GO categories, ranked by probability (p), where N shows the 
number of significant genes within the total number of genes in the category. ‘.’ indicates that the 
term is a ‘child’ term of the term above. 
Class Rank Term ID p N 
BP 1 immunoglobulin production GO:0002377 3.33e-9 10/47 
BP 2 phagocytosis, recognition GO:0006910 5.86e-9 9/37 
BP 3 positive regulation of B cell activation GO:0050871 7.57e-9 9/38 
BP 4 defense response to bacterium GO:0042742 1.15e-8 11/68 
BP 5 phagocytosis, engulfment GO:0006911 1.23e-8 9/40 
BP 6 B cell receptor signalling pathway GO:0050853 2.41e-8 10/57 
BP 7 proteolysis GO:0006508 1.36e-7 20/307 
BP 8 complement activation GO:0006956 4.25E-05 3/5 
BP 9 .complement activation, classical pathway GO:0006958 1.92e-9 9/33 
MF 1 immunoglobulin receptor binding GO:0034987 2.04e-9 9/36 
MF 2 antigen binding GO:0003823 7.11e-9 9/41 
MF 3 extracellular matrix binding GO:0050840 9.28E-06 5/20 
MF 4 peptidase activity GO:0008233 1.14E-05 12/174 
MF 5 insulin-like growth factor binding GO:0005520 4.37E-05 4/14 
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Table 5.5.13: Orange feature cluster of GO categories, ranked by probability (p), where N shows the 
number of significant genes within the total number of genes in the category. ‘.’ indicates that the 
term is a ‘child’ term of the term above. 
Class Rank Term ID p N 
BP 1 cell adhesion GO:0007155 7.49e-7 18/168 
BP 2 .cell adhesion mediated by integrin GO:0033627 0.000016 5/13 
BP 3 cytokine-mediated signalling pathway GO:0019221 0.0000441 10/77 
 
 
Table 5.5.14: Green feature cluster of GO categories, ranked by probability (p), where N shows the 
number of significant genes within the total number of genes in the category. ‘.’ indicates that the 
term is a ‘child’ term of the term above. 
Class Rank Term ID p N 
BP 1 peptidyl-tyrosine autophosphorylation GO:0038083 0.0000394 9/37 
BP 2 sulfate transport GO:0008272 0.0000668 4/6 
BP 3 .sulfate transmembrane transport GO:1902358 0.0000231 4/5 
MF 1 sulfate transmembrane transporter activity GO:0015116 0.0000227 4/5 
MF 2 non-membrane spanning protein tyrosine kinase activity GO:0004715 0.0000475 9/38 
MF 3 calcium ion binding GO:0005509 0.0000953 32/336 
 
 
Table 5.5.15: Blue feature cluster of GO categories, ranked by probability (p), where N shows the 
number of significant genes within the total number of genes in the category. ‘.’ indicates that the 
term is a ‘child’ term of the term above. 
Class Rank Term ID p N 
BP 1 ATP hydrolysis coupled proton transport GO:0015991 0.00000125 7/19 
BP 2 signal transduction GO:0007165 0.00000182 40/561 
BP 3 response to lipopolysaccharide GO:0032496 0.0000116 12/82 
BP 4 inflammatory response GO:0006954 0.0000246 16/149 
BP 5 defence response to virus GO:0051607 0.0000304 10/63 
MF 1 signal transducer activity GO:0004871 9.14e-8 23/201 
MF 2 proton transmembrane transporter activity GO:0015078 0.0000815 6/24 
MF 3 .proton-transporting ATPase activity, 
rotational mechanism 
GO:0046961 2.12e-8 7/12 
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Table 5.5.16: Cyan feature cluster of GO categories, ranked by probability (p), where N shows the 
number of significant genes within the total number of genes in the category. ‘./..’ indicates that the 
term is a ‘child’ term of the term above. 
Class Rank Term ID p N 
BP 1 immune response GO:0006955 1.05e-13 23/205 
BP 2 .innate immune response GO:0045087 4.41e-8 14/141 
BP 3 chemotaxis GO:0006935 2.47e-13 14/59 
BP 4 response to virus GO:0009615 1.93e-11 12/52 
BP 5 .defense response to virus GO:0051607 2.02e-18 18/63 
BP 6 chemokine-mediated signalling pathway GO:0070098 4.07e-11 11/43 
BP 7 G-protein coupled receptor signalling pathway GO:0007186 6.99e-11 20/206 
BP 8 cellular response to interleukin-1 GO:0071347 8.59e-8 8/37 
BP 9 positive regulation of cAMP-mediated signalling GO:0043950 2.98e-7 4/5 
BP 10 defense response GO:0006952 4.6e-7 6/20 
BP 11 .inflammatory response GO:0006954 1.72e-21 27/149 
BP 12 .innate immune response GO:0045087 4.41e-8 14/141 
BP 13 response to lipopolysaccharide GO:0032496 5.94e-7 10/82 
BP 14 .cellular response to lipopolysaccharide GO:0071222 1.04e-12 14/65 
BP 15 
. .lipopolysaccharide-mediated signalling 
pathway GO:0031663 0.00000321 6/27 
BP 16 negative regulation of viral genome replication GO:0045071 8.63e-7 6/22 
BP 17 interleukin-1 beta secretion GO:0050702 8.83e-7 4/6 
BP 18 
.positive regulation of interleukin-1 beta 
secretion GO:0050718 0.0000183 4/11 
BP 19 positive regulation of interleukin-8 production GO:0032757 0.00000353 5/16 
BP 20 positive regulation of cAMP metabolic process GO:0030816 0.00000389 3/3 
BP 21 positive regulation of interleukin-6 production GO:0032755 0.00000618 6/30 
BP 22 positive regulation of gene expression GO:0010628 0.0000163 13/200 
BP 23 positive regulation of chemokine production GO:0032722 0.0000183 4/11 
BP 24 cellular response to tumor necrosis factor GO:0071356 0.0000206 7/54 
BP 25 regulation of cell proliferation GO:0042127 0.0000448 11/160 
BP 26 
positive regulation of interferon-alpha 
production GO:0032727 0.000075 3/6 
BP 27 cellular response to lipoteichoic acid GO:0071223 0.000075 3/6 
MF 1 cytokine activity GO:0005125 2.22e-17 18/68 
MF 2 .chemokine activity GO:0008009 6.95e-14 11/25 
MF 3 CCR chemokine receptor binding GO:0048020 8.54e-8 6/15 
MF 4 carbohydrate binding GO:0030246 0.00000112 9/65 
MF 5 CXCR3 chemokine receptor binding GO:0048248 0.00000452 3/3 
MF 6 double-stranded RNA binding GO:0003725 0.00000602 7/43 
MF 7 lipopolysaccharide binding GO:0001530 0.0000649 4/14 
MF 8 interleukin-1 receptor binding GO:0005149 0.0000872 3/6 
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 Figure 5.5.15: Hypergeometric over-representation test applied to BP categories of G2 vs G3 (G1+) (G2 
higher) 
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Table 5.5.17: Table of significantly enriched BP GO categories taken from the overall gene set, 
containing only those upregulated in FIP and cluster restricted. 
Rank Term ID p N 
1 immune response GO:0006955 4.08e-13 54/205 
2 .innate immune response GO:0045087 2.12e-11 41/141 
3 . .response to interferon-gamma GO:0034341 5.5E-06 7/10 
4 response to lipopolysaccharide GO:0032496 2.13e-9 27/82 
5 .cellular response to lipopolysaccharide GO:0071222 4.89e-8 22/65 
6 chemotaxis GO:0006935 2.34e-9 22/59 
7 response to virus GO:0009615 1.55e-7 19/52 
8 .defense response to virus GO:0051607 5.41e-14 29/63 
9 cellular response to interleukin-1 GO:0071347 2.85e-7 15/37 
10 signal transduction GO:0007165 2.86e-7 86/561 
11 .G-protein coupled receptor signalling pathway GO:0007186 2.75e-11 49/206 
12 . .phospholipase C-activating G-protein coupled receptor 
signalling pathway 
GO:0007200 1.4E-06 10/20 
13 negative regulation of viral genome replication GO:0045071 1.8E-06 11/22 
14 cell adhesion GO:0007155 2.8E-06 35/168 
15 .cell adhesion mediated by integrin GO:0033627 6.9E-05 7/13 
16 cellular response to tumor necrosis factor GO:0071356 3.2E-06 17/54 
17 defense response GO:0006952 3.9E-06 10/20 
18 .inflammatory response GO:0006954 3.38e-20 54/149 
19 . .regulation of inflammatory response GO:0050727 8E-05 13/42 
20 . . .positive regulation of inflammatory response GO:0050729 5.3E-05 10/26 
21 .innate immune response GO:0045087 2.12e-11 41/141 
22 . .response to interferon-gamma GO:0034341 5.5E-06 7/10 
23 positive regulation of interleukin-6 production GO:0032755 5.2E-06 12/30 
24 positive regulation of chemokine production GO:0032722 1.1E-05 7/11 
25 proteolysis GO:0006508 1.2E-05 52/307 
26 endodermal cell differentiation GO:0035987 1.8E-05 10/23 
27 positive regulation of NF-kappaB transcription factor 
activity 
GO:0051092 1.9E-05 20/78 
28 positive regulation of vascular endothelial growth factor 
production 
GO:0010575 4.5E-05 8/17 
29 vacuolar acidification GO:0007035 5.8E-05 6/9 
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Control cats without FIP: those without FCoV detected in the MLN versus those with [G1 over G3 
(G1- over G1+)] 
 
 
 
 
 
 
 
 
 
Figure 5.5.16: Results summary ordered by significance and fold change, where FDR = false discovery 
rate and fc = fold change. There were 12496/19493 features above threshold. 
The overview immediately shows a much lower number (approximately 10%) of significantly 
differentially expressed genes in G1 vs G3 compared to G1 vs G2 or G2 vs G3. The FDR values are 
also far higher (at least 0.9996) implying a low confidence level of individual results.  
At a standard p value and fold change of <0.01 and >2, 111 genes were found to be significant. 
This is in comparison to 1184 with the same criteria in G1 vs G2. These were displayed graphically 
and owing to their low numbers in this comparison, outliers of particular interest are marked 
individually (Fig. 5.5.17).  
The term ‘Upregulated’ in the computer-generated charts refers to G1-. Tables have been labelled 
to convey this as higher or lower.   
 
Figure 5.5.17: Comparison of average expression between G1(-) and G3(G1+). Each dot represents a 
gene, those closest to the line are the most similarly expressed between groups, with significantly 
different genes (p <0.01) highlighted in red.  
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Figure 5.5.18: Log fold changes between G1- and G1+, clearly showing (together with Fig. 5.5.17 above) 
that differentially expressed genes are more commonly higher in G1+ (G3) than G1- (G1); left side of 
the chart. 
 
Owing to the lower numbers of significant genes in this comparison, and the high FDR, only the 
top 10 in each direction are shown (Fig. 5.5.18 and 5.5.19). There were also fewer significant 
clusters identified, in this case red and orange (Table 5.5.20 and 5.5.21). Orange cluster genes 
were all higher in G1- whilst red cluster genes were higher in G1+. 
The five genes with a fold change >10 at p<0.01 included the three S100 genes A8, A9, A12 (shown 
in Fig. 5.5.17), with A8 and A12 being the two genes also significant at the p<0.001 level. These 
were lower in G1+ and all in the orange cluster. The other two top five genes were not annotated.  
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Table 5.5.18: The top 10 genes by fold change which were higher in G3 than G1 (G1+ than G1-). 
Identifier Gene Protein p log2 Ratio fc Function 
^009774 MEF2B myocyte enhancer factor 2B 0.0067 -2.7 6.58 ↑transcription 
^008534 LMO7 LIM domain 7 0.0043 -2.5 5.62 regulation of signalling 
^018226 EAF2 ELL associated factor 2 0.0005 -2.0 3.92 negative regulation of cell growth 
^003525 CENPE centromere protein E 0.0004 -1.9 3.82 mitosis 
^027527 CENPF centromere protein F 0.0024 -1.9 3.79 mitosis 
^028154   0.0061 -1.9 3.63 not found 
^014712 RAD51 RAD51 recombinase 0.003 -1.8 3.37 DNA repair protein 
^022606 DCK deoxycytidine kinase 0.0016 -1.7 3.29 U.P: ATP binding 
^001898 TPX2 TPX2, microtubule nucleation factor 0.0013 -1.7 3.22 mitosis 
^010116 TNFRSF17 TNF receptor superfamily member 17 0.0093 -1.7 3.20 B cell maturation 
 
Table 5.5.19: The top 10 genes by fold change which were lower in G3 than G1 (G1+ than G1-). 
Identifier Gene Protein p 
log2 
Ratio 
fc Function 
^014062 S100A12 S100 calcium binding protein A12 0.00038 4.5 22.0 innate immune response, many 
^003199 S100A9 S100 calcium binding protein A9 0.00112 4.3 20.1 innate immune response, many 
^001290 S100A8 S100 calcium binding protein A8 0.0008 4.2 18.3 innate immune response, many 
^023329   0.00574 3.9 15.2 U.P.: Ig binding 
^024010   0.00317 3.4 10.7 U.P: Ag and Ig R binding 
^000859   0.00181 3.1 8.7 U.P: peptidase inhibitor 
^015790 MMP8 matrix metallopeptidase 8 0.00218 3.0 8.0 endopeptidase 
^013269 CSF3R colony stimulating factor 3 receptor 0.00679 2.8 6.8 neutrophil differentiation and chemotaxis 
^029292 IGKV4-1 Immunoglobulin kappa variable 4-1 0.00714 2.6 6.3 Ig production 
^024242   0.00521 2.6 6.0 U.P.: response to biotic stimulus 
Key: The colour of the fold change (fc) indicates the cluster to which the gene belongs (see below; yellow, cyan, green, red); ^ indicates the prefix ENSFCAG00000; function 
derived from UniProt; U.P.: unclassified protein; R: receptor; Ig: immunoglobulin
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Table 5.5.20: Significant GO categories within the red feature cluster of G1 vs G3. BP: biological 
process; MF: molecular function; Term: description of GO category; ID: identification of GO category; 
p: probability; N: number of genes from the category. 
Class Rank Term ID p N 
BP 1 regulation of G2/M transition of mitotic cell cycle GO:0010389 0.0000019 3/10 
BP 2 mitotic chromosome condensation GO:0007076 2.61E-06 3/11 
BP 3 microtubule-based movement GO:0007018 9.98E-06 4/53 
BP 4 mitotic metaphase plate congression GO:0007080 0.0000621 3/30 
BP 5 activation of protein kinase activity GO:0032147 0.000083 3/33 
MF 1 ATP binding GO:0005524 0.0000119 11/991 
MF 2 motor activity GO:0003774 0.000019 4/64 
MF 3 .microtubule motor activity GO:0003777 8.91E-06 4/53 
 
 
Table 5.5.21: Significant GO categories within the orange feature cluster of G1 vs G3. BP: biological 
process; MF: molecular function; Term: description of GO category; ID: identification of GO category; 
p: probability; N: number of genes from the category. 
Class Rank Term ID p N 
BP 1 neutrophil chemotaxis GO:0030593 0.00000223 3/35 
MF 1 RAGE receptor binding GO:0050786 5.1e-9 3/6 
MF 2 calcium ion binding GO:0005509 0.0000516 4/335 
 
 
Comparing to the complete gene differential expression charts, there are 33 genes in the red 
cluster, which are higher in G1+ and all relate to cell cycle functions. 
The orange cluster (Table 5.5.21) consists of only eight genes, of which all are lower in G3 (G1+) 
than G1(-). 
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Figure 5.5.19: BP (biological process) enrichment showing downregulated GO categories in G1+. The 
gene ratio (x axis) indicates what proportion of genes from a GO category (y axis) are present in the 
dataset, with the colour and size indicating the significance level and absolute gene count. 
 
 
 
Figure 5.5.20: BP enrichment showing GO categories which are upregulated in G1+. 
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The BP terms labelled as ‘enriched down’ (meaning lower in G3 (G1+); Fig. 5.5.20 and Table 5.5.19) 
were entered into the online tool REViGO (reduce and visualise gene ontology). This uses a 
clustering algorithm to assess and visually display the semantic similarity of GO terms after 
filtering the terms for redundancy 315. Fig. 5.5.21. 
 
  
Figure 5.5.21: REViGO generated scatterplot summarising significantly enriched GO categories in G1 
vs G3.   
1. Immunoglobulin production    9. Phagocytosis, recognition 
2. Positive regulation of B cell activation  10. Phagocytosis, engulfment 
3. Immune response 11. Positive regulation of inflammatory 
response 
4. Leukocyte migration involved in inflammation 12. Positive regulation of intrinsic apoptotic 
pathway 
5. Innate immune response    13. Positive regulation of JAK-STAT cascade 
6. Neutrophil chemotaxis    14. G protein coupled receptor signalling 
7. Cellular response to IFN-γ    15. xenobiotic metabolic process 
8. Complement activation, classical pathway   
 
This shows that most of the terms which are lower in G3 (G1+) cluster together or form sub 
clusters, reinforcing the significance of the findings.
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Table 5.5.21: Up-enriched Biological Process categories in G1(-) compared to G3 (G1+) (i.e. lower in G1+). 
 
GO ID P 
va
lu
e
fd
r
Co
un
t
Si
ze Term Gene Names
GO:0030593 0.000 0.01 4 35 neutrophil chemotaxis S100A8; S100A9; CSF3R; CCL24
GO:0050729 0.000 0.07 3 24 positive regulation of inflammatory response S100A8; S100A9; CCL24
GO:0002523 0.000 0.13 2 6 leukocyte migration involved in inflammatory response S100A8; S100A9
GO:0006955 0.000 0.13 5 196 immune response ; CCL24; ; ; 
GO:0046427 0.000 0.13 2 8 positive regulation of JAK-STAT cascade KIT; CYP1B1
GO:0006805 0.000 0.13 2 8 xenobiotic metabolic process S100A12; CYP1B1
GO:0002377 0.000 0.13 3 48 immunoglobulin production ; ; 
GO:0045087 0.000 0.17 4 136 innate immune response S100A8; S100A9; ; 
GO:2001244 0.001 0.60 2 21 positive regulation of intrinsic apoptotic signaling pathway S100A8; S100A9
GO:0006958 0.002 0.83 2 32 complement activation, classical pathway ; 
GO:0007186 0.002 0.83 4 200 G-protein coupled receptor signaling pathway ADGRD2; ; CCL24; ADGRL4
GO:0071346 0.003 0.83 2 28 cellular response to interferon-gamma CCL24; MRC1
GO:0050871 0.003 0.83 2 35 positive regulation of B cell activation ; 
GO:0006910 0.003 0.83 2 35 phagocytosis, recognition ; 
GO:0006911 0.003 0.91 2 38 phagocytosis, engulfment ; 
GO:0050727 0.004 1.00 2 38 regulation of inflammatory response S100A8; S100A9
GO:0060326 0.004 1.00 2 36 cell chemotaxis KIT; 
GO:0006919 0.005 1.00 2 42 activation of cysteine-type endopeptidase activity involved in apoptotic 
process
S100A8; S100A9
GO:0070098 0.006 1.00 2 42 chemokine-mediated signaling pathway ; CCL24
GO:0006954 0.007 1.00 3 141 inflammatory response KIT; ; CCL24
GO:0006027 0.007 1.00 1 3 glycosaminoglycan catabolic process LYVE1
GO:0050853 0.007 1.00 2 56 B cell receptor signaling pathway ; 
GO:0071603 0.008 1.00 1 3 endothelial cell-cell adhesion CYP1B1
GO:0006914 0.008 1.00 2 57 autophagy S100A8; S100A9
GO:0018119 0.009 1.00 1 3 peptidyl-cysteine S-nitrosylation S100A8
GO:0032642 0.009 1.00 1 3 regulation of chemokine production
GO:0061304 0.009 1.00 1 4 retinal blood vessel morphogenesis CYP1B1
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There are 28 categories with a p value <0.001, of which only the first eight have an FDR below 0.2. 
The first two categories carry the most weight and these also have an FDR below 0.1. The same 
five genes (S100A8, S100A9, S100A12, CCL24, CSF3R) are responsible for almost all the pathway 
enrichments detected so that this reflects the breadth of functions of these genes rather than a 
breadth of pathways. 
There are also nine up-enriched MF categories however these are highly overlapping as they again 
comprise the same key genes. 
The counts for these five genes were extracted from the bulk MLN dataset to plot the levels in 
each group as had been done by RT-qPCR (Fig. 5.5.22). The three S100 genes are all significantly 
downregulated in G1+ compared to either G1- or G2. The same can be said of CSF3R whilst CCL24 
only shows a significant difference in the current comparison. 
For all genes except CCL24 which was lower in G2 than G1+, levels in cats with FIP were closer to 
levels in cats without disease or virus. Only CCL24 showed a significant difference between G1- 
and G2 (p=0.006379). 
 
 
 
 
Figure 5.5.22: Box plots showing the distribution across all three groups of the five most downregulated 
genes in G1+ vs G1-. 
 
* * * * * * 
* * * 
* 
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Comparison between NGS and RT-qPCR results on the MLN (Chapter 3) 
As the thousands of genes cannot feasibly be listed here, those targeted and investigated by RT-
qPCR were extracted from the results.  
The genes used for RT-qPCR have been tabulated for each pairwise comparison (Table 5.5.22), 
allowing comparison between the two methods. The sample populations were of course not 
identical, with the NGS cases being a small subset of the PCR cases. 
Within G1 vs G2 there was disagreement for six targets between the two methods (PCR vs NGS) 
in terms of significant versus non-significant results, the significant result always being in PCR. 
These were IL-6, IFN-α, TNF-α, IL-15, MMP13, and TIMP1. Of the cytokines, all except IFN-α would 
be significant also by NGS if the probability threshold had been set at 0.05; IFN-α was close to this 
threshold. The matrix remodelling enzymes showed no agreement.  
There was no agreement with the RT-qPCR positive G1+ vs G1- cases but all PCR significant targets 
in G1+ vs G2 were also significant by NGS. In this last comparison NGS also marked IL-6, STAT3, M-
CSF, and MMP2 as significant. 
 
 
 
Figure 5.5.23: Selected box plots from genes used in RT-qPCR, showing the significant TLRs and the 
chemokines (CCL8 and CXCL10 were the only genes from the panel to be in the top 20 fold change list).
* 
* 
* * * 
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These box plots all show the same (and significant) trends as in RT-qPCR but with a more 
prominent increase in cats with FIP that, unlike in RT-qPCR, shows no overlap.  
Table 5.5.22: Comparison of significance levels between RT-qPCR results and NGS results for each 
target. Targets marked with an asterisk did not reach the required threshold level for number of reads 
in NGS; results have still been presented but must be interpreted with caution. Blue shading indicates 
significance, this was set at p≤0.05 for PCR and a stricter p≤0.01 for NGS. The arrows indicate the 
change in the second group of each comparison relative to the first. N/A indicates that the sequences 
were not available in the database used. 
  G1 vs G2 G1- vs G1+ G1+ vs G2 
Target RT-qPCR NGS RT-qPCR NGS RT-qPCR NGS 
FCoV 0.000 ↑   0.000 ↑   0.000 ↑   
TLR1 0.610   0.225 0.914   0.754 0.794   0.203 
TLR2 0.000 ↑ 0.000 0.724   0.460 0.002 ↑ 0.000 
TLR3 0.569   0.242 0.724   0.771 0.656   0.124 
TLR4 0.019 ↑ 0.002 0.794   0.161 0.022 ↑ 0.000 
TLR5 0.053   N/A 0.508   N/A 0.396   N/A 
TLR6 0.859   0.315 0.286   0.774 0.469   0.184 
TLR7 0.059   N/A 0.770   N/A 0.272   N/A 
TLR8 0.013 ↑ 0.000 0.246   0.483 0.015 ↑ 0.000 
TLR9 0.991   N/A 0.031 ↑ N/A 0.140   N/A 
STAT1 0.000 ↑ 0.001 0.315   0.046 0.000 ↑ 0.007 
STAT2 0.000 ↑ 0.000 0.017 ↑ 0.157 0.000 ↑ 0.001 
STAT3 0.260   0.363 0.569   0.313 0.414   0.009 
IFN-α* 0.041 ↑ 0.063 0.988   1.000 0.077   0.057 
IFN-β* 0.004 ↑ 0.008 0.770   1.000 0.036 ↑ 0.006 
IFN-γ 0.000 ↑ 0.000 0.131   0.048 0.006 ↑ 0.001 
IL-1β 0.026 ↑ 0.000 0.432   0.251 0.031 ↑ 0.000 
IL-6 0.001 ↑ 0.037 0.209   0.467 0.158   0.001 
IL-10 0.296   0.529 0.469   0.767 0.914   0.712 
IL-15 0.019 ↑ 0.042 0.794   0.515 0.039 ↑ 0.000 
IL-17* 0.440   0.327 0.569   0.437 0.818   0.098 
TNF-α 0.004 ↑ 0.031 0.432   0.592 0.346   0.018 
TGFβ 0.430   0.720 0.508   0.585 0.396   0.267 
CCL8 0.000 ↑ 0.000 0.177   0.211 0.000 ↑ 0.000 
CXCL10 0.000 ↑ 0.000 0.396   0.413 0.000 ↑ 0.000 
MMP2 0.035 ↑ 0.003 0.167   0.813 0.548   0.003 
MMP9 0.204   0.270 0.866   0.228 0.432   0.845 
MMP13* 0.011 ↓ 0.420 0.432   0.979 0.187   0.367 
TIMP1 0.000 ↑ 0.367 0.866   0.030 0.012 ↑ 0.000 
TIMP3 0.117   0.040 0.569   0.032 0.095   0.525 
G-CSF* 0.000 ↑ 0.003 0.590   0.704 0.002  ↑ 0.003 
M-CSF 0.476   0.626 0.747   0.085 1.000   0.002 
GM-CSF* 0.921   0.047 0.125   0.999 0.363   0.035 
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G2 versus LCM (bulk MLN from cats with FIP versus LCM MLN lesions from cats with FIP). 
The final pairwise comparison was between G2 and LCM lesion samples, as had been done by PCR 
(see Chapter 4). The numbers of differentially expressed genes at each cutoff, and the distribution 
of these genes is shown in Fig. 5.5.24. 
 
Figure 5.5.24: There are over 2000 genes significant at the standard p<0.01, fc >2 cut off. 12900/19493 
features were above the threshold. 
 
 
Figure 5.5.25: Comparison between average group expressions (left), with significant values indicated 
together with their fold change log ratio (right). A negative log ratio indicates a higher expression in 
G2. 
 
The top dysregulated genes between LCM lesions and bulk MLN from FIP cats appeared highly 
related therefore only the top 10 in each direction are presented (Table 5.5.23 and 5.5.24). 
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Table 5.5.23: The top 10 genes by fold change which were higher in LCM lesion samples than in G2 bulk MLN samples. 
Identifier Gene Protein p log2 Ratio fc Function 
^028590   1.49E-09 7.6 197.54 unknown 
^025213 HIST1H2AC histone cluster 1 H2A family member C 3.70E-07 6.9 117.78 chromatin silencing 
^003805 HIST1H1E histone cluster 1 H1 family member E 1.40E-10 6.6 95.74 chromatin silencing 
^028991   5.58E-08 6.6 95.01 unknown 
^024806 HIST2H2AC histone cluster 2 H2A family member C 4.86E-08 6.1 67.84 chromatin silencing 
^032075 ND6 NADH-ubiquinone oxidoreductase chain 6 1.61E-06 6.0 64.45 redox reactions 
^006079 HIST1H1B histone cluster 1 H1 family member B 1.32E-07 6.0 63.91 chromatin silencing 
^028667 HIST2H2AB histone cluster 2 H2A family member B 1.44E-08 5.8 57.28 chromatin silencing 
^031347   1.36E-07 5.8 56.14 unknown 
^024303 HIST1H2BB histone cluster 1 H2B family member B 1.93E-07 5.8 53.85 chromatin silencing 
 
Table 5.5.24: The top 10 genes by fold change which were lower in LCM lesion samples than in G2 bulk MLN samples. 
Identifier Gene Protein pValue log2 Ratio fc Function 
^029292 IGKV4-1* immunoglobulin kappa variable 4-1 8.50E-05 -6.4 87.00 Ig production 
^027582   0.001134 -6.1 70.52 U.P.: Ig production 
^027673   0.0007427 -5.2 37.90 U.P.: Ig production 
^029623   0.0001193 -5.1 35.16 U.P.: Ag and Ig R binding 
^022825 IGHV6-1 immunoglobulin heavy variable 6-1 0.0001432 -5.0 31.34 Ig production 
^024837   0.001598 -4.9 28.94 U.P.: Ig production 
^000390   0.002542 -4.5 22.96 U.P.: Ig production 
^030776   0.002492 -4.4 20.95 U.P.: Ig production 
^025144   0.007137 -4.3 20.15 unknown 
^022386   0.001261 -4.3 19.27 unknown 
Key: The colour of the fold change (fc) indicates the cluster to which the gene belongs (see below, orange, cyan, blue); ^ indicates the prefix ENSFCAG00000; function derived 
from UniProt; U.P.: unclassified protein; Ig: immunoglobulin; Ag: antigen; R: receptor
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Figure 5.5.26: Cluster plot comparing G2 and LCM; colours on the y axis represent GO (gene ontology) 
category feature clusters, with each individual sample marked on the x axis. The chart colour intensity 
indicates comparative up or down regulation (blue -; red +).  
 
The cluster analysis shows a generally distinct segregation of LCM samples from all other samples 
with orange, red and yellow higher in LCM lesion samples, and blue, cyan and green lower in LCM 
lesion samples. The cluster GO categories are shown below. 
Red contains 590 genes, orange contains 189, yellow 519 genes, all higher in LCM samples. The 
top 10 higher genes all grouped in the orange cluster. Green contains 459, blue 226 and cyan 17 
genes, all lower in LCM samples  
 
Table 5.5.25: Significant GO categories within the orange feature cluster. BP, biological process; MF, 
molecular function; Term, description of GO category; ID, identification of GO category; p, probability; 
N, number of genes from the category. 
Class Rank Term ID p N 
BP 1 nucleosome assembly GO:0006334 8.63e-36 29/74 
BP 2 DNA-templated transcription, initiation GO:0006352 2.75e-12 10/29 
BP 3 chromatin silencing GO:0006342 4.17e-8 7/26 
BP 4 nucleosome positioning GO:0016584 0.000085 3/7 
BP 5 protein heterotetramerization GO:0051290 0.0000895 4/18 
MF 1 protein heterodimerization activity GO:0046982 2.18e-23 35/274 
MF 2 DNA binding GO:0003677 2.69e-21 52/790 
MF 3 histone binding GO:0042393 1.26e-11 15/98 
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Table 5.5.26: Significant GO categories within the red feature cluster. BP, biological process; MF, 
molecular function; Term, description of GO category; ID, identification of GO category; p, probability; 
N, number of genes from the category. 
Class Rank Term ID p N 
BP 1 microtubule-based movement GO:0007018 8.46E-06 12/57 
BP 2 epidermal growth factor receptor signalling pathway GO:0007173 1.03E-05 8/25 
MF 1 microtubule motor activity GO:0003777 6.23E-05 11/58 
MF 2 microtubule binding GO:0008017 7.26E-05 19/151 
 
 
Table 5.5.27: Significant GO categories within the yellow feature cluster. BP, biological process; MF, 
molecular function; Term, description of GO category; ID, identification of GO category; p, probability; 
N, number of genes from the category. 
Class Rank Term ID p N 
BP 1 chromatin remodeling GO:0006338 3E-05 10/54 
MF 1 immunoglobulin receptor binding GO:0034987 2.45e-9 4/36 
MF 2 antigen binding GO:0003823 4.21e-9 4/41 
 
 
Table 5.5.28: Significant GO categories within the blue feature cluster. BP, biological process; MF, 
molecular function; Term, description of GO category; ID, identification of GO category; p, probability; 
N, number of genes from the category. 
Class Rank Term ID p N 
BP 1 translation GO:0006412 1.04e-11 22/203 
BP 2 chemokine-mediated signalling pathway GO:0070098 9.4E-05 6/42 
MF 1 structural constituent of ribosome GO:0003735 3.26E-13 21/152 
 
 
Table 5.5.29: Significant GO categories within the cyan feature cluster. BP, biological process; MF, 
molecular function; Term, description of GO category; ID, identification of GO category; p, probability; 
N, number of genes from the category. 
Class Rank Term ID p N 
BP 1 immunoglobulin production GO:0002377 2.25e-23 11/43 
BP 2 immune response GO:0006955 1.39e-15 11/200 
BP 3 .innate immune response GO:0045087 0.0000764 4/143 
BP 4 phagocytosis, recognition GO:0006910 3.76e-7 4/38 
BP 5 positive regulation of B cell activation GO:0050871 3.76e-7 4/38 
BP 6 phagocytosis, engulfment GO:0006911 5.14e-7 4/41 
BP 7 defense response to bacterium GO:0042742 0.00000427 4/69 
MF 1 immunoglobulin receptor binding GO:0034987 2.45e-9 4/36 
MF 2 antigen binding GO:0003823 4.21e-9 4/41 
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Table 5.5.30: Significant GO categories within the green feature cluster. BP, biological process; Term, 
description of GO category; ID, identification of GO category; p, probability; N, number of genes from 
the category. 
Class Rank Term ID p N 
BP 1 protein N-linked glycosylation GO:0006487 7.56e-8 9/23 
BP 2 carbohydrate metabolic process GO:0005975 2.87E-05 14/102 
 
Comparison with results of selected publications on the transcriptome in feline coronavirus 
infection 
One of the publications which had contributed to our original list of PCR mediators (CCL8 and 
CXCL10) was that of Harun et al. who evaluated the transcriptome of FCoV infected CRFK cells 
compared to controls 242. The current G1(-) vs G2 dataset was compared against their list of top 
up and down regulated genes to assess the similarities. 
Of their top 20 upregulated genes, 16 could be identified. Of these, 12 were significantly 
upregulated also in the current dataset (p≤0.01). In addition to CCL8 and CXCL10, these were 
RSAD2, SLAMF7, AFT3, IFI35, TRIM25, MX1, CD274, PHF11, HERC5, DTX3L. The first three were 
also in the top 20 upregulated of our data. 
13 of their top 17 downregulated genes could be identified, of which only two were significant in 
our dataset but were in fact upregulated. 
An in vitro transcriptome study looking at peritoneal macrophages after experimental infection of 
cats with a virulent cat-passaged strain of FCoV was published after our data was acquired 168. 
Therefore, their main findings were also compared briefly to determine how cell specific the 
changes are.  They found upregulation of 18 pathways in FIP, including apoptosis, TLR signalling 
and JAK-STAT signalling. These were also upregulated in our FIP group (in the MLN intergroup 
comparison rather than the MLN - LCM comparison). Others were against specific but unlikely of 
relevance infectious diseases e.g. trypanosomiasis; these were not compared with our results. 
Only three pathways were downregulated, all involved in cellular metabolism, also consistent with 
our findings 168. 
 
Evaluation of the feline coronavirus transcriptome within infected samples 
A secondary aim had been to compare viral sequences between G3 (G1+) and G2. Levels of the 
viral reads in G1+, already known to be low from PCR, were drowned out by the host reads in the 
software calculations and did not reach a read threshold required to be allocated to a gene. 
However, manual extraction of matching sequences to the genes from the dataset allowed 
intergroup comparisons. 
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Figure 5.5.26: Total reads allocated to a reference FIPV gene sequence (DQ848678) for each sample, 
using an automated approach. It can be seen that two out of the three G2 samples had barely 
detectable levels, and none of the G3 (G1+) samples. Virus was also not detected from one LCM sample. 
 
 
Figure 5.5.27: Proportion of genomic feature reads above threshold for each sample. 
 
The primary aim had been a comparison between FCoV infected cats with and without disease; 
this was therefore not possible using the pre-programmed applications. Instead, by searching the 
raw data for specific sequences it was possible to obtain a count of reads mapping to the individual 
viral mRNA sequences of polyprotein 1ab and the structural proteins. These are shown in the 
graphs below (Fig. 5.5.28). The same statistical comparisons cannot be applied to individually 
extracted data as to the bulk data therefore an ANOVA test was applied, this tests the premise 
that not all results are the same. Of the seven individual viral mRNA coding regions, a significant 
difference was only found between G2 and G3 (G1+) for the envelope and membrane coding 
genes. 
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Figure 5.5.28: Direct expression values of FCoV gene segments across the viral positive groups.  
 
The expression values from each gene were compared by ANOVA across all groups. Significant 
differences, once corrected for by the number of genes compared, were only found for the 
membrane and envelope genes, for which cats with FIP had significantly higher levels than 
infected cats without FIP. These are direct counts, and are not normalised to viral level, therefore 
higher counts from the FIP groups would be automatically expected for all genes. The fact that 
only two genes are affected may be significant and is discussed.   
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Discussion 
Despite decades of research, the precise pathogenesis of FIP remains unclear. Much of what is 
understood has been assumed from piecing together information gleaned from various studies. It 
is so far known that an enteric coronavirus gains access to the systemic circulation, via monocyte 
infection, and that this stage may occur in the majority of infected cats with no ill effect 316. The 
susceptibility of an individual host to FIP is then somehow combined with as yet incompletely 
characterised gain of virulence mutations within the virus, leading to monocyte/macrophage 
activation, with development of typical lesions and non-specific inflammatory clinical signs. Both 
the pathological and clinical features of FIP, including vasculitis, increased vascular permeability, 
recruitment of leukocytes to expanding lesion sites, fever etc., indicate an inflammatory cytokine-
mediated disease 32,42,317. However, the source of these cytokines remains to be fully elucidated. 
Levels in the blood of cats with FIP have not been shown to be markedly elevated, nor have those 
so far studied in haemolymphatic tissues 47,48,134.  
Studies so far have generally been directed at the cytokines themselves, the effector molecules of 
inflammatory pathways. The present study chose here to focus predominantly on molecules 
upstream of these effectors, in particular the Toll-like receptors (TLRs) and the STATs which have 
not been studied before in FIP. Anti-viral cytokines, pro- and anti-inflammatory cytokines as well 
as molecules with a role in cell recruitment and tissue remodelling were also of vital importance 
to determine. TLRs are the most important of the pattern recognition receptors (PRRs) of the 
innate immune system 179. PRRs recognise conserved motifs not associated with self and induce, 
in an ideal model, a targeted and balanced immune response 318. They are also crucial to the link 
between the innate and adaptive immune system, being able to present antigen to specific 
lymphocytes 164. STATs are a family of transcription factors which are able to influence a vast array 
of downstream cellular processes critical for the inflammatory response, including directing 
leukocyte differentiation 319.  
In evaluating these mediators, the two areas the present study most wished to explore were the 
immune profile within the lesions themselves, and the relationship between FCoV infection status 
and FIP disease status within the MLN in terms of immune mediator expression. The MLN is of 
particular interest as the first site of spread beyond the intestine. To this end tissues and lesions 
from cats with FIP were compared with tissues from control cats (with and without detectable 
FCoV in the MLN).  
The lesions of FIP, particularly the pathognomonic pyogranulomatous vasculitis, contain a 
concentrated population of virus-infected macrophages, all with the potential to secrete and 
respond to pro-inflammatory cytokines and exert positive feedback on one another with an 
ensuing cascade effect. The nature of the lesions also gives a direct communication with the 
circulation, hypothetically contributing to clinical signs such as biphasic fever 320. It was predicted 
that the inflammatory mediator production in these local microcosms would far outweigh the 
systemic response. 
Secondarily, certain aspects of the virus were looked at in order to try to disentangle the virus’ 
contribution to disease from that of the host. 
Various complementary methods have been used, beginning with RNA expression analysis by RT-
qPCR in BM, spleen, and MLN, before laser capture microdissection (LCM) of lesions. Finally, a 
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transcriptome wide approach was applied to both MLN and lesion samples to attempt to place 
the PCR results more accurately in the context of cellular pathways as a whole. Comparative BM 
and spleen analyses were performed between uninfected control cases (cats without FIP) and cats 
with FIP, as none of the control cats tested positive by RT-qPCR for FCoV. From the larger cohort 
of cases for which MLN were available, it was possible to split the control group into virus positive 
and virus negative cases. 
With regards to the host response, firstly the effect of virus in the absence of disease is discussed, 
before comparison with haematopoietic tissues in the disease state, and finally with tissues from 
specific lesions. The viral aspects are discussed separately. 
 
FCoV infection, even in the absence of disease, is associated with 
immunomodulatory changes 
In the first instance, mediator expression was compared between control cases with FCoV positive 
and negative MLN, first by RT-qPCR and then by NGS.  
The current state of knowledge on FCoV does not as yet allow distinction between the mystical 
non-pathogenic and pathogenic viruses. As our cases were all natural infections we therefore 
cannot say whether infected cats without FIP were resistant to developing disease or were 
infected with a non-pathogenic virus that nonetheless spread from the intestine. Results are also 
a snapshot in time and it cannot be excluded that control cats with and without virus may have 
interchanged between these groups in the past or would do so in the future. 
Only TLR9 and STAT2 showed a significant increase in expression by RT-qPCR in the infected MLN. 
IL-6, STAT1, and IFN-γ showed tendencies (not reaching significance) to be higher in the infected 
MLN, with levels below that of cats with FIP. These subtle changes indicate a mild upregulation 
from basal levels of pro-inflammatory, antiviral, and signalling molecules associated with the virus, 
suggesting a modulated and controlled response and explaining the lack of observed lesions.  
The precise ligand of TLR9 in the FCoV infected MLN is unclear, however the increase in virus-
positive MLN of control cats compared to uninfected MLN suggests a potentially protective 
effect of TLR9, which may even have helped prevent the development of disease in these 
animals. Stimulation by co-infectious agents could therefore be hypothesised to be protective 
against FIP. There is debate in the literature as to the precise ligand requirements of TLR9 for 
signalling and varying synthetic ligands have induced different effects, triggering either type I 
IFN or pro-inflammatory cytokines 167,198. The initial belief was that the receptor is stimulated 
by CpGs, specifically the unmethylated CpGs which largely distinguish host from microbial 
DNA 181. The unmethylated CpGs of bacteria are also found in mammalian mitochondria, 
released following cell damage such as may be induced by viral infection and resulting in 
upregulated TLR9 signalling (Bao et al., 2016). TLR9 was found to mediate a protective effect 
on enterovirus infected mice by responding to endogenous danger-associated molecular 
patterns (DAMPs); the enterovirus itself had no effect on TLR9 levels 321. Morphologically there 
was no evidence of cell damage within the FCoV-infected MLN, and also no upregulation of TLR9 
in association with the lesions in FIP, leaving the trigger for TLR9 in our cases unknown. 
179 
 
When comparing between control groups by NGS, the number of differentially expressed genes 
was only a fraction (~10%) of those differentially expressed when comparing between control 
groups and FIP. TLR9 and STAT2, significantly higher in infected MLN by PCR were not significantly 
higher in the NGS comparison (most likely due to the samples being only subgroups, added to an 
initial small effect). IFN-y and STAT1 had shown less than significant elevation in infected MLN by 
PCR. These reached significance by NGS only at the p<0.05 level; as a standard, the more stringent 
p<0.01 was used for NGS. 
The majority of differentially expressed genes were higher in the FCoV-infected MLN, and most of 
these related to cell cycle regulation with no direct link to inflammatory responses. This is likely to 
reflect macrophage proliferation and provides an mRNA correlate to the morphological findings 
of previous studies in which healthy FCoV-infected cats exhibited histiocytosis and macrophage 
activation in the MLN 46.  
A very small number of genes showed a significantly lower expression in infected MLN, together 
with a high fold change. Five of these genes stand out in particular; S100A8, S100A9, S100A12, 
CSF3R, and IGKV4-1. These genes had many overlapping features and functions all linked to the 
immune response. Cluster analysis of NGS data groups up or down regulated genes by function, 
determining differential expression of these functional groups (gene ontology [GO] categories) as 
opposed to just of individual genes. The GO categories with significantly lower gene expression in 
infected MLN of control cats were dominated by immune regulatory functions. These included 
neutrophil chemotaxis (the top category), RAGE receptor binding, phagocytosis, immunoglobulin 
production, response to IFN-g, and positive regulation of the JAK-STAT cascade. The genes most 
frequently involved in those functions were the three S100 calcium-binding proteins (A8, A9, A12). 
S100 proteins are involved in diverse functions including regulation of apoptosis, DNA repair, 
migration, differentiation and inflammation 322. Apoptosis induction is part of the host’s armoury 
of defence against viruses, along with inhibition of cell protein synthesis (to block the mechanisms 
hijacked by the viruses) and induction of type I IFN 256. The S100 family, otherwise known as 
calgranulins, includes more than 20 proteins. Three of these, A8, A9, and A12 (i.e., the same three 
found to be decreased in FCoV-infected MLN of control cats) have been specifically linked to 
innate immune functions owing to their expression by phagocytes at sites of inflammation 323,324. 
A8 and A9 can be detected in granulocytes, monocytes and early macrophages, whilst S100A12 is 
more specific to granulocytes 324.   
These S100 proteins have many roles in innate immunity and are amongst the DAMPs to be 
released from damaged cells and trigger an inflammatory response. DAMPs are host proteins 
which typically have a normal intracellular role separate to their extracellular role in danger 
signalling 325. S100A9 stimulates neutrophil migration both in vitro and in vivo 322, helping explain 
the lower S100A9 levels in infected MLN of control cats.  
RAGE (receptor for advanced glycation end products) binding was one of the processes found to 
be downregulated in infected MLN of control cats. RAGE is another PRR and recognises DAMPs. 
There is crossover between the endogenous ligands of RAGE and those of TLR4, which include the 
S100 proteins 326–328. RAGE is able to bind S100A12 alone or the heterodimers S100A8/A9 324,326. 
The influence of the three S100 genes led to statistical downregulation of the terms associated 
with the RAGE-binding process, but the RAGE gene itself (aka AGER) did not differ between control 
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groups. The MLN of cats with FIP, in contrast to FCoV-infected MLN of cats without FIP, had levels 
of S100A8, 9, and 12 levels much closer to those of the uninfected control group MLN (slightly 
above though not significantly so). Calprotectin is a tetramer of S100A8 and A9 and can induce 
pro-inflammatory cytokine production in monocytes and macrophages as well as being involved 
with neutrophil and monocyte migration, as shown by the downregulated GO categories 322. The 
antibody against calprotectin is used as an immunohistological myelomonocytic marker, 
identifying recently-blood derived macrophages (in addition to neutrophils which are easily 
morphologically distinguished) 329. This will be returned to with discussion of the FIP cases. 
CSF3R was another of the five closely linked genes significantly lower in infected than uninfected 
control cat MLN. It is the receptor for G-CSF, a key regulator of neutrophil chemotaxis as well as 
neutrophil differentiation and survival 330. G-CSF mRNA has previously been shown to be induced 
in FIP and to reduce neutrophil apoptosis along with TNF-α and GM-CSF 331. G-CSF and TNF-α but 
not GM-CSF were also upregulated in FIP MLN in our study, this may help provide a renewable 
supply of neutrophils towards the formation of FIP lesions. Consequently, a reduction in G-CSF 
signalling associated with reduced CSF3R in infected control cat MLN may reduce the opportunity 
for lesion development by limiting the number of cells (i.e. monocytes) required for both FCoV 
replication and initiation of lesions. The current results parallel previous results of our group, when 
it was observed that the lowest transcription levels of G-CSF (i.e. the ligand rather than the 
receptor) in the MLN were seen in infected cats without FIP 48. 
The fifth gene to stand out as lower in infected control MLN was IGKV4-1, this gene is responsible 
for part of the antigen recognition binding site of the antibody. Somatic hypermutations in the 
variable (V) region of the Ig gene confer B cells with the ability to recognise a plethora of different 
antigens from a single original genome sequence 332. Its reduction links with the lower levels of 
pathways involved in adaptive immunity in the infected controls (e.g. B cell receptor signalling, 
immunoglobulin production). 
It cannot be said for sure whether FCoV-infected cats show pathway downregulation or have 
inherently lower expression levels of certain genes than uninfected cats. This would ideally be 
evaluated by a prospective study to determine whether constitutively transcribed levels in an 
individual can predict susceptibility to subsequent development of FIP. What we can see is that 
infected MLN of control cats showed a lower level of expression of a number of inflammatory 
genes. The enriched pathways expressed at lower levels included immunoglobulin production, 
phagocytosis and complement activation, all common immune response processes which in FIP 
seemingly contribute to the pathogenesis rather than being beneficial 22,25,333. The phenomenon 
of antibody dependant enhancement is frequently observed in experimental cases, and 
complement deposition is found in vasculitis 25,333–335. The latter is only a small part of the story of 
vasculitis pathogenesis as the lesions, and their predisposition to veins, do not fit the profile of a 
type III (immune complex mediated) hypersensitivity reaction 42. The mediator profile in the 
infected cats supports original theories that mounting a humoral response has a detrimental effect 
in the case of FIP 22,320, and that by downregulating these mechanisms infected cats may avert 
disease.  
In cats with FIP, these same five genes were transcribed in the MLN at levels similar to the 
uninfected controls. This leads to the hypothesis that they are in some way a protective response 
by the host which may contribute to dampening down the inflammatory response by negative 
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regulation of these proteins. Whether this is an active downregulation or whether low basal 
expression is linked to resistance to development of FIP is not clear at this stage. Another 
possibility is that the non-pathogenic FCoV variants repress these genes to help them avoid 
triggering the host immune response. Coronaviruses are known to use various methods of host 
gene suppression including altering ubiquitination as discussed later. Controlled experimental 
infections with viruses of known pathogenicity would be required to make this distinction.  
 
FIP is associated with extensive changes in the immune profile of the MLN, far 
beyond those induced by the presence of FCoV 
The results discussed above show that the presence of virus has a small but potentially crucial 
effect on the immune system in the absence of disease. When applying the same selected RT-
qPCR immune mediator panel to the MLN of cats with FIP and comparing to control groups, 
significant differences were evident for almost all of the mediators. These results prompted a 
deeper look into changes in the transcriptome by means of NGS. This revealed over 1000 
differentially expressed genes between FIP and control groups (with each control group compared 
independently), vastly more than between the two control groups themselves. These genes 
contributed to a multitude of enriched differentially regulated pathways. FIP cats very clearly 
clustered away from both of the control groups and were unsurprisingly seen to be more similar 
to the LCM lesion group by cluster analysis. 
Looking first by RT-qPCR at a combined control group, mediators with altered expression levels 
almost exclusively showed an upregulation in FIP. Significantly higher mRNA levels were found for 
TLR 2, 4, and 8, the pyrogenic cytokines (IL-1β, IL-6, TNF-α), the chemokines CCL8 and CXCL10, the 
transcription factors STAT1 and 2, and the interferons IFN-α, -β, -γ. The changes amongst the 
matrix remodelling enzyme (MMPs and TIMPs) responses were mixed, with MMP13 the only 
downregulated mediator observed.  
The TLRs that can be expected to respond to viruses are TLR3 (dsRNA), 7 (ssRNA), and 8 (ssRNA), 
of which only TLR8 was significantly elevated in FIP. This result was confirmed by NGS. TLR8 is 
often overlooked, or grouped with TLR7 in functional studies 336. This may be as humans but not 
mice or rats detect ssRNA through TLR8 and therefore many experimental (and hence rodent 
based) studies have ignored it. It is thought that in mice the protein, though present, may be non-
functional, and therefore lack downstream signalling ability 181,337. The results of the present study 
show that in cats the response also clearly differs between TLR 7 and 8, at least at the 
transcriptional level.  
TLR8 was the only TLR for which a reliable immunohistological and immunofluorescent protocol 
could be established. It is reportedly broadly expressed by both conventional DCs and 
macrophages in mice 181 and in the present study positive cells in the MLN were most commonly 
of macrophage/dendritic cell morphology. Consecutive sections of MLN stained for the 
macrophage marker Iba-1 also supported this observation, though the frequency of Iba-1 positive 
cells far exceeded that of TLR8 in both control and FIP MLN. 
Immunofluorescence double staining with FCoV antibody was then used, with the expectation of 
localising TLR8 expression to infected cells. Contrary to those expectations, only exceedingly rare 
examples of co-expressing cells could be found despite plentiful cells positive for each marker. 
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This leads to two main questions; what then is the trigger for TLR8 expression (supposedly ssRNA; 
the most likely culprit to respond to FCoV 184), and why do infected cells not appear to upregulate 
TLR8 protein expression? Identifying the precise cell subtype expressing each marker would be an 
informative next step. In theory, flow cytometry would allow simultaneous evaluation of infection 
status, TLR expression, and cell marker co-expression triple immunofluorescence combined with 
confocal microscopy would be another possible, though more limited, modality. In practice, feline 
macrophage/DC characterisation studies unfortunately lag behind those of many other species 
meaning that antibody cross-reactivity is as ever an issue 188,338. TLRs, in contrast to other PRRs, 
detect presented, processed antigen without the requirement that the cell itself is infected. This 
would explain the presence of TLR8 in uninfected cells but not the inverse lack of TLR8 in infected 
cells. The advancements of single cell analysis make in vitro assessment on an individual cell level 
a viable option for future investigation, comparing responses in infected and adjacent uninfected 
cells. It would also allow determination of whether the downstream TLR8 signalling pathway is 
activated.  
In attempting to define the involved cell types there is much confusion in the literature as to the 
classification and ontogeny of the various members of the mononuclear phagocyte system (MPS). 
The MPS includes monocytes, macrophages, and dendritic cells, each with their own multiple 
subsets; a recent publication attempts to classify these to provide a replicable nomenclature 
across species 339. As a result of this confusion, the three cell types have often been used 
interchangeably, further complicated by the many supposedly unique markers that have been 
shown to overlap 339. To my knowledge, the susceptibility of different macrophage/DC subsets to 
FCoV infection has not been assessed in detail (once again due in no small part to antibody 
availability), although at least some members of the DC family are reported to be susceptible in 
vitro 340,341. In learning more about the subtype restrictions of the virus, we may also glean further 
clues to the cell surface receptors it utilises; currently still unknown for serotype I.  
TLR 3 and 7 were predicted to be elevated in FIP, in response to dsRNA replicative intermediates 
and the ssRNA viral genome respectively 93,169. There was instead a less than significant 
downregulation, leading to the suspicion that viral inhibition may be occurring (discussed in more 
detail below).  
As with all virus detecting TLRs, TLR3 induces downstream production of the antiviral type I 
interferons 164. It does this via the adaptor proteins TRAM/TRIF and the interferon regulatory 
transcription factor (IRF) 3, being the only TLR not to signal via the predominantly inflammatory 
Myd88 branch 169. TLR4, unlike the remaining TLRs, is also able to utilise this alternative branch 
but to do this it must first be trafficked to endosomes from its usual cell surface location 181. This 
partly explains the overlap of TLR4 with TLR3 in its ability to induce an anti-viral response in 
addition to its more stereotypical pro-inflammatory cytokine response. TLR3 can, however induce 
a greater anti-viral response than TLR4 in vitro 342. The upregulation of TLR4 and not 3 in FIP MLN 
may partly explain the ineffective response to FCoV that is likely a relevant component of FIP 
pathogenesis.  
TLR3-/- mice have been used to demonstrate the importance of this TLR signalling pathway in 
various viral infections. In experimental infections of mice with West Nile and influenza virus 
(+ssRNA and -ssRNA viruses respectively), the presence of the TLR increased the severity of disease 
203,343. On the other hand, TLR3 signalling is reported to have a protective role in vivo against 
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infection with the murine hepatitis virus (MHV), also a coronavirus 175, and in vitro against 
influenza virus infection of human epithelial cells 344. 
A separate study found mice with intact TLR3 have milder disease in response to SARS-CoV but 
that it is the adaptor protein TRIF rather than TLR3 itself which is most integral to this response; 
TLR3-/- mice are still partially protected if TLR4 is intact (and hence able to signal via TRIF) 176. The 
authors suggest that balanced activation of TRIF/Myd88 pathways is important 176. In our FIP 
cases, Myd88 was significantly upregulated in FIP cat MLN whilst IRF3 (part of the TRIF pathway) 
was significantly downregulated, pushing the balance towards pro-inflammatory Myd88 
signalling.  
Although the virus specific TLRs described above appeared not to be making a large contribution in 
our study, TLR 2 and 4 (classically recognising bacterial ligands) were found by both methods to be 
significantly upregulated in FIP.  
TLR2 has the widest range of ligands of the TLRs, partly owing to its ability to form heterodimers 201. 
It does this with other family members, namely TLR 1, 6, or 10 345. Another feature of heterodimer 
ligand recognition is the ability of different pairings to inhibit or enhance signalling 346. It would 
require more intricate downstream analysis to determine if there is signal inhibition or enhancement 
in FIP. 
In addition to its traditional bacterial ligands, TLR2 can recognise both viral proteins and 
endogenous ligands from damaged cells to promote inflammation and repair 170. This is a potential 
link to one of the function clusters shown by NGS to be upregulated in FIP; the ‘reparative 
response to cell damage’. The TLR trigger in the present study is unknown, and a combination of 
ligands may be involved. In contrast to exogenous ligands, endogenous stimulators of TLR2 and 4 
are not known to induce adaptive immunity 164. As adaptive immune system pathways are 
upregulated in the present study, this suggests that exogenous ligands are involved, either with 
or without additional endogenous ligands. 
Experimentally, it is difficult to precisely determine contribution of different TLRs even in 
genetically engineered mice owing to the level of overlap between the pathways. Examples of 
virus detection by TLR2 include the RNA viruses respiratory syncytial and measles virus as well as 
SARS-CoV, with TLR2 thought to be responsible for mediating the response to the SARS-CoV S 
protein 174,347,348. Most of these examples demonstrate a beneficial effect of TLR2 signalling but in 
some cases a TLR2 deficiency reduces the pathogenic effects of the virus. For example, TLR2-/- mice 
were relatively spared from herpes simplex virus-induced encephalitis 349. The authors’ theory was 
that TLR2 induces too great a pro-inflammatory response and insufficient IFN.  
TLR4 deficient mice are more susceptible to MHV-1 induced respiratory disease than are mice with 
an intact TLR4, as they exhibit increased inflammation and morbidity 350,351. Conflicting examples 
include mouse mammary tumour virus activates TLR4, leading to production of the anti-
inflammatory cytokine IL-10 and allowing the virus to become persistent, whilst respiratory 
syncytial virus also activates TLR4 but instead induces IL-6 which is protective in this case 352. 
TLR agonists have been explored as vaccine adjuvants, e.g. TLR4 agonists as adjuvants in antiviral 
vaccines to induce Th1 responses 180. The future with regards FIP vaccination is unclear as so far 
triggering adaptive immunity has proven unsuccessful (with enhancement of disease rather than 
immunity) 22,24,25. The problem in this disease is not in how to help the immune system to recognise 
the virus but rather how to temper its response. As the virus itself apparently does little to the 
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host cells directly 42, perhaps investigating how to induce immune tolerance would be a more 
profitable direction.  
A number of the related genes (GO categories) found to be upregulated in FIP refer to the LPS 
response. As this response is mediated heavily by TLR4 172 it cannot yet be said if the upregulation 
is merely an overlap labelling of the TLR upregulation or represents a separate trigger. This would 
link to the possibility discussed in the manuscript that co-infections from a deficient intestinal 
barrier in FIP may contribute to the TLR response. 
TLRs 2, 4, and 9 can also all be triggered by another endogenous ligand/alarmin, high mobility 
group box (HMGB)1 which is released from the nucleus in response to cell damage 353. Although 
TLR 2 and 4 were elevated in the FIP MLN, TLR9 was not. This is despite the presence of MLN 
lesions in most animals, which therefore does not support this mechanism of action in FIP. 
Correlation was assessed within the FIP group between FCoV viral loads and mediator mRNA levels 
in the MLN, as well as between individual mediators. It showed that the majority of mediators 
significantly upregulated in FIP were also correlated with FCoV levels. The exceptions were TNF-
a, STAT1, and G-CSF. This suggests that either these non-correlating mediators have a more binary 
on/off response than a proportional response, or that their induction depends more on other 
mediators than on the virus itself. In vitro, TNF-a mRNA expression has been shown to be induced 
in macrophages in response to pathogenic FCoV 240. That study compared TNF-a in infected and 
uninfected cells but did not attempt to differentiate responses to different viral levels 240. It is 
possible that once a certain virus threshold is crossed, TNF-a production is triggered. It is therefore 
still difficult to definitively separate viral from disease effects as the FCoV positive MLN of cats 
without FIP also had much lower virus levels and would consequently be expected to express 
lower levels of mediators.  
Within the panel of mediators, certain molecules might also be expected to correlate with each 
other and not just with virus levels. The STATs for example are triggered by their corresponding 
interferons 286 but showed almost no correlation to them. This is a reminder of the extra levels of 
regulation involved, or it is possible that levels at a single time point do not correspond owing to 
negative feedback loops preventing both rising inexorably together 287. The lack of correlation in 
the MLN may also indicate that these signalling pathways have systemic rather than only local 
triggers such that the local mRNA levels do not need to be directly linked. TLR 2 and 4 ligand 
binding should lead to inflammatory cytokine production 169; in the present study both these TLRs 
correlated with the inflammatory cytokines IL-1b and IL-6. As with the FCoV comparison, TNF-a 
levels were once again independent. One interesting observed correlation was between IL-6, IL-
17, and STAT3. All three correlated to each other though only the former was upregulated in the 
MLN in FIP in the present study. In the case of STAT3 this was unexpected, as it is known to be 
activated by the pro-inflammatory cytokine IL-6 286 which was itself elevated. The triad have been 
referred to as a “holy trinity of auto-immunity” 236; part of the reason for our interest in these 
mediators. Whilst not of course an auto-immune disease per se, it is most likely the over-reaction 
of the host immune response which leads to development and maintenance of the lesions in         
FIP 42,354. In the absence of upregulation of all three, however, their role is unlikely to be a 
prominent one. 
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Following the finding of lower S100A8, A9, and A12 transcription (see above) in infected control 
cat MLN than in uninfected controls, levels were assessed in a pairwise comparison between 
uninfected control MLN and cats with FIP. Levels were slightly higher in FIP but not to any 
significant degree. There was also no significant difference between the lesion samples and the 
bulk MLN of cats with FIP. Calprotectin protein (a tetramer of S100A8/A9) has been shown to be 
expressed at high levels within acute FIP lesions, with lower levels in more advanced lesions 62. 
Immunohistologically it is a marker of blood-derived macrophages, so this reflects the presence 
of these cells in the early lesions which then degenerate or differentiate in older lesions. Its 
expression has also been shown to increase in the BM and spleen of cats with FIP but not in the 
MLN, reflecting an influx of monocytes in the former organs, with proliferation of local 
macrophages in the MLN 48. The MLN findings in that study fit our S100 gene findings, that A8, A9, 
and A12 are not upregulated in the MLN in FIP compared to uninfected MLN (S100 levels were not 
available for BM or spleen). However, the previous study found no difference in calprotectin 
protein expression between infected and uninfected control cats. In the present study there was 
also no difference observed in the lesions compared with the bulk MLN in FIP. This may reflect the 
varying chronicities of our cases or may mean that formation of this tetramer protein is not the 
final destination of most of the expressed mRNA.  
Another of the effects of these three S100 proteins is induction of increased vascular permeability, 
frequently a key feature of FIP. Not all of the FIP cases used for MLN NGS had effusions, which 
may also relate to the lack of significant difference to uninfected controls. Therefore, comparison 
of specific S100 levels between cases with and without effusions/vasculitis warrants further 
investigation. A larger cohort of cases would help to determine whether the small increase in the 
MLN observed in cats with FIP over uninfected controls could reach significance. 
S100A12 has been used as a biomarker of inflammatory diseases, e.g. Familial Mediterranean 
Fever 355. Based on the current results it seems unlikely that it would be a suitable marker in FIP. 
To date, inflammatory markers tested in FIP identify predominantly non-specific inflammation 
without being diagnostic 356,357. 
Amongst the markers of inflammation tested in FIP are the serum amyloid A (SAA) proteins 284,356. 
These are acute phase proteins, two of which were amongst the top ten genes upregulated in FIP 
MLN compared to uninfected control MLN in this study. SAA proteins are pattern recognition 
molecules classically produced by the liver and are used diagnostically in many species as an 
indicator of systemic inflammation 358,359. SAA can bind bacterial surfaces and hence act as an 
opsonin, or bind the complement protein C1q where it can activate the classical complement 
pathway 201. SAA was shown to be upregulated in the serum of cats with FIP 284,356 but this is not a 
specific finding. The specificity of another acute phase serum protein α1-acid glycoprotein (AGP) 
is reported to be higher 356,357,360. However, this could not be identified in the present data. 
The genes which were most upregulated in the MLN of cats with FIP were all involved in the 
immune response including in interferon response pathways (such as IRF7 and ISG15), the 
prototypical antiviral defence 254. Additionally there were genes involved in the humoral immune 
response, known to be detrimental in FIP, and in apoptosis, also a feature of FIP 23,25,46,63,240. 
Surprisingly, one of the top ten upregulated genes had a predicted role in upregulation of TLR 7 
and 9; however, neither TLR was upregulated in FIP MLN by either PCR or NGS. When applying 
cluster analysis to the FIP versus uninfected control MLN comparison, all enriched categories could 
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be linked to known processes observed in cats with FIP, and often also directly to the PCR results. 
These were directly immune response related categories such as chemokine mediated signalling, 
IL-1β and IL-6 production, phagocytosis and immunoglobulin production. The categories included 
‘viral defence’, ‘negative regulation of viral replication’, and ‘interferon gamma signalling’ but 
these were heavily outnumbered by those involved in humoral immunity and in pro-inflammatory 
cytokine responses. 
As mentioned briefly in the introduction, TLRs are only one of the groups of PRRs, albeit arguably 
the most important. Other categories include the retinoic acid-inducible gene I (RIG-I) like 
receptors (RLRs) 163. TLRs and RLRs are the main host responders to RNA virus infection 361. Other 
PRRs include MDA5 and NOD 203. Not all of these could be identified in the current dataset. NOD1 
was detected and was not significantly altered but neither MDA5 nor its alias IFIH1 was identified.  
Unlike the TLRs which are membrane bound but cell type restricted, RLRs are free within the 
cytoplasm and expressed by all cells; they require the cell to be infected by the virus to activate 
their signalling pathways 203. RIG-I is one of the principal responders to viral dsRNA 362. As dsRNA 
only occurs as a replication intermediate of FCoV, a large effect would not be expected, similarly 
to the situation in TLR3 which appeared in our study to respond very little to FCoV infection in the 
MLN (with or without FIP). RIG-I, under its alias DDX58, was however present and upregulated 
over 15 fold in the current NGS dataset in MLN of cats with FIP versus uninfected MLN of control 
cats. It was also upregulated (to a much lesser extent) in FCoV-infected control MLN compared to 
uninfected control cats. RIG-I may therefore play a more significant role than the TLRs, with TLR 
2, 4, and 8 upregulation being in the 4-10 fold range in FIP vs uninfected MLN. The fact that 
elevation of RIG-I can only be from infected cells shows a direct role of the virus. Considering that 
TLRs respond to presented virus and do not require a cell to be infected, and that infected control 
MLN showed no TLR upregulation in the present study, one can assume a very confined, restricted 
response in the MLN to FCoV infection, with infected cells responding to the presence of virus but 
not signalling to amplify the response. 
Interestingly, despite this potentially beneficial RIG-I upregulation in infected MLN of cats without 
FIP over uninfected, comparing RIG-I in MLN LCM lesion samples versus bulk MLN there was no 
significant difference found. As the proportion of infected cells is markedly higher in the lesions, 
this suggests that heavily infected cells are failing to further upregulate their response, or may 
have reached a plateau.  
Another gene family of interest had one member amongst the top 20 upregulated genes in FIP 
compared to both control group MLN, and two members in the top 20 downregulated in FIP. This 
is the C-type lectin family, a group of cell membrane proteins that have a wide range of immune 
functions including cell adhesion and pathogen detection; as PRRs, they are found on the surface 
of macrophages 201,363. One of the C-type lectins is DC-SIGN, identified as an FCoV co-receptor 101. 
Family members can also help deliver pathogens to lysosomes 363. CLEC4D (aka CLECSF8) was the 
upregulated C-lectin. It can be expressed by neutrophils and monocytes and can be upregulated 
by IL-6, TNF-α, and IFN-γ 364. It has been shown to be a phagocytic receptor but there is scant 
further information published 364. The downregulated CLEC4G is also known as LSECtin and has 
been shown in vitro to interact with the SARS CoV spike protein to enhance infection 365. The 
second top 20 downregulated C-type lectin, CLEC10A, has thus far only been implicated in filovirus 
infection 366. The significance that downregulation of transcription of these proteins could have in 
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the feline immune system, and in FCoV infection in particular, is unknown. If both proteins are 
able to act as co-receptors then downregulation may represent a protective attempt by the host. 
Conversely, the upregulation of CLEC4D, as a phagocytic receptor, may contribute to virus uptake. 
The implications on cell function of the regulation discrepancies are unknown. However, the 
observed expression profile may represent a general macrophage activation or be a response to 
a specific stimulus.  
Downregulated genes and pathways in FIP were dominated by those involved in cellular 
metabolism. This is consistent with the downstream effects of the antiviral response, i.e. shutting 
down cell protein synthesis in an attempt to deny the virus access to replication machinery 256.  
Unsurprisingly, given the minimal differences between the two control groups, the comparison of 
MLN from cats with FIP with infected control MLN overlapped heavily with the comparison to 
uninfected control MLN. However, some interesting differences stood out in terms of enriched 
GO categories: ‘positive regulation of vascular endothelial growth factor production’ and ‘vacuolar 
acidification’ were both only significantly elevated in FIP MLN versus FCoV-infected control MLN 
and not in FIP versus uninfected controls. For these pathways to be affected indicates that the 
associated genes must be lower in infected control MLN than in uninfected MLN. This is another 
example of a downregulated/inherently lower inflammatory response in infected control MLN. 
Vascular endothelial growth factor (VEGF; corresponding to VEGFA) has been previously shown to 
correlate with the degree of effusion in FIP 367. By NGS, the mRNA for genes VEGFA-D were all 
detected in our study, of which only VEGFD was significantly differentially expressed between FIP 
and the uninfected control MLN, though in fact lower in FIP. The pathway was however 
significantly up-enriched in FIP compared to the infected control MLN. This lack of alteration in 
VEGF itself may also be explained by only two of the three cats with FIP having had effusions. 
Therefore, it would be worth evaluating the transcription of this cytokine by RT-qPCR in more 
cases, which was not done as part of the present study. 
Vacuolar acidification is a critical step in active TLR function of the intracellular TLR 3, 7, 8, and       
9 178. Drugs which block this are able to also block TLR function 368. Such drugs have in fact already 
been trialled in FIP, with limited success but without specific reference to their mode of action 369. 
Whether the underlying premise is false, or these drugs are ineffectual owing to their specificity, 
could be better assessed by simultaneous TLR pathway evaluation. The lack of efficacy of these 
drugs suggests important parallel roles for TLRs which don’t require vacuolar acidification (e.g. TLR 
2 and 4), supporting the hypothesis of excessive overactivation of pro-inflammatory pathways.  
 
Regulation of pathogen recognition pathways and possible viral interference 
Evaluation of the transcriptome gives us an important insight into cell activity following viral 
infection, especially the activities and direction of differentiation of cells. However, it does not 
give us a three dimensional view of the complete cellular processes owing to the complex layers 
of fine-tuning and alterations possible between gene transcription and formation of a functional 
protein.  
The PRRs are a powerful tool of the innate defence system and correspondingly require tight 
regulation to minimise the chances of over-activation 370. This occurs at many levels, through 
transcriptional, post-transcriptional, translational and post-translational regulation 370. Much of 
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the latter is in the form of post-translational modifications (PTMs). Of these PTMs, the best 
understood are phosphorylation, ubiquitination, methylation, and acetylation yet there are many 
other methods which are only slowly beginning to be understood 371. Defects in any of these 
modification processes can be responsible for inflammatory diseases 372. A number of molecules 
and regulators downstream to PRRs were also found to be amongst significantly upregulated 
genes in the present NGS study. These downstream molecules are frequently the targets for 
modification but the receptors themselves may also be involved 373. Examples of direct receptor 
targeting include TLR4 and RIG-I 372. TLRs addiitonally require chaperoning to their final destination 
(e.g. the plasma or endosomal membrane) and blocking of these chaperones can prevent TLRs 
functioning 374. This reinforces the fact that evaluation of TLR levels themselves is only one aspect 
in determining their end effect. The amino acid sequence of signalling molecules also has a crucial 
impact on their function. For example, once TLR2 has bound its ligand, it requires phosphorylation 
for formation of a signalling complex; small changes in the amino acid sequence can alter 
phosphorylation and completely abrogate their signalling ability 372. This is not specific to TLR2 and 
is another example of the fact that the detection of a TLR, even if at the protein level, does not 
necessarily equate to its ability to signal. Alternatively, small changes may markedly alter the 
receptor specificity such that almost identical TLRs between species respond differently to the 
same ligand e.g. TLR4 in horses and man 375. A follow up to the present study is therefore planned 
in which variant calling on the results we have thus far obtained will be applied, to attempt to 
identify any sequence differences in the TLRs between the groups of cats.  
The effects on function of variations in STAT mRNA levels are particularly difficult to interpret. As 
transcription factors, their location is of course paramount, as well as being dependant on their 
phosphorylation status; the active protein is nuclear and phosphorylated 319. The active form lasts 
a few hours before decaying by being exported from the nucleus, dephosphorylated, or SOCS 
(suppressor of cytokine signalling) suppressed but it can also be recycled so a reduced rate of 
decay would have the same effect as an increase in mRNA template 319. SOCS3 was upregulated 
in the MLN of cats with FIP so may have led to reduced downstream signalling of JAK-STAT 
pathways.  
It had been hoped that IH for STAT2 would allow cell location to be assessed and not only an 
upregulation but an increased nuclear translocation to be observed. This was unfortunately not 
possible at this time owing to a lack of antibody cross-reactivity and is instead a potential subject 
for future study.  
Another major post-translational method in addition to phosphorylation is ubiquitination which 
therefore has an important role in intracellular events. Protein degradation is as critical as protein 
translation to the maintenance of cell homeostasis 376. TLR4 and RIG-I are partially regulated by 
ubiquitin modifications 372. Ubiquitination is a three step process involving enzymes which activate 
(E1), conjugate (E2), and ligate (E3) ubiquitin to a protein 377. Differing ubiquitin protein linkages 
lead to different outcomes, with proteasomal degradation the most well-known of these. 
Regulation of intracellular immune signals is, however also a function of ubiquitination. The TRIM 
(tripartite motif-containing) protein family is an important part of this process. It comprises over 
70 members with E3 ubiquitin ligase activity 378. The family is highly conserved amongst metazoans 
and its members are expressed in response to interferons, having a broad function in innate 
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immunity 378,379. TRIM genes arise from a common ancestral gene but have then evolved 
independently in different species 378.  
Several TRIM family members are reported to exhibit anti-viral activity; one such example is    
TRIM25 377, which was found to be upregulated in the FIP MLN. TRIM25 is induced by type I and II 
IFN and one of its important roles in innate immunity is in RIG-I signalling. After recognition of viral 
dsRNA, RIG-I requires ubiquitin modifications in order to initiate an antiviral signalling cascade, in 
the form of K63-linked polyubiquitin chains mediated by TRIM25 380,381. This leads, via IRF3 and NF-
κB, to predominantly type I IFN and inflammatory cytokine production respectively 377. The ubiquitin 
specific protease USP15 helps promote TRIM25 activity and hence RIG-I signalling382. Interestingly, 
it is upregulated in FIP MLN versus controls. 
Targeting TRIMs is one of the many viral evasion strategies which have been discovered. A number 
of viruses have been reported to target TRIM25 specifically, including influenza virus and SARS-
CoV. Known to downregulate type I IFN, one of the methods SARS-CoV and MERS-CoV use is 
interaction of their N protein with TRIM25 183,383. This interferes with TRIM25 ubiquitination of 
RIG-I and hence downregulates RIG-I signalling. This mechanism, i.e. targeting the protein’s 
function, can of course not be evaluated by TRIM RT-qPCR.  
TRIM21 is another family member that was found upregulated in FIP MLN compared to controls. 
This enzyme can degrade IRFs (3, 5, and 7) and thus reduce the IFN response 384. The present study 
indeed found IRF3 to be significantly downregulated in FIP MLN, but not IRF 5 or 7. TRIM21 can 
also detect intracellular, antibody-opsonised virus which it targets for ubiquitination and 
degradation 384. Subsequently, the viral nucleic acid is released to be detected by PRRs in the 
cytoplasm. So far this has only been identified as a relevant mechanism for non-enveloped    
viruses 384, however the effect of TRIM21 levels on IFN would be an interesting in vitro experiment 
in FCoV infection.  
Viruses commonly use the tactic of degrading host signalling components of viral detection 
pathways. They may use their own proteases to cleave these components or they may hijack the 
host proteasome degradation pathway 180. TLR3 is a frequent target as it can be involved in both 
RNA and DNA virus infections 180. Classical swine fever virus N protein induces IRF3          
degradation 385 whilst enterovirus 3C cleaves IRF7 386. SARS-CoV encodes a papain-like protease 
(PLpro) through which it is able to inhibit both TLR 3 and 7 signalling 113. The main function of the 
viral PLpro is the cleavage of specific ORF1ab proteins to form their individual nsps 93. In the host 
cell, however, the enzyme interferes with TLR pathways by inactivating pathway regulators 113. 
This particular function of the FCoV PLpro has not been studied but could contribute to the lack of 
expected upregulation of TLR 3 and 7 in response to their ligands (ds and ssRNA respectively). As 
this inactivation is at the protein level it cannot be directly concluded that this would cause the 
observed difference at the mRNA level. A similar mechanism can lead to inhibition of type I IFN in 
SARS-CoV infection via physical interaction of PLpro with STING (stimulator of interferon genes, 
aka TMRM173) complexes 114. The STING gene itself was significantly upregulated (though less 
than 3 fold) in FIP MLN but the myriad potential downstream responses require further evaluation.  
Assuming that the TLR inflammatory signalling pathways remain intact, the major downstream 
cytokines would be IL-1β, IL-6, and TNF-α. These were all upregulated in the MLN in FIP, as were 
GO terms involved in positive regulation of IL-1 and IL-6 responses. Within these pathways there 
are again myriad possibilities for interference and inhibition which are also areas for investigation 
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in FCoV infection. Though not elucidating protein levels, RNA-Seq does allow us to simultaneously 
assess the levels of many of these regulators and thus predict their possible effects. IL-6 should 
signal through STAT3, which was not found to be upregulated in the present study. Though the 
activation status of STAT3 is unknown this could suggest the presence of IL-6 decoy receptors 
interfering with signalling. Gp130 is a subunit of the IL-6 receptor and is critical for signal 
transduction when present on the cell membrane 216. In its soluble form it acts as a buffer by 
binding IL-6 and preventing its action 216. Levels of gp130 (IL6ST) mRNA were not significantly 
altered in FIP but the relative distribution of the protein between membrane bound and soluble 
forms cannot be determined from the present data. This would be an interesting area of 
investigation, in particular as the soluble form could potentially be a treatment avenue 226. One of 
the functions of IL-6 is to promote B cell survival 216. Its upregulation, though mild, may help 
explain some of the upregulated clusters related to B cell function in the RNA-Seq analysis. 
 
The virus induces a local inflammatory response, more prominent than the systemic 
effects  
The present study confirms findings of previous studies that investigated the haemolymphatic 
tissues in cats with and without FIP, suggesting that BM and spleen behave very differently to the 
MLN, and differently to each other in response to FCoV infection 48,293.  
FCoV levels in the haematopoietic tissues studied here are up to 100,000 times lower in the BM 
than in the MLN, levels in the spleen range between the other two organs. The BM is a primary 
haematopoietic organ with little direct role in the immune response, and has not been reported 
to be affected by FIP lesions. Virus present here can therefore be assumed to originate from 
circulating monocytes and indicated that the majority of animals were viraemic at the time of 
death 316. These current findings are in agreement with a previous study comparing viral load 
between haematopoietic tissues and between cats with and without FIP 55. Mediator levels in the 
BM can therefore be assumed to give an approximate indication of the inflammatory response 
and or activation status in circulating cells. 
The spleen meanwhile is a sentinel organ of the immune system. Serosal lesions were frequently 
observed in the cats with FIP but were avoided for RT-qPCR. Parenchymal lesions were only 
occasionally observed which is in agreement with previous findings 44. Mediator levels in the 
spleen will therefore predominantly represent the systemic immune response to the circulating 
virus. 
The MLN has a gatekeeper role against enteric pathogens 291. Accordingly, it also had a far higher 
FCoV level regardless of the presence or absence of lesions in the present study and was 
additionally a very frequent site of virus specific lesions. Mediator levels in the MLN will therefore 
be more representative of local viral effects. 
Within control cats, (representing constitutive expression) mediator levels in the BM were all 
lower than in the spleen. Although the significant mediators varied between BM and spleen, 
trends were the same for almost all mediators. Only G-CSF and GM-CSF differed.  
M-CSF mRNA levels were significantly lower (downregulated) in both BM and spleen of FIP cats, 
while G-CSF was significantly decreased only in the BM with no trend in the spleen, and GM-CSF 
showed an upward trend in the BM and downward trend in the spleen. This apparently random 
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pattern goes against a previous finding of increased M-CSF transcription in the BM of cats with 
FIP, but supports the same study’s finding of decreased M-CSF in the spleen in FIP 48. As the CSFs 
are growth factors for granulocytes and macrophages, the primary cells involved in FIP lesions, an 
increase in FIP had been expected across the board, in particular of the less constitutive and more 
reactive G-CSF 268. Whereas M-CSF is produced ubiquitously, GM-CSF is produced mainly by 
activated leukocytes 268. The upward trend of GM-CSF therefore fits with an increase in activated 
monocytes in the BM, as previously observed 44. As the primary site of haematopoiesis, the 
increase in GM-CSF in the BM fits to its role, promoting maturation and differentiation of 
granulocytes and macrophages 387. GM-CSF levels are also reported to rise following IL-1β 
stimulation and the cytokine is also involved in promoting inflammation, e.g. by positive feedback 
to IL-1β stimulation 268. As both GM-CSF and IL-1β were elevated in the BM in the current study, 
this suggests a local or even autocrine effect 270.  
The three TLRs significantly upregulated in both MLN and lesions in FIP were TLR 2, 4, and 8. None 
of these were significantly elevated in the BM and only TLR2 was significantly elevated in the 
spleen in FIP.  
This finding reinforces that cells outwith the lesions contribute to PRR upregulation (with 
upregulation in organs without lesions) but that within lesions the response to virus is enhanced. 
Comparison of results between tissues must be interpreted with a greater level of caution than 
those within tissues as GAPDH levels can vary between organs 303.  
There was only a minimal inflammatory cytokine response by both BM and spleen in FIP; generally 
slight upward trends were observed for the three pyrogenic cytokines (IL-1β, IL-6, TNF-α) but only 
IL-1β transcription in the BM was significantly elevated which could reflect a general monocyte 
activation. These findings are similar to those of a previous study by our group where no significant 
alterations in mRNA levels were found in either the BM or spleen for the inflammatory        
cytokines 48.  
The interferons were similar, an upward trend in all reached significance for IFN-β in both organs 
and for IFN-γ in the spleen. IFN-γ mRNA has previously been found to be decreased in PBMCs in 
cats with FIP, and the protein in the blood 134,259. Separately, effusion levels of the IFN-γ protein 
were higher than serum levels, suggesting a local, i.e. lesional rather than a systemic primary 
source 258. 
The significantly lower transcription of the anti-inflammatory cytokine TGF-β in FIP in BM and 
spleen indicates that although these organs made a low direct contribution to inflammatory 
cytokine production, there was also no systemic application of this particular brake on 
inflammation 245. Potentially this may lead to a similar end result of increased inflammation by 
reducing negative feedback on pro-inflammatory cytokines. Although an effect can never be 
predicted from a single cytokine this suggests that part of the contribution of the BM and spleen 
to systemic inflammation may be permissive rather than active by decreasing the inhibition of 
inflammatory mediators. This would require study of the wider transcriptome. 
The overall impression is that in the absence of lesions, haemolymphatic tissues make only a 
modest individual contribution to systemic cytokine production. We have also observed 
inflammatory cytokine production by the heart and liver (unpublished data), suggesting that 
multiple organs make a small contribution, topping up the more significant input of lesions and 
tissues local to lesions to create a systemic inflammatory environment.  
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Infected cells within the lesions appear to make a greater contribution to 
inflammation than to anti-viral defence 
Specific regions were micro-dissected from tissues with FIP lesions, and non-lesional tissues from 
FIP cases. Lesions were additionally categorised into serositis or granulomatous parenchymal 
lesions 44. In most cases the distinction between serosal and parenchymatous lesions was clear 
histologically, fitting the two described presentations 257. Mediator levels were statistically 
compared with levels within the MLN of cats with FIP, and graphically between BM, spleen, MLN, 
lesions and lymphoid follicles from four cats. Statistical analysis was not performed on the latter 
comparisons owing to the small ‘lymphoid follicle’ group size.  
It had been hypothesised that the mediator patterns observed in the FIP MLN would be 
exaggerated in the lesions themselves, correlating with the highest density of infected cells. This 
was largely the case but with a few notable exceptions. 
The TLRs elevated in the lesions (TLR2, 4, and 8) corresponded with those elevated in the MLN of 
FIP cats versus control cats. This was despite a lack of significance found for TLR4 and 8 when 
comparing between bulk MLN with and without lesions in FIP. This discrepancy has a number of 
possible explanations. It may relate to small subgroup sizes (the ‘non-lesion’ subgroup of FIP cats 
had only seven animals), potentially poor correlation between the tissue samples for PCR and for 
histological examination, or it may be that in the bulk MLN the lesions were diluted within the 
sample and did not dominate the transcriptome as they did in the LCM samples. The cell types 
present in each sample are of course also an important factor. The present results provide clues 
but no simple answer as to the main source of these TLRs. Cells belonging to the mononuclear 
phagocyte system are the most common source, but both B and T lymphocytes in felines have 
been found capable at least of mRNA transcription of TLR 2, 4, and 8 164,165. This was determined 
by cell sorting prior to PCR; other researchers have called into question the accuracy of using PCR 
with cell sorting methods as a very low level of cell contamination could lead to false positives 388.  
Levels of mediators within lymphoid follicles, were generally very similar across a range of origins 
(MLN, spleen, and small intestinal BALT), consistent with a cell type/function specific more than 
an organ specific response. These follicles could reasonably be expected to have markedly 
different (and lower) expression patterns than the other tissues, being dominated by B cells. 
Though a far purer population than an overall organ sample, the follicles will still of course contain 
other cell types such as follicular dendritic cells (FDC) and tingible body macrophages as well as a 
small T cell portion 389, either of which may contribute to the TLR levels observed. Studies on the 
contribution of B cells to TLR production in mice and humans have shown great variability both 
between and within species depending on B cell subsets, with subsets in our cats remaining 
unknown 390. 
TLR 7 and 9 transcription levels, unaltered in FIP vs non FIP bulk MLN, were both significantly lower 
in the LCM samples. This may be a true viral inhibition or be related to the cell type present in 
each case. In humans, TLR7 and 9 are often said to be exclusively plasmacytoid dendritic cell (pDC) 
derived whereas in mice there is significant overlap in TLR expression between DC                       
subsets 181,338,391. pDCS are prototypic anti-viral DCs 185. If they exist in the cat (which is so far not 
known) and are roughly comparable, they would be expected to be found within T cell zones and 
surrounding high endothelial venules185, i.e. not within the sampled follicles. Despite this, the 
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lymphoid follicles in the present study had the highest levels of both TLR 7 and 9 (above bulk MLN 
as well as above levels in the lesions), the antithesis of the expected result. This suggests another 
cell type is likely to be responsible. As the elevated levels in follicles indicate the cell type in 
question should also be concentrated there, the two main suspects are the B cells themselves and 
the FDC. Going against the commonly held consensus of pDC specificity, human B cells have been 
shown capable of intrinsic TLR 7 and 9 signalling, contributing to a mechanism implicated in 
autoimmunity in which the cells respond to self nucleic acids 392. Similarly, FDC have also been 
shown to respond to TLR ligands (at least for TLR 4 and 7) which can themselves also contribute 
to B cell activation 393,394. The FDC is in fact not of DC origin but from perivascular precursors 395. 
In the absence of appropriate antibodies, either for immunohistology or preferably multi-channel 
FACS analysis, it was not possible to investigate our cases further at this timepoint.  
Further evidence that there is an alternative/additional cell type to pDCs responsible for TLR 7 and 
9 production in cats is provided by the IFN levels in various tissues. Though all cell types are 
capable of type I IFN production, by far the most prolific in mice and humans are usually the pDCs, 
known as the professional IFN-α/β producing cells 185. IFN-α levels were higher in the lymphoid 
follicles than in the bulk MLN (though not exceeding the lesion levels), correlating with levels of 
TLR 7 and 9. This is despite the negligible viral levels in the follicles so is not a direct viral effect. 
This correlation supports the role of these two TLRs as the main type I IFN inducers but leaves 
open the question of cell source. The lack of upregulation of TLR 7 and 9 in lymph nodes or lesions 
in FIP is also a possible explanation for the poor ability of the host to combat the virus.  
By NGS, IFN-a, -b, and -g all showed an upregulation in FIP compared to control cats but this was 
minimal; this only reached significance for IFN-g and then only at a p<0.05 level. 
So far, the existence and distribution of pDCs has not been investigated in the cat, again partly 
owing to the availability of antibodies. A human study evaluated their density in reactive LN due 
to different aetiologies 396. Two of the defined aetiological subgroups in that study could be 
apposite with FIP; viral and granulomatous, but these were at opposite ends of the spectrum. 
‘Granulomatous’ lesions contained the highest levels of pDCs and ‘viral’ the lowest 396. This 
appears rather counterintuitive when considering that the pDCs dominant function is anti-viral.  
Returning to receptive cell types for FCoV, one of the viral co-receptors has been identified as DC-
SIGN (dendritic cell (DC)-specific ICAM-3-grabbing nonintegrin/CD209) 101,340. When characterised, 
pDCs in other species (mice, humans, and swine) are reported not to have DC-SIGN 188. Their 
existence in cats is unknown, if the same is true as in other species this may mean they are unlikely 
to be infected. This would help explain why the levels of pDC specific TLRs would not necessarily 
correlate to areas dominated by infected cells. MHV for example is however able to infect both 
DCs and pDCs 397,398. 
TLR3 was tendentially but not significantly lower in the lesion group than in the bulk MLN. For 
TLR7, the difference was significant. This supports the theory of a possible viral inhibition of TLR3 
and 7 as observed in SARS and discussed above 113. Targeted experimental investigations would 
be required to confirm this mechanism, in which protein levels and downstream effects should 
also be taken into consideration.   
All three studied STATs showed lower transcription levels in the lesions than in bulk MLN from 
cats with FIP, the opposite of what had been expected. As they are downstream of cytokines 
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including the interferons, IL-6 and IL-10 this suggests reduced cytokine signalling and loss of 
positive feedback 319. Nonetheless, IFN-α was upregulated in the lesions, however neither IFN-γ 
nor IL-6 were (IFN-β and IL-10 could not be assessed in the lesions). This may be as whilst most 
cells can produce IFN-α, T cells are the main source of IFN-g (and lesions were macrophage 
dominant) 399. It also explains the lower levels of IFN-g found in B cell dominated lymphoid follicles 
than in bulk MLN.  
IL-1β was the only inflammatory cytokine that was significantly higher in the lesions than in the 
bulk MLN. This was unexpected as although macrophages are a main source of IL-1b they are also 
main sources of TNF-α which should be upregulated by FCoV infection 204,240. However, a previous 
study observed that TNF-α expression appears to switch from macrophage-dominant in 
uninfected lymph nodes to lymphocyte-dominant following FCoV infection (including within the 
follicles) 47.  
Transcription of the anti-inflammatory TGF-β was significantly lower in lesions than bulk MLN but 
slightly higher in granulomatous than serosal lesions. TGF-β can be produced by many 
parenchymal and leukocyte cell types and is produced as an inactive form so gene levels do not 
necessarily correlate with levels of active protein 245. Nevertheless, comparing mRNA levels with 
cell types present suggests that within the lesions, macrophages are the main source, but that 
they are not the main contributors in lymphatic tissue. 
Comparing within the LCM sample group between granulomatous and serosal lesions, when a 
significant difference was observed the target level was always higher in the granulomatous 
lesions. The simplest explanation is the relative proportion of macrophages. Areas which were 
macrophage dominant were selected, however serosal lesions more often contained admixed 
neutrophils and fibrin. As neutrophils are far less productive sources of cytokines, this may reflect 
a dilution of the macrophage response 400.  
The levels of the only assessable matrix remodelling enzyme in the lesions (MMP2) were lower in 
lesions than in FIP bulk MLN but were higher in granulomatous than in serosal lesions, suggesting, 
logically, that there was a greater degree of destruction of the pre-existing parenchyma taking 
place in the granulomatous lesions. These lesions may also contain a greater proportion of 
recently blood-derived macrophages, which may use MMPs to break down the basement 
membrane during extravasation 42. This is not necessary in serosal lesions which instead consist of 
effused cells without a developed tissue matrix to infiltrate. The serosal lesions within the lesion 
group may have cancelled out any difference between granulomatous lesions and MLN. MMPs 
and TIMPs showed variable expression patterns between the organs studied with no clear shift in 
balance to favour either proteolysis or inhibition. Taken together the findings suggest that matrix 
remodelling is not a prominent feature in FIP which is also supported by the histological features 
of FIP in general; even in chronic lesions, fibrosis is not observed 29,44.  
The aim had been to take endothelial cells from regions of vasculitis but this proved impossible 
from the available samples. These either lacked vasculitis or vessels were effaced such that 
isolation of pure endothelial cells was not viable. This can never be predicted before histological 
examination of tissues so continued case recruitment, and luck, would be required to obtain these 
samples. With the advancement of FFPE RNA extraction techniques this partially removes one of 
the obstacles in future sample collection (though fresh cases are still a logistical   problem) 401. 
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However the quality is still far below that of fresh frozen samples so the methods should not be 
combined in analysis. 
 
Possible epigenetic effects of feline coronavirus 
The comparison of RNA-Seq data between micro-dissected lesion samples and bulk MLN of cats 
with FIP is the most difficult to attribute significance to as here distinctly different cell populations 
were compared; a lymphocyte dominated versus a macrophage dominated population. This 
comparison was part of an attempt to determine which processes the virus can affect regardless 
of cell type.  
There was a very apparent segregation between the two groups by cluster analysis. This included 
the whole transcriptome as results were not filtered prior to analysis, and hence many genes 
without a role in immunity. In fact there appeared to be surprisingly few immune system 
associated genes upregulated in the lesions compared to the bulk MLN. The main genes found to 
be more highly expressed in the lesions were all histone proteins, responsible for chromatin 
packaging. The top 10 genes alone included six histone (H) cluster genes from clusters 1 and 2, 
with both 2A and 2B members. H2A and 2B are two of the four histone molecules involved in 
forming a core around which DNA is wrapped 402. H1 is a linker protein which helps compact the 
chromatin 402. When closed, the chromatin is not transcriptionally active 403. 
Histone modifications are one of the methods of epigenetic regulation, i.e. any modification which 
alters a phenotype without any alteration to the genotype 404. Modifications include amongst 
others, acetylation, methylation, and phosphorylation of histones, as well as nucleosome 
positioning, and regulatory RNAs 403,405. These alterations may serve to either repress or activate 
transcription. Epigenetic alterations are one of the key methods by which a transcriptional 
response can be tailored to a specific stimulus 403. The promoters of key primary response genes 
such as IFN often contain regions which are resistant to modification, so that the initial response 
is less flexible. Their downstream genes however, such as interferon stimulated genes (ISGs), often 
require remodelling of their promotion sites to allow transcription 403. Indeed, expression levels 
of IFN and ISG have been correlated with disease outcome 403, and specific histone modifications 
have been inversely correlated with ISG levels which regulates the IFN response 406. Crucially, the 
location of the modification is of more importance than the type in determining outcome; for 
example methylation may cause either repression (as in the previous example) or activation 403. In 
another study, macrophages were found to have a huge increase in histone acetylation at TLR 
promoter regions following LPS stimulation 407. Not only do these processes occur as part of 
normal cell regulation of transcription but they are also frequently bidirectional in viral infection. 
As well as a virus using host machinery for its own replication, it may utilise epigenetic methods 
to dysregulate the host immune system and/or to direct cellular function towards viral    
replication 405. DNA viruses more commonly influence host epigenetics but there are also 
examples of RNA viruses, including coronaviruses. Both SARS-CoV and MERS-CoV have been found 
to interfere with the host IFN response; the latter causes a downregulation of IFN responsive 
genes associated with antigen presentation, suggesting it is able to evade the immune response 
in this way 408.   
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Cell culture experiments showed that MHV can enhance its own infectivity through epigenetic 
modifications affecting cell receptor expression; these modifications led to increased levels of 
persistent infection 409. This susceptibility was passed down to the next generation as cells were 
passaged 409.  
In the present study, the normal ratio of histone transcription between a lymph node population 
and a macrophage dominated population is unknown therefore the possible interpretations are 
at this stage hypothetical. It cannot be excluded that the differences represent constitutive cell 
type associated factors. However the results raise fascinating questions regarding the potential 
impact of FCoV infection on the host epigenome. One hypothesis could be that the virus induces 
alterations in histone packaging which then contribute to an ineffectual response. The next logical 
step to investigate this further would be to conduct in vitro infection studies with chromatin 
immunoprecipitation (ChIp) analysis 410. ChIp can also be combined with deep sequencing to 
simultaneously elucidate both the epigenome and transcriptome (ChIp-seq). Although the host 
genome of cats with and without FIP has been compared to try to identify host factors involved in 
susceptibility to disease, and the transcriptome has been evaluated in specific settings, the 
epigenome has not been studied to date 75,168,411,412. Epigenome-wide association studies (EWAS) 
can provide a way to study epigenetic variants associated with disease outcomes 413. However, 
once again application of methods which are routine in other species can be challenging in the 
cat, with this method also relying on antibodies of appropriate specificity.  
The genes found at lower levels in the lesions than the bulk MLN were unfortunately poorly 
annotated, it could only be established that the majority are involved with antibody production. 
The simplest explanation is the paucity of B cells (or more specifically plasma cells) within the 
lesion samples in comparison to the MLN. When in the future more information is available to 
characterise these proteins further, the possibility that they are macrophage expressed proteins 
assisting antibody function can be investigated. In this scenario this would suggest viral-induced 
downregulation in the lesions. This potentially fits with the above described downregulation of 
host cell antigen presentation by MERS-CoV infected cells but is thought to be a far less likely 
explanation at this stage. 
 
Looking beyond the viral spike protein 
Of all the viral mutations postulated to be key to the pathogenesis of FIP, the spike protein 
mutations have come the most tantalisingly close to date. The finding of so called ‘FIP causing’ 
and hence ‘diagnostic’ mutations has sparked much debate since being identified in a comparison 
between tissue samples from cats with FIP and faeces of FCoV infected healthy cats 132. This study 
found that the vast majority of tissue samples contained virus with one of two amino acid 
alterations (at codons 1048 and 1050) 132. Later studies also compared tissue samples of FCoV 
infected healthy cats and found that the viral mutations could also be identified in these samples, 
suggesting they were linked to systemic spread rather than pathogenicity 91,133. Nevertheless these 
mutations are often suggested as tools for use in a diagnostic setting 414–416. For this reason we 
first targeted this mutation site to investigate, comparing a selected region of the S gene between 
FCoV infected control cats and cats with FIP. 
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We found the ‘systemic’ mutations present in all FCoV infected cats without FIP, and found cats 
without FIP which lacked the mutation. This confirmed earlier studies that the codon 1048 and 
1050 mutations are neither specific to FIP nor always present in cats with FIP 91,133. They added 
further support to the hypothesis of these previous studies that the mutations are associated with 
the virus’ ability to spread systemically but not with its virulence 91,133.  
Three cats carried virus associated with the ‘enteric’ form (in BM, spleen, and MLN). Of these three 
cats, additional organs (spleen and MLN) were available from the cat with ‘enteric’ virus in the 
BM, and these carried the ‘systemic’ mutation.  
From another cat, virus from seven different sites was available to sequence. All except one of the 
obtained sequences were identical, this was from lesion free Peyer’s patches and thereby the 
closest site to purely enteric (intestinal epithelial) virus. This site carried the ‘systemic’ mutation 
but results suggest that additional mutations (two bases within the sequenced region) occurred 
before further spread.   
All samples taken from lesions did in fact carry the mutated form regardless of the presence of 
virus in other organs from the same animal. Whilst this warrants further analysis it is of little 
diagnostic advantage as the benefit of a ‘definitive’ PCR over lesion sampling is in allowing testing 
of low invasiveness on easy to access samples. It can also never be possible to ensure that all virus 
types present in an individual infected animal are sampled so the risk of false positives and 
negatives remains.  
FCoV is reported to frequently exist as quasispecies, one theory holds that these overwhelm the 
immune system of a compromised individual 417. A study on blood samples found limited 
quasispecies in the N protein, but a high level in the S protein 119. Many cats in our study showed 
a surprising lack of ‘within host’ viral variation at the nucleotide level within the S gene region 
sequenced; six cats showed no variations at all. This is possibly as our population consisted almost 
exclusively of client-owned pet cats which were hence less prone to FCoV co-infections than 
cattery animals. The degree of viral mutations observed at the genetic level (in this study often 
around 10% from the reference sequence even over only a small 150bp stretch) in comparison 
with the rare mutations at the protein level shows that selection pressure rarely favours 
mutations. Alongside this, the tendency of the virus to vary between organs brings great 
difficulties in interpretation. When viruses with varying protein sequences are present within the 
same organ or different organs of the same cat, it cannot be easily determined which, or if all, are 
responsible for disease. The same was found by Borschensky and Reinacher 125 who looked at the 
FCoV 3c and 7b genes and found multiple sequences within individuals.  
A secondary aim of NGS was to compare the viral transcriptome between cats with and without 
FIP. However, as the library preparation protocol was chosen to suit the primary aim of analysing 
host mRNA differential expression, rather than preferentially amplifying virus, the number of viral 
reads was not amenable to the automated analysis programmes. Nonetheless, it could be 
compared by analysis of the raw data. The genes coding for the virus polyprotein1ab and the 
structural proteins were compared between the FCoV positive groups. The virus from FIP cats 
appeared similar whether or not bulk MLN or lesion was evaluated. Between cats with FIP and the 
infected control cats, the only significantly differentially expressed genes were the envelope and 
membrane protein genes. At this stage, the small group sizes mean that these results must be 
interpreted with a high degree of caution and require further validation. Howeve, they have 
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fascinating implications and could potentially indicate a difference in relative gene transcription 
between virulent and non-virulent virus. The E and M proteins have not been previously linked 
with FCoV pathogenesis, with studies tending to focus on viral mutations. The functions of the E 
protein vary between coronaviruses 93. Some coronaviruses, including the closely related TGEV 
have been found to require E and M but not N for formation of the virion envelope, though this 
may vary with the propagation system 93,418,419. This particular property has apparently not yet 
been investigated in FCoV. Thus, increased levels of these proteins may allow an increased rate of 
virion formation and go some way to explaining the higher viral titres observed in cats with FIP 
than infected cats without, both in this and a previous study 55. The E protein has also been 
implicated in viral egress from cells, altering the host secretory pathways to benefit the virus 419. 
A SARS-CoV E protein deletion was able to replicate but was attenuated in culture. It also caused 
a lower level of pulmonary inflammation in hamsters though this may be more directly linked to 
the lower viral load 420. Another possible explanation for the reduced inflammation, and 
potentially of high impact in FIP, is decreased activation of NF-κB in infected cells by E gene knock 
out viruses 419. 
The M protein is involved in viral assembly 93 but studies on its potential involvement in immune 
modulation have provided conflicting results. The SARS-CoV M protein has been variably found to 
induce IFN-β and to inhibit its production 347,421. To be of relevance in the scenario of FIP, the latter 
effect would be more important. 
 
Summarising the transcriptome approach 
A number of previous studies have looked at the transcriptome in FCoV (FIPV) infected CRFK cells 
in vitro, and a recent study looked at peritoneal macrophages from experimentally infected cats 
in vivo 168,241,242,251,411. Despite the differing cell populations (with CRFK cells far removed from 
macrophages), our results showed a surprisingly high overlap with previous in vitro findings of 
other groups but of course not complete. This is despite the huge biological difference between 
an artificially propagated, experimentally infected, culture-adapted cell type and a natural 
infection of a living organism with all the different cell types and interactions taking place within 
an organ. It demonstrates how preserved the effects induced by FCoV are and supports the use of 
in vitro experiments for more specific cell manipulations (e.g. gene knockouts or protein 
antagonists). However, the differences highlight how crucial it is that in vitro work is validated in 
vivo, e.g. the lack of TLR induction in CRFK cells 167 compared to that observed in our study render 
knock out studies with this method irrelevant. In comparing our results with those of Harun et al. 
who used a CRFK infection system, agreement for upregulated genes was far higher than for 
downregulated genes 412. This suggests that whilst many cells may have a similar initial response 
to infection and upregulate first line defence genes, their downstream responses e.g. 
downregulation of metabolism are more cell-type specific.  
One previous transcriptomic study specifically looked at apoptosis regulation in FIP 251 as this 
feature is observed histologically in lymphatic tissues in FIP and is known to be virus                  
induced 46,63,240. Their results reinforce how important correlation with the pathological picture is 
as, based on gene expression only, the effect on apoptosis could not easily be predicted; up and 
downregulated genes within an apoptosis cluster were evenly detected 411. 
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The S100 protein genes for example were not identified by any previous group as being of interest 
but this also fits with the lack of an ‘intermediate’ group (infected animals without FIP) in the in 
vitro experiments 168,242,411.  
It is of course well known that protein levels cannot be directly extrapolated from mRNA levels. 
The precise figure varies with the biological system being tested, but it can be that only 
approximately 40% of protein variation can be directly explained by mRNA levels 422,423. A far more 
positive finding for NGS interpretation was that when considering only differentially expressed 
genes, the correlation was much improved 424. As already partly discussed there are a wealth of 
post-transcriptional modifications possible before even contemplating functional alterations 
though molecular interactions and post-translational modifications. Nevertheless, knowledge 
gleaned from other models can be used to predict the validity of results, as discussed. 
An in vitro study on human cell lines assessed correlation between mRNA and protein levels in 
detail. The authors found that whilst there was overall poor correlation, for any given RNA the 
ratio was actually very reliable so that application of a correction factor could accurately predict 
one from the other 425. This was within an experimental rather than in vivo situation but is 
nevertheless a promising option for the future. 
One restriction of working with feline samples is the level of gene annotation so far available. 
Although this has expanded greatly in recent years, annotations are still a long way behind those 
of e.g. the human or mouse genome. This also links to the lack of available cross-reacting 
antibodies with which to confirm translation. It is hoped that, as databases are continuously 
updated, repeat analysis of this dataset will offer further insight in the future. 
A common assumption in FIP is that there is an insignificant anti-viral interferon response. Here it 
was hypothesised that the balance between interferons and pro-inflammatory cytokines is swung 
in favour of the latter, with resulting damage to the host. Our results support what can be 
observed both clinically and pathologically, i.e. that the inflammatory upregulation occurring is 
too widespread and non-specific. Anti-viral pathways are upregulated, but this appears 
outweighed by the extensive involvement of the adaptive immune system and inflammatory 
cytokines, causing the severe damage observed which may therefore be a bystander effect.  
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Outlook and perspectives 
As tends to be the case with FIP, each new discovery leads to further questions. 
Returning to the original aims of the project, it has not been possible to address all of these but 
instead, additional channels have been opened and partially explored. This has shed light on 
exciting avenues for further study. Many of these were discussed above but will be summarised 
again here. 
The first hypothesis was that a distinct state might exist in the MLN of FCoV infected cats which 
do not develop FIP. The results provide support for this theory but until more is known of the viral 
factors involved, the distinction between a resistant host and a non-pathogenic virus remains 
obscure in natural infections. 
The results also support a skewing of involved pathways, weighted towards pro-inflammatory at 
the expense of more targeted anti-viral responses.  
We have identified which TLRs are most likely to be involved in the host response to FCoV but 
have also found that results are distinct between organs and cannot be extrapolated from one to 
another. The present results also supported the hypothesis of an inadequate response by viral 
specific cytokines. Using RT-qPCR, no one TLR showed a clear cut off between animals with and 
without FIP but a possible extension of this would be to use machine learning to determine 
whether the panel of results together can predict disease status. 
The primary aims of this study were all directed towards increasing understanding of the host 
immune response rather than of the virus. Nevertheless it goes without saying that viral factors 
cannot be ignored if we are to one day fully unravel the pathogenesis of this elusive disease. 
During the course of this project, discovering more precisely where the current gaps in our 
understanding lay helped to suggest future areas of study. 
The secondary aim of NGS, to evaluate the viral sequence and transcriptome between cats with 
and without FIP has been partially successful but would benefit from deeper investigation of 
increased sample numbers. With this as the primary aim of a project, the sequencing methods 
could be tailored to the virus making this investigation more likely to yield significant results. So 
far investigations into viral sequence have focussed on those mutations which make a difference 
to the protein sequence. By simultaneously comparing viral genomic and amino acid sequences 
with the viral transcriptome it can be determined if nucleotide alterations affect the transcribed 
levels of any genes (and hence replication competence), without alterations in the protein. This 
potential difference relates to the multiple triplets coding for a particular amino acid and would 
represent a highly significant mutation which may also easily slip under the radar. Ribosomal 
profiling could be another useful tool to study viral gene expression and compare pathogenic and 
non-pathogenic viruses.  
The transcriptome approach provides a more informative way to assess the host response in in 
vitro treatment trials without resorting to animal experiments at too early a stage.   
Whilst every attempt has been made to extract the most relevant and salient results from the 
sequencing data, the wealth of information provided by this technique means that there are still 
many avenues which can be explored in greater depth, even before increasing the sample size for 
greater statistical power. This will include variant calling in an attempt to uncover any potential 
functional alterations in proteins. 
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